

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPIC
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPIC now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:56:23 ON 29 MAY 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:56:51 ON 29 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2008 HIGHEST RN 1023436-44-3

DICTIONARY FILE UPDATES: 28 MAY 2008 HIGHEST RN 1023436-44-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10540359.str



```

chain nodes :
11
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18
ring/chain nodes :
19
chain bonds :
7-19 8-11 10-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18
exact/norm bonds :
5-7 6-10 7-8 7-19 8-9 8-11 9-10
exact bonds :
10-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

```

G1:O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS

```


10/ 540,359

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:57:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3555 TO ITERATE

56.3% PROCESSED 2000 ITERATIONS 36 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 67524 TO 74676

PROJECTED ANSWERS: 800 TO 1758

L2 36 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 16:57:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 72035 TO ITERATE

100.0% PROCESSED 72035 ITERATIONS 1304 ANSWERS
SEARCH TIME: 00.00.01

L3 1304 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 16:57:23 ON 29 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 May 2008 VOL 148 ISS 22

FILE LAST UPDATED: 28 May 2008 (20080528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 370 L3

=> s 14 not (isopropyl or cyclopentyl)

81625 ISOPROPYL


10634 CYCLOPENTYL

L5 327 L4 NOT (ISOPROPYL OR CYCLOPENTYL)

=> d 15 1- ibib abs hitstr


YOU HAVE REQUESTED DATA FROM 327 ANSWERS - CONTINUE? Y/(N):y

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FN 1007383-24-6 CAPLUS
CN 5H-Pyrrolo[2,1-e][1,4]benzodiazepine-5-one, 8-[(4-{6-fluoro-2-oxo-4-phenyl-1(2H)-quinazolinyl}butoxy)-1,2,3,11a-tetrahydro-7-methoxy-, (11a)- (CA INDEX NAME)


Absolute stereochemistry.



FN 1007383-25-6 CAPLUS
CN 5H-Pyrrolo[2,1-e][1,4]benzodiazepine-5-one, 8-[(4-{6-fluoro-2-oxo-4-phenyl-1(2H)-quinazolinyl}pentyloxy)-1,2,3,11a-tetrahydro-7-methoxy-, (11a)- (CA INDEX NAME)


Absolute stereochemistry.

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FN 1007383-28-9 CAPLUS
CN 5H-Pyrrolo[2,1-e][1,4]benzodiazepine-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[(4-{6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl}pentyloxy)-, (11a)- (CA INDEX NAME)


Absolute stereochemistry.



IT 1007383-35-8 1007383-36-9 1007383-37-0
R₁, R₂ RCT (Reactant); RACT (Reactant or reagent)
(Preparation of quinazolinone pyrrolobenzodiazepine hybrids as anticancer drugs)


FN 1007383-35-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-bromopropyl]-6-chloro-4-phenyl- (CA INDEX NAME)

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FN 1007383-26-7 CAPLUS
CN 5H-Pyrrolo[2,1-e][1,4]benzodiazepine-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[(4-{6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl}propoxy)-, (11a)- (CA INDEX NAME)

Absolute stereochemistry.



FN 1007383-27-8 CAPLUS
CN 5H-Pyrrolo[2,1-e][1,4]benzodiazepine-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[(4-{6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl}butoxy)-, (11a)- (CA INDEX NAME)

Absolute stereochemistry.

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FN 1007383-36-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(4-bromobutyl)-6-chloro-4-phenyl- (CA INDEX NAME)



FN 1007383-37-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(5-bromopentyl)-6-chloro-4-phenyl- (CA INDEX NAME)




IT 1007383-29-0P 1007383-30-3P 1007383-31-6P
1007383-32-1P 1007383-33-6P 1007383-34-7P
R₁, R₂ RCT (Reactant); RHT (Synthetic preparation); RFP (Preparation); RACT
(Reactant or reagent)
(Preparation of quinazolinone pyrrolobenzodiazepine hybrids as anticancer drugs)
FN 1007383-29-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-[3-{4-[(12S)-2-[bis(ethoxy)methyl]-1-pyrrolo[2,1-e]oxazolyl]-2-methoxy-5-nitrophenyl}propyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

PH 1007187-10-7 CAPLUS
 CH 2(1R)-Quinazolinone, 1-[3-[5-amino-4-[[[2R]-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxyphenyl]propyl]-6-chloro-4-phenyl- (CA INDEX NAME)
 Absolute stereochemistry.

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

PH 1007187-12-5 CAPLUS
 CH 2(1R)-Quinazolinone, 1-[4-[5-amino-4-[[[2S]-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxyphenyl]butyl]-6-chloro-4-phenyl- (CA INDEX NAME)
 Absolute stereochemistry.

15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

PH 1007187-13-4 CAPLUS
 CH 2(1R)-Quinazolinone, 1-[4-[4-[[[2R]-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxy-5-nitrophenyl]butyl]-6-chloro-4-phenyl- (CA INDEX NAME)
 Absolute stereochemistry.


15 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


PH 1007187-13-6 CAPLUS
 CH 2(1R)-Quinazolinone, 1-[5-[4-[[[2R]-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxy-5-nitrophenyl]pentyl]-6-chloro-4-phenyl- (CA INDEX NAME)
 Absolute stereochemistry.



Ph

PH 1067367-74-7 CAPLUS
 CH 2-[18]-Quinoxaline, 3-[5]-[5-amino-4-[[[2S]-2-[[[4S]ethylthio)methyl]-3-pyrrolidinyl]carbonyl]-2-methoxyphenyl]pentyl]-4-chloro-4-phenyl- (CA INDEX 5000)

Absolute stereochemistry.



Ph

15 ANSWER 2 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2007:131464 CAPLUS
 DOCUMENT NUMBER: 148:17847
 TITLE: Quantitative structure-property relationship study of n-octanol-water partition coefficients of some of diverse drugs using multiple linear regression
 AUTHOR(S): Ghazemi, Jahanshah; Saadipour, Saeid
 CORPORATE SOURCE: Chemistry Department, Faculty of Sciences, Bazi University, Kermanshah, Iran
 SOURCE: Analytica Chimica Acta [2007], 604(2), 99-106
 CONTR. ACCTOBY, ISSN: 0003-2675
 PUBLISHED: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A quant. structure-property relationship (QSPR) study was performed to develop models that relate the structures of 150 drug organic compds. to their n-octanol-water partition coeffs. (log Po/w). Mol. descriptors derived solely from 3D structures of the mol. drugs. A genetic algorithm was also applied as a variable selection tool in QSPR anal. The models were constructed using 110 mol. as training set, and predictive ability tested using 40 compds. Modeling of log Po/w of these compds. as a function of the chosen. derived descriptors was established by multiple linear regression (MLR). Four descriptors for these compds. mol. volume (MV) (geometrical), hydrophilic-lipophilic balance (HLB) (constitutional), hydrogen bond forming ability (HB) (electronic) and polar surface area (PSA) (electrostatic) are taken as inputs for the model. The use of descriptors calculated only from mol. structure eliminates the need for synth.
 determination of properties for use in the correlation and allows for the estimation of log Po/w for mol. not yet synthesized. Application of the developed model to a testing set of 40 drug organic compds. demonstrates that the model:
 is reliable with good predictive accuracy and simple formulation. The prediction results are in good agreement with the expnl. value. The root mean square error of prediction (RMSEP) and square correlation coefficient (R2) for MLR model were 0.22 and 0.99 for the prediction set log Po/w.
 IT 22162-18-5, Progesterone
 RI: ANT (Analyte); TST (Therapeutic use); ANST (Analytical study); NGL (Nucleoside analog) (drug); UBS (Use)
 (quant. structure-property relationship study of n-octanol-water partition coeffs. of some of diverse drugs using multiple linear regression)
 PH 22162-18-5 CAPLUS
 CH 2-[18]-Quinoxaline, 7-methyl-1-(1-methylpentyl)-4-phenyl- (CA INDEX 5000)



15 ANSWER 3 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 REFERENCE COUNT: 48
 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

13 ANSWER 2 OF 327 CAPLUS COPYRIGHT 2008 ACS ON SYN
 ACCESSION NUMBER: 20071090523 CAPLUS
 DOCUMENT NUMBER: 147398468
 TITLE: Use of gelatin to diagnose and treat inflammatory diseases
 INVENTOR(S): Fossell, Thomas P.; Magnusson Osborn, Anna Charlotte
 PATENT ASSIGNER(S): Teresaja Tarkowski, Andriej
 SOURCE: The Brigham Women's Hospital, Inc., USA
 DOCUMENT TYPE: PCT Int. Appl., 5pp.
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109056	A3	20070927	WO 2007-086451	20070315
WO 2007109056	A3	20071202		
WI	AE, AG, AL, AM, AT, AO, AU, BA, BB, BG, BR, BY, CA, CB, CH, CO, CY, CZ, DE, DK, DM, DO, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PH	AE, AR, BR, CA, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			
US	AE, AR, BR, CA, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			

PRIORITY AFFILI. INFO.: US 2006-782508 F 20060315

AB The invention relates to the use of gelatin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelatin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

IT 22740-18-5, Fluorazone 37554-40-8, Fluorazone
 RI PAC (Pharmacological activity); 780 (Therapeutic use); RIGL (Rheumatoid study); USBS (Uses)
 (use of gelatin to diagnose and treat inflammatory diseases)

PH 22740-18-5 CAPLUS
 CH 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 4 OF 327 CAPLUS COPYRIGHT 2008 ACS ON SYN
 ACCESSION NUMBER: 20071442375 CAPLUS
 DOCUMENT NUMBER: 147285204
 TITLE: Compositions and methods for effecting controlled posterior vitreous detachment
 INVENTOR(S): Bartels, Stephen P.
 PATENT ASSIGNER(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 15pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007109056	A3	20070923	US 2007-073170	20070306
WO 2007121065	A2	20070907	WO 2007-0862402	20070229
WI	AE, AG, AL, AM, AT, AO, AU, BA, BB, BG, BR, BY, CA, CB, CH, CO, CY, CZ, DE, DK, DM, DO, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PH	AE, AR, BR, CA, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			
US	AE, AR, BR, CA, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SV, SY, TD, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VN, ZA, ZM, ZW			

PRIORITY AFFILI. INFO.: US 2006-715739 P 20060222

AB A composition comprises plasmin or an enzymically equivalent derivative thereof and at least an anti-inflammatory medicament. The composition can be used to effect:

or induce a controlled posterior vitreous detachment ("PVD") to prevent, treat, or ameliorate a potential complication of a pathol. ocular condition. Such a composition can be administered intravitreally.

IT 22740-18-5, Fluorazone
 RI PAC (Pharmacological activity); 780 (Therapeutic use); RIGL (Rheumatoid study); USBS (Uses)
 (plasmin compo. and methods for effecting controlled posterior vitreous detachment)

PH 22740-18-5 CAPLUS
 CH 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 3 OF 327 CAPLUS COPYRIGHT 2008 ACS ON SYN (Continued)
 PH 37554-40-8 CAPLUS
 CH 2118-Quinazolinone, 4-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



13 ANSWER 4 OF 327 CAPLUS COPYRIGHT 2008 ACS ON SYN (Continued)

13 ANSWER 5 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 ACCESSION NUMBER: 2007-006888 CAPLUS
 DOCUMENT NUMBER: 147122287
 TITLE: High-performance liquid chromatographic determination of progesterone and its m-hydroxy metabolite in spiked human plasma and urine
 AUTHOR(S): Bassar, Kham M.; Gary, Azza A.; Abdel-Ray, Mohamed E.; Melal, Tarek S.
 CORRESPONDING SOURCE: Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, University of Alexandria, Alexandria, 21521, Egypt
 SOURCE: Journal of AOAC International (2007), 90(4), 973-976
 PUBLISHER: COMM. SOURCE: ISSN: 1060-3073
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: A simple and rapid high-performance liquid chromatographic method for the determination of progesterone (PQR) and its major metabolite, m-hydroxyprogesterone, in spiked human plasma and urine was developed. Plasma samples were purified using acetonitrile as a protein precipitant, while urine samples were diluted only with the mobile phase and filtered prior to injection.
 Samples: Samples containing the parent compds. and glafenine (internal standard) were eluted from a reversed-phase C18 column using acetonitrile-0.025 M sodium acetate (60:40) adjusted to pH 5 as the mobile phase and detected at 274 nm. Peak area ratios of the analytes vs. internal standard were used for calibration.
 The mean recoveries from plasma and urine samples spiked with PQR and its m-hydroxy metabolite ranged from 91.87 to 101.88%. The relative standard deviation for the within- and between-day analyses was <4%. The proposed method was applied for the assay of PQR in laboratory-made tablets.
 IT 22760-18-5, Progesterone
 EL: FTI (Pharmacokinetic); R10L (Biological study)
 High-performance liquid chromatographic determination of progesterone and its m-hydroxy metabolite in spiked human plasma and urine
 IT 22760-18-5 CAPLUS
 CM 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 6 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 ACCESSION NUMBER: 2007-078811 CAPLUS
 DOCUMENT NUMBER: 146149390
 TITLE: Transdermal delivery of non-steroidal anti-inflammatory drugs
 INVENTOR(S): Kisea, Kathryn Tracy-Tana; Bahalova, Margareta Vladislavova; Morgan, Timothy Matthias; Finnin, Charles; Reed, Barry Leonard
 PATENT ASSURE(S): Aetna DDB Pty Ltd., Australia
 SOURCE: U.S. Pat. Appl. Publ., 13pp., Cont.-in-part of U.S. Ser. No. 759,303.
 COMM. SOURCE: Patent
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COMENT: 7
 PATENT INFORMATION: 7

PATENT NO.	CLASS	DATE	APPLICATION NO.	DATE
US 2007057228	A1	20070405	US 2006-217075	20060906
US 872725	A1	19970821	MO 1997-0078	19970219
US 6199920	B1	20011009	US 1998-125436	19981218
US 5915819	A	19991202	MO 1999-12589	19991001
US 20020528235	A1	20020307	US 2001-910780	20010724
US 692826	B2	20041116		
US 2004146469	A1	20040729	US 2004-759303	20040210
JP 147048	A1	20000289	EP 2003-22951	20030209
JP 200726887	A	20071220	JP 2007-185782	20070717
PRIORITY APPL. INFO.:			MO 1996-8144	A 19960229
			MO 1997-A091	M 19970219
			US 1998-125436	A3 19981218
			US 2001-910780	A2 20010724
			US 2004-759303	A2 20040210
			MO 1997-17134	A3 19970219
			EP 1997-804034	A3 19970219
			JP 1997-528934	A3 19970219
			EP 2005-22951	A3 20051020

13 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 REFERENCE COMPT: 8
 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE EE
 FORMAT

13 ANSWER 8 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 OTHER SOURCE(S): N00387 146140830
 AB The present invention provides a transdermal drug delivery system which comprises a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid enhanced skin penetration of ibuprofen using Padimate O in a transdermal gel composition shows the cumulative amount of ibuprofen penetration into a microdialysis probe, adjusted for individual probe recovery over 14 h.
 IT 22760-18-5, Progesterone
 EL: TBI (Therapeutic use); R10L (Biological study); USES (Uses)
 Transdermal delivery of NSAIDs
 IN 22760-18-5 CAPLUS
 CM 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)




13 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2007:137786 CAPLUS
 DOCUMENT NUMBER: 1461399356
 TITLE: Methods using farnesyl transferase inhibitors for the treatment of synucleinopathies
 INVENTOR(S): Lansbury, Peter T, Jr, Shibus
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
 SOURCE: Anat. Pat. Appl., 5/09p.
 COUNTRY: AUKGCM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2006/070674	A1	2006-11-16	NO 2006-230674	2006-10-19
PUBLISHED APPL. INFO:			NO 2006-230674	2006-10-19

OTHER SOURCE(S): MARGAT 1461399356
 AB The invention provides methods for treating synucleinopathies, e.g. Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, comprising administering a synucleinopathic subject a farnesyl transferase inhibitor.

IT 215074-66-3 215074-66-3D, stereoisomers and salts
 215074-70-9 215074-70-9D, stereoisomers and salts
 RI PAC (Pharmacological activity) TSP (Therapeutic use); RIGL (Biological study) TSP (Therapeutic use)

HN (Farnesyl) transferase inhibitors for treatment of synucleinopathies)
 215074-66-3 CAPLUS
 CH 2118 Quinacolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



HN 215074-66-3 CAPLUS
 CH 2118 Quinacolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

13 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



HN 215074-70-9 CAPLUS
 CH 2118 Quinacolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



HN 215074-70-9 CAPLUS
 CH 2118 Quinacolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



15 ANSWER 8 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005:114398 CAPLUS
 DOCUMENT NUMBER: 144141980
 TITLE: Evaluating molecular similarity using reduced representations of the electron density
 AUTHOR(S): Neuroni, Matthew; Maguire, Gerald M.; Vercauteren, Daniel P.
 CORPORATE SOURCE: Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 85721, USA
 SOURCE: Journal of Molecular Modeling (2005), 11(13), 287-247
 COUNTRY: JMOFF; ISSN: 0948-1021
 URL: <http://www.springerlink.com/media/497LMVTRZRH0LDE>
 TSP (Contributions/Q/O/S/I/QOO3M7954165113.pdf)
 PUBLISHER: Springer GmbH
 DOCUMENT TYPE: Journal (online computer file)
 LANGUAGE: English
 AB A model system of four benzodiazepine-like ligands for the central benzodiazepine receptors (CBRs) and peripheral benzodiazepine receptors (PBRs) is examined using a genetic algorithm procedure (GAGS) designed for evaluating mol. similarity. The method is based on the alignment of reduced representations generated from the critical points of the electron d. computed at medium crystalllog. resolution. The results are further characterized by a comparison with alignments produced by MDCT, a field-based superimposition method that matches both steric and electrostatic mol. fields. The alignments produced by the two methods are generally seen to be consistent. The relationships of the compds.' binding affinities for both CBRs and PBRs to the alignments determined by GAGS yield a set of structural features required for significant binding to benzodiazepine receptors. Benefits of using reduced representations for evaluating mol. similarities and for constructing pharmacophore models are discussed.
 IT 20927-53-1
 RI BDT (Biological study, unclassified); PBP (Properties); BDT (Biological study)
 HN (stereoelectronic mol. of benzodiazepine-type ligand quinacolinone analyzed for binding affinity to central and peripheral benzodiazepine receptors by GAGS and RIGL alignment method)
 HN 20927-53-1 CAPLUS
 CH 2118 Quinacolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS



L5 ANSWER 11 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

15 ANMERKUNG 1105 327 CAPSUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005-825751 CAPSUS
 DOCUMENT NUMBER: 1423-19941
 TITLE: Pharmaceutical combinations of (S)-pantoprazole with
 NMXD or corticosteroids
 INVENTOR(S): Huber, Bernhard; Kohl, Bernhard; Exoner, Wolfgang
 PATENT ASSIGNEE(S): Alnara, Wolfgang-Alexander
 SOURCE: Alnara Pharma A.-G., Germany
 ICT Int. Appl., 44 pp.
 CODES: P2008, P2008
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY AC. NUM. COUNT: 1
 PATENT INFORMATION:

[illegible]

PRIORITY APPLN. INFO.: EP 2004-1755 A 20040128

23 The present invention relates to new combinations and new use of (S)-pantoprazole and/or its salts in the prevention or treatment of medication caused gastrointestinal diseases. The compas. comprise a first active ingredient, which is (S)-pantoprazole and/or its salt; and a second

active ingredient, which is selected from a group consisting of NSAIDs, COX-2 inhibitors, NO-NSAIDs, bisphosphonates and corticosteroids.

EL: PAC (Pharmacological activity); THU (Therapeutic use); BICL (Biological study); USES (Uses)
[pharmaceutical combinations of (S)-pantoprazole with NSAID or
muscle relaxants]

NO	22740-18-5	CAPIUS	
CI	2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl-	(CA INDEX NAME)	

L5 ANSWER 12 OF 327 CAPLUS COPYRIGHT 2008 ACS on STB

ACCESSION NUMBER: 2005:490281 CAPLOS
DOCUMENT NUMBER: 143:49056
TITLE: Novel nanoparticulate nimesulide compositions
INVENTOR(S): Bosch, H. Wallace; Wiles, Christian F.
PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ier.
SOURCE: PCT Int. Appl., 87 pp.
CODING: PINKD2
DOCUMENT TYPE: Patent
LANGUAGE: English

[illegible]

CA	2544404	A1	20050609	CA	2003-2544404	20031031
AU	2003303744	A1	20050617	AD	2003-303744	20031031
EP	1404725	A1	20060902	EP	2003-815810	20031031
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, FI, RO, CY, TR, BG, CZ, EE, HU, SK					
JP	200752207	T	20070809	JP	2003-0150942	20031031
SE	200752207	T	20070809	SE	2003-08230321	20031031

AB The present invention provides nanoparticulate nimesulide compns. The compns. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compns. An

solution of 1% (weight/weight) Placidone S-630 was combined with 4.25 g of nimerulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water.


(10⁶) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.

```

21      KL: THF (Therapeutic use); BGL (Biological study); USES (Uses)
      (novel nanoparticulate nimesulide compns.)
R#  22760-18-5  CAPLUS
CN  2 [1H]-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl-  (CA INDEX
NAME)

```


15 ANWER 14 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM (Continued)
 EXCHANGER INHIBITOR
 RD 42515-16-9 CAPUS
 CD 2118-Quinazolinone, 6-chloro-1-[3-(dimethylamino)propyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANWER 15 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 20051369373 CAPUS
 DOCUMENT NUMBER: 142435774
 TITLE: Compositions treatment of chronic inflammatory diseases
 INVENTOR(S): UNIVERSITY OF TEXAS AT AUSTIN
 PATENT ASSIGNOR(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,977, abandoned.
 COUNTRY: TEXAS
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY NO., NUM. COMPS: 4
 PATENT INFORMATION: A

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005090553	A1	20050408	US 2004-924845	20040804
PRIORITY APPL. INFO.			US 1992-904909	92102470
			US 1994-814609	94050511
			US 1997-814291	97070710
			US 2000-610073	00000705

OTHER SOURCE(S): MARPAT 142435774
 AB This invention defines novel compds. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the class. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compds., the orally administered required primary agents of which are primary amine derivs. of benzoin acid capable of reacting with the carbonyl substances. P-Ambroxol acid (or PAA) is an example of the required primary agent of the present invention. PAA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route; other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulphydryl co-agents, co-agents which may facilitate glutathione activity and

15 ANWER 16 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM (Continued)
 nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.
 IT 21760-15-1, Fingeroquine
 RI 780 (Therapeutic use); RIG (Biological study); USES (Uses) (compd. treatment of chronic inflammatory diseases)
 RD 21760-15-5 CAPUS
 CD 2118-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



15 ANWER 17 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 20051369373 CAPUS
 DOCUMENT NUMBER: 142435774
 TITLE: Inductive GRM descriptors. Distinguishing compounds with antibacterial activity by artificial neural networks
 AUTHOR(S): Cherkasov, Arlen
 CORPORATE SOURCE: Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, V5Z 3Z5, Can.
 SOURCE: International Journal of Molecular Sciences (2005), 6(11-2), 63-68
 COUNTRY: CANADA
 PUBLISHER: URL: http://www.mdpi.org/ijms/papers/16010263.pdf
 DOCUMENT TYPE: Molecular Diversity Preservation International
 LANGUAGE: English
 AB On the basis of the previous models of inductive and steric effects, 'inductive' electrophilicity and mol. capacitance, a range of new 'inductive' GRM descriptor(s) has been derived. These mol. parameters are easily accessible from electroconductivities and covalent radii of the constituent atoms and interact. distances and can reflect a variety of aspects of intra- and intermol. interactions. Using 34 'inductive' GRM descriptors alone we have been able to achieve 97% correct separation of compds. with- and without antibacterial activity (in the set of 617).

The elaborated GRM model based on the Artificial Neural Networks approach has been extensively validated and has confidently assigned antibacterial character to a number of trial antibiotics from the literature.
 IT 40507-23-1, Fingeroquine
 RI 780 (Pharmacological activity); RP (Properties); TD (Therapeutic use); RIG (Biological study); USES (Uses) (quant. structure activity relationship model based on artificial neural network approach showed antibacterial activity and inductive GRM descriptor achieved correct separation of compds. with and without antibacterial activity)
 RD 40507-23-1 CAPUS
 CD 2118-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-[1-methylethyl]- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 16 OF 327 CAPULE COPYRIGHT 2008 ACS ON STM (Continued)

15 ANSWER 17 OF 327 CAPULE COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 2005158522 CAPULE
 DOCUMENT NUMBER: 1421246155
 TITLE: Novel nanoparticulate metaloxane compositions comprising surface stabilizers and use for treating musculoskeletal disorders
 INVENTOR(S): Prewitt, John D.; Ryde, Taula A.; Bosch, William H.
 PATENT ASSIGNEE(S): Elian Pharma International, Ltd.; Irc
 SOURCE: PCT Int. Appl., 70 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY NO. NUM. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005024310	A1	20050224	WO 2004-051910	20040702
W1	AB, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, DE, DK, DP, DM, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LG, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, SM, SN, SV, TH, TR, TT, TZ, UA, US, UZ, VE, VN, YU, ZA, ZM, ZW			
BM, BR, CH, CN, DE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LG, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, SM, SN, SV, TH, TR, TT, TZ, UA, US, UZ, VE, VN, YU, ZA, ZM, ZW				
CA 257494	CA	20050224	CA 2004-251492	20040702
EP 1433189	A1	20060503	EP 2004-776415	20040702
H1	AT, BE, BG, BR, ES, FI, FR, GB, GR, HU, IE, IL, IN, MC, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, SM, SN, SV, TH, TR, TT, TZ, UA, US, UZ, VE, VN, YU, ZA, ZM, ZW			
JP 2007018739	T	20070101	JP 2006-521101	20040702
US 2005024313	A1	20050224		20040606
PRIORITY APPL. INFO.			US 2003-493446P	P 20030708
			WO 2004-051910	W 20040702

AB The present invention relates to novel comops. of metaloxane, comprising metaloxane particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer that is preferably adsorbed to or associated with the surface of the metaloxane particles. The invention further discloses a method of making a nanoparticulate metaloxane composition comprising contacting metaloxane and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate metaloxane composition. The one or more surface stabilizers can be contacted with metaloxane either before, preferably during, or after size reduction of the metaloxane. The present invention is also directed to methods of treatment using the nanoparticulate metaloxane comops. of the invention for treatment of musculoskeletal disorders.

IT 22760-18-5, Froepazone

15 ANSWER 17 OF 327 CAPULE COPYRIGHT 2008 ACS ON STM (Continued)

15a 7267 (Therapeutic use) R000 (Biological study) US05 (Uses)
 (novel nanoparticulate metaloxane comops. comprising surface stabilizers and use for treating musculoskeletal disorders)
 20 22760-18-5 CAPULE
 20 2118-Quinoxaline, 7-methyl-2-[2-methyl-ethyl]-4-phenyl- (CA INDEX NAME)

15 ANSWER 18 OF 327 CAPULE COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 2005160159 CAPULE
 DOCUMENT NUMBER: 1421437075
 TITLE: The pH dependency of the Binding of Drugs to Plasma Protein in Man
 AUTHOR(S): Hindmeyer, Peter B.; Hartmann, Dieter
 CORPORATE SOURCE: Food and Drug Administration, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Rockville, MD, 20852, USA
 SOURCE: Therapeutic Drug Monitoring (2005), 27(1), 71-85
 COUNTRY: TWENTY, ISSN: 0163-1754
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE R2

FORMAT

AB As an anal. of pH-induced changes of drug binding may contribute to the understanding of the mechanisms involved and the clin. relevance. A literature search was performed, and acceptance criteria set up, to select reported data for quant. evaluation. The relationship between percentage of unbound drug, fu, and pH was analyzed, and the relevance of physicochem. characteristics of the ligand drugs and the importance of hydrogen ion-induced changes in plasma proteins for the pH sensitivity of the binding were evaluated. With all basic and the majority of acidic drugs, fu depended linearly on pH. Basic drugs showed a consistent behavior with fu decreasing with increasing pH. Acidic comops. behaved differently: With some, fu decreased, and with others, fu decreased, with pH, and with a third group of acids fu was pH independent. Large differences in the pH sensitivity of the plasma protein binding among individual comops. were found. The fu in plasma for some basic and acids increased up to 1984 and 954, resp., at pH values seen in severe acidosis or alkalosis. These changes in fu could be clin. relevant with narrow-therapeutic-range drugs. Physicochem. properties and other characteristics of the ligands affect the pH sensitivity of the interaction with plasma proteins, but there was clear evidence indicating that pH-induced changes in the plasma proteins are also involved in the observed pH-dependent interaction with ligands. It is generally accepted that the unbound, free fraction in whole blood plasma is an important determinant of the pharmacokinetics and pharmacodynamics of drugs. pH-dependent protein binding and consequent changes in the free fraction have been reported for many drugs. From a basic science point of view, the systematic study of pH-induced perturbations of the drug-protein interaction may provide insight into the mechanism and forces involved in the binding of drugs to plasma proteins. From a clin. viewpoint it may be of interest to know the extent of pH-induced changes in the unbound fraction of drugs under extreme acidosis or alkaline conditions. Arterial blood pH values compatible with life reportedly range between 7.35 and 7.45. pH values as low as 6.3 have been measured in survivors of drowning accidents. To the best knowledge of the authors, a review and interpretation of pH-associated changes in the protein binding of drugs has not been attempted to date. The goals of this investigation were to (1) review published results of studies that determined the impact of pH changes on the protein binding of drugs in man, (2) select representative data using predicted, criteria, (3) determine relevant factors impacting the pH sensitivity of the drug-protein interaction, and (4) attempt to interpret the results and their clin. relevance.

L5 ANSWER 18 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 2276Q-18-5, Proqramizone

KL: PAC (Pharmacological activity); PP (Properties); TH (Therapeutic use); RL (Biological study); US (Uses)

22760-18-5 CAPLITE

CH 2-[1*N*]-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 132 THERE ARE 132 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

1.5 ANSWER 19 OF 327 CAPLUS COPYRIGHT 2008 ACS on STB

ACCESSION NUMBER:

DOCUMENT NUMBER:

DOCUMENT NUMBER: 1421229215
TITLE: Dispersible formulations containing anti-inflammatory agents and other active ingredients for infusion
INVENTOR(S): Britten, Nancy Jean; Maldron, Niki Ann; Watts,

INVENTOR(S)
Jeffrey

JELLE

PATENT ASSIGNMENT(S)

SOURCE:

SOURCE

DOCUMENT TYPE:

DOCUMENT TYPE:
LANGUAGE:

FAMILY ACC. NUM.

[illegible]

OTHER SOURCE(S): _____

28. A method is provided for treatment and/or prevention of an inflammatory

L5 ANSWER 19 OF 327 CAPLUS COPYRIGHT 2008 ACS on BTM (Continued)

condition in a fluid-contg. organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical compn. suitable

for infusion into the organ according to the method of the invention, and a process for prepg. such a compn. For example, a suspension to be

administered by intrammary infusion was prepd. contg. parecoxib 100 ng/mL, Labrafil M-1344CS 50 ng/mL, microcryst. wax 70 ng/mL, and cottonseed oil.

IT 22760-18-5, Proquazone 60507-23-1, Fluproquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diarrhoeal formulation containing anti-inflammatory agents and other

active ingredients for infusion)

CH	NAME	INDEX
2(18)	Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl-	100

O=C1N=C2C(=C1)C=C(C=C2)N

FN 40507-23-1 CASUSE
 CN 2-[1H]-Quinazolinone, 4-(4-fluorophenyl)-7-nethyl-1-(1-nethylethyl)- (CA

INDEX	NAME
1	...
2	...
3	...
4	...
5	...
6	...
7	...
8	...
9	...
10	...
11	...
12	...
13	...
14	...
15	...
16	...
17	...
18	...
19	...
20	...
21	...
22	...
23	...
24	...
25	...
26	...
27	...
28	...
29	...
30	...
31	...
32	...
33	...
34	...
35	...
36	...
37	...
38	...
39	...
40	...
41	...
42	...
43	...
44	...
45	...
46	...
47	...
48	...
49	...
50	...
51	...
52	...
53	...
54	...
55	...
56	...
57	...
58	...
59	...
60	...
61	...
62	...
63	...
64	...
65	...
66	...
67	...
68	...
69	...
70	...
71	...
72	...
73	...
74	...
75	...
76	...
77	...
78	...
79	...
80	...
81	...
82	...
83	...
84	...
85	...
86	...
87	...
88	...
89	...
90	...
91	...
92	...
93	...
94	...
95	...
96	...
97	...
98	...
99	...
100	...

Cc1ccc(cc1)C(=O)N(C)C2=CC=CC=C2

Chemical structure of 4-phenyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid, showing a benzene ring fused to a tetrahydroquinoline ring, with a phenyl group at position 4 and a carboxylic acid group at position 6.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

15 ANSWER 20 OF 327 CAPULES COPYRIGHT 2008 ACS ON STM (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

15 ANSWER 21 OF 327 CAPULES COPYRIGHT 2008 ACS ON STM
ACCESSION NUMBER: 2004-002738 CAPULES
DOCUMENT NUMBER: 141301477
TITLE: Disposable pharmaceutical composition for treatment
of mastitis and otitis disorders
INVENTOR(S): Britten, Nancy J.; Burns, John W.; Hallberg, John W.;
Waldron, Nikl A.; Watta, Jeffrey L.
PATENT ASSIGNMENT(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 58 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNTRY: 2
PATENT INFORMATION(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082719	A1	20040930	WO 2004-18802	20040310
W1, M1, AG, AL, AM, AT, AU, BG, BR, CA, CH, CN, CO, CU, DE, DK, DM, ES, FI, FR, GB, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
BM; BM, GM, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
ES, FI, FR, GB, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
AT 2004022518	A1	20040930	AT 2004-22518	20040310
CA 2519589	A1	20040930	CA 2004-2519589	20040310
EP 1608466	A1	20051228	EP 2004-119429	20040310
RU 1471486	CH	20040419	RU 2004-04007951	20040310
JP 2004050778	T	20040913	JP 2004-18802	20040310
WO 231623	C2	20040410	WO 2005-124762	20040310
TM 25093	B	20040311	TM 2005-091684	20040310
IN 20050903445	A	20070817	IN 2005-090345	20050918
RU 765414	B1	20071009	RU 2005-717570	20050926
WO 2005064777	NO	2005-4777	NO 2005-4777	20051017
PRIORITY APPL. INFO.			US 2003-454201P	P 20030320
			WO 2004-18802	A 20040310

AB A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and optionally the second agent, are administered as a pharmaceutical composition further comprising a vehicle

15 ANSWER 22 OF 327 CAPULES COPYRIGHT 2008 ACS ON STM (Continued)
that comprises an amphiphilic oil that is water dispersible and ethanol insol., microcryst. was and a pharmaceutically acceptable non-aq.
carrier.

Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

Q.S.
IT 40507-23-1, Fluproganone
RU 765414 (Pharmaceutical activity); TM (Therapeutic use); RU (Biological activity); US (Use)
Also provided is such a comp., comprising the antibacterial agent and the second agent. The comp. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained octofluor hydrochloride (microcryst.) 12.5 mg/mL, labelfail M-1944CS 50 mg/mL, microcryst. was 100 mg/mL, octonosed oil

15 ANSWER 23 OF 327 CAPULES COPYRIGHT 2008 ACS ON STM
ACCESSION NUMBER: 2004-000568 CAPULES
DOCUMENT NUMBER: 141301461
TITLE: Disposable formulations of an anti-inflammatory agent
INVENTOR(S): Britten, Nancy J.; Burns, John W.; Hallberg, John W.;
Waldron, Nikl A.; Watta, Jeffrey L.
PATENT ASSIGNMENT(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 45 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNTRY: 2
PATENT INFORMATION(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082588	A1	20040930	WO 2004-18826	20040310
WO 2004082588	A2	20041212		
W1, M1, AG, AL, AM, AT, AU, BG, BR, CA, CH, CN, CO, CU, DE, DK, DM, ES, FI, FR, GB, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
BM; BM, GM, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
ES, FI, FR, GB, GR, HU, IE, IL, JP, KR, LS, LT, LV, LU, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
AT 2004222513	A1	20040930	AT 2004-222513	20040310
CA 2519125	A1	20040930	CA 2004-2519125	20040310
EP 1608467	A2	20051228	EP 2004-119070	20040310
EP 1608467	B1	20060830		
RU 1471486	CH	20040419	RU 2004-04007953	20040310
JP 2004050779	T	20040913	JP 2004-18802	20040310
AT 31792	7	20040913	AT 2004-119070	20040310
RU 227061	73	20070403	RU 2004-119070	20040310
WO 2313189	C2	20040617	WO 2005-124764	20040310
TM 262084	B	20060821	TM 2004-93107507	20040310
IN 20050903444	A	20070814	IN 2005-091684	20050918
NO 2005024260	A	20051212	NO 2005-4260	20050918
PRIORITY APPL. INFO.			US 2003-454201P	P 20030320
			WO 2004-18826	A 20040310

AB A method is provided for treatment of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering to the organ via the exterior orifice, a pharmaceutical composition comprising an anti-inflammatory agent and a vehicle that comprises an amphiphilic oil that is water dispersible and ethanol insol., microcryst. was and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the anti-inflammatory agent. The composition is readily



15 ABSTRACT 24 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
preventing or treating medication-induced gastrointestinal diseases)
EN 22760-18-5 CAPLUS
CN 21181-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



15 ABSTRACT 25 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004157968 CAPLUS
1421126433
TITLE: AIME evaluation in drug discovery. 2. Prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas [Erratum to document cited in CA139:017053]
Rau, T.; J.; Roy, R. V.
AUTHOR(S):
CORPORATE SOURCE: College of Chemistry and Molecular Engineering, Peking University, Beijing, 100070, Peop. Rep. China
SOURCE: Journal of Chemical Information and Computer Sciences (2004), 44(4), 3516
CUBER: JCTIDP; ISSN: 0095-2398
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB: An important paper reported by Wang et al. was not cited; the reference should read: *40. Wang, R. X.; Lei, L. R. Calculating partition coefficient by atom-additive method. *Percept. Drug Discov.* 2000, 19, 47-61. Moreover, the data used in the training set were obtained from *all's* group. (<http://mdl.lpc.pku.edu.cn/>).
IT 25441-63-4
EL: PPT (Pharmacokinetics); BIOL (Biological study)
17 (AIME evaluation in drug discovery and prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas (Erratum))
EN 22760-18-5 CAPLUS
CN 21181-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



15 ABSTRACT 26 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004102709 CAPLUS
1421176722
TITLE: Product class 2: six-membered heterocycles with three heteroatoms. Product subclass 1: 1,2,3-triazines and phosphorus analogues
AUTHOR(S):
CORPORATE SOURCE: Doepp, R.; Doepp, D.
SOURCE: *Makro*, 47(4), Germany
PUBLISHER: CODEN: RSCY99
DOCUMENT TYPE: Georg Thieme Verlag
LANGUAGE: Journal; General Review
AB: A review. Methods for preparing triazines and their phosphorus analogs are reviewed including cyclization, ring transformation, aromatization, and subsequent modification.
IT 55271-19-7
EL: KCI (Reactivity) EXCT (Reactant or reagent)
17 (Preparation of triazines and their phosphorus analogs via cyclization, ring transformation, aromatization, and substituent modification)
EN 55271-19-7 CAPLUS
CN 21181-Quinazolinone, 7-amino-6-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 568
THREE ARE 568 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ABSTRACT 27 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004160387 CAPLUS
1401177661
TITLE: Therapeutic devices for patterned cell growth
INVENTOR(S): Urich, Kathryn E.; Schmalenberger, Kristine
PATENT ASSIGNMENT(S): Rutgers State University, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PTA323
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY KCI. NUM. COUNT: 1
PATENT INFORMATION: 1
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2004004863 A2 20040122 WO 2003-052241 20030717
WO 2004004863 A3 20040826
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, EA, EC, EE, ES, FI, GB, GR, HU, IL, IN, JP, KE, KR, KZ, LG, LU, LV, LY, MA, MG, MK, MN, MU, MY, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PT, RO, RU, SC, SE, SG, SI, SK, ST, SV, TH, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW
M: CH, GM, KR, LG, MG, SE, SG, SI, ST, US, OM, AG, AU, AT, BY, BS, BE, BG, BY, TZ, TM, AT, BE, BG, CH, CY, CS, DE, DK, EE, ES, FI, FG, GB, GR, HU, IL, IT, JP, KR, MA, MY, NL, NO, NZ, OS, PA, PE, PG, PH, PT, RO, RU, SC, SE, SG, SI, SK, ST, SV, TH, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW
X: NO 2002051992 A1 20040020 AS 2003-051992 20030717
US 2004094476 A1 20040520 US 2003-620072 20030717
PRIORITY APPL. INFO.: US 2002-3966289 P 20020717
WO 2003-052241 W 20030717

OTHER SOURCE(S): HARPAT 140.117461
AB: The invention provides therapeutic devices comprising a polymeric anti-inflammatory agent that biodegrades to release anti-inflammatory agents. The therapeutic devices are useful for repair and regeneration of a variety of injured tissues.
IT 22760-18-5 CAPLUS
EL: PEP (Physical, engineering or chemical process); PPT (Physical process); TPT (Therapeutic use); BIOL (Biological study); PDC (Processes); USES (Uses)
(Therapeutic devices for patterned cell growth)
EN 22760-18-5 CAPLUS
CN 21181-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



15 ANSWER 29 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



AB Inhibiting gastric proton pumps in a mammal is accomplished by the use of an acetylated pyrrole compound. A preferred compound is 1 (ML 5000). The treatment ameliorates, diminishes, actively treats, reverses, or prevents any injury, damage or lesions of gastric mucosa, e.g. gastric mucosal lesions and ulceration.

IT 22160-18-5, Propanone

RI: ADV (Adverse effect, including toxicity); PNC (Pharmacological activity); TNO (Therapeutic use); BIO (Biological study); USE (Uses) (labeled pyrrole compd. as proton pump inhibitors for treating ulcers and other gastric acid-related conditions, and use with other agents)

RI: 22160-18-5 CAPLUS
CN 2(18)-Quinolizone, 7-methyl-1-(1-methyl-ethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE CONT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

15 ANSWER 30 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI: 37154-40-8 CAPLUS
CN 2(18)-Quinolizone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 31 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007:855743 CAPLUS
DOCUMENT NUMBER: 17135104
TITLE: Gelatin as a prognostic marker of atherosclerotic diseases
INVENTOR(S): Hossain, Thomas P.
PATENT ASSIGNER(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
ORDER: F102D2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. CONT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089811	A2	20071030	WO 2003-081372	20030416
WO 2007089811	A3	20040226		
RI: AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

AB This invention involves the using blood gelatin levels as a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction, stroke, and peripheral ischemic cardiovascular disease, particularly among subjects with no signs or symptoms of current disease and among nonusers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which subjects at risk will

preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.

IT 22160-18-5, Propanone
RI: B90 (Biological study, unclassified); TNO (Therapeutic use); BIO (Biological study); USE (Uses)
RI: (gelatin as prognostic marker of atherosclerotic diseases)

RI: 22160-18-5 CAPLUS
CN 2(18)-Quinolizone, 7-methyl-1-(1-methyl-ethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 32 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2003:813883 CAPLUS
DOCUMENT NUMBER: 14041652
TITLE: Structural Identification of Local Maxima in Low-Resolution Promolecular Electron Density Distributions
AUTHOR(S): Lebert, Laurence; Dury, Laurent; Vercauteren, Daniel P
CORPORATE SOURCE: Laboratoire de Physico-Chimie Informatique, Facultés Universitaires Notre-Dame de la Paix, Namur, B-5000, Belgium
SOURCE: Journal of Physical Chemistry A (2003), 107(46), 9875-9888
PUBLISHER: CODEN: JPCHAF; ISSN: 1089-5649
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this paper, we present a three method to describe mol. structures in terms of hierarchically related substructures. The approach is based on the location of local maxima (peaks) in promol. electron d. distributions (EDD) established at continuously varying resolution levels. For each of the α -calculated EDD, the local maxima are determined by using a hierarchical clustering algorithm wherein peaks obtained at a given resolution are used as starting points for discovering peaks at the next lower resolution level through gradient trajectories of the EDD. The use of such an approach allows assignment of mol. fragments or chemical groups to peaks at any resolution level. Results, obtained for a set of four benzodiazepine-related mol. and three threonine inhibitors, are presented in terms of dendrograms wherein each node corresponds to a well-defined mol. substructure.

IT 20527-53-1, 6-Chloro-6-phenyl-1-methyl-2(1H)-quinolizone
RI: PFP (Properties)
RI: (structural identification of local maxima in low-resolution promol. electron d. distributions)


RI: 20527-53-1 CAPLUS
CN 2(18)-Quinolizone, 6-chloro-1-methyl-6-phenyl- (CA INDEX NAME)



REFERENCE CONT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

13 ANMER 24 OF 327 CAPULS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 2007.74532 CAPULS
 DOCUMENT NUMBER: 139.35885
 TITLE: Discovery of a novel potent Na/Ca²⁺ exchanger inhibitor: design, synthesis and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives
 AUTHOR(S): Hasegawa, Hiroshi; Murakami, Masami; Matsui, Kazuki; Kojima, Atsuyuki
 CORPORATE SOURCE: Research Center, Sumitomo Pharmaceuticals Co., Ltd., Isonohara-ku, Osaka, 554-0022, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 3471-3475
 CORDIS REFERENCE: 1588: 0940-894X
 PUBLISHER: Elsevier Science B.V.
 JOURNAL: Journal
 LANGUAGE: English
 DOCUMENT TYPE: Journal Article
 ABSTRACT: DESIGN, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR 3,4-DIHYDRO-2(1H)-QUINAZOLINONE DERIV. WITH INHIBITORY ACTIVITIES OF THE Na/Ca²⁺ EXCHANGER ARE DISCUSSED. THESE STUDIES BASED ON THE LEAD 6-CHLORO-3-[3-(4-METHYLETHYL)PROPYL]-3,4-DIHYDRO-4-PHENYL-2(1H)-QUINAZOLINONE LEAD TO THE DISCOVERY OF 6 STRUCTURALLY NOVEL AND HIGHLY POTENT INHIBITOR AGAINST THE Na/Ca²⁺ EXCHANGER SM-15011 [3,4-DIHYDRO-6-PHENYL-3-[1-(4-PHENYLETHYL)-4-PYRIDYL]-2(1H)-QUINAZOLINONE 2-HYDROXY-7,7,3-PROPANESULFONATE] WHICH DIRECTLY INHIBITED THE Na-DEPENDENT CAL²⁺ INFLUX VIA THE Na/Ca²⁺ EXCHANGER IN CARDIOPROTEGES WITH A HIGH POTENCY.
 IT 625035-76-9
 RU PAC (Pharmacological activity): BNF (Synthetic preparation): BGL (Biological study): PRP (Preparation) (Design, preparation and structure-activity relationship of dihydro-2(1H)-quinazolinone deriv. (potent sodium/calcium exchanger inhibitors))
 RU 625035-76-9 CAPULS
 CN 2118: Quinazolinone, 6-chloro-3-[3-(4-methylethyl)propyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

13 ANMER 35 OF 327 CAPULS COPYRIGHT 2008 ACS ON STM (Continued)
 ACCESSION NUMBER: 2003.40745 CAPULS
 DOCUMENT NUMBER: 140.35516
 TITLE: Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis
 AUTHOR(S): Deslitzky, Bery
 CORPORATE SOURCE: Department of Pharmacology, Gazi University, Ankara, 06390, Turk
 SOURCE: Pharmacological Research (2003), 48(1), 37-48
 CORDIS REFERENCE: 1588: 1043-6616
 PUBLISHER: Elsevier Science Inc
 JOURNAL: Journal
 LANGUAGE: English
 DOCUMENT TYPE: Journal Article
 ABSTRACT: THE EFFECTS OF SELECTIVE ((5,5-DIETHYL-3-(3-FUOROPHENYL)-4-(4-METHYLETHYL)FOLY-2(1H)-FURANONE)) DPU AND NON-SELECTIVE CYCLOOXYGENASE-4-NITROPHENYL-METHANESULFONAMIDE (NS 388)) ON NON-SELECTIVE DILATION AND PROZANOLOL INDUCIBLE CYCLOOXYGENASE (COX-2) INHIBITORS ON THE SURVIVAL, NITRITE (STABLE PRODUCT OF NITRIC OXIDE (NO)) AS AN INDEX FOR INDUCIBLE NO SYNTHASE (iNOS) ACTIVITY AND 6-KETO-PROSTAGLANDIN F1A (6-KETO-PGF1A, STABLE PRODUCT OF PROSTAGLANDIN AS AN INDEX FOR COX-2 ACTIVITY) PRODUCTION IN SERUM, LIVER, BRAIN AND/OR KIDNEY WERE INVESTIGATED IN ENDOTOXIN-INDUCED SEPSIS MODEL IN MICE. ENDOTOXIN (10 MG KG-1, I.P.)-INDUCED MORTALITY WAS PREVENTED BY DPU, NS 388 AND PROZANOLOL (0.1, 10 AND 1 MG KG-1, RESP.) AND ENHANCED 2.6-FOLD WITH 0.1 MG KG-1 DILATION. ENDOTOXIN-INDUCED INCREASE IN THE SERUM LEVELS OF NITRITE WAS ONLY INHIBITED BY 10 MG KG-1 DILATION. ENDOTOXIN CAUSED A SIGNIFICANT DECREASE ONLY IN THE BRAIN LEVELS OF NITRITE WITHOUT AFFECTING 6-KETO-PGF1A LEVELS IN ALL TISSUES. THE DECREASED LEVELS OF NITRITE INDUCED BY ENDOTOXIN IS FURTHER REDUCED BY 0.1 MG KG-1 DPU AND 1 AND 10 MG KG-1 DILATION WHILE 10 MG KG-1 DPU AND 1 MG KG-1 PROZANOLOL INCREASED IT. ON THE OTHER HAND, 10 MG KG-1 DILATION AND PROZANOLOL, AND 10 MG KG-1 NS 388 INCREASED THE ENDOTOXIN-INDUCED LUNG LEVELS OF 6-KETO-PGF1A. THE RESULTS SUGGEST THAT THE COX INHIBITORS MAY HAVE DIFFERENT EFFECTS ON THE SURVIVAL AND NO PRODUCTION DEPENDING ON TISSUE AND DOSE.
 IT 2760-16-5, Prozanolone
 RU PAC (Pharmacological activity): TMO (Therapeutic use): BGL (Biological study): USES (Uses) (Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mouse model of sepsis)
 RU 2760-16-5 CAPULS
 CN 2118: Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

13 ANMER 35 OF 327 CAPULS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 2007.59916 CAPULS
 DOCUMENT NUMBER: 140.22831
 TITLE: Effects of inflammation and antiinflammatory on serum trace elements concentrations
 AUTHOR(S): Akcali, Ethem; Yavuz, Gulnazar; Kocak, Mehmet
 CORPORATE SOURCE: Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turk
 SOURCE: Biomedical Trace Element Research (2007), 32(1-7), 95-103
 CORDIS REFERENCE: 1588: 0143-4966
 PUBLISHER: Humana Press Inc.
 JOURNAL: Journal
 LANGUAGE: English
 ABSTRACT: WE INVESTIGATED THE SERUM CONCENTRATIONS OF ZINC AND COPPER DURING THE INFLAMMATORY PROCESS TOGETHER WITH THE EFFECT OF TREATMENT WITH A NON-STEROID ANTI-INFLAMMATORY AGENT ON THESE TRACE ELEMENTS CONCENTRATIONS. IN THE PRESENT STUDY, WE USED 20 MICE WHICH WERE DIVIDED INTO TWO GROUPS: THE CONTROL GROUP, THE REMAINING 10 WERE THE SAGEL GROUP. TO START WITH, PROZANOLOL (AS AN ANTI-INFLAMMATORY AGENT) WAS ADMINISTERED ORALLY TO 40 QUININE GROSS OF THE SAGEL GROUP AT 20 MG/KG DOSES 2 H BEFORE THE SURGERY. THROUGHOUT THE EXPERIMENTAL PERIOD, THE ABOVE DOSE WAS ADMINISTERED TO THE ANIMALS TWICE A DAY. WE PRODUCED INFLAMMATION IN ALL ANIMALS OF THE SAGEL GROUP BY USING CARAMEXAN (INFLAMMATORY AGENT) DROPPED INTO ABDOMINAL SURGICAL DEFECTS. SERUM CONCENTRATIONS OF ZINC AND COPPER WERE DETERMINED BY ATOMIC ABSORPTION SPECTROPHOTOMETRY IN BOTH GROUPS AT THE 4TH, 8TH, 12TH, 16TH, 20TH, AND 24TH H. THE SERUM ZINC CONCENTRATIONS OF THE CARAMEXAN-ADMINISTERED GROUP DECREASED SIGNIFICANTLY (P < 0.01). WHEN COMPARING THE SERUM ZINC CONCENTRATIONS OF THE CARAMEXAN PLUS PROZANOLOL GROUP WITH THOSE OF THE CONTROL GROUP, THE DECREASE (P < 0.05) AT THE 4TH, 8TH, AND 12TH H WERE STATISTICALLY SIGNIFICANT. WHEN THE COPPER SERUM CONCENTRATIONS OF THE CARAMEXAN-ADMINISTERED GROUP WERE COMPARED WITH THOSE OF THE CONTROL GROUP, AT THE 4TH, 12TH, AND 16TH H, A STATISTICALLY SIGNIFICANT INCREASE (P < 0.01) WAS OBSERVED. HOWEVER, THERE WAS NO SIGNIFICANT CHANGE IN THE CARAMEXAN PLUS PROZANOLOL-ADMINISTERED GROUP AT THE 16TH AND 24TH H. AS A RESULT DURING THE ACUTE PHASE OF INFLAMMATION, SERUM ZINC CONCENTRATIONS DECREASED, WHEREAS SERUM COPPER CONCENTRATIONS INCREASED. THE ALTERATIONS IN ZINC CONCENTRATIONS WERE MORE RAPID THAN THOSE IN COPPER CONCENTRATIONS, BUT THE ADMINISTRATION OF PROZANOLOL ALLOWED THE RATE OF DECREASE IN SERUM ZINC CONCENTRATIONS.
 IT 2760-16-5, Prozanolone
 RU PAC (Pharmacological activity): TMO (Therapeutic use): BGL (Biological study): USES (Uses) (Effects of inflammation and antiinflammatory treatment on serum trace elements conc.)
 RU 2760-16-5 CAPULS
 CN 2118: Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

13 ANMER 35 OF 327 CAPULS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 2003.40745 CAPULS
 DOCUMENT NUMBER: 140.35516
 TITLE: Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis
 AUTHOR(S): Deslitzky, Bery
 CORPORATE SOURCE: Department of Pharmacology, Gazi University, Ankara, 06390, Turk
 SOURCE: Pharmacological Research (2003), 48(1), 37-48
 CORDIS REFERENCE: 1588: 1043-6616
 PUBLISHER: Elsevier Science Inc
 JOURNAL: Journal
 LANGUAGE: English
 DOCUMENT TYPE: Journal Article
 ABSTRACT: THE EFFECTS OF SELECTIVE ((5,5-DIETHYL-3-(3-FUOROPHENYL)-4-(4-METHYLETHYL)FOLY-2(1H)-FURANONE)) DPU AND NON-SELECTIVE CYCLOOXYGENASE-4-NITROPHENYL-METHANESULFONAMIDE (NS 388)) ON NON-SELECTIVE DILATION AND PROZANOLOL INDUCIBLE CYCLOOXYGENASE (COX-2) INHIBITORS ON THE SURVIVAL, NITRITE (STABLE PRODUCT OF NITRIC OXIDE (NO)) AS AN INDEX FOR INDUCIBLE NO SYNTHASE (iNOS) ACTIVITY AND 6-KETO-PROSTAGLANDIN F1A (6-KETO-PGF1A, STABLE PRODUCT OF PROSTAGLANDIN AS AN INDEX FOR COX-2 ACTIVITY) PRODUCTION IN SERUM, LIVER, BRAIN AND/OR KIDNEY WERE INVESTIGATED IN ENDOTOXIN-INDUCED SEPSIS MODEL IN MICE. ENDOTOXIN (10 MG KG-1, I.P.)-INDUCED MORTALITY WAS PREVENTED BY DPU, NS 388 AND PROZANOLOL (0.1, 10 AND 1 MG KG-1, RESP.) AND ENHANCED 2.6-FOLD WITH 0.1 MG KG-1 DILATION. ENDOTOXIN-INDUCED INCREASE IN THE SERUM LEVELS OF NITRITE WAS ONLY INHIBITED BY 10 MG KG-1 DILATION. ENDOTOXIN CAUSED A SIGNIFICANT DECREASE ONLY IN THE BRAIN LEVELS OF NITRITE WITHOUT AFFECTING 6-KETO-PGF1A LEVELS IN ALL TISSUES. THE DECREASED LEVELS OF NITRITE INDUCED BY ENDOTOXIN IS FURTHER REDUCED BY 0.1 MG KG-1 DPU AND 1 AND 10 MG KG-1 DILATION WHILE 10 MG KG-1 DPU AND 1 MG KG-1 PROZANOLOL INCREASED IT. ON THE OTHER HAND, 10 MG KG-1 DILATION AND PROZANOLOL, AND 10 MG KG-1 NS 388 INCREASED THE ENDOTOXIN-INDUCED LUNG LEVELS OF 6-KETO-PGF1A. THE RESULTS SUGGEST THAT THE COX INHIBITORS MAY HAVE DIFFERENT EFFECTS ON THE SURVIVAL AND NO PRODUCTION DEPENDING ON TISSUE AND DOSE.
 IT 2760-16-5, Prozanolone
 RU PAC (Pharmacological activity): TMO (Therapeutic use): BGL (Biological study): USES (Uses) (Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mouse model of sepsis)
 RU 2760-16-5 CAPULS
 CN 2118: Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

LS ANSWER 37 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 37 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007377325 CAPLUS
DOCUMENT NUMBER: 1391367144
TITLE: Soluble CMOG (CD154) as a prognostic marker of atherosclerotic diseases
INVENTOR(S): Schenck, Gary Fisher, Paul M.; Libby, Peter
PATENT ASSIGNER(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
ORDER: F10022
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007040691	A2	20070305	WO 2006-083566	20061105
WO 2007040691	A3	20071113		
W1 AB, AG, AI, AM, AT, AU, AZ, BA, BG, BR, CA, CH, CN, CO, CP, CR, DE, DK, DM, EE, EG, ES, FI, GB, GR, HK, HU, IL, IN, JP, KR, KZ, LG, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SD, SE, SG, SI, SK, SL, SV, TH, TM, TR, TT, TS, UA, UG, US, VN, ZA, ZM, ZW				
BM: GB, GR, HU, IL, IN, JP, KR, KZ, LG, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SD, SE, SG, SI, SK, SL, SV, TH, TM, TR, TT, TS, UA, UG, US, VN, ZA, ZM, ZW				
CA 2464593	A1	20070515	CA 2002-2464531	20021105
AI 2002246453	A1	20070515	AI 2002-2464531	20021105
US 20030102546	A1	20070514	US 2002-088253	20021105
US 7189518	B2	20070513		
EP 1453177	A2	20040923	EP 2002-708070	20021105
FI 1613012	A1	20050504	FI 2002-526711	20021105
JP 200311467	T	20050506	JP 2002-143897	20021105
US 20020052960	A1	20050506	US 2001-716936	20020702
PRIORITY APPL. INFO.:			US 2001-738843P	P 20011105
			US 2002-288253	A1 20021105
			WO 2002-051565	W 20021105

AB The invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonusers. Further, the invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

LS ANSWER 38 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

IT 22762-18-3 CAPLUS 37514-40-8, F100222
R1 PAC (Pharmacological activity); T90 (Therapeutic use); R102 (Biological study) (US) (US)
use (soluble CMOG as prognostic marker of atherosclerotic diseases, and in therapeutic agent assessment)

IN 22762-18-3 CAPLUS
CH 2118-Quinazolinone, 7-methyl-1-(1-methyl-4-phenyl)- (CA INDEX NAME)




IN 37514-40-8 CAPLUS
CH 2118-Quinazolinone, 6-methyl-4-phenyl-1-(2,2-trifluoroethyl)- (CA INDEX NAME)



LS ANSWER 38 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007293606 CAPLUS
DOCUMENT NUMBER: 139137461
TITLE: 5-hydroxytryptamine, -quinazolinones, and -benzoxazepines as serine/threonine kinase inhibitors
INVENTOR(S): David W. Freyne, Eddy Lunny, Yamilch Muller, Philipp Mennig, Gert Pilat, Isabelle Fenelet, Virginie Skrat, Stacy Smith, Gerard Van Dun, Jacky Van Rossum, Peter Venet, Marc Vouters, Walter Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, NJ de Beil, 27506, Fr.
SOURCE: Nucleic Acids & Molecular Chemistry Letters (2007), 13(9), 1543-1547
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139137461
CI



AB The evaluation of structure-activity relationships associated with the modification of the R137777 quinazolinone ring moiety displaying potent in vitro inhibiting activity is described. E.g.,


pyrrol-2-yl-1-(1-quinazolin-4-yl)-

one 1, an analog of R137777, was prepared from 2,3-dihydroindole and its serine/threonine-inhibiting activity was determined
215074-66-5P


IN PAC (Pharmacological activity); R102 (Biological study); R102 (Biological study); R102 (Biological study)
[preparation of indole-3-pyridine, -quinazolinones, and -benzoxazepines as serine/threonine kinase inhibitors]

IN 215074-66-5 CAPLUS
CH 2118-Quinazolinone, 6-[amino(1-chlorophenyl)-(1-methyl-1H-imidazol-5-yl)methyl]-4-(2-chlorophenyl)-1-methyl-1- (CA INDEX NAME)

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




IT 215014-62-1P 215014-84-9P
 RI ACT (Reaction); IPN (Synthetic preparation); PREP (Preparation); RACT (Reaction or reagent)
 [preparation of imidazylquinoxalinoimino, quinoxalinoimino, and hexaazaphenoximino as farnesyltransferase inhibitors]
 RN 215014-62-1 CAPLUS
 CN 2150 Quinoxalinoimino, 4-[(3-chlorophenyl)-4-[[14-chlorophenyl]hydroxy]-3-methyl-18-imidazol-5-yl]methyl]-3-methyl- (CA INDEX NAME)



RN 215014-64-9 CAPLUS
 CN 2150 Quinoxalinoimino, 4-[(4-chlorobenzoyl)-4-[(3-chlorophenyl)-3-methyl- (CA INDEX NAME)

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:282929 CAPLUS
 DOCUMENT NUMBER: 13917013
 TITLE: ADME Evaluation in Drug Discovery. 2. Prediction of Partition Coefficient by Atom-Additive Approach Based on Atom-Weighted Solvent Accessible Surface Areas
 AUTHOR(S): Hsu, T. J.; Xu, X. J.
 CORPORATE SOURCE: College of Chemistry and Molecular Engineering, University, Beijing, 100871, Peop. Rep. China
 SOURCE: Journal of Chemical Information and Computer Sciences (2003), 43(3), 1018-1067
 PUBLISHED: COMPT. C12009, ISBN: 0091-2338
 DOCUMENT TYPE: American Chemical Society
 LANGUAGE: English
 AB A novel method for the calcns. of 1-octanol/water partition coefficient (log P) of organic mole. has been presented here. The method, SLOOP v1.0, ests. the log P values by summing the contribution of atom-weighted solvent accessible surface areas (SASA) and correction factors. Altogether 100 atom/group types were used to classify atoms with different chemical environments, and two correlation factors were used to consider the intramol. hydrophobic interactions and intramol. hydrogen bonds.
 COEFFICIENT values for 100 atom/group and two correction factors have been derived from a training set of 2810 compounds. The parameterization procedure for different kinds of atoms was performed as follows: first, the atoms in a mol. were defined to different atom/group types based on SMILES language, and the correction factors were determined by substructure searching.
 THEN, SASA for each atom/group type was calculated and added; finally, multivariate linear regression anal. was applied to optimize the hydrophobic parameters
 FOR different atom group types and correction factors in order to reproduce the exptl. log P. The correlation based on the training set gives a model with the correlation coefficient (r) of 0.988, the standard deviation (SD) of 0.388 log units, and the absolute unsigned mean error of 0.261. Comparison of various procedures of log P calcns. for the external test set of 178 organic compounds demonstrates that our method bears very good accuracy and is comparable or even better than the fragment-based approaches. Moreover, the atom-additive approach based on SASA was compared with the simple atom-additive approach based on the number of atoms.
 THE calculated results show that the atom-additive approach based on SASA gives better predictions than the simple atom-additive one. Due to the connection between the mol. conformation and the mol. surface areas, the atom-additive model based on SASA may be a more universal model for log P estimation especially for large mols.
 IT 2141-63-4
 RI: PRT (Pharmacokinetics); BIOL (Biological study)
 [ADME evaluation in drug discovery and prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas]
 RN 2141-63-4 CAPLUS
 CN 2140 Quinoxalinoimino, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE SE
 FORMAT

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE SE
 FORMAT

15 ANWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 200717023 CAPLUS
 DOCUMENT NUMBER: 139147937
 TITLE: Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists
 AUTHOR(S): Barreiro, Maria Letizia; Gato, Rosaria; Quatrecas, Silvana; De Lenc, Leticia; De Marco, Giovambattista; Churruarín, Azka
 CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Università di Messina, Messina, 98165, Italy
 SOURCE: Journal of Chemical Information and Computer Science (2002), 42(1), 851-855
 CODES: ACI208; ISSN: 0095-2338
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: A three-dimensional pharmacophore model for the binding of noncompetitive AMPA receptor antagonists was developed to map common structural features of highly active compounds. This hypothesis, which consists of two hydrophobic regions, one hydrogen bond acceptor and one aromatic region, was successfully used as framework for the design of a new class of allosteric modulators containing a tetrahydroquinoline skeleton and for in silico screening. The promising label results suggested that the identified moieties might be useful "lead compounds" for future drug development.
 IT 23441-88-5, SE 21400
 RI PAC (Pharmacological activity); FRP (Properties); TRD (Therapeutic use); RIGL (Biological study); DEES (Uses)
 CH 23441-88-5 CAPLUS
 RI Pharmacophore modeling and discovery of novel noncompetitive AMPA receptor antagonists
 CH 2148: Quinoxalinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

15 ANWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)

15 ANWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 200749279 CAPLUS
 DOCUMENT NUMBER: 139159420
 TITLE: Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
 AUTHOR(S): Murcia-Soler, Rogelio; Perez-Guerra, Francisco; Garcia-March, Francisco J.; Salazar-Salvador, M. Teresa; Diaz-Villanueva, Mladimir; Medina-Camargo, F. Rafael
 CORPORATE SOURCE: Facultad de Pharmacy, Department of Physical Chemistry, Universidad de Valencia, Valencia, Spain
 SOURCE: Journal of Molecular Graphics & Modelling (2003), 11(5), 375-390
 CODES: RHEATY ISSN: 1093-1263
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a good integration of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.
 IT 40207-22-1, Fingeroquinone
 RI PAC (Pharmacological activity); TRD (Therapeutic use); RIGL (Biological study); DEES (Uses)
 CH 40207-22-1 CAPLUS
 RI Discrimination and selection of new potential antibacterial compounds using simple topol. descriptors
 CH 2148: Quinoxalinone, 6-(4-fluorophenyl)-7-methyl-1-(1-methyl-1H-quinolin-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

15 ANWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 200714609 CAPLUS
 DOCUMENT NUMBER: 139114601
 TITLE: Steroid hormone and nonsteroidal anti-inflammatory drug (NSAID) combinations for inducing tumor cell apoptosis
 INVENTOR(S): Andrews, Peter; Dykewicz, Daniel
 PATENT ASSIGNEE(S): Georgetown University, USA
 SOURCE: PCT Int. Appl., 49 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2002098403 A1 20021212 WO 2002-0817193 20020603
 Wt: AR, AU, AL, AM, AT, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GR, GU, HK, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LA, LC, LI, LR, LV, LU, LY, MA, MD, ME, MG, MK, MN, MU, MV, MY, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RU, SC, SE, SG, SI, SK, SL, SV, TH, TJ, TN, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW
 Mw: GB, GR, HK, HU, ME, MG, SE, SI, SK, TH, TJ, TN, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW
 Rf: BF, BF, CF, CY, CI, CM, GH, GN, GT, GU, HK, HU, ME, SE, SV, TH, TJ, TN, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW
 AO 2002312204 A1 20021216 AS 200212104 20020603
 PRIORITY APPL. INFO.: OS 2001-294583 A 20020603
 WO 2002-0817193 W 20020603

AB: A pharmaceutical composition is described, having at least one nonsteroidal anti-inflammatory drug (NSAID), at least one steroid hormone, a pharmaceutically acceptable carrier, and optionally, one or more antigens, wherein the at least one NSAID and the at least one steroid hormone are present in amounts sufficient to induce tumor cell apoptosis. Also described is a method of inducing apoptosis of cancer cells in which therapeutically effective amounts of at least one NSAID and at least one steroid hormone are administered to a subject. The NSAID and steroid hormone may be administered prophylactically to a subject having nonmeasurable tumor burden, or may be administered to a subject having a detectable tumor.
 IT 22760-18-5, Fingeroquinone
 RI PAC (Pharmacological activity); TRD (Therapeutic use); RIGL (Biological study); DEES (Uses)
 CH 22760-18-5 CAPLUS
 RI Steroid hormone and nonsteroidal anti-inflammatory drug combination for inducing tumor cell apoptosis
 CH 2148: Quinoxalinone, 7-methyl-1-(1-methyl-1H-quinolin-2-yl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 44 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

15 ANSWER 45 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2002:595743 CAPLUS
DOCUMENT NUMBER: 1371150228
TITLE: Anticarcinogenic compositions and methods for therapy through enhanced tissue regeneration
AUTHOR(S): Uchida, Kichiro T.; Mowday, Raul
PATENT ASSIGNER(S): Rutgers, The State University of New Jersey, USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
COUNTRY: US2002
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002/0190145	A1	20020909	US 2000-732516	20001007
US 6605928	R1	20040203		
US 2002/0190145	A1	20040601	US 2000-201974	20000509
US 2002/0190145	A1	20050710	US 2000-524664	20000501
PRIORITY APPL. INFO.:			US 1999-304190P	F 19991007
			US 1999-455861	A 19991007
			US 2001-19565	A3 20001007
			US 2000-732516	A1 20001007
			WO 2000-083337B	A1 20001007
			US 2003-368288	R1 20030218

AB The invention provides methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting

the tissue or the surrounding tissue with an anti-inflammatory agent, preferably in a controlled-release form, e.g. by dispersing the agent through a polymer matrix, appending the agent to a polymer backbone, or incorporating the agent directly into a biodegradable polymer membrane. These methods are useful in a variety of dental and orthopedic applications. Expts. are presented which demonstrate that implantation of a film comprising an aromatic polyphosphazene that hydrolyzes to form a therapeutically useful scaffold resulted in less swelling in tissues adjacent to the film and a decrease in the d. of inflammatory cells as compared to other polyphosphazene films. Reproduction of e.g. poly[1,6-bis(iso-carboxyphenyl) hexane] is described.

IT 22760-18-5, Frequencies
EL PAC (Pharmacological activity); TMO (Therapeutic use); BICL (Biological study) (USE) (Use)
(anti-inflammatory compo. and methods for therapy through enhanced tissue regeneration)
NH 22760-18-5 CAPLUS
CN 21180-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 46 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

15 ANSWER 47 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN


ACCESSION NUMBER: 2002:406976 CAPLUS
DOCUMENT NUMBER: 137149790
TITLE: Structure-based Classification of Antibacterial Activity
AUTHOR(S): Cronin, Mark T. D.; Aptula, Ayman O.; Dearden, John C.; Duffy, Judith C.; Hecova, Tatiana J.; Patel, Hiren; Rose, Philip H.; Schultz, T. Nayee North, Andrew P.; Voutoulidis, Konstantinos; Schenck, Gert
CORPORATE SOURCE: School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, L3 3AF, UK
SOURCE: Journal of Chemical Information and Computer Sciences (2002), 42(4), 662-678
COUNTRY: US2002
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to develop a simple quant. structure-activity relation (QSAR) for the classification and prediction of antibacterial activity, to enable in silico screening. To this end a database of 661 compds., classified according to whether they had antibacterial activity, and for which a total of 167 physicochem. and structural descriptors were calculated, was analyzed. To identify descriptors that allowed separation of the two classes (i.e. those compds. with and without antibacterial activity), anal. of variance was utilized and models were developed using linear discriminant and binary logistic regression analyses. Model predictivity was assessed and validated by the random removal of 30% of the compds. to form a test set, for which predictions were made from the model. The results of the analyses indicated that six descriptors, accounting for hydrophobicity and inter- and intramolecular hydrogen bonding, provided excellent separation of the data. Logistic regression anal. was shown to model the data slightly more accurately than discriminant anal.
IT 40507-23-1, Flupropione
EL PAC (Pharmacological activity); BICL (Biological study) (structure-based classification of antibacterial activity)
NH 40507-23-1 CAPLUS
CN 21180-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT


15 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



HN 303778-19-4 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[5-methoxyphenyl]-2-oxo- (CA INDEX NAME)




HN 303778-21-8 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[5-hydroxyphenyl]-2-oxo- (CA INDEX NAME)




HN 303778-22-9 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-[3-pyridylmethoxyphenyl]-2-oxo- (CA INDEX NAME)


15 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



HN 303778-17-2 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[4-phenyl]-2-oxo- (CA INDEX NAME)




HN 303778-19-3 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)




● HCl

HN 303778-24-1 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)

15 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



HN 303778-23-0 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)




HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P
HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P

HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P
HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P


HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P
HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P

HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P
HN 303778-16-1P 303778-17-2P 303778-18-3P
303778-24-1P 303778-25-2P 303778-32-1P
303778-33-2P


15 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



HN 303778-25-2 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)




HN 303778-32-1 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)



● HCl

HN 303778-33-2 CAPLUS
CN 3(2R)-Quinazolinacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(1-piperidyl)propoxyphenyl]-2-oxo- (CA INDEX NAME)

1.5 ANSWER: 52 OF 327 CAPTUS COPYRIGHT 2008 ACS on STN (Continued)



```

17 303738-30-3
18 RL: RCT (Reactant); RACT (Reactant or reagent)
19 (preparation of quinazolinones as cholesterol acyltransferase
20 inhibitors for
21 treatment of hyperlipemia and arteriosclerosis)
22 303738-30-3 CAPLOS
23 C2 2[1E]-Quinazolinone, 1-butyl-4-[3-methoxyphenyl]- (CA INDEX NAME)

```




```

IT   3QJ738-11-6P 3QJ738-13-8P 3QJ738-10-7P
      3QJ738-28-5P 3QJ738-29-6P 3QJ738-11-0P
MI   ICTC (Reactants); DSM (Synthetic preparation); PREP (Preparation); RACT
      (Reagent or reagents)
      [RECTION OF QUINOLINONES as cholesterol acyltransferase
inhibitors for
treatment of hyperlipidemia and arteriosclerosis]
KH   3QJ738-13-6 CAPH.05
CN   3[2H]-2-methyl-2-oxo-4-(4-hydroxy-1,4-dihydro-2-oxo-4-phenyl-
      1-butyl)-6-oxo-1,4-dihydro-2-oxo-4-phenyl-
      [CA INDEX NAME]

```

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Cont. Inued)




FBI 303738-29-6 CASLUS
 CH 21K]-Quinazolinone, 1-butyl-3,4-dihydro-4-[3-methoxyphenyl)- (CA INDEX NAME)



303738-31-0 CASLOS
3[28]-Quinazolinacetic acid, 1-butyl-1,4-dihydro-4-(3-methoxyphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on 5TH (Continued)



```

H24 303738-13-8 CAPLUS
CN 3-[2H]-Quinoxalineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-
[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]phenyl]-1,4-dihydro-2-oxo-4-
phenyl- (CA INDEX NAME)

```



```

NN 303738-20-7 CAPLUS
CN 3(2R)-Quinoxalineacetic acid, 1-butyl-1,4-dihydro-4-(3-methoxyphenyl)-2-oxo- (CA INDEX NAME)

```



FN 303738-28-5 CAPLUS
 CN 3(2H)-Quinoxalineacetic acid,
 1-butyl-6-chloro-1,4-dihydro-2-oxo-4-phenyl-
 , ethyl ester (CA INDEX NAME)


L5 ANSWER 53 OF 327 CAPLOB COPYRIGHT 2008 ACS on STB

ACCESSION NUMBER: 2000:513681 CAPLOS
DOCUMENT NUMBER: 133:120346
TITLE: Preparation of polyanaphthalene derivatives
useful
as alpha la adrenoreceptor antagonists
INVENTOR(S): Rock, Mark G.; Patane, Michael A.; Steele, Thomas G.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: ICT Int. Appl., 105 pp.
CODEN: PIKXSD
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
LAWYER INFORMATION:

[illegible]


OTHER SOURCE(S) : MARPAT 133:120346
GT

15 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




● HCl

HN 265328-76-5 CAPLUS
 CN 2(18)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 265328-77-6 CAPLUS
 CN 2(18)-Quinazolinone, 3-[2-(cyclohexylmethyl)-4-piperidinyl]-3-methyl-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 265328-79-7 CAPLUS

15 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




● HCl

HN 265328-81-2 CAPLUS
 CN 2(18)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-1-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 265328-82-3 CAPLUS
 CN 2(18)-Quinazolinone, 1-(cyclohexylmethyl)-3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


15 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

CN 2(18)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-1-methyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 265328-78-8 CAPLUS
 CN 2(18)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-1-benzyl-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

HN 265328-80-1 CAPLUS
 CN 2(18)-Quinazolinone, 2-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-1-(2-methoxyethyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




15 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

HN 265328-86-7 CAPLUS
 CN 2(18)-Quinazolinone, 2,4-dihydro-3-[1-[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




HN 265328-87-8 CAPLUS
 CN 2(18)-Quinazolinone, 3,4-dihydro-3-[1-[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 265328-88-8 CAPLUS
 CN 2(18)-Quinazolinone, 3,4-dihydro-3-[2-(hydroxymethyl)-3-[1-[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




HN 265328-89-9 CAPLUS
 CN 2(18)-Quinazolinone, 3,4-dihydro-3-[2-(hydroxymethyl)-3-[1-[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-, ethanediolate (salt) (9CI) (CA INDEX NAME)

CN 1

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



FN 215074-63-4 CAPLUS
 CH 2-[18]-Quinoxalinone, 6-[4-chlorophenyl]-(1-methyl-1H-imidazol-5-yl)methyl-4-[17-chlorophenyl]-2-methyl- (CA INDEX NAME)




ET 215074-60-9P 215074-61-0P 215074-64-3P
 215074-66-5P 215074-69-7P 215074-69-8P
 215074-70-1P 215074-71-2P 215074-72-3P
 215074-73-4P 215074-79-9P

EL: SAC [Biological activity or effector, except adverse]; RSO

[Biological study, unclassified]; SPH [Synthetic preparation]; THO [Therapeutic use];
 BEC [Biological study]; PGP [Preparation]; USE [Use]
 [Preparation of fattyacyltransferase inhibiting quinoxalones]

FN 215074-60-9 CAPLUS
 CH 2-[18]-Quinoxalinone,
 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




CH 2

CHN 144-62-7

CMF C3 B3 O4




FN 215074-60-8 CAPLUS
 CH 2-[18]-Quinoxalinone, 6-[amino-4-(4-chlorophenyl)]-(1-methyl-1H-imidazol-5-yl)methyl-4-[2-chlorophenyl]-1-methyl- (CA INDEX NAME)




FN 215074-69-7 CAPLUS
 CH 2-[18]-Quinoxalinone,
 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1H-imidazol-3-ylmethyl]-1,4-dihydro-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



FN 215074-61-0 CAPLUS
 CH 2-[18]-Quinoxalinone,
 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1-(4-pyridylmethyl)- (CA INDEX NAME)




FN 215074-64-3 CAPLUS
 CH 2-[18]-Quinoxalinone, 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-, ethanedione (1:1) (CA INDEX NAME)

CHN 1


CHN 215074-69-2

CMF C26 B20 C12 B4 O


L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



FN 215074-69-8 CAPLUS
 CH 2-[18]-Quinoxalinone,
 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)




FN 215074-70-1 CAPLUS
 CH 2-[18]-Quinoxalinone,
 4-[3-chlorophenyl]-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl-3,4-dihydro-1-methyl- (CA INDEX NAME)




FN 215074-71-2 CAPLUS

13 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([4-chlorophenyl]hydroxy[1-methyl-1*H*-indazol-5-yl)methyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)



KN 215034-72-3 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([4-chlorophenyl] [1-methyl-1*H*-indazol-5-yl)methyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)




KN 215034-73-4 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([4-chlorophenyl] [1-methyl-1*H*-indazol-5-yl)methyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)




15 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



KN 215034-86-9 CAPLUS
 CN 21181-Quinazolinone, 6-([4-chlorobenzoyl]-4-([3-chlorophenyl]-1-methyl- (CA INDEX NAME)




KN 215034-87-0 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([4-chlorobenzoyl]hydroxymethyl)-3,4-dihydro-1-methyl- (CA INDEX NAME)




KN 215034-89-3 CAPLUS
 CN 21181-Quinazolinone, 6-([4-chlorobenzoyl]methyl)-4-([3-chlorophenyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)

15 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




KN 215034-78-9 CAPLUS
 CN 21181-Quinazolinone, 6-([4-chlorobenzoyl] [1-methyl-1*H*-indazol-5-yl)methyl]-4-([3-chlorophenyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



IT 215034-85-8P 215034-86-9P 215034-87-0P
 215034-88-1P 215034-89-2P 215034-90-5P
 215034-91-6P 215034-92-7P 215034-93-8P
 215034-94-9P
 Re: PCT (Reactant); STN (Synthetic preparation); PREP (Preparation); SACT (Reactant or reagent)
 (Preparation of kinase/transferase inhibiting quinazolinones)

KN 215034-85-8 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-methyl- (CA INDEX NAME)

15 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



KN 215034-89-2 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-methyl- (CA INDEX NAME)




KN 215034-90-5 CAPLUS
 CN 21181-Quinazolinone, 4-([3-chlorophenyl]-6-([2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



KN 215034-91-6 CAPLUS
 CN 21181-Quinazolinone, 6-([4-chlorobenzoyl]-4-([3-chlorophenyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)

LS ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



NH 215014-91-8 CAPLUS
 CN 21181-Quinacolinone,
 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-3,3-dioxolan-
 2-yl]-1-(4-hydroxyethyl)-3,4-dihydro- (CA INDEX NAME)



LS ANSWER 58 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1991:682123 CAPLUS
 DOCUMENT NUMBER: 12379993
 TITLE: Means of ascertaining an individual's risk profile for atherosclerotic disease based on systemic inflammation
 INVENTOR(S): marker levels
 INVENTOR(S): Kidder, Paul; Benekens, Charles H.
 PATENT ABSTRACTOR(S): Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CDDM: P10002
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9443630	A1	19981008	WO 1998-056613	19980402
US, AU, CA, JP, NZ, AT, BR, CH, CY, DE, DK, EE, FI, FR, GB, GR, IT, LT, LU, MC, NL, PT, SE				
CA 2285090	A3	19981008	CA 1998-2285091	19980402
AU 9811058	A	19981002	AU 1998-71058	19980402
EP 1003101	AL	20000321	EP 1998-927992	19980402
EP 1003521	N3	20000309		
AT, AU, BR, CH, DE, DK, EE, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, TR, PT, CY				
JP 2003125058	T	20031304	JP 1998-542023	19980402
JP 20031301	B2	20080802		
JP 2003128352	A	20030508	JP 2002-220351	19980402
EP 1481419	A1	20050105	EP 2004-10414	19980402
AT, AU, BR, CH, DE, DK, EE, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, TR, PT, CY				
AT 290375	T	20050315	AT 1998-817992	19980402
PT 1003101	T	20050729	PT 1998-527992	19980402
SE 2239401	T3	20031001	SE 1998-37992	19980402
PRIORITY APPL. INFO.:			US 1997-430509	P 19970402
			US 1997-430599	P 19970402
			US 1998-708949	P 19980109
			EP 1998-517992	A3 19980402
			JP 1998-542023	A3 19980402
			WO 1998-056613	W 19980402

AS The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder. The primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo-controlled trial of aspirin and β -carotene in the primary prevention of cardiovascular disease conducted among 20,000

LS ANSWER 58 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)

NH 215014-94-8 CAPLUS
 CN 21181-Quinacolinone,
 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-
 2-yl]-1-(4-hydroxyethyl)-3,4-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

LS ANSWER 59 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
 apparently healthy men. In that trial, baseline level of C-reactive protein, a marker for underlying systemic inflammation, was found to det. the future risk of myocardial infarction and stroke, independent of a large array of lipid and non-lipid risk factors. Baseline C-reactive protein level was not assoc. with venous thrombosis, a vascular event generally not assoc. with atherosclerosis. Further, the data indicate that the magnitude of benefit that apparently healthy individuals can expect from prophylactic aspirin is dependent in large part upon baseline level of C-reactive protein.

IT 22760-18-5, Propagator 37554-40-8, Plaquarone
 RU 880 (Biological study, unclassified); TH0 (Therapeutic use); B10L (Biological study); USE (Uses)
 (systemic inflammation marker level in evaluation of cardiovascular disorder risk reduction by)

NH 22760-18-5 CAPLUS
 CN 21181-Quinacolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



NH 37554-40-8 CAPLUS
 CN 21181-Quinacolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

13 ANWER 19 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 129126466
DOCUMENT NUMBER: 129126466
TITLE: Spray formulations of antihypertensive opiates and method of treating topical hypertensive conditions thereof
INVENTOR(S): Maygood, Alan L.; Chang, An-chih; Farar, John J.; Meeb, Dave
PATENT ASSIGNER(S): Adolor Corp., USA
SOURCE: U.S. Pat. Off.
COUN: US0000
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY AC. IPR. COUNT: 2
PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5812178 A	A	19990921	US 1997-018059	19970214
US 5780403	A	19990921	US 1997-092399	19970714
PRIORITY APP. INFO.			US 1997-018059	AJ 19970214

OTHER SOURCE(S): MEDPAT 129126466
AB Spray formulations of anti-hypertensive opiates comprise an anti-hypertensive opiate having a peripheral selectivity of 251 to 1,000 as an aqueous air mixture containing up to 15% ethanol, propanol, and/or isopropanol. Thus, 10% of 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-4,4-diphenyl-1-piperazine compound was dissolved in 2.2 of a 5:4 ethanol/95:5 water mixture with agitation and the solution was transferred to a pump action spray bottle.
IT 22160-18-1, Proprietary
RI 752 (Pharmacologic use) BOC (Biological study) USES (Uses) (topical) applies containing anti-hypertensive opiates and active ingredients to promote wound healing
NI 22160-18-1 CAPUS
CH 2118-Quinazolinone, 2-methyl-1-(1-methyl-4-phenyl-1-piperazin-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

13 ANWER 41 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 129122708 CAPUS
DOCUMENT NUMBER: 129122708
TITLE: New in organic synthesis. XII. Synthesis of 2-amino-1-chlorobenzyldienes and their heterocyclization
AUTHOR(S): Sakharov, A. A.; Shtrykova, V. V.; Vostretsov, S. N.
CORPORATE SOURCE: Tomsk Polytechnic University, Tomsk, Russia
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (1997), 33(4), 457-459
COUN: RUSSIA
COUN: RUSSIA
FUEL 12584: 1076-4289
DOCUMENT TYPE: MUX Nuts/Interpolioda Publishing
LANGUAGE: English
OTHER SOURCE(S): CHEMABCT 129122708
AB A synthetic method was developed for alol. active 2-amino-1-chlorobenzyldienes based on reaction of the corresponding benzaldehydes with urea in sulfuric acid. The 2-amino-1-chlorobenzyldienes were cyclized to 2-substituted 1,2,4,4-tetrahydro-4-phenyl-1,4-chloroquinazolin-2-one.
IT 26772-31-2P 19978-16-3P
RI SPH (Synthetic preparation) PREP (Preparation) (Preparation and heterocyclization of aminochlorobenzyldienes)
NI 26772-31-2 CAPUS
CH 2118-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



NI 203785-16-3 CAPUS
CH 2118-Quinazolinone, 1-acetyl-4-chloro-3,4-dihydro-6-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

13 ANWER 45 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 129131733 CAPUS
DOCUMENT NUMBER: 129131733
TITLE: Thermal decomposition of test-butyl o-(phenyl)- and o-(acilino)phenylisopropylcarbamates
AUTHOR(S): Calatoni, Gianluigi; Leonardini, Alvaro; McNab, Ian; Nanni, Giancarlo; Nanni, Giuseppe
CORPORATE SOURCE: Dipartimento di Chimica Generale, di Inorganica, Anal. Chim. Fis., Università di Parma, Parma, I-43100, Italy
SOURCE: Journal of the Chemical Society, Perkin Transactions 1 Organic and Bio-Organic Chemistry (1998), (11), 1813-1814
COUN: ITC94; ITC98 0500-922X
FUEL 12584: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129131733
AB Some o-phenyl- and o-(acilino)phenylisopropylcarbamates were generated by thermal decomposition of suitable test-butyl isopropylcarbamates. The

isopropyl group was disposed to give 7-membered cyclization on the Ph group. In some cases, products were found that can be rationalized through a 1,6-sigmatropic shift of the isopropyl radical followed by homolytic 1,5-migration of the Ph group from the isopropyl to the isopropyl nitrogen; this seems to be the first instance of such a process.
Evidence

was found for the formation of isomers through hydrogen abstraction by the isopropyl; with two o-phenyl-substituted precursors these isomers have been unambiguously isolated. The reactions have also afforded significant in some cases major units of other products (acilino, quinazolinone and indole derivatives) presumably deriving from carbon radical mechanisms are suggested to account for the formation of these compounds. The structure of a quinazolinone derivative was determined by X-ray crystallography.
IT 209413-03-2P
RI PEP (Properties); SPH (Synthetic preparation); PREP (Preparation) (Preparation of quinazolinone)
NI 209413-03-2 CAPUS
CH 2118-Quinazolinone, 1,4-diphenyl- (CA INDEX NAME)



REFERENCE COUNT: 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

13 ANWER 41 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 129154618 CAPUS
DOCUMENT NUMBER: 129154618
TITLE: Development of a genetic algorithm method especially designed for the comparison of molecular models: application to the elucidation of the benzodiazepine receptor pharmacophore
AUTHOR(S): Muehle, Nathaniel; Lebrun, Laurence; Vautour, Daniel F.; Bourguignon, Jean-Jacques; Wernth, Camille G.
CORPORATE SOURCE: Laboratoire de Physico-Chimie Informatique, Facultés Universitaires, Namur, B-5000, Belg.
SOURCE: Computer-Aided Lead Finding and Optimization: Current Tools for Medicinal Chemistry, European Symposium on Quantitative Structure-Activity Relationships (QSAR), 12th, Lausanne, Sept. 14-19, 1996
NI 26772-31-2 CAPUS
CH 2118-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

Abstract: The benzodiazepine receptor pharmacophore is not yet unequivocally known, the direct elucidation of the interaction mode between their active binding sites and their potent ligands is rather difficult. The comparison of selected ligands is thus an indirect approach which could help to determine the pharmacophore elements. In the present work, ligands for the benzodiazepine receptors are characterized using electron d. maps at medium resolution, reconstructed from calculated structure factors using crystallographic simulation programs. As the obtained three-dimensional maps are rather complex, they then can be simplified by a topol. anal. in order to represent the ligands as connected graphs. An original genetic algorithm method is finally elaborated and implemented to carry out graph comparison. The design of the algorithm implies appropriate and efficient coding and evaluation of the generated graph superimpositions. The major aim of this study consists in determining the nature and arrangement of the mol. fragments taking part in the binding of ligands to their benzodiazepine receptor sites.
IT 209413-03-1
RI PEP (Properties); SPH (Synthetic preparation); PREP (Preparation) (Preparation of benzodiazepine receptor pharmacophore determination by genetic algorithm method)
NI 209413-03-1 CAPUS
CH 2118-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

LS ANMERK 63 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM (Continued)



LS ANMERK 63 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 1997-060840 CAPSULE

DOCUMENT NUMBER: 1271108821

TITLE:

Preparation of (aminoalkyl)-substituted benzothiazine compounds with antihypertensive and antihypercholesterolemic activities

INVENTOR(S): Ashu, Subhanshu Lamsfeld, Hans, Deimlow, Henricus, Mayard, Olivier; Rumber, Jacques, Scheld, Gerard

PATENT ASSIGNER(S): Merck, Hans-Peter, J., Yu-Bao

SOURCE: Eur. Pat. Appl., 40 pp., CORDIS EPCOLIM

LANGUAGE: Patent

FAMILY ACC. NUM. COUNTRY: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 778271	A2	19970611	EP 1996-119172	19961119
EP 778271	A2	20000522		
US AT, BE, CH, DE, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	A1	19970609	CA 1996-2190768	19961119
CA 2190768	A1	19970609	JP 1996-245555	19961106
JP 0916123	A	19970609	CH 1996-121593	19961106
CH 1161228	A	20010704		
BR 9647991	B	19960105	US 1996-762367	19961206
US 5856563	A	19960618	BR 1996-5506	19961009
BR 9605904	A	19960618	CH 1995-7490	19951208

PRIORITY APPL. INFO.: MARPAT 1271108821

OTHER SOURCE(S):

GI

AB The title compds. [1] dotted line = optional double bond; R = (un)substituted heterocyclic atom group; Q = (un)substituted cycloalkyl, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted aryl, etc.; R = (un)substituted aminoalkyl; T = H, alkyl, (un)substituted H2C, COME, N(C), CF, CH, useful as antihypertensive and antihypercholesterolemic, are prepared and 1-containing formulations prepared. Thus, allyl-[1-[4-bromophenyl]benzo[d]thiazine-6-yl]oxy]hexylmethanamine fumarate, prepared in 4 steps from benzyl mercaptan, demonstrated a IC50 of 3.7 nM for 3,3'-indoleamine-1-methanol cyclase.

IT 192442-83-4P

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

15 ABSTRACT 64 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
 22760-18-5 CAPLUS
 CN 2118-Quinolizone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



15 ABSTRACT 65 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
 antiinflammatory drugs, prep. of compds. of the invention is included, as are comparative in vivo analgesic, antiinflammatory, and gastric lesion activities.
 IT 22760-18-5, Proquarone
 RE ADJ (adverse effects, including toxicity); THE (therapeutic use); BOLD (biological study); USES (uses)
 (100-substituted nonsteroidal antiinflammatory compound preparation for compds. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)
 NO 22760-18-5 CAPLUS
 CN 2118-Quinolizone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



15 ABSTRACT 66 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1996-756296 CAPLUS
 12614758
 DOCUMENT NUMBER:
 TITLE:
 INVENTOR(S):
 PATENT ASSIGNMENT(S):
 SOURCE:
 ICS Int. Appl., 99 pp.
 CODEN: PICAL2
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY AC: NIM, COINT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 96/23946	A1	1996-10-24	MO 1996-084972	1996-04-11
WI AU, CA, JP, US				
BR, AT, BE, CH, DE, ES, FI, FR, GB, GR, IR, IT, LU, MC, NL, PT, SE				
US 6951588	A	20000418	US 1995-425090	1995-04-19
US 5765973	A	19971210	US 1995-541308	1995-10-13
AO 9654493	A	19961107	AO 1996-54493	1996-04-11
AO 710951	B2	19990930		
EP 821589	A1	19990204	EP 1996-316485	1996-04-11
FI 11569139	Z	19990604	JP 1996-531797	1996-04-11
US 6943232	A	20000708	US 1999-238062	1999-04-12
US 6163774	A	20001107	US 2000-495151	2000-09-11
AO 773374	B2	20040509	AO 2001-91447	2001-11-11
PRIORITY APPL. INFO.			US 1995-425090	A 1995-04-19
			US 1995-541308	A 1995-10-13
			MO 1996-084972	W 1996-04-11
			US 1997-899238	A3 1997-07-23
			US 1999-238062	A1 1999-01-12
			AO 1999-65551	A3 1999-12-30

OTHER SOURCE(S): MARPAT 12614758
 AB Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compds. comprising: (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group [preferably as a charged species, particularly nitrosonium]; and methods of treatment of inflammation, gastrointestinal lesions and/or fever using the compds. are disclosed. The compds. and compds. protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal.

15 ABSTRACT 67 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1996-756296 CAPLUS
 DOCUMENT NUMBER: 12615212
 TITLE:
 stationary phase
 AUTHOR(S): Finkle, William R.; Bruce, L.; Jonathan Treflo, Gerald F.
 CORPORATE SOURCE: School of Chem. Sci., Univ. of Illinois, Urbana, IL, 61801, USA
 SOURCE: Journal of Chromatography, A (1996), 753(1), 109-119
 CODEN: JCHAS7, ISSN: 0021-9673
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Review
 LANGUAGE: English
 AB Incorporation of chiral selector into a polysiloxane which is then immobilized on silica affords a chiral stationary phase (CSP) capable of resolving a broad array of enantiomers by either HPLC or supercritical fluid chromatography (SFC). Like its heptakis-type analog, the new version of which is known as the Whelk-O-1, CSP 1, the polyWhelk-O, is stable to normal and reversed-phase conditions and to a wide range of temp., mobile phases and additives. In most cases, the polyWhelk-O affords greater enantioselectivity and less retention than does the heptakis-type Whelk-O 1 under the same conditions. An extensive collection of segs. of the enantiomers of a variety of types of compds. is presented to illustrate the scope and level of performance typically afforded by the polyWhelk-O column.
 IT 26772-87-2 196296-36-6 196296-37-7
 RE: INT (Analyt.); JMET (Analytical study)
 subunit and supercrit. carbon dioxide and polyWhelk-O chiral stationary phase)
 NO 26772-87-2 CAPLUS
 CN 2118-Quinolizone, 3,4-dihydro-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



NO 196296-36-4 CAPLUS
 CN 2118-Quinolizone, 3,4-dihydro-1-[1-methylethyl]-4-phenyl-, (R)- (C12)
 (CA INDEX NAME)

Absolute stereochemistry.

IT 22760-18-5, Prostaglandin synthase inhibitors in gastric cancer
 KL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nonparticulate nonsteroidal antiinflammatory drug compo-)
 RN 22760-18-5 CAPUS
 CN 2(1N)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- ICA
 NAME:

15 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RR 36943-71-9 CAPLUS
 CN 2(1R)-Quinoxalinone,
 1-(cyclopropylmethyl)-3, 4-dihydro-6-methoxy-4-phenyl-
 (CA INDEX NAME)




RR 37555-95-8 CAPLUS
 CN 2(1R)-Quinoxalinone, 6-chloro-1-[(2-fluorophenyl)methyl]-4-phenyl- (CA INDEX NAME)



RR 49930-99-9 CAPLUS
 CN 2(1R)-Quinoxalinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 71 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 72 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RR 59253-25-7 CAPLUS
 CN 2(1R)-Quinoxalinone,
 1-(cyclopropylmethyl)-3, 4-dihydro-7-methoxy-4-phenyl-
 (CA INDEX NAME)



RR 59253-26-8 CAPLUS
 CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3, 4-dihydro-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RR 155402-72-5 CAPLUS
 CN Piperidine, 1-[1-(6-chloro-2-oxo-4-phenyl-1(2R)-quinoxalinyloxy)acetyl]-
 (CI) (CA INDEX NAME)

15 ANSWER 73 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

1594144167 CAPLUS
 DOCUMENT NUMBER: 120144167
 ORIGINAL REFERENCE NO.: 130153279, 253304
 TITLE: Surface-modified nonsteroidal anti-inflammatory drug
 (NSAID) nanoparticles
 INVENTOR(S): Liveridge, Gary G.; Conestabile, Philip; Cundy,
 Kenneth C.; Saperstein, Frank F.
 PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
 SOURCE: PCT Int. Appl., 27 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325190	A1	1993-12-23	MO 1993-085082	1993-06-01
WI: AU, CA, HU, JP				
RU: AT, BE, CH, DE, DK, ES, FR, GB, GR, IL, IT, LU, MC, NL, PT, SE				
AD 914384	A	1994-01-04	AD 1993-0384	1993-06-01
AD 67783	B2	1997-05-08		
EP 644755	A1	1999-03-29	EP 1993-014224	1993-06-01
EP 644755	B1	1997-03-19		
RU: AT, BE, CH, DE, DK, ES, FR, GB, GR, IL, IT, LU, MC, NL, PT, SE				
HU 70952	A2	1999-11-28	HU 1994-3543	1993-06-01
JP 08501073	T	1996-02-06	JP 1994-501515	1993-06-01
AD 150297	T	1997-04-15	AT 1993-014224	1993-06-01
BE 2103223	T	1997-07-01	BE 1993-014224	1993-06-01
CA 2118517	C	2003-10-14	CA 1993-2118517	1993-06-01
US 5551460	A	1996-06-03	US 1995-023662	1993-03-13
PRIORITY APPL. INFO.:			US 1992-897193	A 1992-06-10
			US 1991-647105	A2 1991-01-15
			MO 1993-055082	A 1993-06-01

AB Dispersible particles consist of a crystalline NSAID having a surface modification adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 600 nm.
 Pharmaceutical compns. containing the particles exhibit reduced gastric irritation following oral administration and/or hastened onset of action. A nanoparticulate dispersion containing naproxen and Pluronic F-68 was prepared using emulsion beads.
 17 27760-18-5, Frogazone
 RU: FR (Proprietary)
 (surface adsorption on surface of, oral compns. containing)
 RU 27760-18-5 CAPLUS
 CN 2(1R)-Quinoxalinone, 7-methyl-1-(1-methylbutyl)-4-phenyl- (CA INDEX NAME)

15 ABSTRACT 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




15 ABSTRACT 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:612423 CAPLUS
 DOCUMENT NUMBER: 117121423
 ORIGINAL REFERENCE NO.: 117124699a, 26499a
 TITLE: Synthesis and renal vasodilator activity of substituted 4-alkyl(aryl)-2-oxoquinazolin-1-ylalkanoic acids
 AUTHOR(S): Fuscelly, F.; Agostini, M. A.; Mandruco, V.; Corbse, D. M.; Kanyja, L. M.; Malloy, T.; Malloy, E.; Mettally, J. J.; Mulvey, D. M.; et al.
 CORPORATE SOURCE: Div. Med. Chem., R. W. Johnson Pharm. Res. Inst., Killybeg, NJ, 08033-0625, USA
 SOURCE: European Journal of Medicinal Chemistry [1992], 27(1), 277-84
 DOCUMENT TYPE: CHEM: 6UNCA; ISSN: 0223-5234
 LANGUAGE: English
 C1




AB The synthesis and cardiovascular evaluation of a novel series of title acids and their esters 2 [R = H, 6,7-(MeO)2, 6,7-,7,8-, or 5,6-(MeO)2, 6,7-(RO)2; R1 = H, R, Me, cyclohexyl; R2 = Me, Et, Pr, MeCH2, Ph, 4-FC6H4; n = 1-4] as renal vasodilators is presented. 1 [R = 6,7-(MeO)2, R1 = H, R2 = Me, n = 2] was a potent and selective renal vasodilator.
 IT 143697-69-22 143697-71-69
 RU: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); SACT (Reactant or reagent)
 (Preparation and reaction with hydrochloric acid)
 RN 143697-69-2 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 6,7-dimethoxy-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)


15 ABSTRACT 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RU 143697-71-6 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 4-(4-fluorophenyl)-6,7-dimethoxy-2-oxo-, methyl ester (CA INDEX NAME)




IT 143697-70-39 143697-72-79 143697-60-2P
 RU: RCT (Reactant); PREP (Preparation)
 (Preparation and renal vasodilator activity of)
 RU 143697-70-3 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 6,7-dihydroxy-2-oxo-4-phenyl- (CA INDEX NAME)




RN 143697-72-7 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 4-(4-fluorophenyl)-6,7-dihydroxy-2-oxo- (CA INDEX NAME)

15 ABSTRACT 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 144139-60-3 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 6,7-dihydroxy-2-oxo-4-phenyl-, monohydrobenzamide (FICI) (CA INDEX NAME)



● RHZ

RN 144139-61-3 CAPLUS
 CN 11281-Quinazolinopropanoic acid, 4-(4-fluorophenyl)-6,7-dihydroxy-2-oxo-, monohydrobenzamide (FICI) (CA INDEX NAME)



● RHZ

15 ANMER 73 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 73 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1992:602498 CAPUS
 DOCUMENT NUMBER: 117:2498
 ORIGINAL REFERENCE NO.: 117:5314,5344
 TITLE: A QSAR model of teratogenesis
 AUTHOR(S): Goodwin, V. J.; Moulton, R.; Knudsen, H.
 FIRM: Hart, Jeffrey B.; Blake, Benjamin W.
 CORPORATE SOURCE: Health Div., Inc., Rochester, NY, 14604, USA
 SOURCE: Quantitative Structure-Activity Relationships (1991), 10(4), 504-52
 CORDIS NUMBER: 0931-6771
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: Four related QSAR models of teratogenesis in esp. animals have been developed: one each for heteroatom, carbocyclic, allylic, and acyclic compounds. The new model of teratogenesis in esp. animals is based on the allylic model to 144 for the carbocyclic model. As determined by cross-validation using the leave-one-out, or jackknife, technique, the accuracy of the model is discriminating between teratogenic and nontoxic ranges from 92.46 to 94%. A simple overall assessment of esp. teratogenesis was chosen as the Mol. similarity, taking into account such factors as dosage, maternal toxicity, and affected organ systems remain to be subjects of further studies.
 IT 60507-23-1, Fipronil
 RI: ADV (Adverse effect, including toxicity); PEP (Properties); BOLD (Biological study)
 AB (Teratogenesis in laboratory animals from, QSAR model of)
 RI 60507-23-1 CAPUS
 CN 2118: Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



15 ANMER 74 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1992:602497 CAPUS
 DOCUMENT NUMBER: 117:2497
 ORIGINAL REFERENCE NO.: 117:5314,484
 TITLE: Mechanism of allergic cross-reactions. I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody
 AUTHOR(S): Varga, James M.; Kaleshinski, Gerdtrud Klein, Georg F.; Fritsch, Peter
 CORPORATE SOURCE: Dep. Dermatol., Univ. Innsbruck, Innsbruck, 6020, Austria
 SOURCE: Molecular Immunology (1991), 28(6), 641-54
 CORDIS NUMBER: 0161-5890
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE.
 IT: All DNP-antigen acids, that were tested inhibited the binding of the radio-labeled 1 to DNP covalently attached to polystyrene microplates; however, the concentration for 50% inhibition varied within four orders of magnitude, DNP-L-lysine being the most and DNP-L-proline the least potent inhibitor. In addition to DNP analogs, a large number of drugs and other compounds were tested for their ability to compete with DNP for the binding site of 1. At the concentration used for screening, 59% of compounds had significant inhibitory 19% inhibited the binding of 1 more than 50%. Several families of compounds, tetraepine, polymyxins, phenothiazines, salicylates, and quonolones, that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with 1 is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.
 IT 22760-18-5
 RI: BOLD (Biological study)
 AB (Binding of, to anti-dinitrophenyl monoclonal antibody, allergic cross-reaction mechanism in relation to)
 RI 22760-18-5 CAPUS
 CN 2118: Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANMER 75 OF 327 CAPUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1991:623028 CAPUS
 DOCUMENT NUMBER: 115:23028
 ORIGINAL REFERENCE NO.: 115:371794,371824
 TITLE: Aspirin-like drugs, ethanol-induced rat gastric injury and mucosal oleosinoid release
 AUTHOR(S): Trautwein, Marion; Pekar, Brigitta M.; Pekar, Bernhard A.
 CORPORATE SOURCE: Dep. Exp. Clin. Med., Ruhr-Univ., Bochum, D-4630/1, Germany
 SOURCE: European Journal of Pharmacology (1991), 201(1), 53-8
 CORDIS NUMBER: 0931-6771
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: The effect of oral administration of various nonsteroidal anti-inflammatory drugs on ethanol-induced rat gastric injury and mucosal release of leukotrienes C4, 6-keto-prostaglandin F1a and 15-hydroxy-5,8,11,13-tetraene was investigated. It was found that besides sodium salicylate and high doses of aspirin, other type drugs, such as diflunisal, 4-aminosalicylic acid, 2,4-dihydroxybenzoic acid and the salicylate, and several non-acidic compounds, such as piroxicam, benzydolone and paracetamol, were gastroprotective. All these drugs inhibited as well leukotriene C4 formation by ethanol-stimulated gastric mucosa. However, naproxen, ibuprofen, ibuprofen, gentamicin acid, and 5-aminosalicylic acid also inhibited leukotriene C4 formation, but were not protective. Gastroprotection was independent of 6-keto-prostaglandin F1a formation. Both protective and non-protective drugs inhibited the ethanol-stimulated, but not the basal, release of 15-hydroxy-5,8,11,13-tetraene. The results indicate that the differential effects of various nonsteroidal anti-inflammatory drugs on gastroprotection against ethanol are not correlated with specific effects on mucosal cyclooxygenase, 5-lipoxygenase or 15-lipoxygenase activity.
 IT 22760-18-5, Proquione
 RI: BOLD (Biological study)
 AB (Ethanol-induced gastric injury and mucosal oleosinoid release response to)
 IT 22760-18-5 CAPUS
 CN 2118: Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 76 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1991:488777 CAPLUS
 DOCUMENT NUMBER: 1114:88777
 ORIGINAL REFERENCE NO.: 115:15175A,15175B
 TITLE: Substances to improve the recovery of amnesia during anesthesia
 INVENTOR(S): Roemisch, Joergens; Amersbach, Bernhard; Pelzer,
 PATENT ASSIGNER(S): Behringwerke A.-G., Germany
 SOURCE: Eur. Pat. Appl., 4 pp.
 COUNTRY: EP0000000
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. INTR. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 437927	A2	19900616	EP 1990-124704	19901215
EP 437927	A3	19900203		
EP 437927	B2	19900920		
DE 3942091	A1	19900617	DE 1989-3942091	19891220
AZ 142639	F	19901013	AZ 1990-124704	19901215
DE 3942091	T3	19901216	DE 1990-124704	19901215
CA 505751	A1	19900613	CA 1990-025751	19901219
AO 904233	A	19900617	AO 1990-68233	19901219
AO 644742	A2	19900734		
JP 6420857	A	19900730	JP 1990-417897	19901219
JP 591253	B2	19901106		
US 559950	A	19961205	US 1993-46908	19970415
FR108177 APPLA. DMTD.			DE 1989-3942091	A 19891220
			US 1990-629718	B1 19901215

AB A medium which stabilizes amnesia for anal. studies contains an anticonvulsant, a chelating agent, and 21 platelet aggregation inhibitor (e.g. chloroquine, quinine, dibucaine). Thus, human blood was drawn into a solution containing 124 mM EDTA, 16 mM hydroxychloroquine sulfate, and 26,000 units heparin/L for determination of the platelet factor 4 and platelet protein 4 content by immunoassay.

IT 22760-18-5, Freqoquine
 RI: RIOL (biological study)
 (anesthetics stabilization with, in anal.)
 RI: 22760-18-5 CAPLUS
 CH 2118-Quinacilimone, 7-methyl-2-[1-(methyl-ethyl)-4-phenyl]- (CA INDEX)

13 ANSWER 77 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1991:440162 CAPLUS
 DOCUMENT NUMBER: 1114:40162
 ORIGINAL REFERENCE NO.: 114:40125A,40325B
 TITLE: Effects of nonsteroidal antiinflammatories on mouse ear edema induced with dithranol
 AUTHOR(S): Gabor, Miklos; Balpa, Z.
 CORPORATE SOURCE: Inst. Pharmacodyn., Albert Szent-Gyorgyi Med. Univ., Szeged, H-6720, Hung.
 SOURCE: Acta Physiologica Hungarica (1991), 75(4), 287-91
 COUNTRY: HUNGARY; ISSN: 0231-482X
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Mouse ear edema induced with dithranol in mice of the C57BL strain was decreased significantly, in a concentration-dependent manner, by the oral administration of the following nonsteroids 10 min before induction of the

edema: piroxicam, piroxicam, aspirin, aspirin, niflumic acid, and phenylbutazone. An approx. 50% inhibitory effect could be attained with the following doses: 1.3 mg/kg piroxicam, 5 mg/kg aspirin, 5 mg/kg aspirin, and 5 mg/kg niflumic acid. Administration of the largest dose (15 mg/kg) of phenylbutazone, used for comparison, resulted in an

edema decrease of 41%.
 (edema response to)
 RI: RIOL (biological study)
 RI: 22760-18-5 CAPLUS
 CH 2118-Quinacilimone, 7-methyl-2-[1-(methyl-ethyl)-4-phenyl]- (CA INDEX)



15 ANSWER 76 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



13 ANSWER 78 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1991:220616 CAPLUS
 DOCUMENT NUMBER: 114:220616
 ORIGINAL REFERENCE NO.: 114:36949A,36952A
 TITLE: Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification
 AUTHOR(S): Lillkampe, P.; Korte, T.
 CORPORATE SOURCE: Dep. Biochem., Natl. Public Health Inst., Helsinki, SF-00300, Finland
 SOURCE: Journal of Analytical Toxicology (1991), 15(2), 71-81
 COUNTRY: FINLAND; ISSN: 0146-4760
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A simple and sensitive identification system for the detection of a broad spectrum of drugs is described. ChemLit extraction tubes were used for the

isolation of drugs from human urine. Specimens were screened by TLC and confirmed by GC/mass spectrometry. Special procedures for hexenophorin, oxazolinoids, cocaine, LSD, morphine, phenylbutazone, halogenated hydrocarbons, paracetamol, and alcohols were used. This system is useful

for screening samples in misuse, impaired driving, poisoning, and other forensic cases. It covers about 200 substances including all potentially abused drugs and their metabolites.

IT 22760-18-5, Freqoquine
 RI: RIOL (Analyte) NMR (Analytical study)
 (determination of, in urine of humans, by TLC and GC and mass spectrometry)
 RI: 22760-18-5 CAPLUS
 CH 2118-Quinacilimone, 7-methyl-2-[1-(methyl-ethyl)-4-phenyl]- (CA INDEX)



15 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3T 10824-66-8P 70724-06-0P 108497-74-1P
108497-75-1P 108497-76-3P 108497-77-4P
108497-78-1P 108497-79-4P 108497-80-2P
108497-81-0P 108497-82-1P 108497-83-2P
108497-84-1P
3L4 SPB [Synthetic preparation]; PREP (Preparation)
[preparation of]

3H 10824-65-0 CAPLUS
CN 2-[18]-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



3H 10724-06-0 CAPLUS
CN 2-[18]-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



3H 108497-74-1 CAPLUS
CN 2-[18]-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl-6-(9H-xanthen-9-yl)- (CA INDEX NAME)

15 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3H 108497-79-5 CAPLUS
CN 2-[18]-Quinazolinone, 4-[[2,4-dioxan-2-yl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



3H 108497-79-5 CAPLUS
CN 2-[18]-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl-4-(9H-xanthen-9-yl)- (CA INDEX NAME)



3H 108497-82-3 CAPLUS
CN 2-[18]-Quinazolinone, 1-ethyl-4-[[1-(ethylthio)ethyl]-3,4-dihydro-4-phenyl-, (R*,R*)- (PCC) (CA INDEX NAME)

Relative stereochemistry.

15 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3H 108497-75-2 CAPLUS
CN 2-[18]-Quinazolinone, 4-[[1-ethoxyethyl]-3,4-dihydro-1-methyl-4-phenyl-, (R*,R*)- (PCC) (CA INDEX NAME)

Relative stereochemistry.



3H 108497-76-3 CAPLUS
CN 2-[18]-Quinazolinone, 4-[[1-(ethylthio)ethyl]-3,4-dihydro-1-methyl-4-phenyl-, (R*,R*)- (PCC) (CA INDEX NAME)

Relative stereochemistry.



3H 108497-77-4 CAPLUS
CN 2-[18]-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl-4-(tetrahydro-2-furanyl)- (CA INDEX NAME)

15 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3H 108497-81-0 CAPLUS
CN 2-[18]-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl-4-(tetrahydro-2-furanyl)- (CA INDEX NAME)



3H 108497-82-1 CAPLUS
CN 2-[18]-Quinazolinone, 4-[[1-ethoxyethyl]-3,4-dihydro-1-methyl-4-phenyl-, (R*,R*)- (PCC) (CA INDEX NAME)

Relative stereochemistry.



3H 108497-83-2 CAPLUS
CN 2-[18]-Quinazolinone, 4-[[1-(ethylthio)ethyl]-3,4-dihydro-1-methyl-4-phenyl-, (R*,R*)- (PCC) (CA INDEX NAME)

Relative stereochemistry.

13 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI 126497-84-3 CAPLUS
 CN 2-ethyl-4-((1-methyl-1H-imidazol-2-yl)-1,4-dihydro-4-phenyl-1H-1,2,3-triazol-5-yl)-1H-imidazole-5-carboxamide
 (a,5)-(1-NC5) (CA INDEX NAME)

Relative stereochemistry.



13 ANSWER 83 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1990:42458 CAPLUS
 DOCUMENT NUMBER: 11242458
 ORIGINAL REFERENCE NO.: 11270238,12064
 TITLE: Solid surfactant solutions of active ingredients in sugar esters
 AUTHOR(S): Rehn, Lorenz; Bucher, Heinz
 CORPORATE SOURCE: Bundes A.-O., Basel, CH-4002, Switz.
 SOURCE: Pharmaceutical Research (1989), 6(11), 958-60
 CODEN: PERED; ISSN: 0724-8741
 JOURNAL
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB The penetration of solid solns. of olosporin as model solubilize in water-soluble sugar esters, which are solid, biodegradable, and nontoxic surfactants, was described. Sugar esters were excellent solubilizers for poorly water-soluble drugs such as olosporin. Such system are suitable for the preparation of solid dosage forms for the purpose of oral administration. Addition of water to the solid solns. yields clear solns. of the solubilizer.
 IT 22760-18-5, Proquazone
 RI 22760-18-5 CAPLUS
 CN 22760-18-5 CAPLUS
 (solubilizers for, sugar esters as, in solid solns. for pharmaceutical dosage forms)
 RI 22760-18-5 CAPLUS
 CN 21181-Quinazolinone, 7-methyl-1-(1-methyl-1H-imidazol-2-yl)-4-phenyl-1H-imidazole-5-carboxamide
 (CA INDEX NAME)



13 ANSWER 84 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1990:49616 CAPLUS
 DOCUMENT NUMBER: 11249616
 ORIGINAL REFERENCE NO.: 11211679,11678
 TITLE: Quantitation by computerized visual image analysis of gastric mucosal lesions induced in mice and rats by non-steroidal anti-inflammatory drugs
 AUTHOR(S): Mainford, R. D.
 CORPORATE SOURCE: Anti-Inflammatory Res. Unit, Strangeways Res. Lab., Cambridge, UK
 SOURCE: Acta Physiologica Hungarica (1989), 7(12-3), 371-3
 CODEN: APHWHQ; ISSN: 0231-424X
 JOURNAL
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB A method is described for the quant. determination of gastric mucosal lesions induced by non-steroidal anti-inflammatory drugs in mice and rats. The area and number of gastric lesions present in formalin-fixed, glyoxal-cleared mucosa is determined by computerized visual image anal. using instrumentation as described. The method is also applied to the determination of the protective effects of antileuk agents (e.g. prostaglandin E₂, piroxicam). This method affords unambiguous sensitive and determination of the percentage area of the mucosa damaged and the number of the lesions.
 IT 22760-18-5
 RI 22760-18-5 CAPLUS
 CN 21181-Quinazolinone, 7-methyl-1-(1-methyl-1H-imidazol-2-yl)-4-phenyl-1H-imidazole-5-carboxamide
 (CA INDEX NAME)



13 ANSWER 84 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1989:62509 CAPLUS
 DOCUMENT NUMBER: 11122509
 ORIGINAL REFERENCE NO.: 11137184,37188
 TITLE: Role of low Na cyclic AMP phosphodiesterase in tracheal relaxation and bronchodilation in the guinea pig
 AUTHOR(S): Harris, Alex J.; Connell, Mary J.; Ferguson, Edward W.; Wallace, Kenneth W.; Gordon, Robert J.; Papani, Edward D.; Silver, Paul S.
 CORPORATE SOURCE: Dsg. Pharmacol., Sterling Res. Group, Kenilworth, NY, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1989), 251(1), 189-200
 CODEN: JPHEDJ; ISSN: 0022-3265
 JOURNAL
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB The relationship between inhibition of the milipram-sensitive and CI-930-sensitive low Na GMP-specific phosphodiesterase (PDE) isoenzymes (PDE IIIBO and PDE IIIC, resp.) and bronchomotor tone was examined in the guinea pig. Rolipram and CI-930 exhibited biphasic concentration-response relations for relaxation of carbachol-, histamine-, and LTD4-contracted trachea. However, each agent produced a monophasic (isoprenaline)-concentration-response curve when tested in the presence of a fixed concentration (3 µM) of the other. The same relations were observed for inhibition of tracheal peak III PDE isolated via DEAE-cellulose chromatog. Whereas CI-930 was approx. equipotent in inhibiting PDE IIIC and relaxing rolipram-precontracted trachea, rolipram was substantially more potent (IC50 = 0.02 µM) in relaxing CI-930-precontracted trachea than in inhibiting CI-930-precontracted PDE III (PDE IIIBO, IC50 = 2.4 µM). Among a series of PDE inhibitors, there was a correlation between PDE IIIC inhibition (i.e., PDE III in the presence of rolipram) and rolipram-precontracted tracheal relaxation, but not between PDE IIIBO inhibition and CI-930-precontracted tracheal relaxation. None of the PDE inhibitors used in this study have been reported to displace rolipram from a high-affinity binding site in rat brain. A correlation between relaxation of CI-930-precontracted trachea and displacement of rolipram binding by these agents was observed between in vitro bronchodilation (inhibition of histamine-induced bronchoconstriction) and PDE IIIC inhibition (equipotent-displacing potency, and relaxation of rolipram-precontracted trachea, but not PDE IIIBO inhibition. These data suggest that in the guinea pig, PDE IIIC inhibition promotes bronchodilation whereas rolipram-induced bronchodilation is associated with a high-affinity binding site, which may or may not be the PDE IIIBO isoenzyme.
 IT 22760-18-5, Proquazone
 RI 22760-18-5 CAPLUS
 CN 21181-Quinazolinone, 7-methyl-1-(1-methyl-1H-imidazol-2-yl)-4-phenyl-1H-imidazole-5-carboxamide
 (CA INDEX NAME)

15 ANSWER 85 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM (Continued)



15 ANSWER 85 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 1989-001638 CAPUS

DOCUMENT NUMBER: 111-201438

ORIGINAL REFERENCE NO.: 111-233979, 233964

TITLE: Intravenous pharmaceutical solutions containing

water-soluble peptides and polyol monomers of

C6-18-fatty acids as solubilizers

Hahn, Lorenz

Daimler-Patent-G.m.b.H., Fed. Rep. Ger.; Hoechst AG

Ger. Offen., 31 pp.

CDBSI; CACUS

Patent

German

FAMILY ACC. NUM. COUNTRY

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3870494	A1	19890123	DE 1988-3870494	19890900
DE 3870494	B4	20060518		
JP 45484	A2	19891030	JP 1988-4518	19890901
JP 50510	B	19900330		
FR 2620236	A1	19890317	FR 1988-11953	19890912
FR 2620236	B1	19910225		
FR 2620236	A5	19900316	DE 1988-10444	19890912
GB 683672	A5	19940429	GB 1988-3798	19890912
FR 2620236	A1	19890316	FR 1988-4332	19890912
FI 9404132	C	19950731		
FI 94037	B	19950731		
FI 94037	C	19951130		
NO 880402	A	19890316	NO 1988-4052	19890913
NO 174834	B	19960701		
NO 174834	C	19961009		
DE 8802221	A	19890316	DE 1988-3221	19890913
DE 503279	C	19960513		
AG 8822172	A	19890427	AG 1988-22172	19890913
AG 827877	B2	19940914		
GB 2209671	A	19890514	GB 1988-21443	19890913
GB 1738775	C	19961210	CA 1988-577214	19890913
DK 8805111	A	19890316	DK 1988-5111	19890914
DE 175132	B1	20040614		
JP 0151126	A	19890614	JP 1988-231396	19890914
JP 3090464	B2	20000225		
AT 8802249	A	19920815	AT 1988-2249	19890914
AT 795139	B	19930215		
FR 131084	B1	19900417	FR 1988-11074	19890914
NL 8802215	B	19900403	NL 1988-2275	19890915
NL 130594	C	20031217		
DE 1012118	A6	19960301	DE 1988-2031	19890915
ZA 8806485	A	19900530	ZA 1988-4885	19890915
US 5756450	A	19990526	US 1974-335523	19911107
			DE 1987-373069	AT 19870915
PRIORITY APPL. INFO.			DE 1988-3862355	AT 19890117

15 ANSWER 85 OF 327 CAPUS COPYRIGHT 2008 ACS ON STM (Continued)

ACCESSION NUMBER: 1989-045447 CAPUS

DOCUMENT NUMBER: 111-146447

ORIGINAL REFERENCE NO.: 111-424214, 24244a

TITLE: Comparative study of nonsteroidal inflammation

inhibitors, using a new combined method

Gabor, Miklos; Ratra, Smol

Gyorgyhehatarati Zrt., Szent-Gyorgyi Albert

Orvostud. Egy., Szeged, Hung.

Kiesleles Orvostudomány (1989), 41(3), 234-9

CDBSI; CACUS

Journal

Hungarian

AB The simultaneous inhibition of croton oil-induced ear edema and

carapace-induced paw edema by 4 nonsteroidal anti-inflammatory agents

was studied in rats. Piroxicam at 10 mg/kg caused 42.3 and 52.9%

inhibition of the 2 types of edema, resp. Phenylbutazone at 50 mg/kg

caused 36.8 and 44.6% inhibition, piroxicam at 100 mg/kg caused 28.1 and

57.6% inhibition, and staropirone at 200 mg/kg caused 20.5 and 46.9%

inhibition, resp.

IT 27602-18-5, Propanolone

R1: AC (Biological activity or effector, except adverse); BSI

(Biological)

study, unclassified; THU (Therapeutic use); BSL (Biological study);

USK (See)

(Inflammation inhibition by, in edema model)

PM 22760-18-5 CAPUS

CN 2118-Quinacrine, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX

NAME)

a

satisfactory manner and the addition of water effects the formation of a

micellar solution from which the active agent is directly bioavailable.

IT 22760-18-5

R1: BSL (Biological study)

(pharmaceutical injections containing polyol fatty acid monomers

and)


PM 22760-18-5 CAPUS

CN 2118-Quinacrine, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX

NAME)



15 ANKHEA 92 OF 327 CAPULUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1989152194 CAPULUS
 DOCUMENT NUMBER: 11112634
 ORIGINAL REFERENCE NO.: 11129399, 209824
 TITLE: Structure of peptidamido-benzophenone and peptidamido-benzylol metabolites
 Sivakova, V. G.; Golovenko, N. Ya.; Totorova, M. Tr-F
 AUTHOR(S):
 Tr-F
 CORPORATE SOURCE: Rudenko, O. P.
 SOURCE: Odessa Gos. Univ., Odessa, USSR
 Khimiko-Farmatsveticheskii Zhurnal (1989), 23(6), 451-3
 COUNTRIES: RUSSIA ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 CIT



AB The metabolism of 5-iodo-2-peptidamido-benzophenone (I; R1 = H, R2 = Oly-Oly, Oly-Oly-2, Oly-Ala-2) and 5-iodo-2-peptidamido-benzylol (II) was studied in mice and rats. The metabolites involved N-demethylation, hydroxylation, hydrolysis, and methylation. Some of the metabolites had a benzodiazepine structure which may explain the psychotropic benzodiazepine-like activities of I and II.

440254-5

12 (a) Metabolite of benzodiazepine
 R1 R2OL (Biological study)
 CH 440254-5 CAPULUS
 CH 2118-Quazabolone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANKHEA 92 OF 327 CAPULUS COPYRIGHT 2008 ACS on STM (Continued)
 R1 cellulose-07, 0.4 g disodium (I) and 40 mg 94N R2OL was stirred rapidly into 100 ml H₂O, R2OL was evapd, and the particles thus formed were isolated by filtration. The particle size was 0.116 µm and the polydispersion factor was 294. A soln. contained the above formulation

mg I and isotonic glucose, and a 100 µg/kg dose I was administered to rabbits by injection. As a result, pulse, blood pressure, ventricular blood pressure, cardiac contractility, cardiac output, and peripheral blood circulation were the same as those in a control receiving an injection over 2, R2OL, and polyethylene glycol.

27 22760-18-5, Progesterone
 R1 R2OL (Biological study)
 (pharmaceutical injectable hydroalcoholic containing)

27 22760-18-5 CAPULUS
 CH 2118-Quazabolone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANKHEA 92 OF 327 CAPULUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1989199224 CAPULUS
 DOCUMENT NUMBER: 1101199224
 ORIGINAL REFERENCE NO.: 110129799, 239824
 TITLE: Pharmaceutical injectable hydroalcoholic containing water-insoluble active agents
 Inventor(s): Last, Matyja Sucker, Heinz
 Patent Assignee(s): Danke, G. A., Dtlitz.
 SOURCE: Fr. Danke, 26 pp.
 COUNTRIES: FR, DE
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY NO., NUM. CONTR.: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2609427	A1	19800624	FR 1987-17792	19871217
FR 2609427	B1	19910208		19871217
NL 8702398	A	19800710	NL 1987-2990	19871211
NL 194638	B	20000607		
NL 194638	C	20001004		
JP 52341	A2	19900928	JP 1987-5601	19871215
JP 526861	B	19910728		
DE 3742473	A1	19800728	DE 1987-3742473	19871215
DE 3742473	C2	19901313		
DE 679452	A1	19920228	DE 1987-4895	19871215
DE 679452	A	19900620	DE 1987-4841	19871217
DE 177319	R1	20000704		
DE 679043	A	19800620	DE 1987-5047	19871217
DE 163625	A	19800620		
DE 2200048	A	19800707	GB 1987-2904	19871217
DE 2200048	C	19910206		
DE 1900848	A1	19800418	DE 1987-1461	19871217
DE 201344	A5	19800620	DE 1987-33841	19871217
IL 84855	A	19920229	IL 1987-04855	19871217
CA 1204516	C	19910213	CA 1987-554638	19871217
AU 8703730	A	19910315	AU 1987-3330	19871217
AU 8703730	A	19870228		
JP 6145112	R2	19910221		
JP 6145112	A	19800708	JP 1987-22622	19871218
ZA 870253	ZA	19800930	ZA 1987-953	19871218
DE 2028492	A6	19870701	DE 1987-2635	19871218
GB 539392	A	19950214	GB 1991-442104	19950116
DE 173745	B1	20000607	DE 2000-364	20000211
DE 1986-3647392	A	19861219		
			OS 1987-134337	19871217
			OS 1989-436147	19891213

AB I.v. pharmaceutical hydroalcoholic have the form of aqueous suspensions or dry osmotic, that may be resuspended in aqueous medium; the hydroalcoholic contains the pharmaceut. active agent in a solid, particulate form. A solution containing 1 g

15 ANKHEA 92 OF 327 CAPULUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 1989199224 CAPULUS
 DOCUMENT NUMBER: 1101128359
 ORIGINAL REFERENCE NO.: 110129799, 239824
 TITLE: Effect of peripheral benzodiazepine receptor ligands on the contraction of isolated heart atrium and papillary muscle of rats

Author(s): Sano, Nelsjo Ratty, Matyja Sucker, Heinz
 Corporate Source: Dep. Pharmacol. Toxicol., Univ. Hospital, Stockholm, Sweden
 Source: Pharmacology & Toxicology (Oxford, United Kingdom) (1989), 64(1), 147-9
 COUNTRIES: SE, NO, SWE ISSN: 0951-9288
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The affinities of 14 ligands for peripheral benzodiazepine receptors in the rat heart (determined by inhibition of [³H]Ro 5-5844 binding) and their effects on the also stimulated contractions of the isolated atrium and papillary muscle were determined. The potencies in altering the contractile force were independent of the receptor d. In various regions of the heart.

This lack of correlation between binding affinity and contractile effects suggests that the peripheral benzodiazepine receptors are not involved in the actions of these ligands on the heart.

27 22760-18-5, Progesterone

R1 R2OL (Biological study)
 (heart contraction responses to, benzodiazepine receptors in relation to)

27 22760-18-5 CAPULUS
 CH 2118-Quazabolone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANWER 94 of 327 CAPUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 11087929
 DOCUMENT NUMBER: 11087929
 ORIGINAL REFERENCE NO.: 11214359A,14354
 TITLE: Drug distribution in the body: in vitro prediction and pharmacological interpretation
 AUTHOR(S): Sunderling, P. H.
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Progress in Pharmacology (1989), 6(4), 1-50
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Human and animal data reported in the literature for drugs on unbound steady state volume of distribution ($V_{d,ss}$), blood cell/buffer partitioning (K_p), ratio of bound to unbound fraction in plasma (K_1), octanol/buffer partition coefficient (P), and pK_a were collected. The data were critically evaluated in accordance with defined selection criteria. After selection, values on $V_{d,ss}$, K_p , K_1 , P and pK_a were available for 36-38 basic and 15 acidic drugs in humans and on 13 barbituric acid drugs. In rats, regression anal. were performed with $V_{d,ss}$ on each of K_p , K_1 , P and pK_a to test if a reliable in vitro prediction of drug distribution in vivo is possible and if the values obtained for the parameters K_p and $V_{d,ss}$ have physiol. meaning. Significant correlations existed between $V_{d,ss}$ and each of K_p , K_1 and P for the tested bases in humans and for the acids in rats. Significant correlations were also found between $V_{d,ss}$ and each of K_p and P for the studied acids in humans, whereas $V_{d,ss}$ apparently did not depend on P . Among the in vitro predictors tested, K_p was the most reliable with a precision of prediction ranging between 22-50% suggesting that prospective in vitro distribution forecasting based on K_p is possible. The bases studied in humans and the barbituric acid drugs investigated in rats had unrestricted cellular uptake, were distributed throughout the total body water and excreted addn. binding and/or partitioning. In contrast, several of the acids tested in humans showed restricted cellular uptake. Lipophilicity was the major determinant for the unspecific cellular binding/partitioning of the bases and acids with unrestricted cell penetration. The largest fractions of the drugs resided within the cells in the bound/partitioned form explaining why P was a reliable in vitro predictor of drug distribution.

16 $V_{d,ss}$ for bases and acids with unrestricted cellular uptake. With the bases tested in humans, the blood cells contained 0.2-4.2% of the total, plasma unbound amt. present in the body at steady state, whereas with the acids in humans and barbituric acids in rats, these percentages ranged resp. between 0.4-17.3 and 12.7-35.4%. These results suggested that acidic compds. with unrestricted cellular uptake can exhibit higher relative affinities to blood cells than bases. The regression of $V_{d,ss}$ on K_p yielded values for total body water and extracellular space, which were in agreement with the generally accepted values for these physiol.

15 ANWER 95 of 327 CAPUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 11088219
 DOCUMENT NUMBER: 11088219
 ORIGINAL REFERENCE NO.: 11213545A,13548
 TITLE: Differential pulse polarographic determination of proganoone
 AUTHOR(S): Twine, Aytakin, Kir, Sedef, Omar, A. Nur
 CORPORATE SOURCE: Fac. Pharm., Hacettepe Univ., Ankara, 06100, Turk.
 SOURCE: Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical (1989), 27A(9), 821-824
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GC



16 The differential pulse polarogr. behavior of proganoone (1) was investigated in different media. The complex of electrolytes, height of the mercury column, temperature and the other parameters were so selected that the determination of this drug can be accomplished down to below ppb level. The reduction of 1 to proganoone is a reversible reaction and occurs with one electron transfer.

17 2760-18-5, Proganoone
 RL: ANI (Analytical) / ANI (Analytical study)
 Determination of 1 in capsules by differential pulse polarogr.

18 2760-18-5 CAPUS
 CD 2 (18)-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



17 119031-59-7, Proganoone
 RL: ANI (Analytical) / ANI (Analytical study)
 (proganoone electrochem. reduction product)

18 119031-59-7 CAPUS
 CD 2 (18)-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)

15 ANWER 94 of 327 CAPUS COPYRIGHT 2008 ACS on STM (Continued)
 volcs. in humans and rats. It cannot be ruled out that these aut. and the similar values obtained in the present study are both subject to bias. Indications are however, that this possible bias is small.

17 2760-18-5, Proganoone
 RL: RIOL (Biological study)
 (distribution of, process simulation of, in humans)


18 2760-18-5 CAPUS
 CD 2 (18)-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



15 ANWER 95 of 327 CAPUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 11088219
 DOCUMENT NUMBER: 11088219
 ORIGINAL REFERENCE NO.: 11213545A,13548
 TITLE: Differential pulse polarographic determination of proganoone
 AUTHOR(S): Twine, Aytakin, Kir, Sedef, Omar, A. Nur
 CORPORATE SOURCE: Fac. Pharm., Hacettepe Univ., Ankara, 06100, Turk.
 SOURCE: Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical (1989), 27A(9), 821-824
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GC



13 ANSWER 96 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1988:107400 CAPLUS
 DOCUMENT NUMBER: 109:10400
 ORIGINAL REFERENCE NO.: 109:102474,282704
 TITLE: Acid and alkaline hydrolysis of 2-amino-7-chloro-5-phenyl-1,3,4-benzoxiazepines
 AUTHOR(S): Kuehner, P.; Schleuder, M.; Riedewald, Petra
 CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
 SOURCE: Pharmazie (1989), 43(1), 262
 CODEN: PHARAZ; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 109:104000
 GI



AB The hydrolysis of title compds. I (R = H, Me) and II in refluxing HCl gave quinazolinones III (R = H, Me) and IV, resp. III (R = H, Me) were hydrolyzed to give quinazolinone V (R1 = H), whereas the hydrolysis of IV gave V (R1 = Me). Refluxing I (R = H, Me) and II in ethanolic KOH gave V (R1 = H and Me, resp.).
 IT 109:17-53-1P
 RI: NCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 [preparation and ring cleavage of]
 RI 109:17-53-1 CAPLUS
 CH 2-[R1]-Quinazolinone, 6-chloro-3-methyl-6-phenyl- (CA INDEX NAME)

13 ANSWER 97 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1988:10393 CAPLUS
 DOCUMENT NUMBER: 109:10393
 ORIGINAL REFERENCE NO.: 109:10393a,10393b
 TITLE: Synthesis of 5-phenyl-2-thioxo-1,3,4-benzoxiazepines
 AUTHOR(S): Kuehner, P.; Hengstenberg, O.; Barch, Anita
 CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
 SOURCE: Pharmazie (1989), 43(1), 5-10
 CODEN: PHARAZ; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 109:10393
 GI



AB The synthesis of the title compds. I (R1 = H, Me, R2 = H, Cl, R3 = H, Me, C6H4CH3) is achieved by reaction of 3-iodothiopyranato- or 2-acetylthiopyranato-1,3-benzoxepinones with alkylhydrazines, by thermal cyclization of 3-aminothiopyranone thiosemicarbazones or -methylthio thiosemicarbazones and by heating the 2-oxo-5-phenyl-1,3,4-benzoxiazepines with phosphorus(III) sulfide.
 IT 109:10-12-1P
 RI: SYN (Synthetic preparation); PREP (Preparation)
 [preparation of]
 RI 109:10-12-1 CAPLUS
 CH 2-[R1]-Quinazolinone, 6-chloro-3-methyl-6-phenyl- (CA INDEX NAME)



13 ANSWER 96 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



13 ANSWER 98 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1988:43171 CAPLUS
 DOCUMENT NUMBER: 109:31713
 ORIGINAL REFERENCE NO.: 109:32376,32404
 TITLE: Interaction of O-β-hydroxyethylrutin (ER) with nonsteroidal inflammation inhibitors
 AUTHOR(S): Gabor, Miklós; Engi, Erőks
 CORPORATE SOURCE: Gyógyszerkutatási Intézet, Szeged, Orvostud. Egy., Szeged, Hung.
 SOURCE: Készletes Orvostudomány (1985), 40(1), 9-14
 CODEN: KOTOM; ISSN: 0023-2378
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 AB The interaction of nonsteroidal inflammation inhibitors with ER was studied in rats. Carrageenan-induced foot edema was reduced by ER at 100 mg/kg, propofol at 5 mg/kg, nifedipine at 5 mg/kg and piroxicam at 2.5 mg/kg. ER had anti-inflammatory effects alone and potentiated the effects of the other drugs.
 IT 22760-18-5, Propofol
 RI: RIOL (Biological study)
 [inflammation inhibition by hydroxyethylrutin and]
 RI 22760-18-5 CAPLUS
 CH 2-[R1]-Quinazolinone, 7-methyl-2-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



13 ANMER 77 of 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1988:105947 CAPLUS
 DOCUMENT NUMBER: 108:07613
 ORIGINAL REFERENCE NO.: 108:142779,142784
 TITLE: The inhibitory effect of some nonsteroidal anti-inflammatory compounds on calmodulin dependent cAMP phosphodiesterase and structure-activity relationships
 AUTHOR(S): Nabokov, Boris Kuzov, Saliba, Ruykhanbek, Erdem, Ali, Kuyum Nabokov, Sergii
 CORPORATE SOURCE: RSCA LLC PAK, A. O., Ankara, Turk.
 SOURCE: Ruykhanbek Dargals (1987), 32(1), 31-9
 CORDIS NUMBER: ISSN: 0250-4885
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The inhibitory effects of progesterone, flufenamic acid, and aspirin on calmodulin-dependent cAMP phosphodiesterase were determined with respect to lipophilicity and the mol. connectivity index. Some relations between structure and inhibitory activity are described.
 IT 22760-18-5
 RI RSC (Biological activity or effector, except adrenergic); RSC (Biological) study, unclassified); PFP (Properties); RSC (Biological study) (cAMP phosphodiesterase inhibition by, structure in relation to)
 RI 22760-18-5 CAPLUS
 CN 21184-Quinolizone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 101 of 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:101 CAPLUS
 DOCUMENT NUMBER: 108:0501
 ORIGINAL REFERENCE NO.: 108:142779,142784
 TITLE: Comparative evaluation of equilibrium dialysis methods employing biological and artificial membranes for the determination of protein binding of drugs
 AUTHOR(S): Rindler-Schjerve, P. R.
 CORPORATE SOURCE: Biocent., Univ. Basel, Basel, CH-4056, Switz.
 SOURCE: Therapeutic Drug Monitoring (1987), 9(3), 321-6
 CORDIS NUMBER: ISSN: 0163-4356
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The performances of the conventional equilibrium dialysis method using artificial membranes (AED) and of an alternative equilibrium dialysis method employing buol. membranes of red blood cells (RED) were compared. Plasma protein binding values by AED and RED were available for a total of 22 nonsteroidal and electrolytic compounds, including the entire possible range of binding values. Plots of the mean plasma unbound fractions as obtained by AED and RED for the compounds studied could be fitted by a straight line with slope and intercept not different from unity and 0, resp. Also, the precision of the 2 methods appeared to be similar. However, the times required to reach equilibrium dialysis were different with RED and AED, this time span ranged 2-65 and 180-960 min, resp. Overall, the RED method offers an advantage over the AED procedure: it is less time consuming and hence possibly more reliable.
 IT 22760-18-5, Progesterone
 RI RSC (Biological study)
 RI 22760-18-5 CAPLUS
 CN 21184-Quinolizone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 102 of 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1988:07613 CAPLUS
 DOCUMENT NUMBER: 108:07613
 ORIGINAL REFERENCE NO.: 108:142779,142784
 TITLE: Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro
 AUTHOR(S): Tameratani, Christine Fuchel, Richard, Ruri, Hermann
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Munich, Munich, Fed. Rep. Ger.
 SOURCE: European Journal of Drug Metabolism and Pharmacokinetics (1987), 32(1), 163-7
 CORDIS NUMBER: ISSN: 0368-7639
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB For warfarin and several non-steroidal anti-inflammatory drugs (NSAID), i.e. acetylsalicylic acid, ibuprofen, ketoprofen, and cephendolone, there was no difference between the free drug content, in the homogenized and in non-homogenized samples from rabbit liver. This suggests that the binding of these drugs to liver tissue was not altered by homogenization. Whether NSAIDs interfere with binding of warfarin to liver tissue was studied. Acetylsalicylic acid, flubiprofen, ibuprofen, ketoprofen, cephendolone, and procoumarin markedly increased the free concentration of warfarin both in liver slices and homogenates. The extent of displacement did not differ between slices and homogenates.
 IT 22760-18-5
 RI RSC (Biological study)
 RI 22760-18-5 (Binding of, by liver, warfarin interaction with)
 RI 22760-18-5 CAPLUS
 CN 21184-Quinolizone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 102 of 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987:59727 CAPLUS
 DOCUMENT NUMBER: 107:197373
 ORIGINAL REFERENCE NO.: 107:216484,216466
 TITLE: 1,4-Benzodiazepines and 1,3-diazepines. Part IX. Effects of para- and meta-fluoro substitution on the 5-phenyl ring on its solution-state conformation in lactam-type 5-phenyl-1,4-benzodiazepines
 AUTHOR(S): Finner, Emil, Seeger, Ernst
 CORPORATE SOURCE: Pharm. Div., Kali-Chem. A.-G., Hannover, D-3000, Fed. Rep. Ger.
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1987), 32(1), 179-82
 CORDIS NUMBER: ISSN: 0365-6223
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB IRM data for benzodiazepines (I; R = H, p-F, m-F) are reported. Conformation effects caused by the F substituents are discussed. While I (R = H, p-F) exhibit only signals for a single rotational conformer, I (R = m-F) exhibit signals of two rotational isomers. Rotational barriers were determined.
 IT 110953-84-9 110953-84-9
 RI: PFP (Properties) (conformation anal. of)
 RI 110953-84-9 CAPLUS
 CN 21184-Quinolizone, 4-(4-fluorophenyl)-1-methyl-6-nitro- (CA INDEX NAME)



RI 110953-84-9 CAPLUS
 CN 21184-Quinolizone, 4-(4-fluorophenyl)-1-methyl-6-nitro- (CA INDEX NAME)

15 ANSWER 102 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 102 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987-432439 CAPLUS
 DOCUMENT NUMBER: 10712479
 ORIGINAL REFERENCE NO.: 10743287a, 5270a
 TITLE: Propanolone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states
 AUTHOR(S): Clissold, Stephen P.; Benford, Rosemary
 CORPORATE SOURCE: ADIS Brng Inf. Serv., Auckland, N. Z.
 SOURCE: Drugs (1987), 27(1), 478-502
 CDBR: DRUGS; ISSN: 0012-4667
 DOCUMENT TYPE: Journal General review
 LANGUAGE: English
 AB A review with approx. 50 refs.
 IT 22765-18-4, Propanolone
 RI RIOL (Biological study)
 Laboratory pharmacodynamic and pharmacokinetic properties of, in human and laboratory animals
 RI 22765-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 104 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987-119377 CAPLUS
 DOCUMENT NUMBER: 106119367
 ORIGINAL REFERENCE NO.: 10612381a, 2254a
 TITLE: Synthesis of quinazolinones
 AUTHOR(S): Bergman, Jan; Brynolf, Anna; Elman, Bjorn; Vuorinen, Rino
 CORPORATE SOURCE: Dep. Org. Chem., S. Inst. Technol., Stockholm, S-100 44, Swed.
 SOURCE: Tetrahedron (1986), 42(13), 3637-706
 CDBR: TETRA; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106119377
 AB Reaction of 2MeX (X = Me, Et, Ph, 4-MeC6H4, MeCO, Bu; X = Cl, Br, Iodo) with 2-H2NCE4CH gave the intermediate 2-H2NCE4CH- (I), which were cyclized to quinazolones by reaction with carbonyl compds. (e.g., acid chlorides, anhydrides, formates, and oxalates). Reaction of I with aldehydes, e.g. PhCHO, gave 1,4-dihydroquinazolinones, which were readily dehydrogenated. Reaction of I with C6H5OMe gave 4-phenyl-1-quinazolinone, which was reduced to 3,4-dihydro-4-phenyl-1-quinazolinone by H2/Ni in AcOH.
 IT 107189-02-32
 RI SPH (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 107189-02-9 CAPLUS
 CN 2118-Quinazolinone, 4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



15 ANSWER 105 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987-119363 CAPLUS
 DOCUMENT NUMBER: 106119363
 ORIGINAL REFERENCE NO.: 10612447a, 1949a
 TITLE: Carbon dioxide: A reagent for the simultaneous protection of nucleophilic centers and the activation of alternative locations to electrophilic attack. Part III. A new synthetic method for the ortho-substitution of N-monomethylanilines
 AUTHOR(S): Ratilsky, Alan R.; Fan, Wei Qiang; Anagnostou, Nimala
 CORPORATE SOURCE: Dep. Chem., Univ. Florida, Gainesville, FL 32611, USA
 SOURCE: Tetrahedron (1986), 42(14), 4027-34
 CDBR: TETRA; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106119363
 AB N-Methyl- and N-ethylaniline were regioselectively converted to ortho-substituted derivs., using CO2 both for N-protection and as an intermediate carbanion stabilizing group, and MeONi to lithiate the ortho-C atom. The resulting 1-N-ortho-substituted phenyl-3-methyl- and -N-ethylcarbamates underwent acid catalyzed decarboxylation under mild conditions. No o-substituted products were detected. I.e., lithiation of PhMeCO2Li (2) and then addition of R2S followed by acid hydrolysis gave 6A o-PhCH(OH)C6H4NHMe. 1 was prepared by the reaction of PhMeLi and CO2.
 IT 26331-07-2P
 RI SPH (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 26331-07-2 CAPLUS
 CN 2118-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



13 ANWERS 106 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1986105311 CARLOS
 DOCUMENT NUMBER: 105105511
 ORIGINAL REFERENCE NO.: 105105511, 174204
 TITLE: Treating dysmenorrhea with 4-aryl-quinazolinone
 INVENTOR(S): Von Graefenberg, Beat; Menach, Krish
 PATENT ASSIGNEE(S): Sande A.G., Belfs
 SOURCE: Pat. Specif. (Aust.), 11 pp.
 DOCUMENT TYPE: Patent ALXAP
 LANGUAGE: English
 FAMILY ACT. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AO 550249	AO	19860227	AO 1981-71301	19810403
AO 501702	A	19910122		
EE 089646	A1	19911202	EE 1981-10239	19910602
JP 5741432	A	19820125	JP 1981-05553	19810403
FR10177 APPL. REF.			FR 1980-18519	A 19800604

G2



AB Title compds. (1) R=Cl-4 alkyl or haloalkyl, allyl, propargyl, cyclopropylmethyl, R=Cl-4 alkyl, alkoxy, alkylthio, or alkylamino, R, Cl, Br, SO₂, H₂N, diaethylamino, R₂N, R, Cl, Br, Cl-4 alkyl or alkoxy or R₂N-CO₂R₂, R₂N, R, Cl, Br, Cl-4 alkyl or alkoxy, CH₃, CF₃, R₂N, R, Cl, Cl-4 alkyl are useful for treatment of dysmenorrhea. For example, flupropaque (1) R=CH₂CH₂, R₂N=CH₂, R₂N=CH₂, R₂N=CH₂-F provided good to very good improvement at 5mg 3 times a day in patients with primary dysmenorrhea.

IT 40167-03-1
 RI RI 2102 (Biological study)
 (dysmenorrhea treatment with)
 RI 40167-03-1 CARLOS
 CH 2188-Quinazolinone, 4-(4-fluorophenyl)-1-methyl-1-(1-methylthio)- (CA INDEX 1006)

13 ANWERS 107 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1986107599 CARLOS
 DOCUMENT NUMBER: 105107699
 ORIGINAL REFERENCE NO.: 105107699, 172684
 TITLE: A method for measuring specific activities of carbon-14-labeled compounds by gas chromatography-mass spectrometry-computer system
 AUTHOR(S): Yamamaru, Hiroshi; Takai, Ryozo; Morita, Masao; Nakamura, Toshiyuki; Matsui, Takahiro; Ise, Gen; Sumitani, Ken-ichi, Co., Ltd., Takahara, Japan
 SOURCE: Radiocarbon (1983), 34(2), 47-71
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A method was developed for measuring specific activities of 14C-labeled compds. by gas chromatography-mass spectrometry-computer system. A precise and accurate determination for specific activities of various 14C-labeled compounds is possible. The method is convenient and applicable to small amt. of samples as well as to volatile compounds. The anal. of the mass spectra provides information on the labeling patterns and synthetic procedures of the analyzed materials.

IT 103151-58-3
 RI RI 2057 (Analytical study)
 (determination of specific activity of, by gas chromatography-mass spectrometry-computer system)
 RI 103151-58-3 CARLOS
 CH 2188-Quinazolinone-4-(4-Cl-1-cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX 1006)



15 ANWERS 106 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM (Continued)



13 ANWERS 108 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1986107599 CARLOS
 DOCUMENT NUMBER: 105107699
 ORIGINAL REFERENCE NO.: 105107699, 172684
 TITLE: Affinity of various compounds for benzodiazepine binding sites in rat brain, heart and kidneys in vitro
 AUTHOR(S): Sano, N.
 CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Univ. Nagoya, Nagoya, 467-02
 SOURCE: Acta Pharmacologica et Toxicologica (1984), 59(1), 333-8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Binding of several psychoactive, antiinflammatory, antihypertensive, and anticholinergic drugs to central and peripheral benzodiazepine (BE) binding sites was studied in the brain, heart and kidneys of rats. Biazepam [439-14-5] exhibited the highest affinity for all binding sites (K_i values at 0.01 μM level); another 1,4-BE, oxazepam [604-75-1] had markedly lower affinity for peripheral binding sites (K_i 21-37 μM). Non-BE compounds, had low affinity for central BE receptors; propaque [1-2760-18-5] was the most potent (K_i 9.5 μM). The affinities of non-BE compounds were higher for peripheral BE binding sites. The K_i value for propaque was approx. 0.1 μM and many other antihypertensive agents, and the vasodilators oxydiazepam [148-59-7] and nifedipine [21823-25-4], produced K_i values in the micromolar level. β-Blockers, drugs, and several other antihypertensive and anticholinergic agents lacked affinity for both central and peripheral BE binding sites. According to the results, the affinity for peripheral binding sites is independent of an affinity for central BE receptors. Non-BE compounds that bound to brain BE receptors bound with equal affinity to both BE and BE2 subgroups of receptors. The compounds with affinity for peripheral BE binding sites did not select between heart and kidney, which suggests that these organs have similar binding sites. The role of the peripheral BE binding sites has not yet been established. The findings of the study allow the selection of a more varied group of ligands to be used when investigating the physiol. significance of these binding sites.

IT 2760-18-5
 RI RI 2002 (Process)
 (binding of, to benzodiazepine receptors of brain and heart and kidney)
 RI 2760-18-5 CARLOS
 CH 2188-Quinazolinone, 7-methyl-1-(1-methylthio)-4-phenyl- (CA INDEX 1006)



14 ANSWER 108 OF 327 CAPLIS COPYRIGHT 2008 ACS on STN (Cont.) need

1	ANMER 109 OF 327	CONTRIBUTOR	2000 ACS on STN
2	ACCESSION NUMBER:	1995-121979	
3	DOCUMENT NUMBER:	1995-121979	
4	ORIGINAL REFERENCE NO.:	141243174,343526	
5	TITLE:	A study comparing the anti-inflammatory and microbicidal activities of azagospirone with those of other nonsteroidal anti-inflammatory drugs in the rat	
6	AUTHOR(S):	Jahn, D.	
7	INSTITUTIONAL SOURCE:	Amgen, Inc., San Diego A-6, San Diego, CA 92160	
8	SOURCE:	JOURNAL: ANKER, 123(8): 1173, 12-7	
9	DOCUMENT TYPE:	ORIGINAL	
10	ABSTRACT:	See 123(8): 1173, 12-7	
11	COMPETITIVE EVALUATIONS OF THE ANTI-INFLAMMATORY AND MICROBICIDAL ACTIVITIES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN THE RAT HAVE SHOWN AZAGOSPIRONES [1, 123:39-59, 12] TO OCCUPY AN INTERMEDIATE POSITION IN SUBSTITUTED BENZYLAMIDES. HOWEVER, THERE IS A VARYING DEGREE OF ADVERSE EFFECT ON THE GASTRIC MUCOSA, AND A COMPARISON OF THE KIDNEY AND LIVER OF AZAGOSPIRONES WITH OTHER ANTI-INFLAMMATORY DRUGS PLACES IT AT THE TOP WHEN COMPARED TO THE OTHERS. POSSIBLE REASONS FOR THIS PHENOMENON ARE DISCUSSED.		
12	REU (BIOLOGICAL STUDY):	See 123(8): 1173, 12-7	
13	REU (PHYSIOLOGICAL STUDY):	See 123(8): 1173, 12-7	
14	REU (TOXICOLOGICAL STUDY):	See 123(8): 1173, 12-7	
15	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
16	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
17	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
18	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
19	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
20	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
21	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
22	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
23	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
24	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
25	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
26	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
27	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
28	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
29	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
30	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
31	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
32	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
33	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
34	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
35	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
36	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
37	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
38	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
39	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
40	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
41	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
42	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
43	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
44	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
45	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
46	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
47	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
48	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
49	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
50	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
51	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
52	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
53	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
54	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
55	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
56	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
57	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
58	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
59	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
60	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
61	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
62	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
63	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
64	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
65	REU (PHARMACODYNAMICS):	See 123(8): 1173, 12-7	
66	REU (PHARMACOTHERAPY):	See 123(8): 1173, 12-7	
67	REU (PHARMACOLOGICAL STUDY):	See 123(8): 1173, 12-7	
68	REU (PHARMACOKINETICS):	See 123(8): 1173, 12-7	
69	REU (PHARMACODYNAMICS):</		



LS ANMERK 119 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STW
ACCESSION NUMBER: 1986;142260 CAPLOS
DOCUMENT NUMBER: 104;142260
ORIGINAL REFERENCE NO.: 104;023787, 22336a
TITLE: A-arykylsulfonolone compositions
INVENTOR(S): Skrifvars, No Viktor
PATENT ASSIGNER(S): Sandoz A.-G., Sutter.
SOURCE: Pat. Specif. (Aust.), 12 pp.
CODEN: ALKMAN
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNTRY: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 545003	B2	19850627	AU 1980-61836	19800828
AU 8061836	A	19810719		
BE 884935	A1	19810227	BE 1980-5939	19800827
JP 56036418	A	19810409	JP 1980-115678	19800828
PRIORITY APPL. INFO.			GB 1979-7872	A 19790830

55

[illegible]


L5 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (autoimmune diseases treatment with)
 FN 22760-18-5 CAPLUS
 CN 2(1H)-Quinazolinone, 7-methyl-3-[1-methylethyl]-4-phenyl- (CA INDEX
 NAME)



HN 40507-23-1 CAPLUS
 CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA
 INDEX NAME)



13 ANMER 113 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1985:559262 CARLOS
 DOCUMENT NUMBER: 107189922
 ORIGINAL REFERENCE NO.: 107189922
 TITLE: Determination of progesterone and its n-hydroxy metabolite by high-performance liquid chromatography. Clinical application: pharmacokinetics of progesterone in children with juvenile rheumatoid arthritis
 Lempiäinen, Matti; Mäkelä, Anna Liisa
 Rep. Clin. Chem., Univ. Cent. Hosp., Turku, Finland
 Journal of Chromatography (1985), 341(1), 105-13
 CODEN: JOCMAJ 1985: 0021-9673
 JOURNAL
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AS A method for the determination of progesterone [1] [27760-18-5] and its n-hydroxy metabolite [2] [57760-07-3] in serum and urine by reversed-phase HPLC is described. The technique is based on a single extraction of the unchanged drug, its metabolite and an internal standard from serum or urine with C18. The column was packed with μ bondapak C18 and the mobile phase was MeOH:H₂O (50:50) [pH 3]. The detection limits for progesterone and its metabolite were 0.02 nmol/L using 500 μ L of sample. For the determination of the total n-hydroxy metabolite only 100 μ L of sample are needed. The method described is suitable for routine clin. and pharmacokinetic studies. The clin. application of this method suggests that the pharmacokinetics of progesterone in adults and children are similar.
 IT 57760-07-3
 RI: RIOL (Biological study)
 (determination of Δ^4 progesterone metabolite by HPLC)
 RI 57760-18-5 CARLOS
 CH 21181-Quinoxalinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX 1986)

13 ANMER 114 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1985:553387 CARLOS
 DOCUMENT NUMBER: 107153587
 ORIGINAL REFERENCE NO.: 107153587
 TITLE: Modulation by drugs of leukotriene and prostaglandin production from mouse peritoneal macrophages
 Bruns, K.; Peakar, S. A.
 Dep. Pharmacol., Tulane Univ., Erlangen-Ruehrberg, Erlangen, D-8520, Fed. Rep. Ger.
 International Journal of Tissue Reactions (1985), 7(2), 97-103
 CODEN: IJTRDV 1985: 0250-0868
 JOURNAL
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

AS In mouse peritoneal macrophages, the tumor promoter 12-O-tetradecanoylphorbol-13-acetate, despite initiating the release of prostaglandin E₂ [28326-64-6], had little effect on the release of leukotriene C₄ [70205-60-6] like-immunoreactivity. The divalent cation ionophore A 23187 [15265-69-7] at concentrations between 10⁻⁴ and 10⁻⁶ mol/L initiated prostaglandin as well as leukotriene release. This prostaglandin and leukotriene release could be modulated by drugs. Nonsteroidal antiinflammatory drugs inhibited prostaglandin release but enhanced leukotriene production. The aspirin compound BM 7550 [56002-40-1] inhibited prostaglandin and leukotriene production, whereas the antiinflammatory compound mafenacetone [59040-30-1] inhibited the production of leukotriene C₄ like-immunoreactivity but enhanced the prostaglandin E₂ production. Nordihydroguajacetic acid [500-38-9] inhibited prostaglandin and leukotriene production. The results show that the metabolism of arachidonic acid [104-22-1] in macrophages via the cyclooxygenase [29311-18-3] or the lipoxygenase [18033-64-6] pathway is dependent on the stimulus applied. Both pathways can be inhibited noncovalently or selectively by drugs. The aspirin system does appear to be involved in the potency of drugs to inhibit the lipoxygenase and the cyclooxygenase pathway of arachidonic acid metabolism.
 IT 27760-18-5
 RI: RIOL (Biological study)
 (leukotriene and prostaglandin formation by peritoneal macrophage response to)
 RI 27760-18-5 CARLOS
 CH 21181-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX 1986)




15 ANMER 113 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM (Continued)

IT 27760-18-5
 RI: RIOL (Analytical study)
 (determination of, in human blood and urine by HPLC, pharmacokinetic relation to)
 RI 27760-18-5 CARLOS
 CH 21181-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX 1986)



13 ANMER 113 OF 327 CARLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1985:547278 CARLOS
 DOCUMENT NUMBER: 107147238
 ORIGINAL REFERENCE NO.: 107147238
 TITLE: Analytical study of piroxicam
 Vire, J. C.; Kaufmann, J. M.; Braun, J.; Patrasche, G. J.
 Inst. Pharm., Univ. Libre Bruxelles, Brussels, 1050, Belg.
 Journal de Pharmacie de Belgique (1985), 40(3), 133-8
 CODEN: JPHBAA 1985: 0047-2144
 JOURNAL
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI



AS Piroxicam [1] [36322-90-4] was determined in pharmaceuticals by differential pulse polarography. The method allowed the determination of I at a concentration of 37 μ g/L with a detection limit of 5 \times 10⁻⁸ M. I could be differentiated in the presence of other nonsteroidal antiinflammatory agents, niflumac acid [694-00-7], ketoprofen [10207-13-4], tolmetex [10371-23-3], sulindac [28194-50-2], indometacin [53-86-1], oxametacin [70205-30-9], and progesterone [12760-18-5]. In addition formulation excipients did not interfere in the determination. I was also determined in urine.
 IT 27760-18-5
 RI: RIOL (Analytical study)
 (piroxicam determination in presence of, by polarogr.)
 RI 27760-18-5 CARLOS
 CH 21181-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX 1986)




```

1  ANMER 116 16 OF 327  ACCESSION NUMBER: 19851058973
2  ACCESSION NUMBER: 19851058973
3  DOCUMENT NUMBER: 19851058973
4  GENBANK REFERENCE NO.: 121735.313534
5  TITLE: Isolation and characterization of cDNA libraries by compression
6  AUTHOR (1): Kawa, A.; Sauer, R.
7  CO-AUTHOR (1): Kawa, A.; Sauer, R.; Ch. 3501, Weiz.
8  JOURNAL: J. Theor. Chem. Phys. Advantages Probl.
9  PUBLICATION: Fed. Tech. (1994), Meeting in 2. 1992,
10  27-30. Editor (A): Glatz, R.; de Blaisy, C. 2. 1992,
11  Barcelona, Spain.
12  ORGAN: 313534
13  SOURCE:
14  CONFERENCE
15  ACCESSION TYPE:
16  LANGUAGE:
17  AB: Apoptotites are obtained by compression of granules prepared with or
18  without silicates and apogranules (19851058973)
19  CM-cellline:
20  19851058973, relation, and heterozygous cell lines (19851058973)
21  Apoptotites are obtained by compression of granules prepared with or
22  without silicates and apogranules (19851058973)
23  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
24  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
25  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
26  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
27  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
28  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
29  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
30  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
31  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
32  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
33  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
34  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
35  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
36  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
37  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
38  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
39  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
40  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
41  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
42  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
43  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
44  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
45  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
46  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
47  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
48  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
49  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
50  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
51  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
52  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
53  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
54  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
55  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
56  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
57  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
58  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
59  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
60  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
61  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
62  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
63  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
64  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
65  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
66  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
67  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
68  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
69  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
70  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
71  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
72  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
73  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
74  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
75  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
76  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
77  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
78  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
79  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
80  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
81  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
82  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
83  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
84  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
85  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
86  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
87  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
88  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
89  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
90  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
91  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
92  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
93  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
94  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
95  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
96  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
97  19851058973 and H 5 [19371-14-9], Massachusetts 01462-027, R
98  15 [1249-65-7] H 35 [19371-14-9] and H 5 [4104-63-9], Newark NJ
99  19851058973 and H 5
```




LS	ARMHZA 118 of 17	CARLOS COPIEOSTRAT 2008 ACS on SYN
ACCESSION NUMBER:	1985:95620	CARLOS
DOCUMENT NUMBER:	102195620	
ORIGINAL REFERENCE NO.:	102195620	
TITLE:	102195620, 150404	
AUTHOR(S):	Acid hydrolysis of 5-phenyl-1,3,4-benzotriazines	
CORPORATE SOURCE:	Schleudner, M.; Butzki, Susanne; Richter, P. Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ges. Ber. p.	
SOURCE:	Pharmazie (1984), 39(7): 505-6	
DOCUMENT TYPE:	CODEN: PHARAT; ISSN: 0033-7346	
LANGUAGE:	Journal	
CS	German	



AN	Refluxing benzotriazepinediones I (R = Me, R1 = H, R = H, R1 = H, Me) in dilute aqueous HCl resulted in ring cleavage and contraction, giving 5,4-c1(2N8)CH2CO2P and hydroxyquinoxalinediones II. Acid hydrolysis of R1 = Me, R1 = H) also gave the 8-oxo derivative.
IT	9490-10-25 R1: FORM (Formation, nonreparative); PREP (Preparation) (formation of, in benzotriazepinedione derivative acid hydrolysis) 9490-10-2 CAPLOS R1: 2,1-Quinoxalinedione, 3-phenyl-6-oxo-7,4-dihydro-4-hydroxy-1-methyl-4-methyl-1-CA (HUSK NAME)



15. ABBREVIATION OF JST CARLOS COPPEFIGHT 2000 ACE ON STR
 ACCESSION NUMBER: 1985:400299 CARLOS
 DOCUMENT NUMBER: 1071299
 ORIGINAL REFERENCE NO.: 1071554,58a
 TITLE: Anti-inflammatory activity of SL-573 [cycproquazone]
 POPA, Yoshiaki; Tani, Yoshikazu
 CORPORATE SOURCE: Takarazuka Res. Cent., Suntoro Chem. Co., Ltd.,
 Japan
 SOURCE: Ensho (1984), 6(4), 309-10
 CROSS REFERENCE, ISSN: 0359-4290
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese



AB	In addition to these potent anti-inflammatory effect, SM-573 (2) 1-37453-23-5) also showed analgesic and antipyretic effects without causing significant damage to gastrointestinal tract. SM-573 strongly inhibited cyclooxygenase (EC 1.1.1.64) activity, but not peroxidase function, but only slightly inhibited lipooxygenase (EC 1.1.1.17) activity. Thus, SM-573 appears to be a new type of anti-inflammatory drug.
IT	37453-23-5 En: BIOL (Biological study) En: Anti-inflammatory activity of, mechanism of
EN	37453-23-5 CASNo
EN	1-((2S)-2-oxo-3-oxo-1,3-cyclohexadienyl)-6-methoxy-4-phenyl- CA 12826



L5 ANMERK 115 OF 327 CAPLOS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 1985J72551 CAPLOS
ORIGINAL NUMBER: 1985J72551
ORIGINAL REFERENCE NO.: 102:131247a,11250a
TITLE: MOLECULAR MECHANISMS OF THE GASTRIC TOXICITY
OF ANTITUMORATIC DRUGS
AUTHOR(S): Ashworth, C.J., Waller, R.J., Peckar, B. A.J., Peckar,
B.
N.
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Ruhr-Univ., Bochum, 4630,
Fed. Rep. Ger.
SOURCE: Archives of Toxicology, Supplement (1994), 7(1)is.
Metab. Rept. on Toxicology Drugs Other Chem.:
323-7

ACCION TYPE: **COUNTRY:** Argentina **DATE:** 01-17-1970

LANGUAGE: English

ABSTRACT: Propranolol (I) [268-33-5] was considerably more effective than cimetidine (II) [513-65-3] in inhibiting the release of PGE₂ [34-34-4] from a whole cell preparation of human gastric mucosa incubated with arachidonic acid.


In vitro. This indicates that I, which is less ulcerogenic than II, is a potent inhibitor of human gastric mucosa cyclooxygenase [39392-10-3]. The results also indicate that there is lower incidence of gastrointestinal side effects of I as compared with II is not correlated with a less pronounced inhibition of prostaglandin formation in vivo, and added support to the assumption that the difference between the two drugs further supports, the capacity of quinuacrine pig gastric mucosa to synthesize leukotriene C₄ [70255-80-4]-like immunopig was demonstrated.

The same pattern of response was observed in experiments conducted in the presence of nonsteroidal antiinflammatory drugs could contribute to the gastric toxicity of these drugs.

JT 22760-18-5 (Biological study)
 RL: BIOL. (Biological study)
 (prostaglandin metabolism in human gastric mucosa response to,
 ulcerogenic
 potency in relation to)
 FN 22760-18-5 CAP/LUS
 CH 2(2E)-Quinazolinone, 7-methyl-3-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)




15 ANSWER 121 OF 327 CAPLOS COFFTSIGET 2008 ACS ON STN (Continued)




●, BC1

RU 91852-69-5 CAPLOS
 CN 2181-Quinazolinone,
 1-((cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy)- (CA INDEX NAME)




RU 91852-69-6 CAPLOS
 CN 2181-Quinazolinone,
 1-((cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)

15 ANSWER 121 OF 327 CAPLOS COFFTSIGET 2008 ACS ON STN (Continued)




RU 91852-70-9 CAPLOS
 CN 2181-Quinazolinone,
 1-((cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, hydrochloride (SCI) (CA INDEX NAME)




●, BC1

RU 91852-71-0 CAPLOS
 CN 2181-Quinazolinone, 1-methyl-4-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




15 ANSWER 121 OF 327 CAPLOS COFFTSIGET 2008 ACS ON STN (Continued)


RU 91852-72-1 CAPLOS
 CN 2181-Quinazolinone, 4-phenyl-1-((phenylmethyl)-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RU 91852-73-2 CAPLOS
 CN 2181-Quinazolinone, 1,4-dihydro-6-phenyl-1-((phenylmethyl)-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




RU 91852-76-5 CAPLOS
 CN 2181-Quinazolinone, 1-((cyclopropylmethyl)-6-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RU 91852-77-6 CAPLOS
 CN 2181-Quinazolinone,
 1-((cyclopropylmethyl)-6-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)


15 ANSWER 121 OF 327 CAPLOS COFFTSIGET 2008 ACS ON STN (Continued)



RU 91852-79-8 CAPLOS
 CN 2181-Quinazolinone, 1-((cyclopropylmethyl)-6-[2-hydroxy-3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]-4-phenyl-, compd. with 3,4,4'-trinitrophenol, (1:1) (PCI) (CA INDEX NAME)

CN 1

CRN 91852-78-7
 CNF C29 H32 N6 O3





CN 2

CRN 88-89-1
 CNF C6 H3 N3 O7



RU 91852-80-1 CAPLOS
 CN 2181-Quinazolinone, 1-((cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-[3-[4-phenyl-1-piperazinyl]propoxy]- (CA INDEX NAME)

LS ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



LS ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:497091 CAPLUS
 DOCUMENT NUMBER: 10197691
 ORIGINAL REFERENCE NO.: 10114867a, 14870a
 TITLE: Analgesic combinations
 INVENTOR(S): Cooper, Stephen A.
 PATENT ASSIGNER(S): Sandoz A.-G., Svita.
 SOURCE: PCT Int. Appl., 17 pp.
 COBERT: PEXX82
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8402173	A1	1984-06-21	WO 1983-8P326	1983-12-07
US 4423752	A	1984-07-05	US 1984-23362	1983-12-07
JP 6050026	T	1985-02-10	JP 1984-500121	1983-12-07
EP 35519	A2	1985-07-29	EP 1984-201	1983-12-07
DE 346126	B	1985-02-08		
IL 70407	A	1985-03-19	IL 1983-70407	1983-12-08
EP 111454	A1	1984-06-20	EP 1983-810581	1983-12-09
EP 111454	B1	1989-07-12		
US 4730196	A	1985-07-21	US 1983-8196	1983-12-09
CA 1237077	A	1985-02-04	CA 1983-442921	1983-12-09
AT 44461	T	1989-07-15	AT 1983-810581	1983-12-09
DE 4423745	A	1984-08-02	DE 1984-2742	1984-02-01
US 4392319	A	1986-07-08	US 1984-64899	1984-10-17
US 4794112	A	1988-12-27	US 1986-829571	1986-02-14
PRIORITARY APPL. INFO.			US 1982-448390	A 1982-12-09
			WO 1983-8P326	A 1983-12-07
			EP 1983-810581	A 1983-12-09
			US 1984-586566	A2 1984-03-06
			US 1984-586567	A1 1984-03-06
			US 1985-783014	A1 1985-07-08

AS An analgesic combination for oral or rectal administration contains hydroxyzine [50-85-7] or the salts and at least 1 of a nonsteroidal anti-inflammatory analgesic and/or acetaminophen [107-95-2]. Capsules were prepared containing 200 mg ibuprofen [15687-27-2] and 50 mg hydroxyzine [10246-75-0]. Clin. tests were given showing the synergistic effects of the combinations compared to administration of the single compd.
 IT 22760-18-5
 RX 22760-18-5 CAPLUS
 CH 2-[1R]-Oxirane-2-ylmethyl-4-phenyl-1-[(cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-[13-14-(2-pyridyl)-2-pyridyl]-propoxy]-1-CA INDEX NAME

LS ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

LS ANSWER 122 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




13 ANMERK 127 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-443714 CAPLUS
 DOCUMENT NUMBER: 10145714
 ORIGINAL REFERENCE NO.: 10145709, 127324
 TITLE: Effect of propargione and indomethacin on gastric prostaglandin synthesis in vitro and in vivo
 AUTHOR(S): Weiler, Horst; Meyer, Christiane; Froehlich, Joergens; Pescher, Brigitte M.
 CORPORATE SOURCE: Dep. Gastroenterol., Univ. Freiburg, Freiburg, F-7800,
 F-7800,
 SOURCE: Fed. Rep. Ger.
 Agents and Actions [1994], 25(1-2), 93-5
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Regulab
 DOCUMENT TYPE: Regulab
 LANGUAGE: AS

Although propargione [12760-18-5] is less ulcerogenic than indomethacin [53-56-1] in rat and man, it inhibits gastric mucosal synthesis of 6-keto-PGF_{1α} [59942-14-8] more effectively in both species in vitro. The more pronounced inhibitory activity of propargione can be observed on formation of 6-keto-PGF_{1α} from endogenous substrate by fragments of gastric mucosa as well as on conversion of exogenous arachidonic acid by a microsomal fraction of mucosal homogenates isolating high affinity of propargione for gastric mucosal cyclooxygenase [5979-35-7]. After oral administration, however, both drugs exhibit equal inhibitory potency on gastric formation of 6-keto-PGF_{1α} in the rat. Apparently, the pharmacokinetic properties of nonsteroidal antiinflammatory drugs contribute to their inhibitory action on gastric prostaglandin formation in vivo. The ulcerogenic effects of these drugs result not only from inhibition of the gastric prostaglandin system but also from their effects on other processes and other enzyme systems.

27 12760-18-5 CAPLUS
 EL: R10L (Biological study)
 12760-18-5 CAPLUS
 CH: 2-[(1R)-Quinoxalinone, 7-methyl-1-[(3-methylthio)-4-phenyl]- (CA INDEX NMR)



13 ANMERK 124 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



13 ANMERK 124 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-443709 CAPLUS
 DOCUMENT NUMBER: 10145709
 ORIGINAL REFERENCE NO.: 10145709, 127324
 TITLE: Polarography of heterocycles. 16. Polarographic studies on 1,4-benzodiazepine series
 AUTHOR(S): Pflieger, Peter; Buchstaber, Christa; Richter, Peter
 CORPORATE SOURCE: Inst.-Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2300, Ger. Dem. Rep.
 SOURCE: Wissenschaftliche Zeitschrift der Ernst-Moritz-Arndt-Universität Greifswald, Mathematisch-Naturwissenschaftliche Reihe [1992], 31(2), 37-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: German



AS Polarity of the title compds. was carried out in Britton-Romanson buffers in 50% EtOH and interpretation of the reduction mechanism given. For example
 10 I: X = O, R = H; X = O, R = Me; X = S, R = H; X = S, R = Me) cathodic diffusion-controlled 4e/4H waves were obtained with the 1st 2 members and 2e/2H waves were obtained with the latter 2 members. However a 3e wave was observed in addition these 2 latter compds. yield in waves caused by formation of the

By anal. In some cases, depending on the concentration, a dimer may be formed.
 27 17485-01-3P
 EL: PREP (Preparation)
 (Formation of, electrochem.)
 NN 17485-01-3 CAPLUS
 CH: 1,1'-(2,2',2'')-Biquinoxaline]-2,2''-dithione, 6,6''-dichloro-4,4''-diphenyl- (CA INDEX NMR)

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English

13 ANMERK 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984-150596 CAPLUS
 DOCUMENT NUMBER: 100150596
 ORIGINAL REFERENCE NO.: 100129154, 229164
 TITLE: Pharmacokinetics of the antitubercular propargione in healthy humans
 AUTHOR(S): Hinderling, Peter H.; Ross, Andre
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences [1984], 73(3), 322-40
 CORDIS ACCUMNO: 2591-0065-6239
 JOURNAL: Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: English



AB The pharmacokinetics of propargione (2) [12760-18-5] and of the measured metabolites in healthy humans after i.v. administration and after

the 300-mg oral dose were 1st order, whereas deviations from linear kinetics were observed at the 900-mg oral dose level. The apparent half-lives of the α, β, and γ phases of propargione in plasma were 2.14, and 76 min, resp. after i.v. administration. The total clearance of propargione was 700 ml/min, which indicated a high hepatic extraction. The apparent volume of distribution at steady state was 40 L.

Implying extensive binding or partitioning of the lipophilic drug in the tissues. Unchanged propargione (<0.02%), the α-hydroxy metabolite [15785-07-1] (<0.01%), and the conjugated α-hydroxy metabolite (10%) were readily excreted after i.v. administration. The extent of absorption

of propargione was approx. 74 and was entirely the result of a large 1st-pass effect. Digital computer anal. of the data after i.v. administration was performed with a linear 3-compartment model. A model-independent approach was used in the anal. of the peroral data.

27 12760-18-5 CAPLUS
 EL: R9 (Biological process); R97 (Biological study, unclassified); R10L (Biological study); R10C (Process)
 (Pharmacokinetics of, in humans)
 NN 12760-18-5 CAPLUS
 CH: 2-[(1R)-Quinoxalinone, 7-methyl-1-[(3-methylthio)-4-phenyl]- (CA INDEX NMR)

13 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 1993:49247 CAPLUS
 DOCUMENT NUMBER: 99:08147
 ORIGINAL REFERENCE NO.: 99:13621a,13604a
 TITLE: Synthesis, structure and properties of 4-phenylquinazolin-2-one with chlorine-containing substituents
 AUTHOR(S): Gerdichy, G. M.; Andromati, S. A.; Voronina, T. A.; Sakhamkulova, I. Kh.; Tarant'ev, P. R.; Sharbatyan, P. A.; Pavlovskiy, A. S.
 CORPORATE SOURCE: Fil.-Khim. Inst., Kiev, USSR
 SOURCE: Farmologicheskii Aktivnyi Veshchestva (1992), 14, 76-9
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 99:08147
 QA



AB 1 (R = H, XI = CHF2SO2 (III), CF3SO2 (VIII), CF3SO2 (IV), CHF2SO2 (VI))
 1 (R = Me, XI = CHF2SO2 (VII), CF3SO2 (VIII), CF3SO2 (IX), CF3SO2 (X), CF3SO2 (XI), CHF2SO2) were prepared. The analgesic activity of 1 (R = H) increased systematically with the value of the Hammett substituent constant for R1,
 a.e.,
 II < III < aseq. IV < V < aseq. VI. The analgesic activities of 1 (R = Me) increased in the order VII < VIII < IX < X < aseq. XI; analgesic activities increased in the order VII < VIII < XI < X < aseq. IX.
 IT 79:08-39-39 86:15-04-39 86:15-01-29
 86:15-04-39 86:15-07-49 86:15-08-59
 R1: RAC (Biological activity or effector, except adrenergic) / BIO (Biological study, unclassified) / STM (Synthetic preparation) / BICL (Biological study) / PREP (Preparation)
 (preparation and analgesic activity of)
 RII 79:08-39-39 86:15-04-39 86:15-01-29
 CH 2 (1R)-Quinazolinone, 6-[(difluoromethyl)thio]-1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 RII 86:15-07-4 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-[(difluoromethyl)sulfonyl]-1-methyl-4-phenyl- (CA INDEX NAME)

 RII 86:15-08-5 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-[(4-fluorophenyl)-1-methyl-4-phenyl]- (CA INDEX NAME)



15 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

 RII 86:15-04-1 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-[(4-fluorophenyl)-1-methyl-4-phenyl]- (CA INDEX NAME)



RII 86:15-05-2 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-methyl-4-phenyl-6-[(trifluoromethyl)- (CA INDEX NAME)

 RII 86:15-06-3 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-methyl-4-phenyl-6-[(trifluoromethyl)thio]- (CA INDEX NAME)



13 ANSWER 132 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 1993:405643 CAPLUS
 DOCUMENT NUMBER: 99:5643
 ORIGINAL REFERENCE NO.: 99:10354,10364
 TITLE: Quinazolinone derivative
 INVENTOR(S): Popert Antonio, Rafael; Ortiz Hernandez, Jose A.
 PATENT ASSIGNER(S): Ferrer Internacional S. A., Spain
 SOURCE: Span., 9 pp.
 CUBER: SPOLAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 1
 PRIORITY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 509087	A3	19930101	ES 1992-509087	19920112
PRIORITY APPL. INFO.:				19920112

 GI



13 The analgesic and antiinflammatory (no data) quinazolinone (I) was prepared by converting 4,2-methylquinazolin-2-one to its oxime and cyclizing the latter with COCl2 or CH2OCl2 to the 6-oxide of I which was treated with PCl3 to give I.
 IT 86:11-00-49
 R1: RCT (Reactant); RPH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RII 86:11-00-6 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-[(4-fluorophenyl)-7-methyl-1-(3-methylthio)-3-oxide (CA INDEX NAME)

15 ANSWER 132 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



27 40507-37-1P

R1: SP1 [Synthetic preparation]; PREP (Preparation)

R2: 40507-37-1 CAPLUS

R3: 2-[18]-Quinoxalinoine, 4-(4-fluorophenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)



15 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

R3: 26772-96-3 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6,7-dimethyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



R3: 26772-97-4 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



R3: 26772-98-5 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



R3: 26772-99-4 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-(3-methylphenyl)- (CA INDEX NAME)

15 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1987198135 CAPLUS

DOCUMENT NUMBER: 98198135

ORIGINAL REFERENCE NO.: 98198135, 98198135

TITLE: 1-Alkyl-4-aryl-3,4-dihydro-2-[18]-quinoxalinoines and

thiones. Synthesis and proton-NMR spectra

Hoshiban, William J.; Cooke, George; Denier, Max

Winkler, Joseph

CORPORATE SOURCE: Sandoz, Inc., East Hanover, NJ, 07926, USA

SOURCE: Journal of Heterocyclic Chemistry (1992), 19(4),

145-6


CODEN: JHETCA; ISSN: 0022-152X

JOURNAL

English

OTHER SOURCE(S): CASREACT 98198135

CI



AB: Alkylaryldihydroquinoxalinoines I and II (R = O, S; R = Me, Et, MeCN; R1 =

H, Me, F3C, MeCN, NO2, CO2R, etc.) were prepared by a modification of

the Pictet-Spengler reaction that involves treatment of an N-alkyl-N-arylamine

or thionamide with RUCHACPO in the presence of Me2CO. The IR spectra of

these compounds had unusual methylenedioxy and iso-Pr signals.

27 26772-98-7P 26772-96-3P 26772-97-4P

26772-98-5P 26772-99-4P 26772-01-3P

37749-76-1P 85575-41-7P

R1: SP1 [Synthetic preparation]; PREP (Preparation)

(Preparation of)

R3: 26772-96-7 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



15 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

R3: 26772-96-3 CAPLUS

R4: 2-[18]-Quinoxalinoine, 4-(2,6-dichlorophenyl)-3,4-dihydro-6-methoxy-1-[(1-methylethyl)- (CA INDEX NAME)



R3: 26772-01-3 CAPLUS

R4: 2-[18]-Quinoxalinoine, 4-(2,6-dichlorophenyl)-3,4-dihydro-6-methoxy-1-[(1-methylethyl)- (CA INDEX NAME)



R3: 37749-76-1 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-(4-(1-methylethyl)phenyl)- (CA INDEX NAME)



R3: 85575-41-7 CAPLUS

R4: 2-[18]-Quinoxalinoine, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

15 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




15 ANSWER 134 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1987:154879 CAPLUS
 DOCUMENT NUMBER: 98:154879
 ORIGINAL REFERENCE NO.: 98:23779,23780a
 TITLE: Effect of antiinflammatory drugs on endotoxin-induced diarrhea in mice
 AUTHOR(S): Tsunuma, Kazuo; Fujimura, Hajime
 CORPORATE SOURCE: Sch. Med., Gifu Univ., Gifu, 500, Japan
 SOURCE: Japanese Journal of Pharmacology (1997), 33(1), 165-73
 COUNTRY: JAPAN; ISSN: 0022-5198
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effects of various nonsteroidal antiinflammatory drugs (NSAID) and steroidal antiinflammatory drugs (SAID) on endotoxin (ETX)-induced diarrhea were studied in mice. ETX given orally did not induce diarrhea, but it induced diarrhea after parenteral administration, especially after i.v. injection. All NSAID and SAID tested inhibited ETX-induced diarrhea at dose levels similar to or lower than those commonly producing an acute antiinflammatory effect. The antidiarrheal effects were found in not only acidic NSAID, but also in basic NSAID and SAID which did not inhibit UV erythema, acute death induced by arachidonic acid injection, and PGE₂ biosynthesis. Thus, this test using ETX-induced diarrhea in mice may be used as a new and desirable method for screening or evaluating antiinflammatory drugs. The diarrheogenic action of ETX may be attributed to inhibition of PGE₂ biosynthesis.

IT 22760-18-5
 RI: ETOL (Biological study)
 (endotoxin-induced diarrhea response to, antiinflammatory action in relation to)
 RI 22760-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)




15 ANSWER 135 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1993:126047 CAPLUS
 DOCUMENT NUMBER: 98:126047
 ORIGINAL REFERENCE NO.: 98:19213a,19214a
 TITLE: Polarography of heterocycles. 14. Polarography of 7-chloro-5-phenyl-2-thioxo-1H-2,3-dihydro-1,2,4-benzotriazepines
 AUTHOR(S): Pfeiffer, P.; Knechtel, Christa; Richter, F.; Giesch, Karin
 CORPORATE SOURCE: Sch. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2005, Ger. Dem. Rep.
 SOURCE: Pharmazie (1993), 37(10), 714-17
 COUNTRY: POLAND; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI

15 ANSWER 135 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




AB Polarog. reduction of benzotriazepines I (5 = H, Me) (312 = bond) gave quinazoline II by a 2e/2e reaction, via 2e product I (51 = H). At pH >10, I (R = H, 312 = bond) was reduced by a 2e/2e mechanism to the 1,4a-quinazoline III. III was formed in addition to II in a concentration-dependent competitive reaction at pH 4.7.
 IT 77485-03-37
 RI: 898 (Synthetic preparation); PREP (Preparation)
 (preparation of, by reductive polarog. of benzotriazepinethione)
 RI 77485-03-9 CAPLUS
 CN 11:128,288-Siquinazoline-2,2'-dithione, 6,6'-dichloro-4,4'-diphenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPRIGHT 2008 ACS on STN (Continued)



320 83770-19-8 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-(13-methylbutoxy)-4-phenyl- (CA INDEX NAME)




321 83770-20-1 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-(heptyloxy)-4-phenyl- (CA INDEX NAME)




322 83770-21-2 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-[1,1,7-dimethylbutoxy]-4-phenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPRIGHT 2008 ACS on STN (Continued)



323 83770-21-6 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-[1,4-methoxyphenylmethoxy]-4-phenyl- (CA INDEX NAME)




324 83770-26-7 CAPLUS
 CN Pentamethylene, 5-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]- (CA INDEX NAME)




325 83770-27-8 CAPLUS
 CN 2-[18]-Quinazolinone, 6-[(13-methyl-2-butenyl)oxy]-4-phenyl-1-propyl- (PCI) (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPRIGHT 2008 ACS on STN (Continued)



326 83770-22-3 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-(decyloxy)-4-phenyl- (CA INDEX NAME)




327 83770-23-4 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-(decyloxy)-4-phenyl- (CA INDEX NAME)




328 83770-24-5 CAPLUS
 CN 2-[18]-Quinazolinone, 6-(cyclohexylmethyl)-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPRIGHT 2008 ACS on STN (Continued)




329 83770-28-9 CAPLUS
 CN 2-[18]-Quinazolinone, 1-methyl-6-[(3-methyl-2-butenyl)oxy]-4-phenyl- (PCI) (CA INDEX NAME)



330 83770-29-0 CAPLUS
 CN 2-[18]-Quinazolinone, 6-[(3-methyl-2-butenyl)oxy]-4-phenyl-1-[2,2,2-trifluoroethyl]- (PCI) (CA INDEX NAME)




331 83770-30-3 CAPLUS
 CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-7-[(3-methyl-2-butenyl)oxy]-4-phenyl- (PCI) (CA INDEX NAME)




15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)


RI 83770-33-4 CAPLOS
 CH 21181-Quinazolinone, 6-(pentyloxy)-4-phenyl-3-(2,2,2-trifluoroethyl)-
 (CA INDEX NAME)



RI 83770-32-5 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(octyloxy)-4-phenyl- (CA INDEX NAME)




RI 83770-33-6 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(pentyloxy)-4-phenyl- (CA INDEX NAME)




RI 83770-34-7 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(hexyloxy)-4-phenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 83770-33-2 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(2-(3-methylphenyl)ethoxy)-4-phenyl- (CA INDEX NAME)




RI 83770-45-5 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-7-(pentyloxy)-4-phenyl- (CA INDEX NAME)




RI 83770-41-6 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-7-(pentylthio)-4-phenyl- (CA INDEX NAME)

15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

RI 83770-35-8 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-[[3-methyl-2-butenyl]thio]-4-phenyl- (CA INDEX NAME)




RI 83770-36-9 CAPLOS
 CH 21181-Quinazolinone, 3-ethyl-7-[[3-methyl-2-butenyl]thio]-4-phenyl- (CA INDEX NAME)




RI 83770-38-1 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(pentylthio)-4-phenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 83770-42-7 CAPLOS
 CH 2-butenal, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-6-phenyl-6-quinazolinyl]oxy]-3-methyl- (CA INDEX NAME)




RI 83770-43-8 CAPLOS
 CH 2-butenal, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-6-phenyl-6-quinazolinyl]oxy]-3-methyl- (CA INDEX NAME)




RI 83770-44-9 CAPLOS
 CH 21181-Quinazolinone, 3-(cyclopropylmethyl)-6-(pentylsulfonyl)-4-phenyl- (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3N 83770-45-0 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-47-2 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-49-3 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3N 83770-52-9 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-53-0 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-54-1 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3N 83770-48-4 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-50-7 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-51-8 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



3N 83770-55-2 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-56-3 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)




3N 83770-57-4 CAPLUS
 CN 3-[2-(8-quinazolinylmethoxy) acid, 6-[[13-methyl-2-butenyl]oxy]-2-oxo-4-phenyl-1-(2R)-] (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



320 83770-58-5 CAPLOS
CN 2-Butenoic acid, 4-([1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy)-2-hydroxy-3,5-dimethyl-, (CA INDEX NAME)




321 83770-59-6 CAPLOS
CN 2-[18]-Quinoxalinone, 1-([4-(acetyl)-3-methyl-2-butenyl]oxy)-1-(cyclopropylmethyl)-4-phenyl-, (PCI) (CA INDEX NAME)




322 83770-60-9 CAPLOS
CN 2-[18]-Quinoxalinone, 1-(cyclopropylmethyl)-6-([4-hydroxy-3-methyl-2-butenyl]oxy)-4-phenyl-, (PCI) (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



323 83770-64-3 CAPLOS
CN 3-[18]-Quinoxalinone, 1-(cyclopropylmethyl)-2-oxo-4-phenyl-, ethyl ester (PCI) (CA INDEX NAME)




324 83770-65-4 CAPLOS
CN 3-[18]-Quinoxalinone, 1-(cyclopropylmethyl)-2-oxo-4-phenyl-, ethyl ester (PCI) (CA INDEX NAME)




325 83770-66-5 CAPLOS
CN 2-[18]-Quinoxalinone, 1-(cyclopropylmethyl)-6-([4-(acetyl)-3-methyl-2-butenyl]oxy)-1-(3-methyl-2-butenyl)-4-phenyl-, (PCI) (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



326 83770-61-0 CAPLOS
CN 2-Butenoic acid, 4-([1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy)-2-hydroxy-3,5-dimethyl-, (CA INDEX NAME)




327 83770-62-1 CAPLOS
CN 2-Butenoic acid, 4-([1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy)-2-hydroxy-3,5-dimethyl-, (CA INDEX NAME)




328 83770-63-2 CAPLOS
CN 3-Pyridinecarboxylic acid, 4-([1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy)-2-methyl-2-butenyl ester (PCI) (CA INDEX NAME)


15 ANSWER 137 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




329 83770-67-6 CAPLOS
CN 2-Butenoic acid, 4-([1,2-dihydro-1-(3-methyl-2-butenyl)-2-oxo-4-phenyl-6-quinazolinyl]oxy)-2-methyl-, (PCI) (CA INDEX NAME)




330 83784-53-6 CAPLOS
CN 2-[18]-Quinoxalinone, 1-(cyclopropylmethyl)-6-([3-methyl-2-butenyl]oxy)-4-phenyl-, (PCI) (CA INDEX NAME)



331 83784-54-7 CAPLOS
CN 2-[18]-Quinoxalinone, 6-([4-hydroxy-3-methyl-2-butenyl]oxy)-1-(3-methyl-2-butenyl)-4-phenyl-, (PCI) (CA INDEX NAME)



15 ANWEEA 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RI 83517-80-5 CAPLUS
 CI 2181-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-4-(phenylmethoxy)-
 (CA INDEX NAME)



15 ANWEEA 138 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:556139 CAPLUS
 DOCUMENT NUMBER: 97:156139
 ORIGINAL REFERENCE NO.: 97:25533a,25554a
 TITLE: Effects of nonsteroidal antiinflammatory drugs on rat gastric mucosal phosphodiesterase activity
 AUTHOR(S): Sulvela, J.; Kumpulainen, M.; Takola, O.; Vapaatalo, H.;
 COMPANATE SOURCE: Dep. Rheum. Sci., Univ. Tampere, Tampere,
 SF-33101/Finland
 SOURCE: Agents and Actions [1982], 11(4), 516-30
 CODING: AGCARS; ISSN: 0005-4739
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effects of acetylsalicylic acid [50-78-2], diclofenac [15707-06-5], ibuprofen [15487-27-1], indomethacin [53-86-1], naproxen [15204-57-1], phenylbutazone [50-33-9], propargene [22760-18-1], fluprogesterone (BF 46-790 N) [60507-23-1], validol [15194-10-2], sulindac sulfide [49627-27-2], and tolafenamic acid [27720-18-7] were compared on rat gastric mucosal cyclic nucleotide phosphodiesterase (PDEs) [9040-59-9]. Some of the drugs inhibited PDEs effectively, the RI values being clearly lower than those of theophylline.
 Mostly the type of inhibition was apparently competitive.

Acetylsalicylic acid and ibuprofen were ineffective. No unambiguous correlation between the inhibition of mucosal PDEs and clin. observed gastric irritation was found. However, the inhibition of PDEs may modulate gastric side effects of nonsteroidal antiinflammatory drugs.

IT 22760-18-5 60507-23-1
 RI: RIOL (Biological study)
 (cyclic nucleotide phosphodiesterase of stomach mucosa response to)
 RI 22760-18-5 CAPLUS
 CI 2180-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 60507-23-1 CAPLUS
 CI 2180-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

15 ANWEEA 139 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANWEEA 139 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:507745 CAPLUS
 DOCUMENT NUMBER: 97:103745
 ORIGINAL REFERENCE NO.: 97:17058a,17058a
 TITLE: GLC-ECD determination of 1-(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3-dihydro-5-(10-fluorophenyl)-2H-1,4-benzodiazepin-2-one (SAS 643) in plasma and urine and identification of its main biotransformation products
 AUTHOR(S): Nardone, Salvatore; Blochi, Carlo; Nani, G. Mario
 COMPANATE SOURCE: Anal. Res. Dep., Schiapparelli Farm. S.p.A., Turin, Italy
 SOURCE: Therapeutic Drug Monitoring [1981], 3(4), 351-6
 CODING: TDMOVS; ISSN: 0163-4256
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB A gas-liquid chromatog.-electron-capture detection method for rapid, accurate determination of SAS 643 [3] [40762-15-0] in plasma and urine is described. The drug was extracted from biol. fluid with benzene and converted to the O,O'-bis(trimethylsilyl) derivative with bis(trimethylsilyl) trifluoroacetate. The glucuronide form of the drug was extracted after hydrolysis with β -glucuronidase. Nontetragone was used as internal standard. Moreover, some metabolites such as glucuronide and the N-1-dealkylated [17017-62-6] and N-1-ethylated [17780-39-2] products were identified. All compds. were confirmed by thin-layer chromatog.
 RI 37554-35-4
 CI 2180-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-3-(2-hydroxyethyl)- (CA INDEX NAME)

RI 37554-35-4 CAPLUS
 CI 2180-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-3-(2-hydroxyethyl)- (CA INDEX NAME)

13 ANSWER 119 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



13 ANSWER 140 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1982:155263

DOCUMENT NUMBER: 96:155263

ORIGINAL REFERENCE NO.: 96:257829,25783a

TITLE:

Prevention of the platelet alpha-granule release reaction by membrane-active drugs

AUTHOR(S):

Prosser, Christopher; Pepper, Duncan; Dawes, Joan; Edinburgh South-East Scotland Reg. Blood Transfus. Serv., E. Infirmary, Edinburgh, UK

CORPORATE SOURCE:

Thrombosis Research (1982), 25(1), 219-27
CODEN: THREAA; ISSN: 0049-2848

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

A range of membrane-active drugs were tested for their ability to prevent P-thromboxane and platelet factor 4 release from freshly collected blood platelets. While all the drugs tested could inhibit collagen-induced platelet aggregation, only a few, notably procaine

[59-46-1] and the antianimal drugs chlorzoxime [54-05-7], hydroxyphenylacetate [118-42-7], norgestrel [56-40-0] and quinine (bepazine) [53-59-0], effectively prevented the alpha-granule release reaction.

IT

22760-18-5

EI: 310L (Biological study)

In-vitro release by blood platelet response to, antithrombotic activity in relation to

NH

22760-18-5 CAPLUS

CN 2(18)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- ICA INDEX NAME)



13 ANSWER 141 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1982:159806

DOCUMENT NUMBER: 96:123806

ORIGINAL REFERENCE NO.: 96:123806,12380a

TITLE:

Use of an analgesic and nonhormonal, antiinflammatory agent in the treatment of macrovascular diseases

INVENTOR(S):

Riegler, Howard J.; Watersbury, L. David

PATENT ASSIGNEE(S):

Synthes Corp., USA

SOURCE:

Off. Offen., 16 pp.

CODEN: OXGKGN

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY AC. NUM. COMPT:

PATENT INFORMATION:

1

PATENT NO.:

KIND

DATE

APPLICATION NO.:

DATE

DE 3026402

AL 19820204

DE 1980-3026402

JP 5702229

A 19820220

JP 1980-102214

19800729

PRIORITY APPL. INFO.:

DE 1980-3026402

A 19800711

AS

The microvascular diseases of man and mammals, especially of the skin, kidney,

and retina, as a result of the complications of diabetes mellitus, are treated with a nonhormonal antiinflammatory analgesic. Ther. rate made diabetic with streptozotocin were fed a lab chow diet, or the diet

containing 0.01% lipofen [12607-29-1] (50 mg/kg/day) or 0.01% naproxen [12004-33-2] (15 mg/kg/day) for 3 wk, and flumazenil was injected. One

hour later, the penetration of flumazenil into the vitreous humor was measured. Both drugs reduced the penetration to normal levels, as

compared to more than twice normal values in untreated diabetic rats. Preparation of tablets containing these ingredients is described.

22760-18-5

EI: 310L (Biological study)

(diabetic angiopathy treatment with)

NH

22760-18-5 CAPLUS

CN 2(18)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- ICA INDEX NAME)

5

5

5

5

5

5

13 ANSWER 142 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1982:17404

DOCUMENT NUMBER: 96:37404

ORIGINAL REFERENCE NO.: 96:15825a,1582a

TITLE:

Metoprolol: a biochemical actions among vasodilators

AUTHOR(S):

Greenblatt, Forrest C.; Scott, Cynthia F.; Newquist, Kathryn L.; Zeller, Kathryn M.; Charin, Mark

CORPORATE SOURCE:

Div. Blochem. Res., Ortho Pharm. Corp., Raritan, NJ, 08869, USA

SOURCE:

Journal of Pharmaceutical Sciences (1982), 71(1), 94-100

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

Thirty-four vasodilators were screened in 3 in vitro biochem. assays related to smooth muscle excitation-contraction coupling leading to

P₁, P₂, and alpha-adrenergic receptors, inhibition of phospholipase activity, and antagonism of Ca accumulation. The

results indicate that vasodilators should not be considered as a single drug class since they act on various mechanisms related to coupling of

neuronal excitation to muscular contractility.

IT

22760-18-5

EI: 310L (Biological study)

(vasodilation by, mechanism of)

NH

22760-18-5 CAPLUS

CN 2(18)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- ICA INDEX NAME)



5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

13 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER:
 DOCUMENT NUMBER: 96169021
 ORIGINAL REFERENCE NO.: 96113454, 113454
 TITLE: 2(1H)-Quinoxalines derivatives
 PATENT ASSIGNER(S): Sankyo Chemical Co., Ltd., Japan
 SOURCE: Sankyo Tokkyo Kobo, 10 pp.
 COMPO: CRISM
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. REM. COMENT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54113769	A	19810907	JP 1990-17041	19900213
PRIORITY APPAR. INFO.:			JP 1990-17041	A 19900213
OTHER SOURCE(S):		CASREACT 96169021		
GI:				




AB 2(1H)-Quinoxalines 2 (I, R1 = ROCH2CH2O, Ph ROCH2CH2, Ph ROCH2CH2O, R2 ROCH2CH2CH2O, Ph ROCH2CH2O, Ph 1,2-epoxypropoxy, Ph ROCH2CH(OR)CH2O, Ph PhOCH2CH(OR)CH2O, Ph) and 1 (Ia = ROCH2CH2O, ROCH2CH2O) were prepared and had antitumor activity, analgesic, and platelet aggregation inhibitory activities (see detail). Thus, ethylation of 7.9 g ROCH2CH2O with 5 g I (R = CH3, R1 = Ph) and excess NaOH 9 h at 90-15° gave 4.12 g I (R = ROCH2CH2O, R1 = Ph) (II). Refining 1 g II with DMF4 in EtOH 30 min gave 0.9 g II (R2 = ROCH2CH2O).


IT 75012-10-9
 R1: RCT (Reactant) / RACT (Reactant or reagent)
 (ethylation of, with ethoxyethyl bromide)

RI 75012-10-9 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-hydroxy-4-phenyl)- (CA INDEX NAME)


13 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 80591-33-3 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



RI 80591-31-7 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-(1-methylethoxy)ethoxy)-4-phenyl- (CA INDEX NAME)




RI 80591-32-8 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-[(1-hydroxypropyl)oxy]-4-phenyl- (CA INDEX NAME)

15 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 80591-27-1P
 RI: RCT (Reactant) / RYM (Synthetic preparation) / PREP (Preparation) / RACT (Reactant or reagent)
 (preparation and reduction of)


RI 80591-27-1 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-ethoxyethoxy)-4-phenyl- (CA INDEX NAME)




IT 80591-28-2P 80591-29-2P 80591-31-2P
 80591-32-8P 80591-33-3P 80591-34-0P
 80591-35-1P 80591-36-2P
 RI: RYM (Synthetic preparation) / PREP (Preparation)
 (preparation of)

RI 80591-28-2 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-ethoxyethoxy)-3,4-dihydro-4-phenyl- (CA INDEX NAME)


15 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 80591-33-9 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(1-oxo-3-phenylpropoxy)-4-phenyl- (CA INDEX NAME)




RI 80591-34-0 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(3-ethoxy-2-hydroxypropoxy)-4-phenyl- (CA INDEX NAME)




RI 80591-35-1 CAPLUS
 CH 2(1H)-Quinoxalines, 1-(cyclopropylmethyl)-6-(2-hydroxy-3-phenoxypropoxy)-4-phenyl- (CA INDEX NAME)

15 ANSWER 143 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



3N S0191-36-2 CAPLOS
 CN 2(18)-Quinazolinone, 1-(4-phenyl-1-methyl-1H-quinazolin-2-yl)-3,4-dihydro-4-[(5-hydroxypentyl)oxy]-1,4-bis(4-phenyl)- (CA INDEX NAME)



15 ANSWER 143 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:27946 CAPLOS
 DOCUMENT NUMBER: 96:27946
 ORIGINAL REFERENCE NO.: 96:45205,45204
 TITLE: Prazosin
 AUTHOR(S): Sandoz Ltd., Basel, Switzerland
 CORPORATE SOURCE: Sandoz Ltd., Basel, Switzerland
 SOURCE: Drugs Made in Germany (1982), 24(3), 81-4, 86-8
 COUNTRY: DUMAS; ISSN: 0012-6689
 DOCUMENT TYPE: Journal General Review
 LANGUAGE: English
 CI



AB A review with 15 refs. of the pharmacokinetics of the analgesic tramadol
 [1] (40507-23-1).
 IT 40507-23-1
 RI RFL (Biological process); RFL (Biological study, unclassified); RFL
 (Biological study); RFL (Pharmacokinetics of drugs in humans and laboratory animals)
 (Pharmacokinetics of drugs in humans and laboratory animals)
 3N S0191-36-2 CAPLOS
 CN 2(18)-Quinazolinone, 1-(4-phenyl-1-methyl-1H-quinazolin-2-yl)-3,4-dihydro-4-[(5-hydroxypentyl)oxy]-1,4-bis(4-phenyl)-1,4-dihydro-4H-quinazolin-2-one (CA INDEX NAME)



15 ANSWER 144 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:29498 CAPLOS
 DOCUMENT NUMBER: 96:29498
 ORIGINAL REFERENCE NO.: 96:45204
 TITLE: Combination of TLC, GLC, HPLC and UV for the rapid detection of drugs, intermediates and related compounds
 AUTHOR(S): Dalsgaard, T.; Sørensen, F.; Michelsen, P.
 CORPORATE SOURCE: Inst. Pharmaceut., Univ. Denmark, Copenhagen, Denmark
 SOURCE: J. Pharm. Med. (1981), 308(5), 413-27
 COUNTRY: Denmark
 DOCUMENT TYPE: Journal
 AB - Retention retention times for 570 drugs and related compounds on 8 chromatograms were reported. TLC employing silica gel plates, gas chromatography employing OV-1 on Chromosorb W-HP, and reversed-phase high-pressure chromatography employing octadecylsilanized columns were described.
 IT 27760-18-5
 RI RFL (Analytical); RFL (Analytical study)
 (Determination of drugs by chromatography)
 3N S0191-36-2 CAPLOS
 CN 2(18)-Quinazolinone, 1-(4-phenyl-1-methyl-1H-quinazolin-2-yl)-3,4-dihydro-4-[(5-hydroxypentyl)oxy]-1,4-bis(4-phenyl)-1,4-dihydro-4H-quinazolin-2-one (CA INDEX NAME)


15 ANSWER 144 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:24742 CAPLOS
 DOCUMENT NUMBER: 96:24742
 ORIGINAL REFERENCE NO.: 96:45204,45204
 TITLE: Percutaneous absorption of griseofulvin and proquazone
 AUTHOR(S): Franz, T. M.; Gelland, A.; Meibohm, R. I.; Schweitzer, A.
 CORPORATE SOURCE: Div. Biopharm., Sandoz Ltd., Basel, Switzerland
 SOURCE: Archives of Dermatology (1982), 118(1), 27-32
 COUNTRY: DUMAS; ISSN: 0360-3696
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB - Griseofulvin and proquazone [27760-18-5], resp., were made up of monoglycerides of medium chain length and an aprotic solvent, glycerol. The ointments were applied to the back of shaved anesthetized rats. The total amount absorbed percutaneously and the permeability coefficients of both drugs were considerably higher for the ointments than for single solvents of the drugs without monoglycerides. Distribution of the labeled drugs in rat skin was demonstrated by microautoradiography. Contents of the drugs in the different layers of human skin together with the medium flow rates were determined after administration of the ointments onto isolated human skin. Monoglycerides of medium chain length significantly enhanced the permeability of the stratum corneum for solutes.



15 ANSWER 144 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:24742 CAPLOS
 DOCUMENT NUMBER: 96:24742
 ORIGINAL REFERENCE NO.: 96:45204,45204
 TITLE: Percutaneous absorption of griseofulvin and proquazone
 AUTHOR(S): Franz, T. M.; Gelland, A.; Meibohm, R. I.; Schweitzer, A.
 CORPORATE SOURCE: Div. Biopharm., Sandoz Ltd., Basel, Switzerland
 SOURCE: Archives of Dermatology (1982), 118(1), 27-32
 COUNTRY: DUMAS; ISSN: 0360-3696
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB - Griseofulvin and proquazone [27760-18-5], resp., were made up of monoglycerides of medium chain length and an aprotic solvent, glycerol. The ointments were applied to the back of shaved anesthetized rats. The total amount absorbed percutaneously and the permeability coefficients of both drugs were considerably higher for the ointments than for single solvents of the drugs without monoglycerides. Distribution of the labeled drugs in rat skin was demonstrated by microautoradiography. Contents of the drugs in the different layers of human skin together with the medium flow rates were determined after administration of the ointments onto isolated human skin. Monoglycerides of medium chain length significantly enhanced the permeability of the stratum corneum for solutes.




13 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 1982:20034 CAPLUS
 DOCUMENT NUMBER: 9612054
 ORIGINAL REFERENCE NO.: 9612739, 2342a
 TITLE: Synthetic studies on quinazoline derivatives. II. The reactions of 5-chloro-2-trichloroacetamidobenzophenones with primary amines
 AUTHOR(S): Yamanaka, Michikazu; Yamamoto, Hisao
 AFFILIATION: Pharm. Div., Sumitomo Chem. Co., Ltd., Takatsukasa, 443, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1993), 29(10), 2111-16
 COUNTRY: JAPAN; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SUBJECT(S): CASREACT 9612054
 OR:




AB The reaction of 5-chloro-2-trichloroacetamidobenzophenone (I) with several primary alkylamines in Me2SO gave high yields of the quinazolinones II (R = Me, Et, Pr, Et2NCH2CH2, morpholinomethyl, PhCH2, etc.), which were formed by base-catalyzed and/or thermal cyclization and simultaneous rearrangement of the isomeric 5-chloro-2-trichloroacetamidobenzophenone alkylamines III. Both compds. II and III were obtained when the reaction was effected in benzene. Treatment of the compound I with bulky amines such as Me2CHNEt2 and cyclohexylamine gave, under similar conditions, the corresponding benzophenone imines III (R = Me2C, cyclohexyl) exclusively.

15 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RI 80170-87-2 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)




IT 20927-53-3P 26772-95-2P 23453-19-9P
 36842-76-4P 43210-74-6P 80170-75-5P
 80170-73-4P 80170-74-7P 80170-75-5P
 80170-88-3P
 RI SPH (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 20927-53-3 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3-methyl-4-phenyl- (CA INDEX NAME)




RI 26772-95-2 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3,4-dihydro-3-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 and these could be transformed into II on heating in pyridine. The reaction of N-substituted trichloroacetamidobenzophenones with N-(2-aminoethyl)morpholine as well as NMP/Me2SO yielded the 1-alkylaminobenzophenone imines, IV (R = Me, Et, N, morpholinomethyl, R = cyclopropylmethyl, RI = O) which on treatment with Cl3CCOCl were easily cyclized to give the corresponding 1-substituted 4-trichloromethylquinazolinones. The trichloromethyl group of the 1-substituted quinazolinones II were easily displaced by a nucleophile such as hydride, alkoxide or hydroxide under base catalysis to give the 3,4-dihydro-2(1R)-quinazolinone deriv., e.g. V. The IR and redn. of II (R = Me) at room temp. mainly affected the trichloroacetamidobenzophenone, which underwent thermal cyclization to the quinazolinones V. In contrast, the reaction of 5-chloro-2-trichloroacetamidobenzophenone with some primary alkylamines in Me2SO produced the trichloroacetamidobenzophenone alkylamines, which on treatment with NaOH could be converted only to 3-substituted 6-chloro-3,4-dihydro-4-phenyl-2-trichloromethylquinazolinones. These products were successfully utilized in syntheses of the imidazo[1,2-c]quinazolinone (VI), oxazolo[1,2-c]quinazolinones, and 1,3-oxazino[3,2-c]quinazolinones.
 IT 80170-89-4P
 RI RCT (Reagent); SPH (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and hydrolysis of)
 RI 80170-86-1 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3,4-dihydro-3-methyl-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)




IT 80170-86-1P 80170-87-2P
 RI RCT (Reagent); SPH (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and hydrolysis of)
 RI 80170-86-1 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3,4-dihydro-3-methyl-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)


15 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RI 33453-19-9 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)



RI 36842-76-4 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)



RI 41230-84-4 CAPLUS
 CN 2(1R)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)


15 ANSWER 147 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



HN 80170-72-5 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3,4-dihydro-1-methyl-3-[2-(4-morpholinyl)ethyl]-4-phenyl-, (2S)-2-butenedioate (11) (CA INDEX NAME)

CH 2

CHN 80170-73-4
 CHF C21 R24 C1 N0 O2



CH 2


CHN 110-34-7
 CHF C4 R4 O4

Double bond geometry as shown.



HN 80170-73-6 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3-ethyl-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 147 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




15 ANSWER 147 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



HN 80170-74-7 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



HN 80170-75-8 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)



HN 80170-88-3 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3,4-dihydro-1-methyl-3-[2-(4-morpholinyl)ethyl]-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)

15 ANSWER 148 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 158215063 CAPLOS
 DOCUMENT NUMBER: 9615063
 ORIGINAL REFERENCE NO.: 9614879,2490a
 TITLE: Reduction of inflammatory brain edema by nonsteroidal antiinflammatory drugs
 AUTHOR(S): Levine, Seymour; Carner, Nancy; Compitello, Robert; Sade, Ahmed M.; Plachouras, Fotios M.
 CORPORATE SOURCE: Pathol. Dep., New York Med. Coll., Valhalla, NY, 10595, USA
 SOURCE: Experimental Neurology 1991, 74(2), 370-8
 CDB#: EXNAC; ISSN: 0014-4886
 JOURNAL: Journal
 LANGUAGE: English
 AB: After the implantation of Cu-wire into the right cerebral hemispheres of rats, the resulting inflammation and necrosis were accompanied by severe edema with water content increased from approx. 79% to 91-92%. Treatment with dexamethasone [50-02-2] after the implantation and on the next 3 days caused marked reduction in the edema. Alleviation of edema, albeit of lesser degree, was obtained with the common analgesic-antipyretic drug, acetaminophen [103-05-2]. This result was not due to adrenal stimulation. The drug penetrated the brain and reached slightly higher amounts in the edematous right hemisphere than in the relatively normal left hemisphere. Encouraging results were also obtained with acetophenetidin [52-44-2] and benoxaprofen [13274-19-7], but not with other nonsteroidal antiinflammatory drugs. The mechanism for the beneficial effects of acetaminophen is unknown but it probably does not involve inhibition of prostaglandin synthesis.
 IT 22760-18-5 40507-23-1
 RU: RTEL (Biological study) (brain edema response to)
 HN 22760-18-5 CAPLOS
 CH 2-[18]-Quinoxalino-6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)




HN 40507-23-1 CAPLOS
 CH 2-[18]-Quinoxalino-6-(4-fluorophenyl)-7-methyl-1-[2-methylethyl]- (CA INDEX NAME)

15 ANSWER 149 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 149 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:602063 CAPLUS
 DOCUMENT NUMBER: 95:202845
 ORIGINAL REFERENCE NO.: 95:24065a,24064a
 TITLE: Synthesis and pharmacological properties of 4-phenylquinazolin-2(1H)-one
 AUTHOR(S): Voronina, T. A.; Gordienko, G. N.; Andronati, S. A.; Garkova, T. I.; Zhilina, E. I.
 CORPORATE SOURCE: Nauchno-Issled. Inst. Farmakol., Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal [1991], 15(7), 55-7
 DOCUMENT TYPE: JOURNAL
 LANGUAGE: Russian
 C1



AB Twelve quinazolinones 1 (R = H, Br, Cl, OCH₃, OCF₃, SCF₃, Me, SCF₃, SO₂CF₃, SO₂CF₃); R2 = H, Me) were prepared. E.g., treatment of benzophenone
 IT with NEH gave 38% quinazolinone 1 (R = SCF₃, R2 = H). 1 showed antiproliferative properties, antiparasitic activity, weak muscle relaxant activity and low toxicity. The pharmacol.
 properties
 of 1 were not inferior to those of chloridazepoxide and lometil.
 IT 20927-53-1P 79885-38-4P 79885-39-5P
 RI: INH (Synthetic preparation); FRP (Preparation)
 (Preparation and pharmacol. properties of)
 RI 20927-53-1 CAPLUS
 CN 2(18)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RI 79885-38-4 CAPLUS
 CN 2(18)-Quinazolinone, 1-(difluoromethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 149 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 79885-39-5 CAPLUS
 CN 2(18)-Quinazolinone, 6-[(difluoromethyl)thio]-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 150 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:543409 CAPLUS
 DOCUMENT NUMBER: 95:149409
 ORIGINAL REFERENCE NO.: 95:2495a,2494a
 TITLE: Mass spectral studies of 4-phenyl-2(1H)-quinazolinone
 AUTHOR(S): Kamal, Ahmad; Sattar, P. B.
 CORPORATE SOURCE: Pmg. Res. Lab., Hyderabad, 500 009, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry [1991], 29(17), 600-1
 DOCUMENT TYPE: JOURNAL
 LANGUAGE: English
 AB: 4-Phenyl-2(1H)-quinazolinone with no substituent on N-1 fragment via loss
 of 2 H⁺ radicals and a CO mol. When N-1 carries a Me group, only 1 H atom is lost to give the (M-1) ion, which fragments further via expulsion of Me⁺ direct loss of the RCN radical from the mol. ion is also observed. Fragmentation pathways proposed are supported by 2 labeling and by the presence of metastable peaks.
 IT 17629-04-8 79246-07-4 79332-40-9
 79332-41-0
 RI: FRP (Properties)
 (Mass spectrum of)
 RI 17629-04-8 CAPLUS
 CN 2(18)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RI 79246-07-4 CAPLUS
 CN 2(18)-Quinazolinone, 1-(methyl-4-phenyl)- (PCI) (CA INDEX NAME)



RI 79332-40-9 CAPLUS
 CN 2(18)-Quinazolinone, 1-methyl-4-phenyl-, monochloro deriv: (PCI) (CA INDEX NAME)

15 ANSWER 150 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



DI-C1

FI 79113-41-0 CAPLOS
 CH 2118-Quanzolinone, 3-methyl-4-phenyl-, dichloro deriv. (PCI) (CA INDEX NAME)



2 (DI-C1)

15 ANSWER 151 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981526251 CAPLOS
 DOCUMENT NUMBER: 95126251
 ORIGINAL REFERENCE NO.: 95126251a, 12042a
 TITLE: Use of threonase-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels
 INVENTOR(S): Hamilton, James C.; Lands, William E. M.; Sullivan, Ann Clarey Tobias; Lawrence E.; Trinzara, Joseph
 PATENT ASSIGNOR(S): Hoffman-La Roche, F., and Co. A.-G., Swiss.
 SOURCE: Eur. Pat. Appl., 18 pp.
 DOCUMENT TYPE: OTHER: EPACLM
 LANGUAGE: Patent
 FAMILY EXT. NUM. COUNTRY: German
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 28410	A1	19810513	EP 1980-106714	19801031
EP 28410	B1	19870920		
FI AT, DE, CH, DK, ES, FR, GB, IT, JP, NL, SE				
ZA 8906531	A	19810604	ZA 1980-6531	19801013
NL 8905948	A	19810601	NL 1980-5346	19801019
JP 56097267	A	19810605	JP 1980-157400	19801031
DE 3641090	A1	19810903	DE 1980-3641090	19801031
AT 23984	T	19811015	AT 1980-106714	19801031
AO 9264264	A	19810507	AO 1980-44054	19801102
AO 53104	R2	19830901		
US 4190540	A	19890219	US 1980-387712	19800611
US 435194	A	19860527	US 1984-680706	19841212
US 4731363	A	19860315	US 1986-815719	19860216
PRIORITY APPL. INFO.			US 1979-90950	A 19791102
			US 1979-90941	A 19791102
			US 1979-107484	A 19791206
			EP 1980-106714	A 19801031
			US 1982-387712	A1 19820611
			US 1984-680706	A1 19841212

OTHER SOURCE(S): MARPAT 95126251
 AB Threonase synthetase inhibitors such as imidazoles, 3-substituted pyrimidines, substituted imidazoles, 4-substituted pyrimidines, a substituted pyrazolidinedione and a substituted quinazolinone are effective in the treatment of obesity and in decreasing insulin levels in diabetic rats. Thus, 3-[2-(4-propylphenyl)imidazole [2,3-b]-4e-3] and 3-[imidazolemethyl]indole [19714-15-3] were effective compds. in decreasing body weight, food intake, and blood insulin concentration
 IT 22760-18-5
 RU R0L (Biological study)
 (insulin and obesity reduction by diabetes in relation to)

15 ANSWER 152 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 FI 72760-18-5 CAPLOS
 CH 2118-Quanzolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 153 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981598920 CAPLOS
 DOCUMENT NUMBER: 95108820
 ORIGINAL REFERENCE NO.: 95126115a, 18128a
 TITLE: Renal function and laboratory safety parameters after two weeks' administration of fligoprazone to man
 AUTHOR(S): Crawford, M.; Thiel, G.
 CORPORATE SOURCE: Int. Clin. Res., Sandoz Ltd., Basel, Switz.
 SOURCE: Arzneimittelforschung 1981; 31(5a), 912-14
 DOCUMENT TYPE: OTHER: ARBAPD; 2589; 0604-4172
 LANGUAGE: Journal
 CI: English



AB 7-methyl-1-(1-methylethyl)-4-phenyl-1,2,3,4-tetrahydroquinazolin-2(1H)-one (fligoprazone) [140507-23-1] given for 14 days (100 mg 3 times daily) to 4 healthy male volunteers produced no clinically relevant effects upon the subjects renal function, urinal microscopic findings, blood coagulation status, or upon their general well-being as shown by a range of laboratory safety tests including hematol. profile and blood urease
 and biochem. Minor and transient side effects mainly affecting the gastrointestinal system were seen in 4 subjects.
 IT 40507-23-1
 RU R0L (Biological study)
 (Kidney function response to)
 FI 40507-23-1 CAPLOS
 CH 2118-Quanzolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



15 ANMER 132 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 19811505593 CAPLUS
 DOCUMENT NUMBER: 95105593
 ORIGINAL REFERENCE NO.: 95105593,19072a
 TITLE: Toxicological evaluation of fluproquazone
 AUTHOR(S): Pectin, G.; J. Schwen, R. J. Madsen, M. J. Van Pelt, R. J. Richardson, R. P. Matter, B. E. Freidin, Res. Dep., Sandoz Ltd., Basel, Switz.
 CORPORATE SOURCE: Arzneimittel-Forschung (1991), 21(5A), 872-82
 SOURCE: CODEN: ARMDMD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



1

AB The toxicological characteristics of Tormoxyal (fluproquazone) (1) [40507-23-1] as an analgesic with distinct antinflammatory properties, were evaluated in acute and chronic toxicity studies as well as in reproduction toxicity, carcinogenicity and mutagenicity studies. The following overall results were obtained: the acute oral toxicity in mice, rats, and rabbits is of low order. In the chronic oral studies 1 was generally well tolerated when given to rats and dogs for 13 wk, to dogs and monkeys for 52 wk, to mice for 70 wk and to rats for 104 wk. In particular, there was no indication of substantial irritation or lesions in any of these studies. In dogs and rats showed the major target organs for 1 toxicity was the liver and kidney, where mild, reversible changes were observed. These findings were considerably less severe than those found with several other antihypertensive compounds. In the reproduction toxicity studies, the only drug-related effects seen in male, on female fertility or peri- and postnatal development in rats were a prolongation of pregnancy and an impairment of delivery leading to an increased perinatal mortality. These findings may be related to an inhibition of prostaglandin synthesis by 1. Similar effects are known to occur after administration of other inhibitors of prostaglandin synthesis. In rats and rabbits 1 did not reveal any embryolethal or teratogenic effects. 1 had no mutagenic effects in either the micronucleus test and the dominant-lethal test using mice, or in the Ames-test using *Salmonella typhimurium*. 1 has no carcinogenic potential in rats and mice.
 IT 40507-23-1
 RI: ADW (adverse effect, including toxicity); BIOD (biological study)

15 ANMER 134 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 ACCESSION NUMBER: 19811505593 CAPLUS
 DOCUMENT NUMBER: 95105593
 ORIGINAL REFERENCE NO.: 95105593,19072a
 TITLE: The pharmacodynamic properties of fluproquazone
 AUTHOR(S): Pectin, G.; J. Schwen, R. J. Madsen, M. J. Van Pelt, R. J. Richardson, R. P. Matter, B. E. Freidin, Res. Dep., Sandoz Ltd., Basel, Switz.
 CORPORATE SOURCE: Arzneimittel-Forschung (1991), 21(5A), 873-82
 SOURCE: CODEN: ARMDMD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



15 ANMER 135 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 19811505593 CAPLUS
 DOCUMENT NUMBER: 95105593
 ORIGINAL REFERENCE NO.: 95105593,19072a
 TITLE: The pharmacodynamic properties of fluproquazone
 AUTHOR(S): Pectin, G.; J. Schwen, R. J. Madsen, M. J. Van Pelt, R. J. Richardson, R. P. Matter, B. E. Freidin, Res. Dep., Sandoz Ltd., Basel, Switz.
 CORPORATE SOURCE: Arzneimittel-Forschung (1991), 21(5A), 873-82
 SOURCE: CODEN: ARMDMD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



1

AB Tormoxyal (fluproquazone) (1) [40507-23-1] is a potent analgesic and antipyretic compound with antinflammatory properties. It is effective in a variety of animal species, is active after oral and parenteral administration, and has a duration of action of several hours. 1 is many times more potent than acetylsalicylic acid (ASA) and generally resembles the clinically active ibuprofen and indoprofen in its pharmacodynamic effects. 1 is a very strong inhibitor of collagen and arachidonic acid-induced platelet aggregation. It causes mild central nervous system depressant effects in rodents only in very high doses and does not produce physical dependence when administered i.v. over a period of 4 wk to humans. In the anesthetized dog, 1 causes minimal cardiovascular changes. In fasted rats, 1 is 3 times more analgesic than ASA and ibuprofen and about half as potent as indoprofen, whereas after repeated administration for 5 consecutive days, it is 10 times less potent than ASA. 1 was tested. At 3 times the acute HD50 (intraperitoneal dose), 1 does not produce any petechial hemorrhage and even after repeated administration of over 6 times the acute HD50 it only causes tiny gastric lesions. Comparison of the doses of the test compounds, needed to cause analgesia and to inhibit yeast-induced pyrexia with the doses required to produce gastric lesions after acute and following repeated administration in the rat clearly show that 1 has the greatest safety margin. It is evident from the results that the pharmacodynamic effects of 1 are due to a marked inhibition of the synthesis of prostaglandins and their metabolites as the order of potency of 1 and the 3 reference compounds in the prostaglandin synthetase assay correlates reasonably well with the rank order recorded in other tests.
 IT 40507-23-1
 RI: BOD (biological activity or effector, except adverse); BUD (biological study, unclassified); THO (therapeutic use); BIOD (biological study);
 USES

15 ANSWER 154 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (Data)
 (pharmacol. of)
 40107-23-3 CAPLUS
 2 (1R)-Quinoxaline, 4-(4-fluorophenyl)-7-methyl-3-(1-methylethyl)- (CA INDEX NAME)



15 ANSWER 155 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981.508747 CAPLUS
 DOCUMENT NUMBER: 95-108347
 ORIGINAL REFERENCE NO.: 95-108099,19012a
 TITLE: The biotransformation of flupropazone in man and several animal species
 AUTHOR(S): Orwig, B. A.; Duggen, H. A.; Khuta, S. I.; Tallbot, K. C.; Schaefer, R. G.
 CORPORATE SOURCE: Drug Metab. Sect., Sandoz, Inc., East Hanover, NJ, USA
 SOURCE: Arzneimittelforschung 1991, 31 (5A), 904-11
 DOCUMENT TYPE: CORDIS: AR0040; ISSN: 0004-4172
 LANGUAGE: English
 C1



AB The biotransformation of toremyl (flupropazone) [1] [40107-23-3] was investigated in man, mouse, rat, rabbit, and dog. Single oral doses of [3H]flupropazone [15 mg/kg] were administered to the animals. Human volunteers received 100 mg [3H]flupropazone 3 times daily for 5 days [15 mg/kg]. The human urinary metabolites of flupropazone were separated and purified by a combination of extraction and liquid chromatog. on reversed-phase columns. Definitive structures were assigned to 5 metabolites. Flupropazone and its metabolites were characterized and quantitated in the blood, urine, and feces of man, mouse, rat, rabbit, and dog by high-pressure liquid chromatog. coupled to a radioactivity monitor or by reverse isotope dilution anal. Significant quantities of flupropazone were noted in the blood of all species. Two biotransformation pathways were identified. The major pathway was sequential oxidation with or without conjugation of the 7-methyl group; aromatic hydroxylation and conjugation were a minor pathway.
 IT 40107-23-3
 RL: BPP (Biological process); BSG (Biological study, unclassified); BIOL (Biological study); PRCO (Process) (metabolism of)

15 ANSWER 156 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 40107-23-3 CAPLUS
 2 (1R)-Quinoxaline, 4-(4-fluorophenyl)-7-methyl-3-(1-methylethyl)- (CA INDEX NAME)




IT 79039-54-6 79039-55-7
 RL: BIOC (Biological study)
 [preparation as flupropazone metabolite]
 79039-54-6 CAPLUS
 2 (1R)-Quinoxalinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-3-(1-methylethyl)-2-oxo- (CA INDEX NAME)



80 79039-51-7 CAPLUS
 2 (1R)-Quinoxaline, 4-(4-fluorophenyl)-7-(hydroxymethyl)-3-(1-methylethyl)- (CA INDEX NAME)



13 ANSWER 116 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1981108246 CAPLUS
 DOCUMENT NUMBER: 95102846
 ORIGINAL REFERENCE NO.: 95102846, 19012a
 TITLE: Absorption, distribution, and excretion of fluprogestone in several animal species
 AUTHOR(S): Williams, J. I.; Mvuta, S. I.; Jaffer, J. M.;
 Mupfema, B. N.; Schwarz, R. J.; Talbot, E. C.; Broutillard, J. P.; Lemaire, P. J.; Bodel, C. J. et al.
 CORPORATE SOURCE: Drug Metab. Sect., Sandoz, Inc., East Hanover, NJ
 SOURCE: Arzneimittelforschung (1981), 31(5A), 897-904
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



A8 Sample oral doses of 14C-labeled fluprogestone (I) [40507-23-1], were administered to mice, rats, rabbits, and dogs [10 and/or 15 mg/kg]. I.v. doses were administered to rats at 1.5 mg/kg and to mice, rabbits and dogs at 5 mg/kg. Multiple oral doses of non-radioactive I were studied in the rat (15 and 45 mg/kg/day) and dog (15, 15, and 50 mg/kg/day). 1-14C was administered orally to rats (10 mg/kg) for whole-body autoradiography studies. I was well absorbed in all species but the dog in which approx. 50% of the dose was absorbed. Peak blood plasma radioactivity was measured at 30 min (mouse) and 2-4 h (rat, rabbit, dog). Radioactivity was present in all tissues examined after oral or i.v. administration to mice and rats. Except for liver and kidney, which had higher amounts, most tissue levels were in the range of the corresponding blood levels. No evidence of accumulation or retention in any tissue was noted. Elimination of radioactivity from blood and tissues was significantly faster in male rats than in females. In the rat chronic administration resulted in changes in pharmacokinetic parameters, possibly due to enzyme induction. Pharmacokinetic parameters did not change after chronic administration in the dog. Radioactivity was transmitted to the fetuses of orally dosed pregnant rats and rabbits. I and its metabolites were secreted in the milk of orally dosed lactating rats at amounts greater than those of the blood and were transferred to the nursing neonates. Excretion in urine and feces was rapid in all species after both oral and i.v. dosing. Urinary excretion was the major excretory pathway in the mouse and rabbit and fecal excretion was dominant.

13 ANSWER 117 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1981108246 CAPLUS
 DOCUMENT NUMBER: 95102846
 ORIGINAL REFERENCE NO.: 95102846, 1999a
 TITLE: An automated fluorimetric method for the determination of fluprogestone in plasma and urine
 AUTHOR(S): Pech, M.; Delabarde, C.; Keller, R. P.; Meier, J.; Kietzsch, H.
 CORPORATE SOURCE: Div. Pharm. Res. Dev., Sandoz Ltd., Basel, Switz.
 SOURCE: Arzneimittelforschung (1999), 49(5), 893-6
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



A8 A rapid and sensitive fluorimetric assay was developed for the quant. determination of fluprogestone (I) [40507-23-1] in plasma and urine. The unchanged drug was extracted from alkalized plasma or urine into n-heptane containing 0-1.5% isomyl alc. followed by a back extraction into 5 M HCl. After oxidation with potassium persulfate the fluorescence measurements were taken at 326 nm excitation and 520 nm emission. Detection limits were about 15 ng/mL plasma and 6 ng/mL urine, using 1 mL plasma and 2 mL urine, resp. The automated assay had a 5 times higher sample capacity and better reproducibility than the manual assay. The method was applied to animal studies including assays in milk and proved to be suitable in human studies after oral doses in the therapeutic range.
 IT 40507-23-1
 RU: ANZ (Analytic); ANMT (Analytical study)
 (determination of, in plasma and urine by fluorometry)
 RU 40507-23-1 CAPLUS
 IN 21181-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methyl-ethyl)- (CA INDEX NAME)

13 ANSWER 116 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 in rat and dog.
 IT 40507-23-1
 RU: ANZ (Biological process); ANMT (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism and pharmacokinetics of, species in relation to)
 RU 40507-23-1 CAPLUS
 IN 21181-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methyl-ethyl)- (CA INDEX NAME)



13 ANSWER 117 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 in rat and dog.
 IT 40507-23-1
 RU: ANZ (Biological process); ANMT (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism and pharmacokinetics of, species in relation to)
 RU 40507-23-1 CAPLUS
 IN 21181-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methyl-ethyl)- (CA INDEX NAME)



13 ANWER 138 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1981490373 CARLUS
 DOCUMENT NUMBER: 94192973
 ORIGINAL REFERENCE NO.: 94131794,15182a
 TITLE: Effects of fluproquazone on platelet aggregation in man
 AUTHOR(S): Beveridge, T.J.; Crawford, M.
 CORPORATE SOURCE: Chas. Heub. & Sons Ltd., Basel, Switz.
 SOURCE: Arzneimittelforschung [1993], 21(5A), 937-40
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Thrombolytic investigations on platelets from healthy volunteers showed inhibitory effects of fluproquazone [2] (49505-23-1) and acetylsalicylic acid (ASA) on both the extent and the velocity of aggregation induced by collagen. The threshold concentration of acetylsalicylic acid needed to induce aggregation was also raised after fluproquazone was given to donors. Whereas the inhibitory effects of fluproquazone disappeared within 24 h, the qual. similar effects of ASA are much longer lasting [12-94 h]. There is no evidence for enhancement of the effects of fluproquazone following 4 days of administration (100 mg, 3 times daily).
 IT 40507-23-1
 RI: ECDC (Biological study)
 (platelet aggregation response to)
 CH 40507-23-1 CARLUS
 CH 21181-Quinazolinone, 4-[(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

13 ANWER 139 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1981490373 CARLUS
 DOCUMENT NUMBER: 94121639
 ORIGINAL REFERENCE NO.: 94131974,15310a
 TITLE: Polarographic reduction of 7-thio-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-1(2H)-one
 AUTHOR(S): Fiebigel, P.; Knechtel, Christa; Knechtel, P.
 CORPORATE SOURCE: Seitz Pharm., Ernst-Moritz-Arzt-Ohls, Giefelsfeld, Giefelsfeld, Ger. Dem. Rep.
 SOURCE: Pharmazie [1991], 36(1), 61-6
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI

AB The title compound was prepared using a known method and the reduction was carried out using a previously described apparatus and method. To carry out the reduction 50 mg of 7-thio-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-1(2H)-one [77494-45-8] was dissolved in 70 mL EtOH and brought to pH 4.6 with acetate buffer. After 1-2 h reduction has (4-thio-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-1(2H)-one) [77495-01-9] precipitated from the solution the reduction continued for a total of 1 h at which time it was separated and dried.
 AS was also 3-thio-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-1(2H)-one [77495-02-0].
 IT 77495-01-9
 RI: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of, by electrochem. reduction)
 CH 77495-01-9 CARLUS
 CH 12112,12121-Quinazolinone, 2,2'-dithio-, 6,6'-dithio-4,4'-diphenyl- (CA INDEX NAME)



15 ANWER 158 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM (Continued)



15 ANWER 159 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1981490373 CARLUS
 DOCUMENT NUMBER: 94120450
 ORIGINAL REFERENCE NO.: 94130474,13050a
 TITLE: The toxicology profile of the antiinflammatory drug propazone in animals
 AUTHOR(S): Van Ryzin, R. J.; Trapold, J. H.
 CORPORATE SOURCE: Randor Pharm., East Hanover, NJ, 07936, USA
 SOURCE: Drug and Chemical Toxicology [1977] (1980), 3(4), 341-79
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Propazone (1) [21760-18-5] is a chemical distinctive non-steroidal antiinflammatory drug (NSAID) and is orally effective as an antiinflammatory, analgesic and antipyretic in animals. As with other NSAIDs the main toxic effect was gastrointestinal irritation with sequelae. Comparative relative potency of propazone with other NSAIDs, with regard to gastrointestinal effects was rat-indomethacin > naproxen > propazone > phenylbutazone. In addition to gastrointestinal effects in animals, inflammatory renal changes occurred; renal changes also occurred in pigs treated with phenylbutazone. No evidence of ototoxicity was seen in rodent ototoxicity studies. Evidence of teratogenicity was not seen in rat and rabbit teratol. studies. In reproduction/perinatal studies in rats dose levels that induced intestinal lesions in the dams resulted in decreased survival of young to weaning. A major human metabolite of propazone, the m-hydroxy [6765-07-3] derivative, was shown to be less toxic than the parent compound.
 IT 6765-07-3
 RI: ECDC (Biological study)
 (as propazone metabolite.)
 CH 6765-07-3 CARLUS
 CH 21181-Quinazolinone, 4-[(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

15 ANSWER 160 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



IT 22760-18-5
 314 ADV (adverse effect, including toxicity); BIOL (biological study)
 (toxicity of)
 RN 22760-18-5 CAPLUS
 CN 21181-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



15 ANSWER 161 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 161 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1981149992 CAPLUS
 DOCUMENT NUMBER: 94149992
 ORIGINAL REFERENCE NO.: 94149992, 24352a
 TITLE: Protein binding and erythrocyte partitioning of the anti-infective proquazone
 AUTHOR(S): Rosen, Andrey; Rumberg, Peter M.
 CORPORATE SOURCE: Bionext, Inc., Basel, Basel, 4056, Switz.
 SOURCE: Journal of Pharmaceutical Sciences (1993), 70(7), 212-7
 C/DEN: JPMSEA; ISSN: 0022-3549
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB The kinetics of proquazone (1) [22760-18-5], a new nonsteroidal antiinflammatory drug, was investigated by equilibrium dialysis and red blood partitioning methods on human blood and its subcompartment: erythrocytes, plasma, and plasma water. The binding of this lipophilic compound to plasma proteins and albumin was high (98%) and was not concentration-dependent or altered in the presence of large amounts of metabolites. The plasma protein binding of proquazone increased with increasing pH. The apparent solubility of the hydrophobic drug was largely increased in buffers in which albumin was solubilized in high contents. Albumin as a biol. solubilizer permits i.v. administration of significantly larger amts. of the drug. The erythrocyte-buffer partition coefficient averaged 5.5 and was pH dependent. Equilibrium between red blood cells and the buffer was obtained quickly after drug addition (<2 min). The erythrocyte-plasma partition coefficient value of 0.09 indicated that only unbound drug partitions into red cells.
 IT 22760-18-5
 EL: PROC (Process)
 (erythrocyte partitioning and protein binding of)
 RN 22760-18-5 CAPLUS
 CN 21181-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 162 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN


ACCESSION NUMBER: 1981149994 CAPLUS
 DOCUMENT NUMBER: 94149994
 ORIGINAL REFERENCE NO.: 94149994, 24352a
 TITLE: Application of column switching in high-performance liquid chromatography to on-line sample preparation for complex separations
 AUTHOR(S): Ertel, F.; Seiler, H. P.; Meier, C.; Schmitt, H.
 CORPORATE SOURCE: Anal. Res. Dev., Bionext Ltd., Basel, Switz.
 SOURCE: Journal of Chromatography (1993), 264, 45-76
 C/DEN: JCHM; ISSN: 0021-9679
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A flexible column-switching set-up for high-performance liquid chromatog. (HPLC) which uses 2 4-port valves as switching devices is presented. The apparatus is suitable for automation and can easily be put together from available components. The arrangement can be used for different kinds of cuts (front-cut, heart-cut, end-cut), for back-flushing, and for on-line concentration. Varying the separation parameters with gradient elution and/or different stationary phases in the sub-separation systems offers many possibilities, including 2-dimensional HPLC. The set-up presented proved to be valuable both during optimization and for routine work. Applications of this technique to the anal. of biol. samples (urine, plasma, etc.) for drugs are discussed. They demonstrate that a chromatog. clean-up is very efficient and may be the method of choice when the compds. to be analyzed are chemical labile and when there is a high risk of artifact formation with classical clean-up techniques.
 IT 60507-23-1
 EL: ANT (Analyte); NMR (Analytical study)
 (determination of, in feed by high-performance liquid chromatog. with column switching)
 RN 60507-23-1 CAPLUS
 CN 21181-Quinazolinone, 4-[(4-fluorophenyl)-7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



15 ABSTRACT 183 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1981121593 CARLUS
 DOCUMENT NUMBER: 94121593
 ORIGINAL REFERENCE NO.: 94139914, 1994a
 TITLE: 1,4-disubstituted 2,3-dihydroquinazolin-3-one
 SOURCE: Shionogi and Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 9 pp.
 SOURCE: COMPO: 000000
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC: STM, COMPT
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55141472	A	19801105	JP 1979-06428	19790428
FOREIGN APPL. INFO.			JP 1979-06428	A 19790428
OTHER SOURCE(S):	CASREACT	94121593		
GI				



AS Quinazolinones I (R = H, alkyl, alkoxy, halogen; R1 = alkyl, alkoxy, halogen; R2 = H, halogen) were prepared. Thus, refluxing 5.34 g of 2-aminobenzophenone (I) (R = H) (R2 = CH3) with 12.8 ml 2.45 M BrCN in MeOH gave 5.13 g II (R3 = CH3), which was treated with 2 N HCl at 100°C to give I (R = H, R2 = Me/CH3, R1 = Ph).

IT 17629-04-89 22760-18-19 40507-23-1P
 76854-08-19
 R1: STM [Synthetic preparation]; FRPE (Preparation)
 (preparation of)
 R2: 17629-04-8 CAPLUS
 CH 21181-Quinazolinone, 3-methyl-4-phenyl- (CA INDEX NAME)



RH 22760-18-5 CAPLUS

15 ABSTRACT 183 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
 CH 21181-Quinazolinone, 7-methyl-3-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RH 40507-23-1 CAPLUS
 CH 21181-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-3-(1-methylethyl)- (CA INDEX NAME)



RH 76854-08-5 CAPLUS
 CH 21181-Quinazolinone, 8-methoxy-3-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ABSTRACT 184 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1981121443 CARLUS
 DOCUMENT NUMBER: 94121443
 ORIGINAL REFERENCE NO.: 94139839, 1994a
 TITLE: A new route to 4-phenyl-2(1H)-quinazolinones;
 reactions of 2-aminobenzophenones with chloroacetyl
 isocyanate
 AUTHOR(S): Yama, Akemi; Kato, Y; Kana, Satoru, P. B.
 CORPORATE SOURCE: Fuy. Res. Lab., Hyderabad, 500009, India
 SOURCE: Synthetic Communications 1990, 20(10), 799-804
 COMB. SYNTH. J. 1991, 0039-7911
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 94121443
 GI



AS Phenylquinazolinones I (R = H, Me; R1, R2 = H, Cl) were prepared in 64-83% yield by condensing 2-aminobenzophenones II with ClO2EPPO.

IT 17629-04-89 20857-33-1P
 R1: STM [Synthetic preparation]; FRPE (Preparation)
 (preparation of)
 R2: 17629-04-8 CAPLUS
 CH 21181-Quinazolinone, 3-methyl-4-phenyl- (CA INDEX NAME)



RH 20857-33-1 CAPLUS
 CH 21181-Quinazolinone, 6-chloro-3-methyl-4-phenyl- (CA INDEX NAME)


15 ABSTRACT 184 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



13 ANSWER 165 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981114294 CAPLOS
 DOCUMENT NUMBER: 94114294
 ORIGINAL REFERENCE NO.: 94118574, 18530a
 TITLE: A radioassay for proteolytic cleavage of isolated cartilage proteoglycan. 2. Inhibition of human leukocyte elastase and cathepsin G by antiinflammatory drugs
 AUTHOR(S): Shewen, R. M.; Walton, E. A.; Ghosh, P.; Taylor, T. F. F.; (James, M. J.; Savemann, K.; Raymond Purvis Res. Lab., 8 North Shore Bosp., Sydney, Australia
 SOURCE: Arthritis Rheumatism (1980), 30(12), 2108-12
 COUNTRY: AUSTRALIA
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: Twenty nonsteroidal antiinflammatory drugs and other agents were evaluated for their effectiveness in directly inhibiting the proteolytic activity of human leukocyte elastase and cathepsin G. The proteolysis of hide powder azide by leukocyte granule azide was used for initial testing, and selected drugs were then studied further using a radioassay of the proteolysis of isolated proteoglycan by purified leukocyte elastase and cathepsin G. The results indicated that at drug concns. likely to be attained in vivo, phenylbutazone may significantly inhibit elastase, while gold thiomalate and Artepaxon (methylsulfonylacetate polyacrylic acid ester) would limit the action of cathepsin G. Oleic acid may provide a useful starting point for development of agents specifically designed to inhibit cartilage erosion.
 IT 22760-18-5
 R1: R10L (Biological study)
 (cathepsin G and elastase of leukocytes response to, cartilage proteoglycan cleavage in relation to)
 R1: 22760-18-5 CAPLOS
 CN 2118-Quinalonone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 167 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19811554 CAPLOS
 DOCUMENT NUMBER: 941554
 ORIGINAL REFERENCE NO.: 941218, 123a
 TITLE: Modification of EAE by nonsteroidal anti-inflammatory drugs
 AUTHOR(S): Bolton, C.; Currier, M. L.
 CORPORATE SOURCE: Inst. Neurol., Natl. Hosp., London, WC1 2NG, UK
 SOURCE: Suppl. Exp. Allergy. Rheumatology (1980), Meeting Date 1979, 139-47. Editor(s): Davison, Alan Nelson; Currier, M. L.; Amsterdam London, Engl.
 COUNTRY: AUSTRALIA
 CONFERENCE: Conference
 DOCUMENT TYPE: English
 GI:



AB In guinea pigs with hyperacute exptl. allergic encephalomyelitis (EAE) prophylactic or therapeutic administration of the nonsteroidal antiinflammatory drugs indomethacin [53-86-1], flurbiprofen [1304-61-6], and RP 46-790 [40907-23-1] increased the severity of the disease. However, 16,16-dimethyl PGGE (1) [19746-25-2] inhibited it. The suppressive effect would not be repeated with prostaglandin precursors or with drugs which increased the conversion to E-type prostaglandins. The lymphotase drug cyclopentanone A [53865-11-3] was the most effective immunosuppressant and had greater prophylactic than therapeutic activity.
 IT 40507-23-1
 R1: R10L (Biological study)
 (encephalomyelitis response to)
 R1: 40507-23-1 CAPLOS
 CN 2118-Quinalonone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

13 ANSWER 166 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19811766 CAPLOS
 DOCUMENT NUMBER: 941766
 ORIGINAL REFERENCE NO.: 9411314
 TITLE: Pharmaceutical for treating a benign prostate adenoma
 PATENT ASSIGNEE(S): Becton Holdings (Netherlands Antilles) N.V., Becton Fr. Besmeder, 9 pp.
 SOURCE: CEMEX PRESS
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO.:
 FIRM DATE APPLICATION NO.: DATE
 PRIORITY APPL. INFO.:
 FR 2437838 A1 19900430 FR 1978-23535 19790409
 DE 1978-282531 A 19790725

OTHER SOURCE(S):
 AB Complex, such as salicylic acid deriv., capable of inhibiting or reducing the bioactivity of prostaglandins are used effectively in the treatment of benign prostate adenoma. Among the complex, used were acetylsalicylic acid [50-78-2] (5000-6000 mg), mephenamic acid [61-83-7] (1000 mg), diclofenac [15307-86-5] (75-150 mg), naproxen [13558-28-4] (500-1500 mg), sulindac [18134-50-2] (500-600 mg), and piroxicam [122760-18-5] (600-1200 mg).
 IT 22760-18-5
 R1: R10L (Biological study)
 (benign prostate adenoma treatment by)
 R1: 22760-18-5 CAPLOS
 CN 2118-Quinalonone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 167 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 19811554 CAPLOS
 DOCUMENT NUMBER: 941554
 ORIGINAL REFERENCE NO.: 941218, 123a
 TITLE: Modification of EAE by nonsteroidal anti-inflammatory drugs
 AUTHOR(S): Bolton, C.; Currier, M. L.
 CORPORATE SOURCE: Inst. Neurol., Natl. Hosp., London, WC1 2NG, UK
 SOURCE: Suppl. Exp. Allergy. Rheumatology (1980), Meeting Date 1979, 139-47. Editor(s): Davison, Alan Nelson; Currier, M. L.; Amsterdam London, Engl.
 COUNTRY: AUSTRALIA
 CONFERENCE: Conference
 DOCUMENT TYPE: English
 GI:



13 ANSWER 149 OF 327 CAPLOS COPYRIGHT 2006 ACS on STM (Continued)
 ACCESSION NUMBER: 198151 CAPLOS
 DOCUMENT NUMBER: 94151
 ORIGINAL REFERENCE NO.: 94151,64
 TITLE: High-performance liquid chromatographic column switching technique in the analysis of medicated feed for an automated clean-up procedure
 AUTHOR(S): GILLER, J. C.; STACHNITZ, M.
 CORRESPONDENCE SOURCE: Pharm. Dep., BASF AG, BASF, D-6000, Wuppertal, Germany
 SOURCE: Journal of Chromatography (1990), 199(2), 142-8
 CODEN: JOCRAH ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB A high-performance liquid chromatographic column switching technique for sample clean-up treatment was used for the determination of Fluoropropane (I) [40507-23-1] in medicated feed. Methanol was used for the extraction of I from feed. The samples were chromatographed on a Lichrosorb RP-8 column with a mobile phase consisting of MeCN-AcOH and a Lichrosorb RP-8 column was used for the sample clean-up. The sample extracts were treated on a pre-column with different methanolic mobile phases before separation on the anal. column. Water was used for the clean-up procedure. I was detected at 240 nm. The limit of detection was 0.0015 µg/g. Recovery studies of spiked feed extracts indicate a recovery 295%. Samples were stable for up to 2 wk at temp. from -15° to -25°. The column switching technique for sample clean-up treatment is very efficient for the determination of I in medicated feed. The method is simple, sensitive, reproducible, and rapid.
 IT 40507-23-1
 RI: ACT (Analytical); RNT (Analytical study)
 (determination of, in feed by high-performance liquid chromatographic column switching technique)
 RI: 40507-23-1 CAPLOS
 CI: 21181-Quinazolinone, 6-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

13 ANSWER 149 OF 327 CAPLOS COPYRIGHT 2006 ACS on STM (Continued)
 ACCESSION NUMBER: 1980060488 CAPLOS
 DOCUMENT NUMBER: 931204882
 ORIGINAL REFERENCE NO.: 931204882,12684
 TITLE: Quinazolinone derivatives
 PATENT ASSIGNMENT(S): Benzaldehyde, Fe.
 SOURCE: Jpn. Tokkyo Koho, 6 pp.
 CODEN: JAKOAB
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACT. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 55025505 B 19800207 JP 1973-89492 19711111
 PRIORITY APPL. INFO.: JP 1973-89492 A 19711111
 CI



AB Quinazolinone derivs. (I; R = NH2, CH3, CO2H, alkoxyarabonyl), effective antidiarrheal agents and analgesics at 100 mg-2.5 g/day in adults, were prepared. Thus, R = CH3 (I) in MeCN was reduced with 27 g SnCl2 to give 380 mg I (R = NH2), which (5 g) was dissolved with NaOH in EtOH and treated with OCN solution to give 1.80 g I (R = CH3) (II). Hydrolysis of 5.4 g II in refluxing HCl gave 70% acid (I; R = CO2H), which (2.4 g) was esterified with CH3OH in EtOH to give 80% Me ester (I; R = CO2Me).
 IT 71388-42-4P
 RI: ACT (Reactant); RNT (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation and separation of)
 RI: 71388-42-4 CAPLOS
 CI: 21181-Quinazolinone, 6-amino-1-methyl-4-phenyl- (CA INDEX NAME)



IT 71388-42-4P
 RI: ACT (Reactant); RNT (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

13 ANSWER 149 OF 327 CAPLOS COPYRIGHT 2006 ACS on STM (Continued)
 ACCESSION NUMBER: 198151 CAPLOS
 DOCUMENT NUMBER: 94151
 ORIGINAL REFERENCE NO.: 94151,64
 TITLE: High-performance liquid chromatographic column switching technique in the analysis of medicated feed for an automated clean-up procedure
 AUTHOR(S): GILLER, J. C.; STACHNITZ, M.
 CORRESPONDENCE SOURCE: Pharm. Dep., BASF AG, BASF, D-6000, Wuppertal, Germany
 SOURCE: Journal of Chromatography (1990), 199(2), 142-8
 CODEN: JOCRAH ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



13 ANSWER 149 OF 327 CAPLOS COPYRIGHT 2006 ACS on STM (Continued)
 ACCESSION NUMBER: 1980060488 CAPLOS
 DOCUMENT NUMBER: 931204882
 ORIGINAL REFERENCE NO.: 931204882,12684
 TITLE: Quinazolinone derivatives
 PATENT ASSIGNMENT(S): Benzaldehyde, Fe.
 SOURCE: Jpn. Tokkyo Koho, 6 pp.
 CODEN: JAKOAB
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACT. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 55025505 B 19800207 JP 1973-89492 19711111
 PRIORITY APPL. INFO.: JP 1973-89492 A 19711111
 CI



AB Quinazolinone derivs. (I; R = NH2, CH3, CO2H, alkoxyarabonyl), effective antidiarrheal agents and analgesics at 100 mg-2.5 g/day in adults, were prepared. Thus, R = CH3 (I) in MeCN was reduced with 27 g SnCl2 to give 380 mg I (R = NH2), which (5 g) was dissolved with NaOH in EtOH and treated with OCN solution to give 1.80 g I (R = CH3) (II). Hydrolysis of 5.4 g II in refluxing HCl gave 70% acid (I; R = CO2H), which (2.4 g) was esterified with CH3OH in EtOH to give 80% Me ester (I; R = CO2Me).
 IT 71388-42-4P
 RI: ACT (Reactant); RNT (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation and separation of)
 RI: 71388-42-4 CAPLOS
 CI: 21181-Quinazolinone, 6-amino-1-methyl-4-phenyl- (CA INDEX NAME)



IT 71388-42-4P
 RI: ACT (Reactant); RNT (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

15 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN 2-[18]-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1980:556401 CAPLUS
 DOCUMENT NUMBER: 97186401
 ORIGINAL REFERENCE NO.: 97:297396,29722a
 TITLE: 1-Polyhaloalkyl-2-[18]-quinazolinone derivatives
 INVENTOR(S): Isabe, Shigehy Ishizumi, Kikuo Mori, Kazuo
 Yamamoto, Hisayo Yamamoto, Michihiko
 Sumitomo Chemical Co., Ltd., Japan
 U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 157,051,
 abandoned.
 COUNTRY: ESJCAN
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACT: NUM. CONT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4320995	A	19800513	US 1974-479454	19740214
PRIORITY APPL. INFO.			US 1973-157051	A2 19740604
OTHER SOURCE(S):			NAFAT 93116401	
CI				



AB The quinazolinones I (R = C2-3 polyalkyl containing 2 F atoms; R1, R2, R3 = H)
 AB = H
 C1-4 alkyl, C1-4 alkoxy, NO2, F, Cl, halo) were prepared. Thor, 5.13 g
 4-phenyl-6-chloro-2-[18]-quinazolinone was treated with FPOCH2I to give
 2-5
 g I (R = FPOCH2, R1 = 6-Cl, R2 = R3 = H) (11) and 2 g 2-(2,2,2-trifluoroethyl)-4-phenyl-6-chloroquinazolinone II was also prepared by
 epoxidation of 5,2-Cl-IFPOCH2NO2/CH3COOPh with Et carbonate. I were
 48.11% (analytical and elemental) (no data).
 IT 36943-01-8 59255-64-4 59255-65-5
 74854-20-5 74854-21-6
 RI: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of)
 CN 63930-33-6 CAPLUS
 2-[18]-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)
 CN 74854-20-5 CAPLUS
 2-[18]-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI 59253-64-4 CAPLUS
 CN 2-[18]-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 59253-65-5 CAPLUS
 CN 2-[18]-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 74854-20-5 CAPLUS
 CN 2-[18]-Quinazolinone, 3-(1,1,1-difluoroethyl)-3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 74854-21-6 CAPLUS
 CN 2-[18]-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



IT 63930-33-6
 RI: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of)
 CN 63930-33-6 CAPLUS
 2-[18]-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



IT 37554-40-8P 40852-44-6P 40852-52-6P
 48870-89-9P 52805-75-6P 59253-70-2P
 74854-11-6P 74854-13-6P 74854-15-8P
 74854-16-9P 74854-25-0P 74854-26-1P
 RI: SYN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 CN 37554-40-5 CAPLUS
 2-[18]-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 40852-44-6 CAPLUS
 CN 2-[18]-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 170 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



BN 74856-15-6 CAPLOS
CN 2(1H)-Quinoxaline, 6-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-15-6 CAPLOS
CN 2(1H)-Quinoxaline, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-15-6 CAPLOS
CN 2(1H)-Quinoxaline, 6-methyl-1-(2,2,2,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 170 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)
BN 59253-70-2 CAPLOS
CN 2(1H)-Quinoxaline, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-11-4 CAPLOS
CN 2(1H)-Quinoxaline, 6-chloro-4-(2-methoxyphenyl)-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-13-6 CAPLOS
CN 2(1H)-Quinoxaline, 6-(trifluoroethyl)-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-15-8 CAPLOS
CN 2(1H)-Quinoxaline, 1-(1,1-difluoroethyl)-4-nitro-6-phenyl- (CA INDEX NAME)

15 ANSWER 170 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



BN 74856-16-9 CAPLOS
CN 2(1H)-Quinoxaline, 6-methoxy-4-phenyl-1-(2,2,2-trichloroethyl)- (CA INDEX NAME)



BN 74856-15-9 CAPLOS
CN 2(1H)-Quinoxaline, 6-bromo-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



BN 74856-16-1 CAPLOS
CN 2(1H)-Quinoxaline, 6,8-dichloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 171 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN

1580560979 CAPLOS
DOCUMENT NUMBER: 93160979
ORIGINAL REFERENCE NO.: 93284976, 25500a
TITLE: Effects of vorinastatin, cyclo-oxygenase inhibitors, and dexamethasone on enzyme secretion by macrophages
AUTHOR(S): Raggiolini, M.; Bewald, S.; Schwyder, J.
CORPORATE SOURCE: Friedlin, Inc., Mendocino, Calif., U.S.A.
SOURCE: British Journal of Pharmacology (1995), 69(2), 269-270
COPD: RTICM; ISSN: 0007-1189
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Dexamethasone [50-02-2] (0.1 or 1.0 mM) blocked plasminogen (2) [5001-31-8] activator secretion and reproducibly lowered release of lysosomal glycosides by 40-80% from mouse peritoneal macrophages. Wortmannin (22) deriv. (1-10 μM) also blocked 1 activator secretion and also lowered lysosome release, but had virtually no effect on lysosomal hydrolases, and did not inhibit cyclooxygenase. Indomethacin [53-86-1], diclofenac [15307-86-5], and piroxicam [22760-18-5] all (0.1-1.0 μM) all enhanced 1 activator secretion by 40-100%, but the release of the other enzymes was unchanged. Retinoid and nonsteroidal antiinflammatory compds. had opposite effects on 1 activator secretion by macrophages. In this respect, the effects of 12 derive. resemble those of glucocorticosteroids.
IT 22760-18-5
EI: RIOL (Rheological study)
BN 22760-18-5 CAPLOS
CN 2(1H)-Quinoxaline, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANWERS 112 OF 327 CARLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1980:515856
 DOCUMENT NUMBER: 93:125956
 ORIGINAL REFERENCE NO.: 93:125956, 24738a
 TITLE: Pharmacological administration forms
 INVENTOR(S): Dehmel, Alwin; Riva, Aldo; Becker, Heinz
 PATENT ASSIGNEE(S): Sandoz Patent (G.m.b.H., Weiz, Austria)
 SOURCE: Ger. Offen., 37 pp.
 COUNTRY: AUSTRIA
 DOCUMENT TYPE: Pat.
 LANGUAGE: German
 FAMILY AC. ID. NO. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3914363	A1	19800410	NO 1979-3914363	19790407
DE 3914363	C2	19801119		
DE 4780151	A1	19800716	NO 1979-4780151	19790411
FR 2471026	A1	19800410	FR 1979-9150	19790411
FR 2471026	B1	19800716		
AT 3962639	A	19801015	AT 1979-2639	19790411
NL 734680	B	19840505		
NL 734680	A	19800401	NL 1979-1065	19790419
JP 55049110	A	19800409	JP 1979-51997	19790415
JP 62027044	A	19870611		
DK 7923973	A	19800710	DK 1979-1937	19790920
DK 7923973	A	19800710	SE 1979-1770	19790920
SE 439243	B	19800610		
SE 439243	C	19800610		
FI 68762	B	19800731	FI 1979-2927	19790920
FI 68762	C	19801111		
NO 7923214	A	19800401	NO 1979-1034	19790921
NO 151551	B	19800106		
NO 151551	C	19800416		
CA 1114248	A1	19801026	CA 1979-136504	19790927
NO 7911287	A	19800401	NO 1979-10187	19790928
AO 520914	A2	19800804		
NO 144248	A	19800804	NO 1979-11888	19790928
NO 12617	A2	19800629	NO 1979-04301	19790928
NO 12617	B	19800818		
CS 112158	A2	19800118	CS 1978-6390	19790928
CS 112158	A2	19800118	CS 1978-10194	19790929

FIGURE 1 APPL. 2890.1

AB Suppositories are prepared by compression at low temp. (<10°) to avoid problems associated with high temperature n-melting processes, e.g., drug decomposition and sedimentation. There is no need for binders in the masses. The humidity should be controlled to avoid H₂O crystallization propylamine. [479-52-3], methacetal [17-46-9] and anhydrous caffeine [58-08-2] were mixed, sieved, and milled and stirred with pulverized Nitropol H15 with cooling (H₂O). The cooling H₂O was heated to 60°. Large lumps were formed upon continued stirring. The mass was removed and cooled to 40°, sieved to a 1.5 mm mesh granulate and compressed at -10 to 5°.

13 ANWERS 113 OF 327 CARLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1980:515870
 DOCUMENT NUMBER: 93:125972
 ORIGINAL REFERENCE NO.: 93:125972, 1987a
 TITLE: Study on small intestine lesions induced by nonsteroidal anti-inflammatory drugs. I. Effect of single administration of various nonsteroidal anti-inflammatory drugs and influence of fasting or bile-duct ligation on it in rats
 AUTHOR(S): Ryohi, Nobuo
 CORPORATE SOURCE: Res. Med., Gifu Univ., Gifu, Japan
 SOURCE: Gifu Daigaku Igakubu Kiyo (1980), 28(2), 141-51
 COUNTRY: JAPAN, ISSN: 0013-0921
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese

AB At 48 h following oral or parental administration of nonsteroidal anti-inflammatory drugs to rats, the indole, phenylacetic acid, and anthranilic acid deriv. produced intestinal ulcers, whereas the pyrazolidinone deriv., propylated, and basic groups, had no effect. The active groups were indolethene [51-86-1], ketoprofen, ibuprofen [15489-27-1], diclofenac-Na [15307-78-6], flufenamic acid [550-79-9], mefenamic acid [45-85-7], 7AI-28 (1980-02-4), and benazoprofen [15124-28-7], whereas the inactive groups were phenylbutazone [150-35-1], oxipropazone [129-20-4], Na salicylate [14-21-7], salicylic acid [149-72-7], aspirin [100-75-7], mefenamic acid [10036-10-9], and proquazone [100-75-7]. Thus, intestinal lesions may be produced by different mechanisms than stomach ulcers. Thus, intestinal lesions caused by parental administration of the nonsteroidal anti-inflammatory drugs were similar to those produced by oral administration. The intestinal lesions were decreased by starvation of the rat and were prevented by ligation of the bile duct. Thus, biliary secretion and enterohepatic circulation of nonsteroidal anti-inflammatory drugs is the important factor in causing intestinal lesions.

IT 2760-18-5
 RI: BCL (Biological study)
 [Intestinal lesions in relation to]
 NO 2760-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANWERS 112 OF 327 CARLOS COPYRIGHT 2008 ACS ON STN (Continued)
 to give suppositories.
 IT 2760-18-5
 RI: BCL (Biological study)
 [suppositories containing, cold compression of]
 NO 2760-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANWERS 114 OF 327 CARLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1980:514669
 DOCUMENT NUMBER: 93:114669
 ORIGINAL REFERENCE NO.: 93:125756, 19332a
 TITLE: Oxidation of 4-(2-chloromethyl)-1,4-benzodiazepine derivative
 AUTHOR(S): Mikoski, M.; Buschman, E.; Kuehnbecker, H.
 CORPORATE SOURCE: Sparte Pharma, Kali-Chem. A.-G., Hannover, D-3000, Fed. Rep. Ger.
 SOURCE: Journal of Heterocyclic Chemistry (1980), 17(2), 313-6
 COUNTRY: GERMANY, ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 AB 7-Chloro-1-methyl-2-(chloromethyl)-3-phenyl-1,3-dihydro-1H-1,4-benzodiazepine is oxidized with KMnO₄ and chromic acid. The products of oxidation are discussed. With KMnO₄ in dilute HCl, the main product is the 7-chloro-1-methyl-3-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one whereas with chromic anhydride/pyridine the addl. oxidation at C3 increases and the N-H group is affected to a larger extent.
 IT 20927-53-19
 RI: SPN (Synthetic preparation); FREE (Preparation of)
 NO 20927-53-1 CAPLUS
 CN 2118-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 175 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1980;433932 CAPLUS
 DOCUMENT NUMBER: 93;53992
 ORIGINAL REFERENCE NO.: 93;87474,87504
 TITLE: Dependence of area under the curve on proquazone particle size and in vitro dissolution rate
 AUTHOR(S): Nimmerfall, Fritz; Rosenbaler, Joachim
 CORPORATE SOURCE: Pharm. Dr. Barm. Bern, Bern, Switz.
 SOURCE: Journal of Pharmaceutical Sciences (1980), 69(15), 405-7
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The in vitro dissoln. and GI absorption of various sieve fractions of proquazone (I) [2760-18-5] were studied (particle-size ranges of 41-74, 100-200, and 500-1000 μ m). The dissoln. rates of proquazone 74 μ , F100, and F500 were determined in vitro in a flow-through assembly artificial gastric juice at 37°. The time required for 61% of the maximum amount of soluble drug to pass into solution was characterized by the

dissoln. variable k_D . The in vitro dissoln. rates for the proquazone differed significantly in the order k_D 745 < k_D F100 < k_D F500. After oral administration of 300 mg of the fractions to each of 8 healthy monkeys, the area under the plasma level-time curve (AUC) differed significantly in the order: AUC 745 > AUC F100 > AUC F500. The dissoln. rate increased with decreasing particle size. The AUC increased with decreasing particle size and with increasing dissoln. rate. These results indicate that the dissoln. rate probably sets the extent of absorption when dissoln. is rate limiting.

IT 22760-18-5
 RI: RIOL (Biological study)
 (Absorb. and bioavailability of various particle size fractions of)
 ZN 22760-18-5 CAPLUS
 CH 2118-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 175 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



13 ANSWER 176 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1980;438989 CAPLUS
 DOCUMENT NUMBER: 93;18889
 ORIGINAL REFERENCE NO.: 93;30704,30704
 TITLE: The effect of antacid and food on the absorption of proquazone (Baxson) in man
 AUTHOR(S): Chhabra, R. E.
 CORPORATE SOURCE: Dep. Med., Chir. Bern, Bern, Switz.
 SOURCE: International Journal of Clinical Pharmacology, Therapy and Toxicology (1980), 18(3), 134-9
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The effect of food and antacid was studied on the absorption of proquazone (I) [2760-18-5] in healthy volunteers when administered orally as a single dose. Each subject received, in a randomized cross-over sequence, 600 mg I after a 12 h overnight fast, 15 min after 20 ml of an antacid (Maaloxan), and 15 min after a standard breakfast. The only effect of antacid, compared to fasting, was to slow the rate of absorption without appreciably altering the extent of absorption. Food, on the other hand, markedly increased the maximal plasma concentration and also the area under the plasma concentration/time curve. Administration of I with or after food should be doubly advantageous for the patient, as it ought to offer protection from local gastrointestinal irritation and at the same time lead to an enhanced bioavailability.

IT 22760-18-5
 RI: RIOL (Biological study)
 (absorption of, by intestine, antacid and food effect on)
 ZN 22760-18-5 CAPLUS
 CH 2118-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 176 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



13 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

ACCESSION NUMBER: 1990:498201 CAPLUS

DOCUMENT NUMBER: 9108203

ORIGINAL REFERENCE NO.: 911511a, 1514a

TITLE: 2(1R)-Quinoxalimethione derivatives

INVENTOR(S): Tamura, Takamitsu; Kawasaki, Tomeni; Kita, Yasuyuki

PATENT ASSIGNEE(S): Japan Kokai Tokkyo Koho, 11 pp.

SUMMARY: COINT. JACQAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 64144796	A	1979-11-10	JP 1978-53009	1979-05-21
JP 61023477	B	1980-05-27		
FR208277 APPLS. INFO.:			JP 1978-13009	A 1979-05-21

01



AB Eighteen title deriva. 2 (R = H, alkyl, alkenyl, alkynyl, substituted alkyl, etc.; R1 = H, Ph, aryl, cycloalkyl, heterocyclyl; R2, R3 = H, NO2, halo, alkyl, etc.) were prepared by reaction of 13 with Ph3P(SO)2. 1 had antitumor activity, analgesic, and antileukemic activities (no data). Thsa., 492.5 mg 2-(5HNE)2(6OPh) In CH2Cl2 was added to 3 mmol Ph3P(SO)2 in CH2Cl2 at -67 under N. The mixture kept 1 h at -60°, and stirred overnight to give 12a (mg 1 (R = H) = R2 = H, R1 = Ph).

27 2614-98-4P 26920-10-5P 26920-11-7P
26920-11-0P 26920-11-4P 26461-18-4P
53720-97-1P 53720-98-2P 53720-99-3P
53721-00-0P 53721-01-0P 73877-10-0P
73877-11-1P 73877-12-2P 73877-21-3P
R1, R2 (Synthesis preparation); PREP (Preparation)

28 2614-98-4 CAPLUS
CN 2(1R)-Quinoxalimethione, 4-phenyl-1-(2-propenyl)- (PCI) (CA INDEX NAME)

13 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



28 2614-98-4 CAPLUS
CN 2(1R)-Quinoxalimethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



28 53720-97-1 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



28 53720-98-2 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



28 26920-10-5 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



28 26920-12-7 CAPLUS
CN 2(1R)-Quinoxalimethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



28 26920-15-0 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-methyl-4-phenyl- (CA INDEX NAME)



28 26920-57-4 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-ethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



28 53720-99-3 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



28 53721-00-9 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



28 53721-01-0 CAPLUS
CN 2(1R)-Quinoxalimethione, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RN 73877-20-0 CAPLUS
CN 2(18)-Quinazolinethione, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-21-1 CAPLUS
CN 2(18)-Quinazolinethione, 7-methyl-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-22-2 CAPLUS
CN 2(18)-Quinazolinethione, 1-(2-methylpropyl)-7-(methylthio)-4-phenyl- (CA INDEX NAME)

15 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)

ACCESSION NUMBER: 1390128950 CAPLUS
DOCUMENT NUMBER: 92128950
ORIGINAL REFERENCE NO.: 92128950, 1039a
TITLE: Quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNER(S): Sandoz A.-G., Switz.
SOURCE: Rev., 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	INTD	DATE	APPLICATION NO.	DATE
NO 53491	AS	19701215	NO 1968-50070	19680611
CS 157638	B2	19740916	CS 1968-981	19680605
CS 157639	B2	19740916	CS 1977-992	19770219
			NO 1968-50070	19680611

PRIORITY APPLS. INFO.:

GI:



AS Phenylquinazolinones: R = H, F, Bu, Cl; R1 = H, halo, HO, alkyl, Cl-4 alkyl, having antiinflammatory, antipretic, and analgesic activities (no

data), were prepared Thus, refluxing 6-phenylquinazolinone with MeI 8 h

gave 1-methyl-4-phenylquinazolinone iodide, whose oxidation gave 1 (R=R2 = H).

IT 17629-04-8P 20827-03-2P 20824-08-5P

20824-17-2P 20824-04-2P 20824-06-4P

20824-07-5P 20824-00-2P 20824-08-3P

20824-07-8P

AL STM (Synthetic preparation); PREP (Preparation)

BY (Preparation info)

RN 17629-04-8 CAPLUS

CN 2(18)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RN 73877-23-3 CAPLUS
CN 2(18)-Quinazolinethione, 6-methoxy-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-21-1 CAPLUS
CN 2(18)-Quinazolinethione, 7-methyl-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-22-2 CAPLUS
CN 2(18)-Quinazolinethione, 1-(2-methylpropyl)-7-(methylthio)-4-phenyl- (CA INDEX NAME)

15 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RN 20827-53-1 CAPLUS
CN 2(18)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 20824-88-5 CAPLUS
CN 2(18)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 20824-77-1 CAPLUS
CN 2(18)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 20824-94-2 CAPLUS

13 ANSWER 179 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2 [18]-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-96-4 CAPLOS
 CN 2 [18]-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-97-5 CAPLOS
 CN 2 [18]-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26831-06-1 CAPLOS
 CN 2 [18]-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



13 ANSWER 179 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 1390121782 CAPLOS
 DOCUMENT NUMBER: 94121782
 ORIGINAL REFERENCE NO.: 9413973a, 1973a
 TITLE: General pharmacological studies on ciproquazone (SU-573) and its metabolites
 AUTHOR(S): Miyagishi, Akira; Tsuda, Masafumi; Hara, Yoichi; Nakatsu, Hiroshi
 CORPORATE SOURCE: Oyo Yakuri (1979), 19(1), 9-22
 SOURCE: OYAAJ; ISSN: 0369-0035
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GC



AB The antiinflammatory drug SU-573 (I) [33453-23-5] (>1 mg/kg, i.v.) given to rats decreased blood pressure and the 3-3 interval in the ECG pattern, increased heart rate, cardiac activity, but had no significant effect on the pO₂, isotropic and chronotropic responses. In isolated guinea pig lungs, I induced contraction, but in isolated vas deferens I inhibited the contraction. I and its metabolites had no marked effect on the movement of small intestine.

IT 73052-29-4 73052-30-9
 RL: BZOL (Biological study)
 (as ciproquazone metabolite, pharmacol. of)
 RN 73052-29-4 CAPLOS
 CN 2 [18]-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-hydroxyphenyl)-6-methoxy- (CA INDEX NAME)

15 ANSWER 179 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




RN 26831-08-3 CAPLOS
 CN 2 [18]-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26840-07-8 CAPLOS
 CN 2 [18]-Quinazolinone, 1-methyl-4-[5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



15 ANSWER 179 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 73052-30-9 CAPLOS
 CN 2 [18]-Quinazolinone, 1-(cyclopropylmethyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



IT 33453-23-5
 RL: BZC (Biological activity or effect, except adverse); BZD (Biological study, unclassified); TRO (Therapeutic use); BZOL (Biological study);
 (uses)
 (pharmacol. of)
 RN 33453-23-5 CAPLOS
 CN 2 [18]-Quinazolinone, 1-(cyclopropylmethyl)-4-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 179 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:41909 CAPLUS
 DOCUMENT NUMBER: 92:41989
 ORIGINAL REFERENCE NO.: 92:70114, 70164
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Bachmann, Gert; Heidey, Schmitt; Hans Jakoby, Pap.
 EUGENE ANTHONY
 PATENT ASSIGNMENT(S): Sandoz Patent-G.M.B.H., Switzerland.
 SOURCE: Ger. Offen., 34 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY NO., NUM. CONT.: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2809210	A1	19790906	DE 1978-2809210	19780703
PRIORITY APPL. INFO.			DE 1978-2809210	A 19780703

01



AB The antiinflammatory (no data) compds. 1 (R = H, F, Cl, Br, CH₃, alkyl, aryl, allyl, R1 = alkyl, cycloalkyl, heteroalkyl; R2 = CO₂H, SO₂CH₃, H, F, Cl, Br, NO₂, alkyl; R3 = H, F, Cl, Br; R4 = H, F, Cl, Br, CH₃, CF₃, alkyl).

were prepared. Thus, 1 (R = R3 = R4 = H, R1 = MeCO₂, R2 = 7-Me) was brominated with N-bromosuccinimide to give 1 (R2 = CBr₂), with was hydrolyzed to 1 (R2 = CO₂H).

IT 22762-18-5 65745-08-4

Re: RCT (Reactant); RACT (Reactant or reagent)

(bromination of)

FN 22762-18-5 CAPLUS

CM 2 (18i)-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



320 65745-08-4 CAPLUS
 CM 2 (18i)-Quinazolinone, 4-[(3-(acetoxy)phenyl)-7-methyl-1-[(1-methylethyl)-

(CA INDEX NAME)



IT 65745-06-2
 Re: RCT (Reactant); RACT (Reactant or reagent)

320 65745-06-2 CAPLUS

CM 2 (18i)-Quinazolinone, 4-[(3-methoxyphenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)



IT 65745-07-3P
 Re: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oxidation and acetylation of)

320 65745-07-3 CAPLUS

CM 2 (18i)-Quinazolinone, 4-[(3-hydroxyphenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)

15 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 50817-66-8P 65745-09-5P 72410-31-2P

Re: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

FN 50817-66-8 CAPLUS

CM 2 (18i)-Quinazolinone, 7-(bromomethyl)-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



FN 65745-09-5 CAPLUS

CM 2 (18i)-Quinazolinone, 4-[(3-(acetoxy)phenyl)-7-(bromomethyl)-1-[(1-methylethyl)- (CA INDEX NAME)



FN 72410-31-2 CAPLUS

CM 2 (18i)-Quinazolinone, 7-(bromomethyl)-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



3T 65765-05-1P 65765-11-9P 66154-89-0P
66154-91-4P 69104-02-5P 72410-32-7P
Nu. 3T8 (Synthetic preparation) / PREP (Preparation)
(preparation of)

3H 65765-05-5 CAPLUS
CH 2(18)-Quinazolinone, 7,6-dihydro-4-(3-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



3H 65765-11-9 CAPLUS
CH 2(18)-Quinazolinone, 7-(hydroxymethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



3H 66154-89-5 CAPLUS
CH 7-Quinazolinocarbonylic acid, 1,2-dihydro-4-(3-methoxyphenyl)-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



3H 66154-91-4 CAPLUS
CH 7-Quinazolinocarbonylic acid, 1,2-dihydro-4-(3-hydroxyphenyl)-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



3H 69104-02-5 CAPLUS
CH 2(18)-Quinazolinone, 7-(hydroxymethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



3H 72410-32-3 CAPLUS
CH 2(18)-Quinazolinone, 7-(hydroxymethyl)-4-(3-hydroxyphenyl)-1-(1-methylethyl)- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)




15 ANSWER 191 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM

1980/41975 CAPLUS
DOCUMENT NUMBER: 92/41979
ORIGINAL REFERENCE NO.: 92/7009A, 7012A
TITLES: Quinazolinones
SUBJECT(S): Cyt. Base
PATENT ASSIGNER(S): Sandoz A.-G., Switz.
SOURCE: Rev., 4 pp.
CODING: BUC03A3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 53394	A1	19781015	NO 1968-56975	19690611

PRIORITY APPL. INFO.:

GI



3B Benzophenones I (R = H, F, Cl, Br; R1 = alkyl, allyl, methylallyl, propargyl; R2 = H, CN, alkoxyl, alkyl; CFS; R3 = H, halo, CN, alkyl, alkoxyl) were treated with HIBOCER and SmCl2 to give quinazolinones II, useful as analgesics, antipruritics, and anti-inflammatory agents (no data).

A mixture of 2-(HIBOCER)CHCl3, HIBOCER, and SmCl2 was heated at 180-200° to give II (R = R2 = R3 = H, R1 = H).

3T 17629-04-8P 20927-53-1P 23461-64-7P
23461-80-5P 26732-06-1P 26824-71-5P
26824-77-3P 26824-80-6P 26824-81-7P
26824-82-9P 26824-84-0P 26824-86-2P
26824-86-4P 26824-97-7P 26831-04-2P
26831-07-2P 26831-08-3P 26831-09-4P
26831-11-8P 26840-07-8P 27524-92-3P
27524-92-2P 27529-23-3P 27559-10-0P
Nu. 3T8 (Synthetic preparation) / PREP (Preparation)
(preparation of)

3H 17629-04-8 CAPLUS
CH 2(18)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 181 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26827-53-1 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-5-methyl-4-phenyl- (CA INDEX NAME)



RI 23441-64-7 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-4-methyl-4-phenyl- (CA INDEX NAME)



RI 23441-68-5 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-3-methyl- (CA INDEX NAME)



15 ANSWER 181 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26824-81-7 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-5-(n-propyl)-4-phenyl- (CA INDEX NAME)



RI 26824-92-9 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-5-(n-butyl)-4-phenyl- (CA INDEX NAME)



RI 26824-94-0 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-5-(2-methyl-2-propenyl)-4-phenyl- (CA INDEX NAME)



RI 26824-94-2 CAPLOS
 CN 2(1H)-Quinazolinone, 6-(3-chlorophenyl)-3-methyl- (CA INDEX NAME)

15 ANSWER 181 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26773-86-1 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(3-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 26824-73-5 CAPLOS
 CN 2(1H)-Quinazolinone, 6-phenyl-5-(2-propenyl)- (CA INDEX NAME)



RI 26824-77-1 CAPLOS
 CN 2(1H)-Quinazolinone, 4-(2,6-dimethylphenyl)-3-methyl- (CA INDEX NAME)



RI 26824-80-6 CAPLOS
 CN 2(1H)-Quinazolinone, 4-phenyl-1-propyl- (CA INDEX NAME)

15 ANSWER 181 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26824-96-4 CAPLOS
 CN 2(1H)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RI 26824-97-5 CAPLOS
 CN 2(1H)-Quinazolinone, 6-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)



RI 26831-06-1 CAPLOS
 CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-3-methyl- (CA INDEX NAME)

1.5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 26831-07-2 CAPLUS
 CH 2 (18)-Quinazolinone, 5-ethyl-4-phenyl- (CA INDEX NAME)



XX 26831-08-3 CAPLUS
 CH 2 (18)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



XX 26831-09-4 CAPLUS
 CH 2 (18)-Quinazolinone, 6-chloro-4-[2-chlorophenyl]-1-(1-methylethyl)- (CA INDEX NAME)

1.5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 27524-93-2 CAPLUS
 CH 2 (18)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



XX 27529-23-3 CAPLUS
 CH 2 (18)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (PCI) (CA INDEX NAME)



XX 27559-10-0 CAPLUS
 CH 2 (18)-Quinazolinone, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)

1.5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 26831-11-8 CAPLUS
 CH 2 (18)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



XX 26940-07-8 CAPLUS
 CH 2 (18)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



XX 27524-90-1 CAPLUS
 CH 2 (18)-Quinazolinone, 1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)

1.5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



13 ANWEN 182 OF 327 CARLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:551345 CARLOS
 DOCUMENT NUMBER: 91:181345
 ORIGINAL REFERENCE NO.: 91:181345, 91:358a
 TITLE: Biopharmaceutical studies of lipid-containing oral dosage forms: relationship between drug absorption rate and digestibility of vehicles
 AUTHOR(S): Yamahira, Yoshiyuki; Naguchi, Takashi; Takemura, Kazuo; Maeda, Tadao
 CORPORATE SOURCE: Pharm. Div., Sanitono Chem. Co., Ltd., Thoraki, 567, Japan
 SOURCE: International Journal of Pharmaceutics (1979), 3(1), 23-31
 CORDIS 197926; ISSN: 0378-5173
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GC



AB The gastrointestinal absorption characteristics of a drug in a lipid-containing oral dosage form were studied in rats in relation to digestibility of lipid. DL-512 (I) [1985:50-0] was selected as a model of a lipid soluble drug with very low water solubility
 Media: chole-
 triglyceride (MCT) was employed as a model of a well digestible lipid and N-methyl-2-oxo-1,3-dioxol-5-yl (II) [1417:88-0] as model of a poorly digestible lipid. The in vitro release experiment of I from lipid vehicle to the water phase showed a strong affinity of I to vehicle lipids. In an oral administration study of lipid preps. to rats, the serum level of I was much higher from an MCT preparation than from an II preparation. In an in situ recirculation experiment I was not absorbed from lipid vehicles, although it was easily adsorbed from the aqueous solution. These facts suggest that digestion of the lipid was a major premise for absorption of I. In an intraduodenal administration study the serum levels of I from MCT and norm oil preps. were depressed by ligation of the bile duct. Thus, the decrease of the amount of the lipid by digestion in the gut was important for the absorption of I in lipids.
 IT 1985:50-0
 RI: 810L (biological study)

13 ANWEN 183 OF 327 CARLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:551347 CARLOS
 DOCUMENT NUMBER: 91:181347
 ORIGINAL REFERENCE NO.: 91:181347a, 4292a
 TITLE: Autoradiographic methods for the evaluation of ulcerogenic effects of antiinflammatory drugs
 AUTHOR(S): Bruns, K.; Gubler, H.; Schwaizer, A.
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, CH-4056, Switz.
 SOURCE: Pharmacology & Therapeutics (1979), 5(1-3), 199-207
 CORDIS 197927; ISSN: 0163-7258
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GC



AB Autoradiog. methods were used to monitor the absorption and distribution of nonsteroidal antiinflammatory drugs (NSAID) in situ. After oral administration, the acidic drug acetylsalicylic acid (I) [50-78-2] was absorbed rapidly and concentrated in a few parietal cells of the stomach while the nonacidic drug, proquazone [12760-18-5] remained in the stomach lumen for hours without entering the stomach wall in measurable amts. The effects observed may be correlated with the ulcerogenic effects both comds. exert on the stomach. While ulcer formation due to salicylates took place within the 1st h after administration, reached a peak at 2 h and thereafter declined, with proquazone only minor removal. Damage of the stomach was observed and was most pronounced at 4 h after administration. Thus, acidic NSAIDs may rapidly enter functioning parietal cells of the stomach by nonionic diffusion, get trapped in the neutral environment of the cell interior and destroy these cells by osmotic and acidic shock thereby forming the initial focus of ulcer formation.
 IT 12760-18-5
 RI: 810L (biological study)
 (ulcerogenic activity of, method for evaluation of)
 RI 12760-18-5 CORDIS
 CH 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANWEN 182 OF 327 CARLOS COPYRIGHT 2008 ACS on STN (Continued)
 (lipid oral dosage form compg., gastrointestinal absorption of)
 RI 1985:50-0 CARLOS
 CH 2118-Quinazolinone, 6-(chloro-1-cyclopropyl-4-phenyl)- (CA INDEX NAME)



13 ANWEN 183 OF 327 CARLOS COPYRIGHT 2008 ACS on STN (Continued)

13 ANMER 194 of 327 CAPLOS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1979:437493 CAPLOS
 DOCUMENT NUMBER: 91:03493
 ORIGINAL REFERENCE NO.: 91:131431a, 13422a
 TITLE: Studies on the prednisolone-sparing effect of glucocorticoids
 AUTHOR(S): Mathies, R.; Wolff, R.
 CORPORATE SOURCE: J. Med. Klin., Rheuma-Zent., Regensburg, D-8403, Fed. Rep. Ger.
 SOURCE: 121(13), 459-60
 CODEN: JMRMDQ; ISSN: 0341-3029
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI



AB Progesterone (1) [22760-18-5] (500 mg 4 times daily) given orally to polyarthritic patients treated with prednisolone [50-24-8] produced an average steroid-sparing effect amounting to 52.2% of the previously required prednisolone daily dose.
 IT 22760-18-5
 RI: PPR (Progesterone)
 CH 21(12) Glucocorticoids, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)
 (Continued)



13 ANMER 195 of 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 1979:463939 CAPLOS
 DOCUMENT NUMBER: 91:03493
 ORIGINAL REFERENCE NO.: 91:131431a, 13422a
 TITLE: Studies on the prednisolone-sparing effect of glucocorticoids
 AUTHOR(S): Mathies, R.; Wolff, R.
 CORPORATE SOURCE: J. Med. Klin., Rheuma-Zent., Regensburg, D-8403, Fed. Rep. Ger.
 SOURCE: 121(13), 459-60
 CODEN: JMRMDQ; ISSN: 0341-3029
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI



AB Since an increased biosynthesis of proteoglycans can be observed in the anabolic phase of inflammation, the mechanism of action of the antiinflammatory drug progesterone (1) [22760-18-5] was studied by determining its effect on the incorporation of ³⁵S-Met- and glucosamine-3H into proteochondroitin sulfate and proteokeratan sulfate in calf cornea. I (2.7 x 10⁻⁶M) inhibited the incorporation of both labels into both proteoglycans. A mechanism is proposed in which I inhibits the de novo protein synthesis of proteoglycans and the secondary biosynthesis of the glycosaminoglycan chains. The action of antiinflammatory drugs is probably based on an inhibitory effect on proteoglycan synthesis in the anabolic phase of inflammation.
 IT 22760-18-5
 RI: BIOD (Biological study)
 CH 21(12) Glucocorticoids, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)
 (Continued)

13 ANMER 195 of 327 CAPLOS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1979:470837 CAPLOS
 DOCUMENT NUMBER: 91:10837
 ORIGINAL REFERENCE NO.: 91:13477a, 1260a
 TITLE: Evaluation of lipid-containing oral dosage forms in rats
 AUTHOR(S): Yamahira, Yoshiyuki; Noguchi, Tetsuo; Noguchi, Takeshi; Takemura, Hiroshi; Maeda, Taduo
 CORPORATE SOURCE: Pharm. Dev., Sumitomo Chem. Co., Ltd., Itabashi, 567, Japan
 SOURCE: Journal of Pharmaceutical Sciences (1979), 21(1), 52-9
 CODEN: JOPBQJ; ISSN: 0362-844X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A novel method for evaluation of oral lipid formulation in rats, which enabled a reduced dose level to 2 ml/rat with satisfactory accuracy, was presented. The dose level was fairly comparable to that of clin. unit dose such as soft capsule on mg/kg (lipid dose/body weight) basis. Lipid-containing oral dosage forms were evaluated. A new antiinflammatory agent N-512 (1) [70857-50-0] was selected as a model of poorly water soluble drug. A medium chain triglyceride was mostly used as a lipid vehicle. The characteristics of the lipid formulation were estimated by measuring the gastric emptying rate of the drug or sometimes combined with that remaining in the intestine in rats. These results basically consisted of those obtained from 20 ml/rat dosing regime, previously reported. By reducing the dose level to 2 ml/rat, the drug absorption was less affected by the dosage form factors such as the drug concentration in the preparation or the digestibility of lipid vehicle. In this method compared with an aqueous suspension, the drug absorption of the lipid formulation was less variable and less affected by the concomitant food intake.
 IT 70857-50-0
 RI: BIOD (Biological study)
 CH 21(12) Glucocorticoids, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)
 (Continued)

13 ANMER 196 of 327 CAPLOS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1979:463939 CAPLOS
 DOCUMENT NUMBER: 91:03493
 ORIGINAL REFERENCE NO.: 91:131431a, 13422a
 TITLE: Studies on the prednisolone-sparing effect of glucocorticoids
 AUTHOR(S): Mathies, R.; Wolff, R.
 CORPORATE SOURCE: J. Med. Klin., Rheuma-Zent., Regensburg, D-8403, Fed. Rep. Ger.
 SOURCE: 121(13), 459-60
 CODEN: JMRMDQ; ISSN: 0341-3029
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI



AB Since an increased biosynthesis of proteoglycans can be observed in the anabolic phase of inflammation, the mechanism of action of the antiinflammatory drug progesterone (1) [22760-18-5] was studied by determining its effect on the incorporation of ³⁵S-Met- and glucosamine-3H into proteochondroitin sulfate and proteokeratan sulfate in calf cornea. I (2.7 x 10⁻⁶M) inhibited the incorporation of both labels into both proteoglycans. A mechanism is proposed in which I inhibits the de novo protein synthesis of proteoglycans and the secondary biosynthesis of the glycosaminoglycan chains. The action of antiinflammatory drugs is probably based on an inhibitory effect on proteoglycan synthesis in the anabolic phase of inflammation.
 IT 22760-18-5
 RI: BIOD (Biological study)
 CH 21(12) Glucocorticoids, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)
 (Continued)



15 ANSWER 186 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

15 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:456946 CAPLUS
 DOCUMENT NUMBER: 91:56946
 ORIGINAL REFERENCE NO.: 91:56274, 92304
 TITLE: Cyclic guanidines. VI. Synthesis of hypoglycemic tricyclic guanidines
 Kossayama, Akira; Higashi, Kunio; Ishikawa, Masayasu
 AUTHOR(S):
 Fonyosaki
 CORPORATE SOURCE: Res. Inst., Daiichi Sankyo Co., Ltd., Tokyo, 132, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1979), 27(4), 889-92
 DOCUMENT TYPE: COURSE CATALOG; ISSN: 0009-2363
 JOURNAL: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 91:56946
 CI



I, X=H
 II, X=S
 III, X=O

AB Synthesis of linear and angular tricyclic guanidine derivs., imidazo- or pyrimido[2,1-b]- or [1,2-a]quinazoline derivs., is described.
 Cyclization of 2-[m-(chloroalkyl)-4-phenyl]-3,4-dihydroquinazolines gave two difficult to isolate. 2-Aminodimethylaminomethanol obtained from 2-aminobenzophenone was converted to linear tricyclic guanidine derivs., e.g. I (n = 5,7), and other tricyclic compds. II and III (n = 5,7). Reaction of 2-benzoylaminoethanol also gave angular products. Most of the tricyclic guanidine derivs. showed a hypoglycemic activity.

IT 70888-47-0P 70888-48-1P
 RI: RCT (Reagent); SRP (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and chlorination of)
 CN 70888-47-0 CAPLUS
 CN 2(18)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RI: 70888-48-1 CAPLUS
 CN 2(18)-Quinazolinone, 3,4-dihydro-1-(2-hydroxypropyl)-4-phenyl- (CA INDEX NAME)



IT 70888-52-7P 70888-53-8P
 RI: RCT (Reagent); SRP (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and cyclization of)
 CN 70888-52-7 CAPLUS
 CN 2(18)-Quinazolinethanol, 2-(methylthio)-4-phenyl-, monohydrochloride (PCI)
 (CA INDEX NAME)



● H2

RI: 70888-53-8 CAPLUS
 CN 3(48)-Quinazolinopropanol, 2-(methylthio)-4-phenyl-, monohydrochloride (PCI)
 (CA INDEX NAME)



● H1

IT 68210-70-8P 70888-46-9P

15 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RI: RCT (Reagent); SRP (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and cyclization of)
 CN 68210-70-8 CAPLUS
 CN 2(18)-Quinazolinethione, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



RI: 70888-46-9 CAPLUS
 CN 2(18)-Quinazolinethione, 3,4-dihydro-1-(2-hydroxypropyl)-4-phenyl- (CA INDEX NAME)



IT 70888-49-2P 70888-50-5P
 RI: SRP (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 CN 70888-49-2 CAPLUS
 CN 2(18)-Quinazolinone, 1-(2-chloroethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RI: 70888-50-5 CAPLUS
 CN 2(18)-Quinazolinone, 1-(2-chloropropyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)


15 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



15 ANSWER 188 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1979-439516 CAPLUS
 DOCUMENT NUMBER: 91139516
 ORIGINAL REFERENCE NO.: 91444294, 4452a
 TITLE: Guinazolinone oxides
 du Pont de Nemours & Co., Inc. and Co., USA
 Jpn. Kokai Tokkyo Koho, 1, 1 pp.
 SOURCE: CORNELL RESEARCH
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	FIRM	DATE	APPLICATION NO.	DATE
JP 5405388	A	19790117	JP 1978-73479	19790616
DE 7001763	A	19791217	DE 1978-1763	19790616
AT 787092	A	19791220	AT 1978-37092	19790616
CA 1094069	A	19800210	CA 1978-301472	19790616
NO 7902087	A	19791219	NO 1978-2087	19790616
EP 149	AB	19790110	EP 1978-100163	19790616
RU RE, CH, DE, FR, GB, HU, NLD, SE				
SA 780438	A	19780627	SA 1978-3438	19790616
SE 470828	AS	19791001	SE 1978-478028	19790616
AT 7804366	A	19800215	AT 1978-4366	19790616
EP 79 7575	AS	19800215	EP 1978-267504	19790616
FI 7803128	A	19791217	FI 1978-1528	19790616
PL 123420	AS	19801231	PL 1978-203632	19790616
US 425187	A	19800524	US 1978-959626	19791123
PRIORITY APPL. INFO.			US 1977-067076	A 19790616

OTHER SOURCE(S):
 G1: MARPAT 91139516



AB Amino-benzophenones I (R = H, Me; R1 = Cl, Br, NO2, CF3; R2 = H, Br, Cl; R3 = H) were acylated with N-acyl (R4 = [halo]hydroxymethyl) to give I (R3 = CORNOL) (III) and (or) II. II or III were treated with N-ethyl-N-ethyl to give quinazolinone N-oxides IV. Thus, refluxing I (R1 = Cl, R2 = R3 = H) in CH2Cl2 with N-ethyl-N-ethyl 2 days gave 86% corresponding III, which was refluxed with N-ethyl-N-ethyl in EtOH 187 h to give 83% corresponding IV.
 IT 70547-51-2P


15 ANSWER 189 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 R1: RCT (Reactant); STM (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 R2: (Briquet) and reaction with hydroxylamine, guinazolinone N-oxide from
 R3: 70547-51-2 CAPLUS
 CN 2181-Quinazolinone, 6-chloro-1-methyl-1-phenyl- (CA INDEX NAME)



IT 70547-51-2P
 R1: STM (Synthetic preparation); PREP (Preparation)
 R2: (Briquet) and reaction with hydroxylamine, guinazolinone N-oxide from
 R3: 70547-51-2 CAPLUS
 CN 2181-Quinazolinone, 6-chloro-1-methyl-1-phenyl- (CA INDEX NAME)



15 ANSWER 189 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 1979-439516 CAPLUS
 DOCUMENT NUMBER: 91139516
 ORIGINAL REFERENCE NO.: 91444294, 4452a
 TITLE: A direct synthesis of 1-alkyl-3,4-dihydro-2-oxo-4,7-dihydropyrrolo[2,1-b,3-d]pyrazines. A new hydride-transfer reaction
 Tarzia, Giorgio; Panzone, Giuseppina
 Lab. Ric., Gruppo Lepetit S.p.A., Milan, 20159, Italy
 Gazzetta Chimica Italiana 1979, 109 (11-12), 595-5
 CORN. OCT/79, ISSN: 0016-4609
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 G1



AB Heating 4-(di-alkylamino)-3-benzoylpyrroles I (R = H, R1 = Me, Ph; or R = R1 = Me) and urea at 200°C for 2 h resulted in a redox reaction to give the title pyrrolopyrimidines II along with aldehydes R2CHO. 2-(R2CH2)CH2COOH reacted similarly. The hydride-transfer nature of the reaction was demonstrated by D-labeling experiments.

IT 70724-06-0P
 R1: STM (Synthetic preparation); PREP (Preparation)
 R2: 70724-06-0 CAPLUS
 CN 2181-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 26831-07-2
 R1: RCT (Reactant); RACT (Reactant or reagent)
 R2: (Briquet) and reaction with hydroxylamine, guinazolinone N-oxide from
 R3: 26831-07-2 CAPLUS
 CN 2181-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 189 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:420539 CAPLUS
 DOCUMENT NUMBER: 91120538
 ORIGINAL REFERENCE NO.: 9112441a, 2444a
 TITLE: Nitroquinazolinone compounds having antiviral properties
 INVENTOR(S): Yamamoto, Michihiko; Marooka, Shigeaki; Koshima, Masay; Komatsu, Toshiaki; Noguchi, Hiroshi; Inaba, Shigeo; Yamamoto, Riezo
 PATENT ASSIGNER(S): Swiss Chemical Co., Ltd., Japan
 SOURCE: U.S., 10 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY NO., NUM. COMPS: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4346717	A	19790327	US 1974-454284	19740325
PRIORITY APPL. INFO.			US 1972-242241	A2 19720407
OTHER SOURCE(S):			NAEPAT 91:10538	
US				



AB The nitroquinazolinone 1 (R1 = Ph, thieryl; R2 = furyl, 2-thienyl, pyridyl, tetrahydrofuryl, tetrahydro-3-pyranyl) were prepared. Thus, 4-phenyl-6-nitro-2(1H)-quinazolinone was treated with tetrahydrofuryl bromide to give mainly 1-(tetrahydrofuryl)-4-phenyl-6-nitro-2(1H)-quinazolinone (11) and some 2-(tetrahydrofuryl)-4-phenyl-6-nitroquinazolinone. The min. inhibitory concentration of 11 on vaccinia virus multiplication in chick embryo fibroblast cell culture was 1.0 μ g/ml.
 IT 70413-14-8
 R1: RCT (Reactant); R2CT (Reactant or reagent)
 R3: RCT (Reactant); R4CT (Reactant or reagent)
 R5: 70413-14-8 CAPLUS
 R6: 2(1H)-Quinazolinone, 4-phenyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 70413-13-7P
 R1: RCT (Reactant); R2P (Synthetic preparation); R3P (Preparation); R4CT (Reactant or reagent)
 R5: [preparation and dehydrogenation of]
 R6: 70413-13-7 CAPLUS
 R7: 2(1H)-Quinazolinone, 2,6-dihydro-6-nitro-4-phenyl-1-(2-thienylmethyl)- (CA INDEX NAME)



IT 40812-50-4P 40812-51-5P 40812-54-8P
 40812-56-0P 40812-57-3P
 R1: RAC (Biological activity or effector, except adverse); R3U (Biological study, unclassified); R5P (Synthetic preparation); R10L (Biological study); R10P (Preparation)
 R2: 40812-50-4 CAPLUS
 R3: 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RH 40812-51-5 CAPLUS
 R1: 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (CA INDEX NAME)



RH 40812-54-8 CAPLUS
 R1: 2(1H)-Quinazolinone, 1-(2-furanyl)methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RH 40812-56-8 CAPLUS
 R1: 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RI 40852-57-1 CAPLUS
 CN 2 [18]-Quinoxalinone, 6-nitro-4-phenyl-2-[(2-thienylmethyl)- (CA INDEX NAME)]



IT 40852-55-99 70413-12-62
 Rx 899 [Synthetic preparation]; PREP [Preparation]
 [Preparation of]

RI 40852-55-9 CAPLUS
 CN 2 [18]-Quinoxalinone,
 1-[[4,5-dihydro-1,4-benzodioxin-2-yl)methyl]-6-nitro-
 4-phenyl- (CA INDEX NAME)

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 70413-12-6 CAPLUS
 CN 2 [18]-Quinoxalinone, 6-nitro-1-(isobenzylmethyl)-4-phenyl- (CA INDEX NAME)]




IT 33990-28-8 37554-37-3 37555-40-6
 40852-28-6 40852-31-1 40852-33-3
 40852-34-4 40852-35-5 40852-36-6
 40852-37-7 40852-38-8 40852-40-2
 40852-42-4 40852-43-1 41190-30-1
 Rx 8AC [Biological activity on effector, except address]; BDP
 [Biological]
 study, unclassified; EOL [Biological study]
 (irritant activity of)
 RI 33990-28-8 CAPLUS
 CN 2 [18]-Quinoxalinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)]

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 37554-37-3 CAPLUS
 CN 2 [18]-Quinoxalinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)]



RI 37555-63-6 CAPLUS
 CN 2 [18]-Quinoxalinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)]



RI 40852-38-6 CAPLUS
 CN 2 [18]-Quinoxalinone, 1-[[2-(chlorophenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)]

15 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 40852-31-1 CAPLUS
 CN 2 [18]-Quinoxalinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-nitro- (CA INDEX NAME)]



RI 40852-33-3 CAPLUS
 CN 2 [18]-Quinoxalinone, 1-(cyclopentylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)]



RI 40852-34-4 CAPLUS
 CN 2 [18]-Quinoxalinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)]

10/ 540,359

15 ANSWER 190 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 40852-35-5 CAPLOS
CI 2118-Quinoxalinone, 1-(7-cycloheptylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-36-6 CAPLOS
CI 2118-Quinoxalinone, 1-(7-cyclooctylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 190 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CI 2118-Quinoxalinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-49-3 CAPLOS
CI 2118-Quinoxalinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)




RI 41190-30-3 CAPLOS
CI 2118-Quinoxalinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 190 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)


RI 40852-37-7 CAPLOS
CI 2118-Quinoxalinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-38-8 CAPLOS
CI 2118-Quinoxalinone, 1-(7-cycloheptylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-40-2 CAPLOS
CI 2118-Quinoxalinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-42-4 CAPLOS

15 ANSWER 191 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
1979-420537 CAPLOS
91:20557

ORIGINAL REFERENCE NO.: 91:24419, 3444
TITLE: 4-Arylquinoxalin-2(1H)-ones
INVENTOR(S): Smith, Joseph Antonio
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Chem., 17 pp.
CODING: GMLXEN
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2847409	A1	19790308	DE 1978-387049	19780308
CH 642638	A5	19840430	CH 1978-9045	19780405
FI 7802619	A	19790307	FI 1978-2619	19780307
FI 66362	B	19840629		
FI 66362	C	19841020		
DE 7802620	A	19790307	DK 1978-3820	19780307
DK 144999	B	19820726		
DE 144999	C	19821213		
NO 7802945	A	19790307	NO 1978-2945	19780307
DE 7802946	A	19790307	DE 1978-9008	19780307
GB 2003973	GB	19780321	GB 1978-35143	19780321
GB 2003973	B	19820310		
FR 2401917	A1	19790330	FR 1978-25162	19780331
FR 2401917	B1	19821227		
DE 7808851	A	19790308	DE 1978-8981	19780301
DE 870185	A1	19790305	DE 1978-190237	19780304
JP 54051683	A	19790502	JP 1978-107491	19780504
IL 55492	A	19800931	IL 1978-55492	19780904
DE 475103	A1	19790401	DE 1978-475103	19780405
NO 138457	A5	19791114	NO 1978-207556	19780905
NO 780571	A	19800513	NO 1978-39571	19780505
NO 523728	B2	19800812		
PL 114207	B1	19850131	PL 1978-209428	19780905
CA 1118447	A1	19811103	CA 1978-32045	19780905
RU 900810	A3	19810123	RU 1978-265160	19780905
HU 26336	A2	19810928	HU 1978-66333	19780905
HU 183018	B	19840428		
AT 7806799	A	19840315	AT 1978-6399	19780305
AT 376215	B	19841025		
DE 7805042	A	19800410	DE 1978-5061	19780406
FR 2401917	A1	19790330	FR 1978-25162	19780331

PRIORITY APPL. INFO.:

GI



15 ABSTRACT 191 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM (Continued)
 AS The quinazolines I (R = C1-8 hydrocarbon moiety optionally substituted by
 1,2, or 3 F, Cl, or Br; R2 = monocyclic aryl; R3 = R3 = H, F, Cl, Br,
 Cl-3
 alkyl or alkoxy; R3R3 = OCH2O) were prepared by the dehydrogenation of II
 with S in the presence of a metal oxide, hydroxide, or salt, especially
 those of
 Ca, Fe, or Zn but not Mg, Al, or alkali metals. Thus, II (R = MeOCH, R1
 =
 Ph, R2 = 7-Me, R3 = 4) reacted with S in p-cymene in the presence of FeO
 to give I (R3 same).
 IT 22742-18-10 40507-13-13
 RU 508 (Synthetic preparation); EPK (Preparation)
 (Preparation of)
 2116-13-5 CAPSULE
 CN 2116-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



RU 40507-13-1 CAPSULE
 CN 2116-Quinazolinone, 6-[4-fluorophenyl]-7-methyl-1-(1-methylethyl)- (CA
 INDEX NAME)



15 ABSTRACT 192 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM (Continued)



15 ABSTRACT 192 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1979-413542 CAPSULE
 DOCUMENT NUMBER: 9115252
 ORIGINAL REFERENCE NO.: 9115252A
 TITLE: Studies on the mechanism of action of
 1-(cyclopropylmethyl)-4-phenyl-6-methoxy-2(1H)-
 quinazolinone (II-573). Its effect on several
 functions of rat polymorphonuclear leukocytes and
 mast
 cells
 AUTHOR(S): Yamagi, Yoshiharu; Koga, Yoshitaka; Inoue, Toshiya
 EMP. DEPT., Sumitomo Chem. Co., Ltd., Takatsuka, 665,
 Japan
 SOURCE: Nippon Yakurigaku Zasshi 119(9), 75(1), 45-52
 ORDER REFERENCE JCRN 0015-1493
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 CI



AS II-573 (II) [3453-23-5] was tested for its effect on the
 chemotaxis, phagocytosis, phagocytosis-stimulated O uptake and lysosomal
 enzyme release of rat polymorphonuclear leukocytes and on histamine
 [H1-45] release from rat mast cells. I was a potent inhibitor of
 phagocytosis-stimulated O uptake. The inhibitory activity of I was 17
 times that of indomethacin (IM) and 940 times that of ibuprofen (IP);
 naproxen (NP) and aspirin (AS). In chemotaxis, I showed 50%
 inhibition
 at 50 μ M, while IC50 values of IM, IP, NP and AS were 31, 68, 70, and
 460 μ M, resp. The inhibitory effect of I on lysosomal enzyme release
 was 49.5% at 100 μ M, which was more potent than that of IM. In
 histamine release from mast cells, I showed more potent inhibitory
 activity than IM, IP, AS, and NP.
 IT 33453-23-5
 RU 33453-23-5 (Biological study)
 (histamine release by mast cell and polymorphonuclear leukocyte
 response to)
 RU 33453-23-5 CAPSULE
 CN 2116-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX
 NAME)

15 ABSTRACT 193 OF 327 CAPSULE COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1979-405252 CAPSULE
 DOCUMENT NUMBER: 9115252
 ORIGINAL REFERENCE NO.: 9115252A
 TITLE: Hydroxyquinazolines and their use as intermediates
 for
 pharmaceutical agents
 INVENTOR(S): Middleton, William F.
 PATENT ASSIGNEE(S): du Pont de Nemours & Co., Inc., USA
 SOURCE: U.S., 10 pp.
 ORDER REFERENCE: Patent
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4141956	A	1978-02-27	US 1977-007077	1977-06-16

PRIORITY APPL. INFO.:
 OTHER SOURCE(S): MARPAT 9115252
 CI



AS One hydroxyquinazolinone I (R = Br, Cl, MeO, CF3; R1 = H, Br, Cl, F; R2 =
 Cl, R3) and its diastereoisomers were prepared as intermediates for
 benzodiazepines II (R's the same), which are tranquilizers, sedatives,
 and
 muscle relaxants (no data). Thus, 5,2-Cl(MeO)C(=O)Ph was N-formylated
 with HCOCl (97% yield), the product 5,2-Cl(MeO)C(=O)Ph-NH-CHO was
 cyclized with NaH and MeI (70% yield), and the resulting 5,2-Cl(MeO)C(=O)Ph
 treated
 with HBr and NaCl2 to give 74 5,2-Cl(MeO)C(=O)Ph-NH-Ph (22%);
 Cyclization of III with PCl5/COCl in CH2Cl2 at 25-40° gave IV (R
 = R2 = Cl, R1 = H) at a mixture of diastereoisomers. Heating I (R = R2
 =
 Cl, R1 = H) with NaH in THF gave 22% II (R = Cl, R1 = H). Cyclizing III
 with PCl5/COCl in the presence of NaH in THF gave 34% II (R = Cl, R1 =
 H).
 IT 70395-32-39
 RU 70395-32-39 (Reactant); STM (Synthetic preparation); EPK (Preparation); RACT
 (Reactant or reagent)
 (Preparation and ring expansion of)
 RU 70395-32-3 CAPSULE
 CN 2-Quinazolinol, 6-chloro-2-(chlorofluoromethyl)-1,2-dihydro-1-methyl-4-
 phenyl-, (R,R')-, (PZ) (CA INDEX NAME)

15 ANSWER 193 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

Relative stereochemistry.



IT 70195-33-4p 70195-37-8p 70195-38-8p
 RU: SYN (Synthetic preparation); PREP (Preparation)
 Preparation of

RU 70195-37-8 CAPLUS
 CN 2-Quinoxaline, 6-chloro-2-(chlorofluoromethyl)-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (ICI) (CA INDEX NAME)

Relative stereochemistry.



RU 70195-37-8 CAPLUS
 CN Quinoxaline, 6-chloro-2-(chlorofluoromethyl)-2-ethoxy-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (ICI) (CA INDEX NAME)

Relative stereochemistry.

15 ANSWER 194 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

ACCESSION NUMBER: 1979:204132 CAPLUS
 DOCUMENT NUMBER: 90:204132
 ORIGINAL REFERENCE NO.: 90:32485a, 32488a
 TITLE: Imidazo- and pyrimido[2,1-b]quinoxalines
 INVENTOR(S): Tanemoto, Michiharu; Kashiwa, Masayuki; Nono, Shunji
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Ges. Offen., 22 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 289846	A1	19790715	DE 1978-289846	19780906
JP 54048797	JP	19790417	JP 1977-107643	19770906
FR 2401324	A1	19790330	FR 1978-25459	19780906
FR 2401324	B1	19810508		
GB 228367	A	19801014	GB 1978-239649	19780906
CA 1104372	A1	19810804	CA 1978-310434	19780906
GB 238078	A5	19830630	GB 1978-8213	19780906
GB 238078	A	19791024	GB 1978-35715	19780906
GB 201873	B	19820310		
NO 501425	B1	19791129	NO 1978-39581	19780906
PRIORITY APPL. INFO.:			JP 1977-107643	A 19770906

OTHER SOURCE(S): MARPAT 90:204132

GI



AS The title compounds 1 (R = H, Cl-3 alkyl; R1-R3 = H, halogen, Cl-3 alkyl or alkyl; R4 = Cl-3 aliphatic group, aralkyl, cycloalkylalkyl; R5 = H, OH, or

1, 2, n = 1, 2) were prepared for use as vasodilators and diuretics (test data tabulated). Thus, 6-chloro-1,4-dihydro-2-(2-hydroxyethylamino)-1-butyl-4-phenylquinoxaline was refluxed with NaOH to give 1 (R = R2 = R3 = R5 = H, R1 = 7-C2; R4 = H, n = 1).

IT 70217-44-6P
 RU: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 Preparation and reaction of, with anisopropanol

RU 70217-44-6 CAPLUS
 CN Quinoxaline, 1-butyl-4-chloro-1,4-dihydro-2-(methylthio)-4-phenyl-, monohydrochloride (ICI) (CA INDEX NAME)

15 ANSWER 193 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RU 70195-38-9 CAPLUS
 CN Quinoxaline, 6-chloro-2-(chlorofluoromethyl)-2-ethoxy-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (ICI) (CA INDEX NAME)

Relative stereochemistry.



RU 70195-37-8 CAPLUS
 CN Quinoxaline, 6-chloro-2-(chlorofluoromethyl)-2-ethoxy-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (ICI) (CA INDEX NAME)

Relative stereochemistry.

15 ANSWER 194 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

● HI
 IT 70217-53-7p
 RU: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 Preparation and reaction of, with anisopropanol
 RU 70217-53-7 CAPLUS
 CN Quinoxaline, 6-chloro-1,4-dihydro-1-methyl-2-(methylthio)-4-phenyl-, monohydrochloride (ICI) (CA INDEX NAME)



● HI
 IT 26920-08-1 70217-43-5
 RU: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with Me iodide)
 RU 26920-08-1 CAPLUS
 CN 2(18R)-Quinoxalinethione, 6-chloro-3,4-dihydro-1-methyl-4-phenyl-, (CA INDEX NAME)



RU 70217-43-5 CAPLUS
 CN 2(18R)-Quinoxalinethione, 1-butyl-4-chloro-3,4-dihydro-4-phenyl-, (CA INDEX NAME)

15 ANMER 194 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANMER 195 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979-204128 CAPLOS
 DOCUMENT NUMBER: 90104128
 ORIGINAL REFERENCE NO.: 90104128, 2440a
 TITLE: Quinazolinone oxides
 PATENT ASSIGNEE(S): de Pont de Nemours & Co., Inc. and Co., USA
 INVENTOR(S): Jpn. Kokai Tokkyo Koho, 8 pp.
 SOURCE: CORDIS, 05/24/79
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	FILED DATE	APPLICATION NO.	DATE
JP 54005983	A 19790117	JP 1978-13650	19790616
US 4160012	A 19790103	US 1977-007074	19790616
DE 7803764	A 19781217	DK 1978-1764	19780414
WO 7902044	A 19781213	EP 1978-2004	19790615
EP 148	A1 19790110	EP 1978-100142	19790615
It, BE, CH, DE, FR, GB, LU, NL, SE	SA 7803440	SA 1978-3440	19790615
AY 478923	A1 19791001	ES 1978-478923	19790615
AO 781218	A 19791220	AO 1978-37138	19790615
AT 7804367	A 19800215	AT 1978-4367	19790615
AZ 330017	B 19801017		
FI 7803223	A 19781217	FI 1978-1929	19790616
SG 721023	A3 19800430	SG 1978-2624780	19790616
PRIORITY APPL. INFO.:		US 1977-007074	A 19790616

OTHER SOURCE(S): MARPAT 90104128
 CI



AB Quinazolinone oxides I (R = H, R1 = Cl, R2 = Me, CF3; R2 = H, R1 = Cl) were 8-methylated with MeI to give I (R = Me), the alkali metal salt of which were hydrolyzed to give anti-oximes II. Thus, I (R = H, R1 = Cl, R2 = H) was heated with MeI in DMF at 60° and stirred with MeI 2 h at room temperature to give 581 I (R = Me). This was refluxed with NaH-EGM 2 h to give 594 II (R1 = Cl, R2 = H).
 IT 70294-95-99
 R1: KCT (Reactant); R2: SBN (Synthetic preparation); R3: FEF (Preparation); RACT

15 ANMER 196 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 197 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 198 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 199 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 200 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 201 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 202 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 203 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 204 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 205 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 206 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 207 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 208 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 209 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 210 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 211 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 212 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 213 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 214 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 215 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 216 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 217 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 218 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 219 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 220 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 221 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 222 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANMER 224 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



AB The trihaloacetanilide ketones I (R = H, Me, Et, MeCH2, alkyl, PhCH2, EtOCH2, CF3CH2, cyclopropylmethyl; R1 = H, Cl; R2 = Cl, H; R3 = H, halo, MeOCH2, CF3, Me, COCH3, CH3, Me, MeO, MeO2, R3 = COCH3, R4 = H, MeO, Et, Ph, 2-thienyl, 2-furyl, 2-pyridyl, 2-CIC6H4, 3-CIC6H4, 2-FC6H4, 2-MeC6H4, cyclohexyl, Me; X = Cl, Br, F; 150 compds.), which were also prepared, were readily converted to the corresponding quinazolinone II via treatment with NBr, via loss of the trihaloacetanilide group. Treatment of I (R = H, R2 = R4 = H, R3 = Cl, R1 = Ph, X = Cl) with NBrO3 in Me2SO gave II in 90% yield, whereas I (R = R1 = R2 = R4 = H, R3 = Cl, R1 = Ph, X = F) gave 6-chloro-1-(1-trifluoroacetyl)quinazolinone. 8-substituted derivs. of 2-trichloroacetanilidebenzophenones yielded 2-(R3)-1-benzoxazin-2-one or 2-aminobenzophenone imines, depending on reaction conditions. The trihaloacetanilides containing R2OC, CH, or H groups in the ortho position were converted to the corresponding cyclic or acyclic ureas. Mechanisms for their formations were proposed. In the case of the trihaloacetanilides bearing an ortho-phenyl, cyano or H in the o-position, the corresponding cyclic or acyclic ureas were obtained by this reaction. Mechanisms for their formations are proposed.
 IT 20927-53-1P 23441-64-7P 23441-64-9P
 23443-52-3P 26171-51-9P 26831-31-9P
 24953-46-8P 37453-19-9P 37453-27-5P
 33890-29-6P 37554-40-6P 37555-10-5P
 49030-89-9P

15 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: SYN [Synthesis: preparation], PREP (Preparation)

RXI 20577-53-3 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-3-methyl-4-phenyl- (CA INDEX NAME)



RXI 23441-64-7 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-3-ethyl-4-phenyl- (CA INDEX NAME)



RXI 23441-66-9 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-4-phenyl-1- (2-propenyl)- (PCI) (CA INDEX NAME)



RXI 23465-52-3 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-4-phenyl-1- (phenylethyl)- (CA INDEX NAME)

15 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RXI 33453-13-9 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-1- (cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RXI 33453-23-5 CAPLUS

CN 2 (18)-Quinoxalino, 1- (cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RXI 33830-39-8 CAPLUS

CN 2 (18)-Quinoxalino, 1- (cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RXI 26333-53-9 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-1- (2-ethoxyethyl)-4- (2-fluorophenyl)- (CA INDEX NAME)



RXI 26831-11-8 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-1- (3-methylethyl)-4-phenyl- (CA INDEX NAME)



RXI 26953-46-8 CAPLUS

CN 2 (18)-Quinoxalino, 3-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RXI 37554-40-8 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-4-phenyl-1- (2,2,2-trifluoroethyl)- (CA INDEX NAME)



RXI 37555-10-5 CAPLUS

CN 2 (18)-Quinoxalino, 6-chloro-1- (cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RXI 49930-89-9 CAPLUS

CN 2 (18)-Quinoxalino, 6-methoxy-4-phenyl-1- (2,2,2,2-tetrafluoroethyl)- (CA INDEX NAME)

15 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 197 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979168542 CAPLUS
 DOCUMENT NUMBER: 90168542
 ORIGINAL REFERENCE NO.: 90-28759a,24762a
 TITLE: A new convenient synthesis of 2-thioxo-1,2-dihydroquinazolinethione
 AUTHOR(S): Tamura, Yasuhiro; Kawasaki, Tomoe; Tanio, Masami;
 Kikuchi, Yasuyuki
 CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, Japan
 SOURCE: SYNTHESIS 1979(12), 120-1
 COUNTRY: SWITZER; JSTN: 0039-1083
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 90168542
 GI



AB Treating o-arylamines I (R = Ph, R2 = H, Et, MeOCH3 R2 = H, Cl; or R = Me, R1 = R2 = H) with PEP(ICH2)2 in CHCl3 under N at -40° with warming to room temperature gave 62-88% quinazolinethiones II.
 IT 26324-65-00 CAPLUS 57-48 69964-51-00
 RI: SPM (Synthetic preparation); PEP (Preparation)
 IP: Preparation of
 RI 26324-65-00 CAPLUS
 RI 2180-Quinazolinethione, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)
 CH



RI 26324-65-00 CAPLUS
 CH 2180-Quinazolinethione, 1-ethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 197 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI 69964-51-0 CAPLUS
 CH 2180-Quinazolinethione, 6-thioxo-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 198 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979162097 CAPLUS
 DOCUMENT NUMBER: 90162097
 ORIGINAL REFERENCE NO.: 90-2863a,15634a
 TITLE: Antipretic activity of 1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone (II-573). II
 AUTHOR(S): Yanagi, Yoshiharu; Kurokawa, Hiroshi; Nagao, Yasuko;
 Imokai, Toshiya
 CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takatsuka, Japan
 SOURCE: Nippon Yakurigaku Zasshi 119(8), 74(8), 961-90
 COUNTRY: SWITZER; JSTN: 0011-5693
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GI



AB Antipretic activity of II-573 (II) [3453-23-3] was not influenced by age and sex difference in rats. The combined effect of other drugs on the antipretic activity of I was examined. Cefazolin Na [7704-44-3], ampicillin Na [68-52-3], sodium phosphate [52-28-8], hydrochlorothiazide [58-93-5], and haloperidol [52-86-8] did not show any significant effect on the antipretic activity of I. Dazoguan [639-14-5] itself showed antipretic activity, and its combined use with I resulted in an additive effect. I also showed antipretic activity in mice with fever induced by yeast, as was seen in rats. I diminished the hyperthermic response to bacterial endotoxin and leukoactive pyrogen in rats, but not to 1,4-dinitrophenol. Adm., I did not inhibit the bacterial endotoxin-induced promotion of leukocyte pyrogen and its release.
 IN saline medium, I, therefore, is considered to be a centrally acting antipretic. I.v. injection of prostaglandin E2 and arachidonic acid induced a hyperthermia in mice. I inhibited prostaglandin-induced biosynthesis from arachidonic acid; the prostaglandin biosynthesis inhibition may be one of the main mechanisms of antipretic action of I.
 IT 31451-23-5
 RI: RUC (Biological activity or effector, except adenosine), RSU (Biological study, unclassified), RIOL (Biological study) (antipretic activity of)
 RI 31451-23-5 CAPLUS
 RI 2180-Quinazolinethione, 1-(cyclopropylmethyl)-4-methoxy-4-phenyl- (CA INDEX NAME)
 CH

13 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979-66517 CAPLUS
 DOCUMENT NUMBER: 90-66517
 ORIGINAL REFERENCE NO.: 90-16431a,10434a
 TITLE: 2(1H)-quinazolinones as novel non-acidic anti-inflammatory agents
 AUTHOR(S): Ott, Hans
 CORPORATE SOURCE: Med. Chem. Res. Dep., Sandoz Ltd., Basel, Switz.
 SOURCE: Scandinavian Journal of Rheumatology, Supplement (1979), 21(Frequency), 5-7
 CODEN: SJRDAJ ISSN: 0701-7847
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB Chemical modification of 1-methyl-4-phenyl-2(1H)-quinazolinone produced propanone (2) [22760-15-5], an anti-inflammatory agent comparable to indometacin. Pharmacol. activity of eight 1 analogs was compared with that of phenylbutazone and indometacin, and mol. structure/mol. activity relationship discussed.

IT 22760-15-5 22760-25-4 23441-64-7
 26772-86-1 26771-57-1 27524-95-2
 28340-37-2 28340-44-9
 BIO BAC (Biological activity or effector, except adverse); BTP (Biological study, unclassified); THO (Therapeutic use); BICL (Biological study);

USES (Uses)
 (Antiinflammatory activity of)
 RN 22760-15-5 CAPLUS
 CN 2(1H)-Quinazolinone, 1-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS

13 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2(1H)-Quinazolinone, 1-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
 CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26772-86-1 CAPLUS
 CN 2(1H)-Quinazolinone, 1-[(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26831-97-2 CAPLUS
 CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 27524-93-2 CAPLUS
 CN 2(1H)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-37-2 CAPLUS
 CN 2(1H)-Quinazolinone, 6-[(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-44-9 CAPLUS
 CN 2(1H)-Quinazolinone, 7-[(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 202 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 202 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979:48362 CAPLUS
 DOCUMENT NUMBER: 90:48362
 ORIGINAL REFERENCE NO.: 90:7474,7404a
 TITLE: Analgesic and antipruritic activity of RL-573
 AUTHOR(S): Taniguchi, Yoshihide; Furukawa, Hiroshi; Nagai, Yoshiaki
 COMPANY SOURCE: Aesta, Hiroshige Imaki, Toshige
 Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka,
 Japan
 SOURCE: Nippon Yakurigaku Zasshi (1978), 74(6), 735-47
 CODEN: NYKZAH; ISSN: 0015-5491
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GI



AB Analgesic potency of RL-573 (I) [33453-23-5] was between that of indomethacin and aminopyrine (II) in chemical stimulation tests. Compared to II, the analgesic activity of I was 3.2 times in phenylquinone writhing test, 4.1 times in the acetic acid writhing test, and 6.3 times in the Randall-Selitto test. The analgesic activity of I was not evident in the mech. or heat stimulation test and was not antagonized by naloxone. I showed no antipruritic effect to morphine. Tolerance to the analgesic activity of I was not observed. I had no effect on the evoked potentials recorded from axons in the central pain pathway and the site of analgesic effect was considered to be in peripheral sites of the sensory neurons. The antipruritic activity of I was equal to that of II in feline rabbits and 4 times that of II in feline rats. I did not affect normal body temperature of rabbits and rats. I appeared to have antipruritic-analgesic activity of the same magnitude as that of codeine.
 IT 33453-23-5
 RL: RIOL (Biological study)
 (Analgesic and antipruritic activities of)
 RN 33453-23-5 CAPLUS
 CN 2118)-Quinazolinone, 1-(cyclopropylmethyl)-4-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 203 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 204 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979:34076 CAPLUS
 DOCUMENT NUMBER: 90:34076
 ORIGINAL REFERENCE NO.: 90:5399a,5402a
 TITLE: Influence of proquazone (Baxiron) on the levels of complement components (C3 and C4) in synovial fluid and on IgM in serum in patients with active rheumatoid arthritis. A preliminary report
 AUTHOR(S): Riihelä, B.
 COMPANY SOURCE: Dep. Med. IV, Helsinki Univ. Cent. Hosp., Helsinki, Finland
 SOURCE: Scandinavian Journal of Rheumatology, Supplement (1978), 21(Proquazone), 40-2
 CODEN: SJRSHY; ISSN: 0301-2847
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Proquazone (I) [22760-18-3] (600-900 mg/day) administered for 4-7 wk to patients with erosive rheumatoid arthritis increased the C3 and/or C4 levels in the synovial fluid but not in the serum. The patients with psoriasis arthropathy did not show any reaction. Of the IgG measured, only IgM in serum was increased in the patients, but the level decreased during I treatment.
 IT 22760-18-3
 RL: RIOL (Biological study)
 (complement of synovial fluid and IgG of blood serum response to, in arthritis)
 RN 22760-18-3 CAPLUS
 CN 2118)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979:537539 CAPLUS
 DOCUMENT NUMBER: 89:137539
 ORIGINAL REFERENCE NO.: 89:537539,53702a
 TITLE: Pharmacological properties of proquazone
 AUTHOR(S): Oshida, H. G.; Bagnoli, M.
 CORPORATE SOURCE: Res. Inst. Waser, Waser, Switz.
 SOURCE: Farmacologica Journal of Rheumatology, Supplement (1978), 21(Poquazone), 8-12
 CUMUL INDEXED: YES; DTI: 0701-3647
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 GC



AB A review with 14 refs. on pharmacol. properties of proquazone (I) [22740-18-5].
 IT 22740-18-5
 RI: RBC (Biological activity or effector, except adverse); RBC (Biological)
 study; unclassified; THD (Therapeutic use); RBC (Biological study);
 CUES [Cues]
 [pharmacol. of]
 RI 22740-18-5 CAPLUS
 CH 21(8)-Quinoxalines, 7-methyl-1-(1-methyl-2-phenyl-4-phenyl- (CA INDEX NAME)
 NAME:



13 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1979:537539 CAPLUS
 DOCUMENT NUMBER: 89:137539
 ORIGINAL REFERENCE NO.: 89:537539,53702a
 TITLE: Photochemical decomposition of 1,4-benzodiazepines.
 AUTHOR(S): Dasgupta
 CORPORATE SOURCE: Corliss, P. J. G.; Nijlender van Bennevoenen, G. M. J.; Oosthuis, K. W.
 SOURCE: International Journal of Pharmaceutics (1978), 1(3), 173-81
 CUMUL INDEXED: YES; DTI: 0379-5173
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GC



AB A methanolic solution of diazepam (I) [499-14-5], irradiated with UV light (254 nm) for 17 h led to the formation of benzophenones, 4-phenylquinoxalines, 4-phenylquinoxalones, and glyoxine [56-60-6]. The percentage of the compds. formed depended on the solvent, concentration of the solution, irradiation time, intensity, and the wavelength of light.
 Under the investigated conditions, benzophenones 8, 6-phenylquinoxalines 15, and 4-phenylquinoxalones 10A were formed.
 IT 17629-24-8 20921-55-1
 RI: RBC (Biological study)
 (diazepam photochem. decomposition product)
 RI 17629-24-8 CAPLUS
 CH 21(8)-Quinoxalines, 1-methyl-4-phenyl- (CA INDEX NAME)



RI 20921-55-1 CAPLUS
 CH 21(8)-Quinoxalines, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1978:537534 CAPLUS
 DOCUMENT NUMBER: 89:137534
 ORIGINAL REFERENCE NO.: 89:537534,20722a
 TITLE: Trioleic hetero condensed ring compounds
 AUTHOR(S): Ishikawa, Tomoyoshi; Katsuyama, Akiko; Akiyoshi, Kenji
 CORPORATE SOURCE: Daiichi Sengyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CUMUL INDEXED: YES; DTI: 0701-3647
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 PUBLICATION NO. (MCM. COMM.):
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53044592	A	1978-04-23	JP 1976-116784	1976-09-29
JP 53059074	A	1980-09-04	JP 1976-116784	1976-09-29

PRIORITY APPL. INFO.:
 GI For diagram(s), see printed CA issue.

AB Fifteen title compds. I [X = H, S, C, Cl; Y = H, N, N (X = H, alkyl), O, S,

CH₂ at least either X or Y has an H atom; n = 2-4] and their salts were prepared. I had hypotensive (stronger than that of tolbutamide) and blood platelet aggregation inhibitory activities. Thus, heating 1-(2-hydroxyethyl)-4-phenyl-1,2,7,4-tetrahydro-3-quinoxalines and MeOCH 15 min at 130-60° gave, 5-phenyl-3,2-dihydro-5H-thiazole [3,2-
 a]quinoxaline (as the HCl salt).
 IT 66210-70-8
 RI: RCT (Reactant); RCT (Reactant or reagent)
 (cyclization of thiazoloquinoxaline derivative from)
 RI 66210-70-8 CAPLUS
 CH 21(8)-Quinoxalines, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 227 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER:
 DOCUMENT NUMBER: 89117624
 ORIGINAL REFERENCE NO.: 8918291A, 10994A
 TITLE:
 Physicochemical study of some psychotropic drugs. 1.
 Investigation of the Romanian product diazepam.
 Predescu, I.; Irimia, R.; Bădescu, M.; Bădescu, M.;
 Lab, Chim. Fiz.-Coloidale, Fac. Farm., Bucharest, Rom.
 SOURCE: Farmacia (Bucharest, Romania) (1977), 25(4), 241-4
 CODEN: FARMAS; ISSN: 0014-8237
 DOCUMENT TYPE: Journal
 LANGUAGE: Romanian
 CI



II




III

AB 861180 decomposed diazepam (II) [29-34-5] by 10% within 10 days
 yielding
 7-methyl-5-chloro-2-quinazolinone (III) [1022-13-1]. In 0.1N H2SO4, the
 above benzophenone and 1-methyl-4-phenyl-5-chloro-2-quinazolinone (III).
 [2937-53-1] were formed. In water, I was stable at 65° for
 2 h. I was separated from oxazepam, nitrazepam, and chlorodiazepam by
 thin-layer chromatography using 1 of 4 solvent systems.
 IT 2937-53-1
 R# 1804 (haloalkyl group)
 (diazepam oxidation product)
 RH 2007-53-1 CAPLUS
 CH 2188-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



I

15 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. I (R = H, halo, alkyl, alkoxy, CF3; n = 1, 2; R1 = Cl-5
 aliphatic group; R2 = R3 = H, halo, alkyl, alkylthio, alkoxy, NO2, CF3)
 were
 prepared by the cyclization of II with urea or alkyl carbamates in the
 presence of acid. Thus, 2,5-Bis(4-chlorophenyl)-7-methyl-1-(1-methyl-4-phenyl-5-
 chloro-2-quinazolinone)-1-methyl-4-phenyl-5-chloro-2-quinazolinone was
 used as a starting material. (see data).
 IT 22162-18-59 40507-23-1P
 R# 980 (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RH 22162-18-5 CAPLUS
 CH 2188-Quinazolinone, 7-methyl-1-(1-methyl-4-phenyl-5-chloro-2-quinazolinone)-1-methyl-4-phenyl-5-chloro-2-quinazolinone (CA INDEX NAME)



I



II

RH 40507-23-1 CAPLUS
 CH 2188-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methyl-4-phenyl-5-chloro-2-quinazolinone)-1-methyl-4-phenyl-5-chloro-2-quinazolinone (CA INDEX NAME)



I



II

15 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER:
 DOCUMENT NUMBER: 89109545
 ORIGINAL REFERENCE NO.: 8918291A, 10994A
 TITLE:
 4-Phenyl-2-(1H)-quinazolinone
 Synthesis, Oxidation, Polymerization, and
 Polymerization of
 Patent Assignee(s):
 Source: Chem. Abstr. 10 pp.
 CODEN: CMOGUE
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2133190	A1	19760615	DE 1977-275390	19771203
CH 625512	A5	19010930	CH 1976-15439	19761123
FI 7703459	A	19760614	FI 1977-3619	19771206
FI 64355	B	19010723		
FI 64358	C	19011110		
DE 7705408	A	19760614	DE 1977-5408	19771205
DE 143025	B	19010316		
DE 143025	C	19010938		
NO 7704147	A	19760614	NO 1977-4147	19771205
NO 147484	B	19010310		
NO 147484	C	19010420		
SE 7712742	A	19760614	SE 1977-13742	19771205
SE 442996	B	19860210		
SE 442996	C	19860210		
FR 2773534	A1	19760707	FR 1977-36461	19771206
FR 2773534	B1	19860114		
GB 1526487	A	19010708	GB 1977-51144	19771208
NL 7713611	NL	1977-13611		
CA 1001228	CA	1977-057750		
BE 961775	BE	1977-103308		
JP 53077077	JP	1977-144036		
JP 6104749	B	19860926		
RU 13327	RU	1977-1227	RU 1977-062556	19771212
ES 484966	ES	19770101	ES 1977-464966	19771212
AD 771438	A	19760615	AD 1977-31438	19771212
AO 51733	B2	19010716		
CA 136409	B2	19860331	CA 1977-8360	19771212
RU 136087	A	19861128	RU 1977-043000	19771212
RU 176875	B	19010518		
RU 79393	A3	19861230	RU 1977-2552353	19771212
IL 53588	A	19811130	IL 1977-53588	19771212
AT 7709846	A	19821115	AT 1977-8946	19771212
AZ 371450	B	19860627		
SA 770425	SA	19770725	SA 1977-7425	19771213
US 4236006	A	19861125	US 1977-83728	19780201
FR 2773534	FR	1976-15419	FR 1977-5419	19761213
US 1977-861426	US	1977-861426		
AL 19771213	AL	19771213		

OTHER SOURCE(S): MARKAT 89109545

15 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


13 ANMER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:49025 CAPLUS
 DOCUMENT NUMBER: 89:09905
 ORIGINAL REFERENCE NO.: 89:15174, 15130a
 TITLE: Inhibition of prostaglandin biosynthesis in rat small intestine by SL-573
 AUTHOR(S): Vaseq, Yoshihiko
 COMPANY SOURCE: Res. Dev. Cent., Sumitomo Chem. Co. Ltd., Hyogo, Japan
 SOURCE: Biochemical Pharmacology [1978], 27(5), 723-8
 CORDR: BCP(Ag); ISBN: 0058-2952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Prostaglandin formation by the 20,000-g supernatant of rat small intestine was reversibly inhibited by SL-573 [15453-23-5] (5-20 µg/ml) and indomethacin (15-60 µg/ml) (2.5-14 µg/ml). The compounds giving 50% inhibition of prostaglandin formation were 9.3 and 5.6 µg/ml for SL-573 and indomethacin, resp. Both compounds inhibited formation of all products to the same degree, suggesting that the drugs inhibited the cyclooxygenase. The possible relation between prostaglandin biosynthesis inhibition and ulcer formation is discussed.
 IT 3343-23-5
 RI RIOL (Biological study)
 (prostaglandin formation in response to, in small intestine, ulcer formation on relation to)
 CN 2118-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



13 ANMER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:44574 CAPLUS
 DOCUMENT NUMBER: 89:63474
 ORIGINAL REFERENCE NO.: 89:6785a, 6786a
 TITLE: 3,4-dihydro-2(1H)-quinazolinone derivatives
 INVENTOR(S): Yamamoto, Michiharu; Kashiida, Masayuki; Yamamoto, Hisao
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CORDR: J0004F
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KNOW	DATE	APPLICATION NO.	DATE
JP 53023380	A	1978/0318	JP 1976-78780	1976/0701
PRIORITY APPL. INFO:			JP 1976-78780	A 1976/0701

GI



AR Title deriva 1 R, R1, R2 = cyclopropyl (Q), Me, R, Q, R1, R2, Q, R1, Me
 Q, Me, R, R1, R2 = cyclopropyl (Q), Me, R, Q, R1, R2, Q, R1, Me
 R1X [X = iodine, R] followed by reaction of the resulting quinazolinium
 salts

II with R2O or NaO. I had anti-inflammatory, hypocytotoxic, histamine H2 receptor-inhibiting, and antitumor activities (no detail). Thus, compound 2.2 g (R = Q) with 20 mL Et 17 h gave 2.9 g
 III [R = Q, R1 = Me, R2 = iodine], which (2.1 g) was stirred in 10 mL EtO
 20 mL at 50-60° to give 1.8 g (R = Q, R1 = Me, R2 = R) quant.
 6478-73-77
 RI RIOL (Reaction); SPN (Synthesis preparation); PREP (Preparation); RACT
 (Reaction or reaction)
 (preparation and reaction with water or alcohol)
 RI 6478-73-77 CAPLUS
 CN Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-methyl-4-phenyl-2-oxo-4-phenyl-, iodide (P2) (CA INDEX NAME)

IT 6478-73-77
 RI 6478-73-77 CAPLUS
 CN Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-methyl-4-phenyl-2-oxo-4-phenyl-, iodide (P2) (CA INDEX NAME)

13 ANMER 211 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:47023 CAPLUS
 DOCUMENT NUMBER: 89:70825
 ORIGINAL REFERENCE NO.: 89:10027a, 10030a
 TITLE: In-vivo effects of anti-inflammatory and other drugs on granulocyte emigration in the rabbit skin collection chamber
 AUTHOR(S): Morcl, P.; J. Foster, Camille
 COMPANY SOURCE: Biol. Med. Res. Div., Sandoz Ltd., Basel, Switz.
 SOURCE: Journal of Pharmacology [1978], 24(2), 85-92
 CORDR: JPT(Ag); ISBN: 0022-2413
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A method for measuring localized leukocyte mobilization under in-vivo conditions with a plastic skin collection chamber adapted to the rabbit ear was used for assessing the effects of anti-inflammatory and other agents on granulocyte emigration. Studies on the effect of oral drug administration to rabbits indicated that most anti-inflammatory drugs, 2 cyclooxygenase inhibitors (cyclophosphamide [50-15-0] and dithiazine [64-86-8]), but none of the other compounds exhibiting antihistaminic, β-adrenergic or pericardial properties, inhibited granulocyte mobilization. The results after topical application of some of these agents into the chamber correlated well with those obtained after oral treatment. This technique may thus prove useful in selecting new compounds inhibiting granulocyte mobilization in acute inflammation reactions.
 IT 22765-18-5
 RI RIOL (Biological study)
 (granulocyte migration inhibition by)
 RI 22765-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-5-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 42320-84-6P 6478-74-8P 6478-75-8P
 6478-76-0P 64835-10-5P
 RI SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 42320-84-6 CAPLUS
 CN 2118-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-methyl-4,4-dihydro-4-phenyl- (CA INDEX NAME)



RI 6478-74-8 CAPLUS
 CN 2118-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-methyl-4,4-dihydro-4-phenyl- (CA INDEX NAME)



15 ANSWER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RI 66478-15-9 CAPLUS
 CH 2118-Quinoxalinoone, 6-chloro-4-ethyl-3,4-dihydro-1,3-dimethyl-4-phenyl-
 methyl-4-phenyl- (CA INDEX NAME)



RI 66478-16-9 CAPLUS
 CH 2118-Quinoxalinoone, 6-chloro-4-ethyl-3,4-dihydro-1,3-dimethyl-4-phenyl-
 (CA INDEX NAME)



RI 66483-50-5 CAPLUS
 CH 2118-Quinoxalinoone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-3-methyl-4-phenyl-
 (CA INDEX NAME)



RI 33413-19-9
 RI+ RCT (Reagent); RACT (Reagent or reagent)

15 ANSWER 213 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1378143684 CAPLUS
 DOCUMENT NUMBER: 88163999
 ORIGINAL REFERENCE NO.: 8915611a, 5614a
 TITLE: Analgesic and antiinflammatory activity of Biazoran.
 Clinical experimental studies
 AUTHOR(S): Gabba, J.
 CORPORATE SOURCE: Schloßparklinische, Berlin, Fed. Rep. Ger.
 SOURCE: Muenchener Medizinische Wochenschrift (1978),
 120(10), 331-4
 CODING: MIMAC; ISSN: 0027-2975
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 AB To human subjects, Biazoran (I) [22760-18-5] (600 mg) increased
 the threshold to pain (elec. stimulation of the teeth) by 22.3 nA after
 75 min, compared with a maximum increase of 18 nA in subjects given
 indomethacin
 (100 mg); no differences in antiinflammatory activity between I (900
 mg/day) and indomethacin (140 mg/day) were observed in postoperative
 edema.
 IT 22760-18-5
 RI+ RCT (Biological study)
 (analgesia and inflammation inhibition by)
 RI 22760-18-5 CAPLUS
 CH 2118-Quinoxalinoone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



15 ANSWER 214 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (quaternization of, by KI iodide)
 RI 33453-19-9 CAPLUS
 CH 2118-Quinoxalinoone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX
 NAME)



15 ANSWER 214 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1378163999 CAPLUS
 DOCUMENT NUMBER: 88163999
 ORIGINAL REFERENCE NO.: 8915611a, 5614a
 TITLE: Proquasone (Sandoz 43-715), an unusually potent
 inhibitor of the platelet release reaction and
 malondialdehyde formation
 Zucker, Marjorie B.
 AUTHOR(S): Dep. Pathol., New York Univ. Med. Cent., New York,
 NY, USA
 SOURCE: Proceedings of the Society for Experimental Biology
 and Medicine (1977), 154(12), 509-12
 CODING: PSERA; ISSN: 0037-9727
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 RI



AB Although Sandoz 43-715 (proquasone) [22760-18-5] is not an
 acid, its action on platelets is similar to that of a typical acid
 BRID 7 inhibited the release reaction and associated production of
 malondialdehyde [542-78-9] without affecting primary aggregation caused
 by ADP or epinephrine, and it failed to inhibit the collagen-induced
 release which remained after maximum inhibition by aspirin. It is
 unusually
 active; it may have an effect in vitro at 11 nM, and is at least 50 times
 more active than indomethacin in preventing collagen-induced release from
 human platelets.
 IT 22760-18-5
 RI+ RCT (Biological study)
 (platelet secretion inhibition by)
 RI 22760-18-5 CAPLUS
 CH 2118-Quinoxalinoone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



13 ANMER 215 of 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:163342 CAPLOS
 DOCUMENT NUMBER: 88:163342
 ORIGINAL REFERENCE NO.: 88:163342a, 16348a
 TITLE: Proprasone
 AUTHOR(S): Alsharif, M.
 CORPORATE SOURCE: Spas
 SOURCE: Index of Today (1977), 13(12), 531-7
 DOCUMENT TYPE: COORDIN. MONOGR. 15581: 0023-7244
 LANGUAGE: English/Spanish
 GI



AB: A review with 15 refs., is given on proprasone (2) [22769-18-5], a nonaromatic antiinflammatory drug. This nonaromatic analgesic was rapidly absorbed after oral administration, and was effective in the treatment of inflammation or rheumatic-type symptoms.
 IT: 22769-18-5
 RI: PROC (Process)
 RI: (pharmacol. evaluation of)
 RI: 22769-18-5 CAPLOS
 CH: 2-[1(1-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl)- (CA INDEX NAME)]



13 ANMER 217 of 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:141501 CAPLOS
 DOCUMENT NUMBER: 88:141501
 ORIGINAL REFERENCE NO.: 88:141501a, 14214a
 TITLE: Physico-chemical properties and stabilities of prazepan
 AUTHOR(S): Doi, Tadashi; Ohayama, Akemi; Ohkawa, Yasuaki; Tomoda,
 CORPORATE SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd.,
 Takaoka, Japan
 SOURCE: Yakuhin Kenkyu (1978), 9(1), 205-15
 COORD. TYPE: JOURNAL
 DOCUMENT TYPE: JOURNAL
 LANGUAGE: Japanese
 GI



AB: Solid prazepan (2) [2355-38-6] was stable at room temperature for 24 mo and at 60°C for 3 mo. In solns., 2 was stable at pH 4. 2 was highly soluble in CHCl3 and MeCO, moderately soluble in MeOH and EtOH, but practically insol. in EtO. The maximum UV absorption of 2 is 28204 and anhydrous
 ECH: was at 243 nm ($\epsilon = 2.62 \times 10^3$), 285 nm ($\epsilon = 1.24 \times 10^3$) and 365 nm ($\epsilon = 3.23 \times 10^3$). Characterizations of other spectroscopic properties were also described. PFA value of 2 was 2.89. 2 can be determined by the monog. titration method.
 IT: 23417-13-9
 RI: APT (Analytical), NMT (Analytical study)
 RI: (gas chromatog. m)
 RI: 23417-13-9 CAPLOS
 CH: 2-[1(1-Quinoxalinone, 6-chloro-1-(1-cyclopropylmethyl)-4-phenyl)- (CA INDEX NAME)]

15 ANMER 216 of 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:145925 CAPLOS
 DOCUMENT NUMBER: 88:145925
 ORIGINAL REFERENCE NO.: 88:22871a
 TITLE: Salicylic acid and proprasone: the differences in absorption and blood distribution explain their different
 AUTHOR(S): Schwatzer, Alain; Brune, Ray
 CORPORATE SOURCE: Dep. Pharm., Sandoz A.-G., Basel, Switz.
 SOURCE: Perspect. Inflammation, Proc. Int. Meet., 3rd (1977), 353-60. Editor(s): Willoughby, David A.; Grund, J. E.; Veto, R. J. Univ. Park Press, Baltimore, Md.
 COORD. TYPE: CONFERENCE
 DOCUMENT TYPE: CONFERENCE
 LANGUAGE: English
 AB: After oral administration to young rats, both salicylic acid [49-72-7] and proprasone [22769-18-5] accumulated in inflamed tissue and in the kidney. However, only salicylic acid accumulated in the glandular and non glandular part of the stomach. Proprasone remained in the lumen of the stomach. There was a relation between absorption of salicylic acid by the stomach and cell damage. Proprasone did not cause stomach damage, indicating that it may be an inflammation inhibitor with fewer side effects than salicylic acid.
 IT: 22769-18-5
 RI: RFP (Biological process), RSP (Biological study, unclassified), RCL (Biological study), PROC (Process)
 RI: (metabolism of, stomach accumulation in, chemical damage in relation to)
 RI: 22769-18-5 CAPLOS
 CH: 2-[1(1-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl)- (CA INDEX NAME)]



15 ANMER 217 of 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1976:105408 CAPLUS

DOCUMENT NUMBER: 08:105408

ORIGINAL REFERENCE NO.: 08:165454,165484

TITLE: Hydroxymethyl-substituted-2-(1R)-quinazolinones

INVENTOR(S): Popov, Eugene A.

PATENT ASSIGNER(S): Sandoz, Inc., USA

SOURCE: U.S.; 6 pp.

COUNTRY: US/CA/JP

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNTRY: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 404446	A	19771220	US 1976-731396	19761012
DE 2778920	AL	19780223	DE 1977-275920	19770510
DE 287974	AL	19780220	DE 1977-282723	19770510
FR 2342312	AL	19780317	FR 1977-25770	19770519


FR/JP/IT/AT/BR, JPN.,

US 1976-731396 A 19760820

US 1976-731396 A 19760820

US 1976-731396 A 19761012

GI



AB Quinazolinones I (R = H, F, Cl; R1 = alkyl, cycloalkyl; R2 = H, F, Cl, alkyl; R3 = R, F, Cl, alkyl) (2 compounds) were prepared. Thus, successive bromination of II and hydrolysis gave I (R = R3 = R, R1 = Me/Cl, R2 = 3-Me, and HOCH2 at C-7). These compounds are useful as anti-inflammatory agents at 3-200 mg/kg orally.

IT 65765-05-2P
 RI: RCT (Reagent); RACT (Reagent or reagent)
 (Bromination of)
 (Bromination of)
 RI 65765-05-5 CAPLUS
 CH 2(1R)-Quinazolinone, 7-methyl-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

13 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 65765-05-2P
 RI: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and dehydrogenation of)
 RI 65765-05-1 CAPLUS
 CH 2(1R)-Quinazolinone, 2,4-dihydro-6-(3-methoxyphenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)



IT 65765-06-2P
 RI: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and demethylation of)
 RI 65765-06-1 CAPLUS
 CH 2(1R)-Quinazolinone, 7-(3-methoxyphenyl)-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



IT 50817-66-8P 65765-09-5P
 RI: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and hydrolysis of)
 RI 50817-66-8 CAPLUS
 CH 2(1R)-Quinazolinone, 7-(3-methoxyphenyl)-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

13 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 65765-07-2P
 RI: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and acetylation of)
 RI 65765-07-3 CAPLUS
 CH 2(1R)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)



IT 65765-08-4P
 RI: RCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 (Preparation and bromination of)
 RI 65765-08-4 CAPLUS
 CH 2(1R)-Quinazolinone, 4-(3-acetoxyphenyl)-7-methyl-1-[(1-methylethyl)- (CA INDEX NAME)



13 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RI 65765-09-5 CAPLUS
 CH 2(1R)-Quinazolinone, 4-(3-(acetoxy)phenyl)-7-(3-methoxyphenyl)-1-[(1-methylethyl)- (CA INDEX NAME)



IT 65765-10-8P 65765-11-8P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 65765-10-8 CAPLUS
 CH 2(1R)-Quinazolinone, 4-(3-(acetoxy)phenyl)-7-(hydroxymethyl)-1-[(1-methylethyl)- (CA INDEX NAME)



RI 65765-11-9 CAPLUS
 CH 2(1R)-Quinazolinone, 7-(hydroxymethyl)-3-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANWEX 219 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANWEX 219 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1578:85526 CAPLUS
 DOCUMENT NUMBER: 88:85526
 ORIGINAL REFERENCE NO.: 88:130774,13080a

TITLE: A comparison of the effect of proquazone, a new non-steroidal anti-inflammatory compound, on acetylsalicylic acid on blood platelet function in vitro and in vivo

AUTHOR(S): Holmes, J. E.
 CORPORATE SOURCE: Arch. Med. Res. Div., Sandoz Ltd., Basel, Switz.
 SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1977), 28(1), 175-82
 CORDIS APT/STN: ISSN: 0003-7780

DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB Platelet aggregation induced by collagen and arachidonic acid in vitro was inhibited in a dose-dependent manner by proquazone [1] (22765-18-5) and acetylsalicylic acid (50-78-2). On the basis of concentration for 50% inhibition (IC50), 1 was between 22 and 830 times more

potent than acetylsalicylic acid. That 1 inhibits the platelet release reaction was indicated by regression of collagen-induced serotonin release from preloaded platelets (IC50 = 0.15 - 0.35 μM). Primary ADP-induced aggregation was influenced by 1 only at high counts. Following oral drug administration to rabbits, aggregation induced by collagen in vitro was markedly inhibited. The dose producing 50% inhibition (ID50) was 3.4 and 15.7 mg/kg for 1 and acetylsalicylic acid, resp. Collagen-induced decrease in rat circulating platelet count was reduced following oral administration of 1 or acetylsalicylic acid. In these experiments, 1 (ID50 = 5.0 mg/kg) was 4.7 times more potent than acetylsalicylic acid. I.v. injected 1 inhibited collagen-induced bronchoconstriction in the guinea-pig, which is thought to be caused by vasoactive substances released from aggregating platelets. On the basis of the ID50, 1 (5.8 mg/kg) was 140 times more active than acetylsalicylic acid. The duration of action of 1 in vivo was clearly shorter than that of acetylsalicylic acid. Nevertheless, significant inhibitory activity was still observed in the rat 6 to 16 h after oral administration.

IT 22765-18-5
 RU RUD. (Biological study)
 (Blood platelet aggregation responses to)
 RU 22765-18-5 CAPLUS
 CN 2118-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANWEX 219 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANWEX 220 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1578:61720 CAPLUS
 DOCUMENT NUMBER: 88:61720
 ORIGINAL REFERENCE NO.: 88:97734,9762a

TITLE: Carbon-13 nuclear magnetic resonance studies of anti-inflammatory 2(1H)-quinazolinones
 Nasa, Haruhiko; Kimura, Michio; Yamamoto, Michihiro; Hirachi, Toshiyuki; Yamamoto, Ryo
 SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd., Hyogo, Japan
 Chemical & Pharmaceutical Bulletin (1977), 25(1), 3018-22

CORDIS APT/STN: ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI



AB The 13C NMR spectra of twelve 1-cyclopropylmethyl-4-phenyl-2(1H)-quinazolinones including a potent anti-inflammatory agent SL-573 (1) were investigated, and the all carbon resonances were assigned mainly by the off-resonance technique, substituent effects on the 4-Ph groups and 13C-13P couplings. Good correlations were found between Hammett parameters σ and the 13C chemical shifts of the para-substituted quinazolinone frame carbons in spite of the large diastereal angles between the quinazolinone and Ph ring planes (42.8° for 1).

IT 33453-22-4 21453-23-5 59555-47-5
 51525-49-5 43910-1-1 65386-95-0
 45384-96-1 65386-97-2 65386-98-3
 45386-99-4 45387-00-0 45387-01-1
 RU FRP (Fragrance)
 (Carbon-13 NMR of)
 RU 33453-22-4 CAPLUS
 CN 2118-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)




15 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RI 59453-33-5 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl-
 (CA INDEX NAME)



RI 59553-47-3 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)-
 (CA INDEX NAME)



RI 59553-49-5 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methylphenyl)-
 (CA INDEX NAME)



15 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RI 63386-96-1 CAPLUS
 CN 2181-Quinacollinone, 4-(2-bromophenyl)-1-(cyclopropylmethyl)-6-methoxy-
 (CA INDEX NAME)




RI 63386-97-2 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-(2-methoxyphenyl)-
 (CA INDEX NAME)




RI 63386-98-3 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-(2-methoxyphenyl)-
 (CA INDEX NAME)

15 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RI 63386-99-4 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methoxyphenyl)-
 (CA INDEX NAME)



RI 63386-95-0 CAPLUS
 CN 2181-Quinacollinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-methoxy-
 (CA INDEX NAME)


15 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RI 63386-99-4 CAPLUS
 CN 2181-Quinacollinone, 1-(cyclopropylmethyl)-4-(4-fluorophenyl)-6-methoxy-
 (CA INDEX NAME)




RI 63387-00-0 CAPLUS
 CN 2181-Quinacollinone, 6-(4-chlorophenyl)-1-(cyclopropylmethyl)-6-methoxy-
 (CA INDEX NAME)

15 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



720 65107-02-1 CAPLUS
CN 2-[18]-Quinolizone, 4-(4-bromophenyl)-1-(cyclopropylmethyl)-4-methoxy- (CA INDEX NAME)



15 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



720 20927-53-1 CAPLUS
CN 2-[18]-Quinolizone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



720 26953-46-9 CAPLUS
CN 2-[18]-Quinolizone, 1-methyl-4-nitro-4-phenyl- (CA INDEX NAME)





720 50817-16-0 CAPLUS
CN 2-[18]-Quinolizone, 1,6-dimethyl-4-phenyl- (CA INDEX NAME)



720 64820-94-9 CAPLUS
CN 2-[18]-Quinolizone, 6-bromo-1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1978:6829 CAPLUS
DOCUMENT NUMBER: 88:6829
ORIGINAL REFERENCE NO.: 88:1414,1144
TITLE: 1,4-Benzodiazepines, their cyclic homologs and analogs. 2007. Synthesis, structure, and properties of some 6-phenylquinolizine derivatives
Bogatchi, A. V.; Andromak, G. A.; Shilina, E. I.; Danilina, N. I.
Dokl. Akad. Nauk, Khim., Otdel., USSR 1977, 17(8), 1773-80
CORREL: 109046; ISSN: 0514-7492
JOURNAL: Journal
FUSION
OTHER SOURCE(S): CASREACT 88:6829
CI



AB Quinolizone derivs. I (R = H, R1 = Cl, Br, NO2, H, Me, SCH3, OCH3, SO2CH3, OCF3; R2 = Ph, o-ClC6H4; X = O) were obtained in 25-90% yields by cyclization of II with urea or by cyclization of II with Cl3COCCl to give an acylamino intermediate which was cyclized with HCl. Treatment of I with P2S5 gave 30-54 I (R = H; R1 = Cl, Br, Me, H; R2 = Ph; X = O); methylation of I gave 60-54 I (R = Me; R1 = Cl, Br, NO2, H, Me; R2 = Ph; X = O). Chlorination of I with PCl5 gave 60-98 III (R1 = Cl, Br, Me, H; R2 = Ph; R3 = Cl) which were treated with NaOMe to give 35-60% III (R3 = NO2, NO). Cyclization of the latter by NaOMe-HOH yielded 50-60% IV (R1 = Cl, Br, Me, H; R2 = Ph).
17429-04-SP 20927-53-1P 26953-46-SP
50817-16-SP 64820-94-SP
EI: SPN (Synthetic preparation); PREP (Preparation)
[Preparation of]
88 17429-04-8 CAPLUS
CN 2-[18]-Quinolizone, 1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 ACCESSION NUMBER: 1977552263 CAPLUS
 DOCUMENT NUMBER: 87152263
 ORIGINAL REFERENCE NO.: 87152263, 2400A
 TITLE: 3,4-dihydro-2(1H)-quinazolinone derivatives
 INVENTOR(S): Yamamoto, Mochikazu; Katayama, Shigenori; Hoshida, Masao; Yamamoto, Riezo
 PATENT ASSIGNMENT(S): Swinlow Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 8 pp.
 CORDR: OMUKOS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COMPT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2760550	A1	19770709	DE 1977-2760550	19770121
JP 5293850	A	19770902	JP 1976-4920	19760123
US 4048343	A	19770913	US 1976-754640	19761227
NL 7414374	A	19770126	NL 1976-14574	19761230
FR 2339814	A1	19770919	FR 1977-1170	19770117
AT 358934	BL	19801219		
AZ 7060217	A	19790415	AZ 1977-227	19770117
SE 35274	B	19791112		
SE 7060217	A	19770724	SE 1977-533	19770119
SE 422524	B	19800303		
SE 422524	C	19800630		
DK 7760222	A	19770724	DK 1977-222	19770120
DE 141664	B	19800107		
DE 141664	C	19800603		
CA 1043495	A1	19800108	CA 1977-270156	19770120
BE 14189	B	19791228	BE 1977-80917	19770121
CH 652121	A1	19810915	CH 1977-780	19770121
FR 2302177	APPAR. INFO.		JP 1976-4920	A 19760123

01



AB The title compds. I (R = H, F, Cl, HCF₃, CF₃; R1 = H, R2 = Me, MeO; R3 =

OCH₃; R3 = Ph, 2-chamyl) were prepared for use as analgesics and antiproliferative (no data). Thus, 6-MeOCH₃CH₃COMES (OCH₃) was refluxed with R₂Et and EtOEt in xylene to give 54 I (R = F, R1 = H, R2 = MeO, R3 = Ph).

IT 59233-64-4P 59233-67-7P 63930-36-9P

13 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

ACCESSION NUMBER: 1977551899 CAPLUS
 DOCUMENT NUMBER: 87117899
 ORIGINAL REFERENCE NO.: 87187254, 18728A
 TITLE: 2(1H)-Quinazolinone and -thiones
 INVENTOR(S): Yamamoto, Mochikazu; Katayama, Shigenori; Hoshida, Masao; Yamamoto, Riezo
 PATENT ASSIGNMENT(S): Swinlow Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 11 pp.
 CORDR: OMUKOS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COMPT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2656156	A1	19770623	DE 1976-2656156	19761220
JP 53571489	A	19770614	JP 1975-148279	19751221
NL 7613307	A	19770614	NL 1976-13307	19761130
US 4397223	A	19800607	US 1976-746145	19761206
FR 2376142	A1	19770728	FR 1976-267142	19761207
BE 173530	B	19760628	BE 1976-50934	19761208
DK 7605530	A	19770612	DK 1976-5530	19761209
DE 138689	B	19770612		
DK 138689	C	19770614		
SE 761389	A	19770612		
SE 422578	B	19800303	SE 1976-13899	19761209
SE 422578	C	19800624		
CH 602647	A1	19770721	CH 1976-15505	19761209
CA 1046894	A1	19791224	CA 1976-267562	19761209
AZ 7609159	A	19780315	AZ 1976-9336	19761210
AZ 352737	B	19791010	JP 1975-148279	A 19751221

FR 2302177 APPAR. INFO.

15 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 67930-36-1P 64232-94-0P 64597-44-0P
 RI: SM (Synthetic preparation); PREP (Preparation)
 [para, 47]
 RN 59233-64-4 CAPLUS
 CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,3,3-pentafluoropropyl)- (CA INDEX NAME)



RN 59233-67-7 CAPLUS
 CN 2(1H)-Quinazolinone,
 3,4-dihydro-6-methyl-1-(2,3,3,3-pentafluoropropyl)-
 4-phenyl- (CA INDEX NAME)



RN 67930-36-9 CAPLUS
 CN 2(1H)-Quinazolinone,
 1-(2-chloro-2,2-difluoroethyl)-3,4-dihydro-6-methoxy-
 4-phenyl- (CA INDEX NAME)




RN 67930-36-1 CAPLUS
 CN 2(1H)-Quinazolinone,
 3,4-dihydro-6-methoxy-1-(2,3,3,3-pentafluoropropyl)-
 4-phenyl- (CA INDEX NAME)

15 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 ACCESSION NUMBER: 1977551899 CAPLUS
 DOCUMENT NUMBER: 87117899
 ORIGINAL REFERENCE NO.: 87187254, 18728A
 TITLE: 2(1H)-Quinazolinone and -thiones
 INVENTOR(S): Yamamoto, Mochikazu; Katayama, Shigenori; Hoshida, Masao; Yamamoto, Riezo
 PATENT ASSIGNMENT(S): Swinlow Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 11 pp.
 CORDR: OMUKOS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COMPT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2656156	A1	19770623	DE 1976-2656156	19761220
JP 53571489	A	19770614	JP 1975-148279	19751221
NL 7613307	A	19770614	NL 1976-13307	19761130
US 4397223	A	19800607	US 1976-746145	19761206
FR 2376142	A1	19770728	FR 1976-267142	19761207
BE 173530	B	19760628	BE 1976-50934	19761208
DK 7605530	A	19770612	DK 1976-5530	19761209
DE 138689	B	19770612		
DK 138689	C	19770614		
SE 761389	A	19770612		
SE 422578	B	19800303	SE 1976-13899	19761209
SE 422578	C	19800624		
CH 602647	A1	19770721	CH 1976-15505	19761209
CA 1046894	A1	19791224	CA 1976-267562	19761209
AZ 7609159	A	19780315	AZ 1976-9336	19761210
AZ 352737	B	19791010	JP 1975-148279	A 19751221

FR 2302177 APPAR. INFO.

02



AB The title compds. I (R = cyclopropylmethyl, FMOEt, Et, allyl, FMOEt, etc.)

R1 = H, Me, CF₃, Ac, NO₂, etc.; R2 = H, F, furyl, thienyl; R3 = O, S, etc. were prepared by refluxing 11 with 5 in o-Cl₂CH₂CH₃ in the presence of anisole, antipyrone, and various (no data).

IT 26772-90-7 26772-91-4 26824-74-8
 26750-08-1 26742-67-3 26742-49-5
 26742-70-0 26742-71-9 26742-76-4
 26743-01-8 26748-35-7 26753-22-4
 26753-24-4 26753-25-7 26753-26-8

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

59253-27-9 59253-29-0 59253-29-1
59253-30-4 59253-31-5 59253-32-6
59253-34-8 59253-35-9 59253-39-3
59253-40-6 59253-54-0 59253-55-3
59253-56-4 59253-57-5 59253-58-6
59253-59-7 59253-61-1 59253-63-3
59253-64-4 59253-65-5 59253-66-6
59253-68-8 67611-94-9 67920-25-6
67920-26-7 67920-27-8 67920-28-9
67920-29-0 67920-30-3 67920-31-4
67920-32-5 67920-33-6 67920-34-7
67920-36-9 67920-38-1

3Ls RCT (Reactant); RACT (Reactant or reagent)

(hydrolyzation off)

26772-76-7 CAPLUS
CN 2 (1R)-Quinoxaline, 3,4-dihydro-7-methyl-1-[(1-methylethyl)-4-phenyl]-
(CA INDEX NAME)



26772-77-4 CAPLUS
CN 2 (1R)-Quinoxaline, 3,4-dihydro-6-methoxy-1-[(1-methylethyl)-4-phenyl]-
(CA INDEX NAME)



26824-74-8 CAPLUS
CN 2 (1R)-Quinoxaline, 3,4-dihydro-7-methyl-1-[(1-methylethyl)-4-phenyl]-
(CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



26942-70-8 CAPLUS
CN 2 (1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-phenyl-6-
-trifluoromethyl)- (CA INDEX NAME)



26942-71-9 CAPLUS
CN 2 (1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-6-phenyl-
(CA INDEX NAME)



26942-76-4 CAPLUS
CN 2 (1R)-Quinoxaline, 4-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-
(CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



26920-98-1 CAPLUS
CN 2 (1R)-Quinoxaline, 6-chloro-3,4-dihydro-1-methyl-4-phenyl-
(CA INDEX NAME)



26942-67-3 CAPLUS
CN 2 (1R)-Quinoxaline, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)-3,4-
dihydro- (CA INDEX NAME)



26942-69-5 CAPLUS
CN 2 (1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-6-phenyl-
(CA INDEX NAME)


15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



26942-01-8 CAPLUS
CN 2 (1R)-Quinoxaline, 6-chloro-3,4-dihydro-6-phenyl-1-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)



52568-15-7 CAPLUS
CN 2 (1R)-Quinoxaline, 1-(2-isopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl-
(CA INDEX NAME)



59253-22-4 CAPLUS
CN 2 (1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-phenyl-
(CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RR 59253-24-6 CAPLOS
CN 2(1R)-Quinoxalinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl-
(CA INDEX NAME)



RR 59253-25-9 CAPLOS
CN 2(1R)-Quinoxalinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl-
(CA INDEX NAME)



RR 59253-26-8 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-4-phenyl-
(CA INDEX NAME)


15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RR 59253-30-4 CAPLOS
CN 2(1R)-Quinoxalinone,
6-chloro-1-(cyclopropylmethyl)-4-(2-chlorophenyl)-3,6-
dihydro- (CA INDEX NAME)



RR 59253-31-5 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-nitrophenyl)-
(CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RR 59253-27-9 CAPLOS
CN 2(1R)-Quinoxalinone,
1-(cyclopropylmethyl)-3,4-dihydro-6-(methylsulfonyl)-
4-phenyl- (CA INDEX NAME)



RR 59253-28-0 CAPLOS
CN 2(1R)-Quinoxalinone,
6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-
(CA INDEX NAME)



RR 59253-29-1 CAPLOS
CN 2(1R)-Quinoxalinone, 6,8-dichloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-
(CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

RR 59253-32-4 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-(2-methylphenyl)-
(CA INDEX NAME)



RR 59253-34-8 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclohexylmethyl)-3,4-dihydro-6-nitro-4-phenyl-
(CA INDEX NAME)



RR 59253-35-9 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclohexyl)-3,4-dihydro-6-nitro-4-phenyl-
(CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 RH 59253-39-3 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-chloro-3-methyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RH 59253-40-6 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-7-methoxy-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



RH 59253-54-2 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-[(dimethylamino)-3,4-dihydro-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)




RH 59253-55-3 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2-propenyl)- (CA INDEX NAME) (ICI)



15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RH 59253-59-7 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-(2-methoxyethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RH 59253-63-1 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-(2-chloroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)




RH 59253-67-3 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RH 59253-64-4 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RH 59253-56-4 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(phenylethyl)- (CA INDEX NAME)



RH 59253-57-5 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RH 59253-58-6 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-chloro-3,4-dihydro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RH 59253-45-5 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RH 59253-66-6 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RH 59253-68-8 CAPLUS
 CH 2 (1R)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 RH 67611-34-9 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)



RH 67930-25-6 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RH 67930-26-7 CAPLOS
 CH 2(1R)-Quinoxaline, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RH 67930-27-8 CAPLOS

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 4-phenyl- (CA INDEX NAME)



RH 67930-31-4 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)



RH 67930-32-5 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RH 67930-33-6 CAPLOS
 CH 2(1R)-Quinoxaline, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CH 2(1R)-Quinoxaline, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RH 67930-28-9 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl- (CA INDEX NAME)



RH 67930-29-0 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RH 67930-30-3 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)- (CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 4-phenyl- (CA INDEX NAME)



RH 67930-34-7 CAPLOS
 CH 2(1R)-Quinoxaline, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RH 67930-36-9 CAPLOS
 CH 2(1R)-Quinoxaline, 1-(2-chloro-2,2-difluoroethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RH 67930-38-1 CAPLOS
 CH 2(1R)-Quinoxaline, 3,4-dihydro-6-methoxy-2-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



17 22740-18-5P 22740-25-6P 23441-44-7P

LS ANWEX 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

26313-11-9P 26814-69-1P 26824-70-4P
 26920-12-7P 26920-57-4P 28242-57-0P
 28441-30-8P 28442-28-4P 28443-33-3P
 33443-15-5P 33453-19-9P 33453-22-4P
 33453-23-0P 33890-19-8P 37554-33-12P
 37554-37-3P 37554-39-5P 37554-40-8P
 37554-48-6P 37555-33-6P 37555-17-2P
 40552-14-4P 40552-38-8P 40552-44-6P
 40552-52-6P 42120-20-1P 48920-45-9P
 49870-83-3P 52518-07-7P 52518-22-4P
 53710-97-1P 53710-98-3P 53720-99-3P
 53721-00-9P 53711-01-0P 59253-44-6P
 59253-45-2P 59253-46-2P 59253-47-7P
 59253-48-4P 59253-70-1P 63930-18-7P
 63930-19-3P 63930-20-1P 63930-21-2P
 63930-22-7P 63930-24-4P

314 STB (Synthetic preparation) PREP (Preparation)

721 22745-18-5 CAPLUS
 CN 2181-Quazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



721 22746-25-4 CAPLUS
 CN 2181-Quazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



721 23441-64-7 CAPLUS
 CN 2181-Quazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

LS ANWEX 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



721 26920-12-7 CAPLUS
 CN 2181-Quazolinethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



721 26930-57-4 CAPLUS
 CN 2181-Quazolinethione, 1-ethyl-4-phenyl- (CA INDEX NAME)



721 28242-57-0 CAPLUS
 CN 2181-Quazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



721 33443-20-8 CAPLUS
 CN 2181-Quazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

LS ANWEX 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



721 26333-51-9 CAPLUS
 CN 2181-Quazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



721 26824-69-1 CAPLUS
 CN 2181-Quazolinethione, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



721 26824-70-4 CAPLUS
 CN 2181-Quazolinone, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

LS ANWEX 223 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



721 33443-28-6 CAPLUS
 CN 2181-Quazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



721 33443-33-3 CAPLUS
 CN 2181-Quazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



721 33443-35-5 CAPLUS
 CN 2181-Quazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)




RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (PCI) (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 40852-34-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-38-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 40812-44-6 CAPLOS
CN 2 (18)-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 40812-52-6 CAPLOS
CN 2 (18)-Quinazolinone, 6-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 41190-39-3 CAPLOS
CN 2 (18)-Quinazolinone, 1-[[2-methylphenyl]methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 52568-22-6 CAPLOS
CN 2 (18)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 53720-97-1 CAPLOS
CN 2 (18)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 53720-98-2 CAPLOS
CN 2 (18)-Quinazolinethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-67-9 CAPLOS
CN 2 (18)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 49830-89-9 CAPLOS
CN 2 (18)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 52568-07-7 CAPLOS
CN 2 (18)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

RN 53720-99-3 CAPLOS
CN 2 (18)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



RN 53721-00-8 CAPLOS
CN 2 (18)-Quinazolinethione, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 53721-01-8 CAPLOS
CN 2 (18)-Quinazolinethione, 1-(cyclopropylmethyl)-6-phenyl- (CA INDEX NAME)



RN 59253-44-0 CAPLOS
CN 2 (18)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

1.5 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



XX 59233-45-1 CAPLOS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



XX 59233-46-2 CAPLOS
CN 2(1H)-Quinazolinone, 6-methyl-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



XX 59233-47-3 CAPLOS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)

1.5 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



XX 63930-19-8 CAPLOS
CN 2(1H)-Quinazolinethione, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




XX 63930-20-1 CAPLOS
CN 2(1H)-Quinazolinethione, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



XX 63930-21-2 CAPLOS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)

1.5 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



XX 59233-48-4 CAPLOS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-methylphenyl)- (CA INDEX NAME)




XX 59233-70-2 CAPLOS
CN 2(1H)-Quinazolinone, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



XX 63930-18-7 CAPLOS

1.5 ANSWER 223 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)




XX 63930-22-3 CAPLOS
CN 2(1H)-Quinazolinethione, 1-(2-chloro-2,2-difluoroethyl)-4-methoxy-4-phenyl- (CA INDEX NAME)



XX 63930-24-5 CAPLOS
CN 2(1H)-Quinazolinethione, 6-methoxy-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



15 ANWEX 224 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1977:485043 CAPLUS
 DOCUMENT NUMBER: 87:151873
 ORIGINAL REFERENCE NO.: 87:117034, 177034
 TITLE: On the interaction between the anti-inflammatory
 substance prostanolone (NO 43-713) and phenprocoumon
 Visnager, H.
 COOPERATE SOURCE: Blood Coagulation Lab., Linz, Austria
 SOURCE: International Journal of Clinical Pharmacology and
 Biopharmacy (1977), 15(5), 214-16
 CORDIS 1/CRDA/ 1588: 0140-0026
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The anti-inflammatory drug prostanolone (I) [22702-18-5] had no influence on the degree of hypocoagulability in patients anticoagulated with phenprocoumon (II) [435-93-2]. Administration of I for 2 weeks did not statistically affect the Quick percent, coagulation factors II, VII, and X, or the platelet aggregation induced by collagen or epinephrine. Many anti-inflammatory agents decreased the blood clotting ability of patients receiving oral anticoagulants to below therapeutic levels, resulting in increased bleeding and/or thrombotic tendencies.

IT Ph R¹ R² (diagonal strip)

(Blood coagulation responses to phenprocoumon and)
 EN 26772-18-5 CAPLUS
 CN 2118-Quinazolinone, 3-methyl-1-[1-methylethyl]-4-phenyl- ICA INDEX NAME)



15 ANWEX 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 Ph R = OMe, R¹ = H, R² = OMe, R³ = Ph; R = OMe, R¹ = H, R² = cyclopropylmethyl, R³ = 2-thienyl; R = H, R¹ = Me, R² = OMe, R³ = OMe, R⁴ = Ph were prep. by recycling the waste II with R¹CO in the presence of R².
 IT 56772-90-TP 26772-97-EP 26942-71-SP
 26942-72-CP 59253-24-CP 59253-25-TP
 59253-26-EP 63611-90-EP 63611-91-EP
 63611-92-TP 63611-93-SP 63611-94-PP
 63611-96-TP
 R¹ R² Pyrexia preparation/ PPEP Preparation
 (preparation of)
 EN 26772-90-7 CAPLUS
 CN 2118-Quinazolinone, 3,4-dihydro-6-methoxy-1-[1-methylethyl]-4-phenyl- ICA INDEX NAME)



EN 26772-97-4 CAPLUS
 CN 2118-Quinazolinone, 3,4-dihydro-6-methoxy-1-[1-methylethyl]-4-phenyl- ICA INDEX NAME)




EN 26942-71-9 CAPLUS
 CN 2118-Quinazolinone,
 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- ICA INDEX NAME)

15 ANWEX 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1977:485043 CAPLUS
 DOCUMENT NUMBER: 87:155443
 ORIGINAL REFERENCE NO.: 87:155334, 155334
 TITLE: 3,4-dihydro-2(1H)-quinazolinones and
 -quinazolinolones
 INVENTOR(S): Yamamoto, Michihito; Katayama, Shigenori; Koshida,
 Masay; Tomomoto, Hisao
 PATENT ASSIGNOR(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 10 pp.
 CORDIS 1/CRDA/ 1588: 0140-0026
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACT: NM, COMPT 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 24 47853	A1	19770505	DE 1976-2647053	19761022
JP 53051179	A	19770405	JP 1975-128570	19751024
JP 54016113	B	19790622		
NL 7613350	A	19770405	NL 1976-11210	19761011
NL 161974	B	19810515		
NL 161974	C	19810515		
US 4202974	A	19800511	US 1976-712574	19761012
AT 357786	B	19791210	AT 1976-7709	19761015
FR 1607099	A	19790515		
FR 2120700	A1	19770210	FR 1976-21242	19761019
FR 2128700	R1	19790102		
SE 7611497	SE	19770415	SE 1976-11497	19761011
SE 422577	C	19850115		
SE 422577	C	19850614		
GB 601219	A5	19790630	GB 1976-21218	19761011
DE 7604009	DE	19770425	DE 1976-4009	19761012
US 4040421	A3	19790217	CA 1976-267080	19761012
NO 173529	NO	19760620	NO 1976-50932	19761012
PRIORITY APPL. INFO.: JP 1975-128570	A	19751024		

OTHER SEQU. INFO.: NAMEPAT 87:155443

GI



AB Antiinflammatory and analgesic (no data) quinazolinones I (R = OMe, Me, OMe, R¹ = H, R² = cyclopropylmethyl, R³ = Ph; R = OMe, R¹ = H, R² = cyclopropylmethyl, R³ = 2-thienyl; R = H, R¹ = Me, R² = OMe, R³ = OMe, R⁴ = Ph were prep. by recycling the waste II with R¹CO in the presence of R².
 IT 56772-90-TP 26772-97-EP 26942-71-SP
 26942-72-CP 59253-24-CP 59253-25-TP
 59253-26-EP 63611-90-EP 63611-91-EP
 63611-92-TP 63611-93-SP 63611-94-PP
 63611-96-TP
 R¹ R² Pyrexia preparation/ PPEP Preparation
 (preparation of)
 EN 26772-90-7 CAPLUS
 CN 2118-Quinazolinone, 3,4-dihydro-6-methoxy-1-[1-methylethyl]-4-phenyl- ICA INDEX NAME)

15 ANWEX 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



EN 26942-72-0 CAPLUS
 CN 2118-Quinazolinone,
 1-(cyclopropylmethyl)-3,4-dihydro-6-methyl-4-phenyl- ICA INDEX NAME)



EN 59253-24-6 CAPLUS
 CN 2118-Quinazolinone,
 1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl- ICA INDEX NAME)



EN 59253-25-7 CAPLUS
 CN 2118-Quinazolinone,
 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- ICA INDEX NAME)

15 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



32 59253-26-9 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



33 63611-90-5 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-4-(2-fluorophenyl)-3,4-dihydro-6-methoxy- (CA INDEX NAME)




34 63611-91-6 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-4-(4-fluorophenyl)-3,4-dihydro-6-methoxy- (CA INDEX NAME)

15 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



35 63611-94-9 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)




36 63611-96-1 CAPLUS
 CH 2(18)-Quinoxalino, 1-ethyl-3,4-dihydro-6-methoxy-6-phenyl- (CA INDEX NAME)




15 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

6-methoxy- (CA INDEX NAME)



38 63611-92-7 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-chlorophenyl)- (CA INDEX NAME)



39 63611-93-8 CAPLUS
 CH 2(18)-Quinoxalino, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(12-methylphenyl)- (CA INDEX NAME)

15 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

1577485037 CAPLUS
 ACCESSION NUMBER: 8785037
 ORIGINAL REFERENCE NO.: 87153354,13538a
 TITLE: 1-Cyclopropylmethyl-4-phenyl-6-chloro-2(18)-quinoxalino
 INVENTOR(S): Yamamoto, Michihiko; Koshida, Masao; Ishimori, Kikuo
 PATENT ASSIGNEE(S): Moriy, Kazuo; Yamamoto, Masao
 SOURCE: Bunimoto Chemical Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 4 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53527482	A	19770209	JP 1975-91372	19750725

GI



38 Cyclization of I with PhNO₂ gave II. Thus, 0.5 g I in Me₂CO and 1.4 g PhNO₂ gave II. II had antiinflammatory, analgesic, and

acid-secretion stimulating, and antiviral activities (no data).
 IT 23453-15-99
 NLA: SYN (Synthetic preparation); PREP (Preparation)

(Preparation of)
 39 31453-15-9 CAPLUS
 CH 2(18)-Quinoxalino, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 227 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1977467489 CAPLUS
 DOCUMENT NUMBER: 87147489
 ORIGINAL REFERENCE NO.: 87197254,107254
 TITLE: Mass spectra of trisubstituted 1,3,4,6-tetrahydro-1,5-benzodiazocin-2-one
 AUTHOR(S): Shakhmatov, V. A.; Terent'ev, P. B.; Andronati, G. A.;
 CORPORATE SOURCE: Bogatnikov, A. V.; Fudenko, O. P.; Danilin, V. V.;
 SOURCE: Mosk. Gos. Univ., Moscow, USSR
 Khimya Geterotsiklicheskikh Soedinenii (1977), (4), 529-36
 CUBER: RUSNGP JERN: 0170-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI



AB The mass spectral fragmentation of I (R = H, Me, Cl, Br; R1 = Me, Et, Pr, Bu; R2 = H, Cl) occurred first by loss of CMe2 and then by loss of H+, NO2+, or CO. Loss of ketene with ring contraction also occurred.
 IT 20971-53-1
 RU PREP (Preparation) (mass spectrum of)
 RI 20971-53-1 CAPLUS
 CN 2(18)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)




15 ANSWER 227 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

15 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 197744242 CAPLUS
 DOCUMENT NUMBER: 87144242
 ORIGINAL REFERENCE NO.: 87484842,69484
 TITLE: Pharmaceutical composition for the prevention of a gastroenteral ulcer provoked by a nonsteroid antiinflammatory agent
 INVENTOR(S): Yamauchi, Hisao; Konata, Toshikazu; Arita, Hiroshi
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Belg., 19 pp., COMB: MIXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 842342	A2	19761018	BE 1976-168174	19760222
JP 52001036	A	19770106	JP 1976-61613	19760506
JP 54016509	B	19780622		
NL 7606464	A	19761217	NL 1976-6494	19760616
AD 498021	B2	19780405	AD 1976-15066	19760618
FR 2315281	A2	19770211	FR 1976-16763	19760611
FR 2315281	R1	19780427		
CA 1062415	A2	19770918	CA 1976-255289	19760611
SA 7603700	A	19770525	SA 1976-7700	19760622
IL 49867	A	19680131	IL 1976-49867	19760622
US 4247554	A	19810217	US 1977-795887	19770511

PRIORITY APPL. INFO.: US 1975-589175 A 19750623

OTHER SOURCE(S): NAKPAT 87144242
 GI



AB Pharmaceutical compns. comprise a nonsteroidal antiinflammatory agent and an ulcer-preventing quinazolinone I where R' = alkyl Cl-3, cyclopropylmethyl, or 2,2,2-trifluoroethyl, R2 = halogen, alkyl Cl-3, or alkoxy Cl-3, R3 = Ph or thienyl. For example, with an oral 5% gum arabic suspension containing indomethacin [53-86-1] (10 mg/kg) and l-cyclopropylmethyl-4-methyl-6-methyl-2-(1H)-quinazolinone (II) [31451-25-1] (50 mg/kg) no intestinal perforations occurred.
 IT 20971-53-1P 23461-64-7P 23453-19-3P
 23451-23-5P 27554-40-3P 69030-83-3P
 59253-44-0P 59253-45-1P
 RU PREP (Preparation) (ulcer formation from nonsteroidal antiinflammatory agent inhibition by)
 RI 20971-53-1 CAPLUS

10/ 540,359

13 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CH 2 (1R)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RI 23441-64-7 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RI 23453-19-9 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RI 23453-33-5 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI 37554-40-6 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 49830-89-9 CAPLUS
 CH 2 (1R)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 59253-44-0 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)

13 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RI 59253-45-1 CAPLUS
 CH 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



15 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

157711572 CAPLUS
 DOCUMENT NUMBER: 86115372
 ORIGINAL REFERENCE NO.: 86125176, 1251904
 TITLE: Quinazolinone-containing antiinflammatory agents
 INVENTOR(S): Yamamoto, Hisao; Komatsu, Toshiaki; Awata, Shinichi
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Ger. Offen., 39 pp.
 COUNTRY: GERMANY
 DOCUMENT TYPE: Patent
 LANGUAGE(S): German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52001036	A	19770106	JP 1976-61613	19760526
JP 54016509	B	19790622		
NL 7604494	A	19761227	NL 1976-6494	19760616
AD 493021	B2	19790405	AD 1976-15066	19760628
FR 2315281	A2	19770121	FR 1976-18762	19760621
FR 2315281	B1	19780427		
CA 1062615	A1	19780918	CA 1976-255289	19760621
SA 7603700	A	19770525	SA 1976-3700	19760622
IL 49567	A	19800331	IL 1976-49867	19760622
US 4247554	A	19810127	US 1977-791887	19770511
			US 1975-589573	A 19750623

PRIORITY APPL. INFO.:

QZ



AB The quinazolinone deriva. 1 (R) = Cl-3 alkyl, cyclopropylmethyl or F(COCH3); R2 = halogen, Cl-3 alkyl or Cl-3 alkoxy; R3 = Ph or (3-phenyl) or their salts showed antiinflammatory activity and can be used in combination with non-steroidal inflammation inhibitors. For example, 9 quinazolinone deriva. administered orally at 1 ml/100 g as 18 solns. in 0.9% saline inhibited or prevented indomethacin [57-86]-induced perforations in the intestine. Combined administration of 1-cyclopropylmethyl-4-phenyl-6-methoxy-2 (1R)-quinazolinone [3145]-23-5 and either indomethacin or phenylbutazone [50-33-9] gave an additive antiinflammatory effect against estragemon-induced local

edema in the rat hind foot.
 IT 20937-53-1 23441-64-7 23453-19-9
 23453-23-5 27554-40-6 49830-89-9
 59253-44-0 59253-45-1
 RI, RMC (Biological activity or effector, except adjuvants); BSU (Biological)

15 ABSTRACT 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
study, unclassified); TMO (Therapeutic use); BIOL (Biological study);
OSLES

(Osas)

antitumor activity of)

PH 2057-53-1 CAPLUS

CH 2181-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



PH 23441-64-7 CAPLUS

CH 2181-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



PH 33453-23-5 CAPLUS

CH 2181-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



PH 33453-23-5 CAPLUS

CH 2181-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ABSTRACT 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PH 59253-45-1 CAPLUS

CH 2181-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



15 ABSTRACT 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PH 37554-40-8 CAPLUS

CH 2181-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



PH 49520-39-9 CAPLUS

CH 2181-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



PH 59253-44-0 CAPLUS

CH 2181-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

15 ABSTRACT 230 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 157710517 CAPLUS

DOCUMENT NUMBER: 8610917

ORIGINAL REFERENCE NO.: 8611079, 1766a

TITLE: The crystal and molecular structure of an

anti-inflammatory agent, 1-(cyclopropylmethyl)-4-

phenyl-6-methoxy-2181-quinazolinone (SL-573)

AUTHOR(S): Kuroki, Michio; Kuroki, Michio; Kuroki, Michio; Kuroki, Michio

CORPORATE SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd.,

Takara, Japan

SOURCE: Bulletin of the Chemical Society of Japan (1976),

49(10), 2696-700

COBOL SCHEMA: JSM: 0009-2673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The crystal structure of the title compound (SL-573), crystallized from

an ethyl acetate solution, was determined by single-crystal X-ray

diffraction. The crystals are monoclinic, space group P2₁/a, a 17.395(11), b 8.371(5), c

10.871(7) Å, β 99°56(4)', and Z = 4. The intensities were

measured virtually from equi-inclination integrated MoKα

photographs taken with Cu Kα radiation. The structure was solved by the

symbolic addition method. The final R factor was 0.119 for 3284

reflections.

The mol. are placed in pairs around the centers of symmetry and are

linked by van der Waals' distances less than 3.94 Å. The dihedral

angle between the quinazolinone and Ph ring planes is 42.9°.

IT 33453-23-5

PH: PTP (Properties)

(crystal structure of)

PH 33453-23-5 CAPLUS

CH 2181-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)




13 ANSWER 231 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19761540153 CAPLOS
 DOCUMENT NUMBER: 851302133
 ORIGINAL REFERENCE NO.: Correction of: 81:17959
 TITLE: 81:13045a, 23645a
 INVENTOR(S): Quinazolinones
 INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Nichihiro
 PATENT ASSIGNER(S): Koshida, Masao; Inaba, Shigehiro; Yamamoto, Masao
 SOURCE: Sumitomo Chemical Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 8 pp.
 CDD: 280000
 PATENT: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48080583	A	19731029	JP 1972-12977	19720205
JP 54228555	B	19790904	JP 1972-12977	19720205

PRIORITY APPL. INFO.:

GI:



I



II

AB The title compts. (I) were prepared by hydrolyzing or by heating acyl
 weas.

II (R1-R4 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl,
 polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzoyloxy,
 Me, carboxy, carboxyl, or alkoxy-carboxyl). R-6, 1, R2 & II (R1 =

4-Cl, R2 = R3 = H, R4 = Me, R5 = Et) In EtOH was refluxed 30 min with 5 ml 20%
 NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared

was I (R1, R2, R3, and R4 given): 6-Cl, R1 = R2, R3 = H.

IT 20971-53-1P
 R1: R2 (Synthetic preparation); PREP (Preparation)
 [preparation of]

RI 20971-53-1 CAPLOS
 CH 21(R)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 232 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19761542144 CAPLOS
 DOCUMENT NUMBER: 85142144
 ORIGINAL REFERENCE NO.: 85121979a, 12800a
 TITLE: Mass spectrometry of 1,4-benzodispiro-
 INVENTOR(S): Tendo, R.; Kikawa, L.; Saito, Y.; Kaye, F.;
 PATENT ASSIGNER(S): Kamei, V.; Milder, P.
 SOURCE: Corgenta R&D, Chem., Chiba, Japan, 2000
 CDD: 280000
 PATENT: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:

AB The mass spectra of 4-methyl-1,4-benzodispiro-2-ones, 3 of their in
 vitro biotransformation products, and 5 achiral 1,4-benzodispiro-2-ones are
 reported and their fragmentation paths discussed. Deriv. with C-3
 substituents were useful for determination of fragmentation paths at low
 resolution.

IT 20971-53-1
 R1: PREP (Preparation)
 [mass spectrum of]

RI 20971-53-1 CAPLOS
 CH 21(R)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



I

13 ANSWER 231 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




II

13 ANSWER 232 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19761487035 CAPLOS
 DOCUMENT NUMBER: 85187535
 ORIGINAL REFERENCE NO.: 8513983a, 1398a
 TITLE: Quantitative determination of quinazolinone
 INVENTOR(S): Hasegawa, Masatoshi; Maeda, Tadacy; Takenaka, Hiroshi;
 PATENT ASSIGNER(S): Nippon, Takeda; Yamashita, Toshiaki
 SOURCE: Sumitomo Chemical Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 4 pp.
 CDD: 280000
 PATENT: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 5302193	A	19760901	JP 1974-97697	19740906
JP 5302193	A	1974-97697	JP 1974-97697	19740906

GI:



I

AB Quinazolin-2-ones or quinazolin-2,4-diones are determined in body
 fluids by

electron-capture gas chromatog. Thus, 5 µl SL 573 (1-cyclopropylmethyl-
 4-phenyl-6-methoxy-2(R)-quinazolinone) (I) (3343-23-5) (1
 µg/ml benzene) was determined by electron-capture gas chromatog. (column
 temperature 200°; detector temperature 310°; chromatog. W W 2000 column
 packing N carrier gas). The retention time was 4.5 min.

IT 21760-28-5 21760-28-5 21760-28-5
 21760-28-5 21760-28-5 21760-28-5
 21760-28-5 21760-28-5 21760-28-5

RI: NOT ANALYZED (Analytical study)

(determination of, in blood and urine, by gas chromatog.)

RI 21760-28-5 CAPLOS


CH 21(R)-Quinazolinone, 7-methyl-2-(3-methylthio)-4-phenyl- (CA INDEX

NAME)



I

15 ANSWER 233 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 FH 3343-22-0 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



FH 3343-22-4 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)




FH 3343-23-5 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)


15 ANSWER 234 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1376:436473 CAPLUS
 DOCUMENT NUMBER: 85156473
 ORIGINAL REFERENCE NO.: 85156473, 80144
 TITLE: Inhibition of prostaglandin biosynthesis by SL-573
 AUTHOR(S): Yanagi, Yoshiaki; Komatsu, Yoshiaki
 CORPORATE SOURCE: Res. Dev. Cent., Sumitomo Chem. Co. Ltd., Hyogo, Japan
 SOURCE: Biochemical Pharmacology (1976), 25(8), 937-41
 CORDIS SCPCMS: 1588: 0006-2952
 JOURNAL: Journal
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB SL 573 [3343-23-5] (0.5-10 mg/ml) inhibited prostaglandin biosynthesis from labeled arachidonic acid using bovine seminal vesicle microsomes as enzyme membrane. The relative inhibitory potencies of indomethacin (57-58-1) (0.05-2.0 mg/ml), SL 573, and aspirin (50-78-2) (100-800 mg/ml) were 100%, 27%, and 1.0 resp. The inhibition by SL 573 was reversible, whereas that of indomethacin and aspirin was irreversible.
 SL 573 prevented the progressive increase of the irreversible inhibition of indomethacin and aspirin.
 IT 3343-23-5
 SL 573OL (biological study)
 AB [prostaglandin formation by seminal vesicle microsomes inhibition by]
 FH 3343-23-5 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)




15 ANSWER 233 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FH 53720-97-1 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-4-methoxy-6-phenyl- (CA INDEX NAME)



FH 59253-44-0 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)




15 ANSWER 235 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1376:432045 CAPLUS
 DOCUMENT NUMBER: 85133045
 ORIGINAL REFERENCE NO.: 85133045, 5372a
 TITLE: Quinazolinone derivatives
 AUTHOR(S): Ishikawa, Takayuki; Murai, Kazuo; Inaba, Shigehito
 CORPORATE SOURCE: Yamamoto, Hisao
 SOURCE: Switex Chemical Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 4 pp.
 CORDIS SCPCMS: 1588: 0006-2952
 JOURNAL: Japanese
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50151887	A	19751206	JP 1974-61684	19740530
JP 59018698	B	19840502		
SE 7506140	A	19751201	SE 1975-6140	19750529
SE 414403	E	19800728		
SE 414403	C	19801113		
NL 7506238	A	19751202	NL 1975-6238	19750529
CA 1047987	A3	19780206	CA 1975-23844	19750529
CH 599372	A5	19780512	CH 1975-7026	19750530
			JP 1974-61684	A 19740530

PRIORITY APPL. INFO.:
 JP 1974-61684

GI



AB Quinazolinone I (X = halo, alkyl) were prepared by photohydrogenation of 4-hydroxyquinazolinones II. I are antitumor, antiinflammatory and uric acid excretion stimulating agents (no data). Thus, 1 g II (X = 6-Cl) in Me2SO was uv-irradiated 50 hr to give 0.87 g I (X = 6-Cl). Also prepared was I (X = 6-MeO).

IT 98353-25-7 59825-55-9
 RU: RCT (Reagent); RACT (Reagent or reagent)
 (photohydrogenation of)

FH 59253-25-7 CAPLUS
 CH 2118-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 235 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 59635-55-5 CAPLOS
 CI 21181-Quinoxalinone,
 7-chloro-1-(cyclopropylmethyl)-4-phenyl-
 (CA INDEX NAME)



IT 37555-Q9-2D 59253-45-1P
 RI 520 (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RI 37555-Q9-2 CAPLOS
 CI 21181-Quinoxalinone, 7-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RI 59253-45-1 CAPLOS

15 ANSWER 236 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1976:421431 CAPLOS
 DOCUMENT NUMBER: 85:21431
 ORIGINAL REFERENCE NO.: 85:35594, 3512a
 TITLE: 4-Phenyl-2-[18]-quinoxalinones
 Inaba, Y.; Kohno, M.; Kawan, I.; Inaba, S.; Inaba, Y.
 Yamamoto, H.; Ito, S.
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY AC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50148702	A	19701127	JP 1974-52446	19740510
JP 5740441	B	19821218	JP 1974-52446	A 19740510

PRIORITY APPL. INFO.

GI



RI 4-Phenyl-2-[18]-quinoxalinone I [R1-R3 = H, halo, CF3, NO2, alkyl, alkenyl, alkylthio]; R4 = H, alkyl, aralkyl, alkanoyloxyalkyl, alkoxyalkyl, polyalkyl, cycloalkyl, tetrahydropranyl, pyridinyl, pyridinyl, furanyl, thienyl, thienylmethyl, etc. prepared by cyclizing 2-amino-5-chlorobenzenes II with ClOCH3 or ClOCH2Cl. Thus, 5.0 g

2-methylamino-5-chlorobenzenes II was stirred with 0.79 g ClOCH2Cl in EtOH 2 hr to give 2 (R1 = 6-Cl, R2 = R3 = H, R4 = Me), also prepared from ClOCH3. ClOCH2Cl was prepared by photochem. chlorination of MeOH in ClOCH3 at 100°.

IT 20971-33-1P
 RI 878 (Synthetic preparation); PREP (Preparation)
 (preparation of)

RI 20971-33-1 CAPLOS
 CI 21181-Quinoxalinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)


15 ANSWER 236 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CI 21181-Quinoxalinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)
 17 26772-90-7 26772-95-2 26772-97-4
 26742-47-3 26742-49-5 26742-70-8
 26742-71-9 26742-76-4 26742-01-8
 26742-02-4 26742-03-5 26742-24-6
 26742-25-7 26742-26-8 26742-27-9
 26742-28-0 26742-29-1 26742-30-4
 26742-31-5 26742-32-6 26742-33-7
 26742-34-8 26742-35-9 26742-37-1
 26742-38-2 26742-39-7 26742-40-6
 26742-41-7 26742-43-1 26742-54-2
 26742-55-3 26742-56-4 26742-57-5
 26742-58-6 26742-59-7 26742-60-0
 26742-61-1 26742-62-2 26742-63-3
 26742-64-4 26742-65-5 26742-66-6
 26742-67-7 26742-68-8 26742-69-9
 R1: RCT (Reactant); RACT (Reactant or reagent)
 (Nomenclature 47)
 R2 26772-90-7 CAPLOS
 CN 2188-Quinolizone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl-
 (CA INDEX NAME)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51060287	A	19760123	JP 1974-80506	19740713
JP 1424106	B	19790222		
NL 7507921	A	19760315	NL 1975-7921	19750703
AT 358237	A	19770815	AT 1975-5257	19750706
SE 750792	A	19760114	SE 1975-7922	19750710
SE 414404	B	19800728		
SE 414404	C	19801113		
RU 192223	B	19770428	RU 1975-20895	19750710
RU 621296	A5	19790713	RU 1975-9029	19750710
DK 7503180	A	19760114	DK 1975-1380	19750711
CA 1046062	A1	19790309	CA 1975-231296	19750711
PRIORITY APPL. INFO.			JP 1974-80506	A 19740713

GI



AB Quinolizones I (R1, and R2 = H, halo, alkyl, alkoxy, MeS, MeOS, MeO, CF3, COMe, MeHCO, or R32 = OCH2O) R3 = Ph, halophenyl, nitrophenyl, tolyl, C6H4Me-p, pyridyl, thienyl; R4 = alkyl, alkyl, cycloalkyl, cycloalkylmethyl, haloalkyl) were prepared by treating
 dihydroquinolizones
 II with Cu or Zn in the presence or absence of a base. Thus, 3.08 g II
 (R1 = 6-MeO, R2 = H, R3 = Ph, R4 = cyclopropylmethyl) in dioxane was
 treated dropwise with 2.3 g Zn at 75-85°C for 6 hr to give 3.8 g
 I (R1 = same substituents). Similar oxidation with NaOCl in MeOH gave
 2.9 g
 I (R1 = same substituents). Among 49 more I prepared were R1-4 given): 6-Cl, R, Ph,
 CMe2CF3,
 R1R2 = 7,8-OCH2O, Ph, cyclopropylmethyl; 6-Cl, R, 2-pyridyl,

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



R2 26742-67-3 CAPLOS
 CN 2188-Quinolizone, 6-chloro-3-(2-methoxyethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)



R2 26742-69-5 CAPLOS
 CN 2188-Quinolizone, 3-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



R2 26742-70-8 CAPLOS
 CN 2188-Quinolizone, 3-(cyclopropylmethyl)-3,4-dihydro-6-phenyl-4-trifluoromethyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)
 17 26772-90-7 26772-95-2 26772-97-4
 26742-47-3 26742-49-5 26742-70-8
 26742-71-9 26742-76-4 26742-01-8
 26742-02-4 26742-03-5 26742-24-6
 26742-25-7 26742-26-8 26742-27-9
 26742-28-0 26742-29-1 26742-30-4
 26742-31-5 26742-32-6 26742-33-7
 26742-34-8 26742-35-9 26742-37-1
 26742-38-2 26742-39-7 26742-40-6
 26742-41-7 26742-43-1 26742-54-2
 26742-55-3 26742-56-4 26742-57-5
 26742-58-6 26742-59-7 26742-60-0
 26742-61-1 26742-62-2 26742-63-3
 26742-64-4 26742-65-5 26742-66-6
 26742-67-7 26742-68-8 26742-69-9
 R1: RCT (Reactant); RACT (Reactant or reagent)
 (Nomenclature 47)
 R2 26772-90-7 CAPLOS
 CN 2188-Quinolizone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl-
 (CA INDEX NAME)



R2 26772-95-2 CAPLOS
 CN 2188-Quinolizone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



R2 26772-97-4 CAPLOS
 CN 2188-Quinolizone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



R2 26742-67-3 CAPLOS
 CN 2188-Quinolizone, 3-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-6-phenyl- (CA INDEX NAME)



R2 26742-69-5 CAPLOS
 CN 2188-Quinolizone, 3-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



R2 26742-70-8 CAPLOS
 CN 2188-Quinolizone, 3-(cyclopropylmethyl)-3,4-dihydro-6-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

1.5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



HN 59253-22-4 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



HN 59253-23-5 CAPLUS
CN 2(1R)-Quinoxalinone, 6-bromo-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



HN 59253-24-6 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl- (CA INDEX NAME)

1.5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



HN 59253-28-0 CAPLUS
CN 2(1R)-Quinoxalinone, 6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



HN 59253-29-1 CAPLUS
CN 2(1R)-Quinoxalinone, 6,8-dichloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



HN 59253-30-4 CAPLUS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)

1.5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



HN 59253-25-7 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)



HN 59253-26-8 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methoxythio)-4-phenyl- (CA INDEX NAME)




HN 59253-27-9 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)

1.5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




HN 59253-31-5 CAPLUS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)



HN 59253-32-6 CAPLUS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-(2-nitrophenyl)- (CA INDEX NAME)



13 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 RI 59253-33-7 CAPLUS
 CI 2 (18)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methylphenyl)- (CA INDEX NAME)



RI 59253-34-8 CAPLUS
 CI 2 (18)-Quinazolinone, 1-(cyclohexylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RI 59253-35-9 CAPLUS
 CI 2 (18)-Quinazolinone, 1-(cyclohexylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)

13 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 59253-40-6 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-7-methoxy-1-(1-methylethyl)-6-phenyl- (CA INDEX NAME)



RI 59253-43-7 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 59253-51-1 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-3,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 59253-54-2 CAPLUS
 CI 2 (18)-Quinazolinone, 6-[(dimethylamino)-3,4-dihydro-1-(1-methylethyl)-4-phenyl]- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 59253-37-1 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RI 59253-38-2 CAPLUS
 CI 2 (18)-Quinazolinone, 6-chloro-3,4-dihydro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)




RI 59253-39-3 CAPLUS
 CI 2 (18)-Quinazolinone, 6-chloro-1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 59253-55-3 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2-propenyl)- (PCI INDEX NAME)



RI 59253-56-4 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RI 59253-57-5 CAPLUS
 CI 2 (18)-Quinazolinone, 3,4-dihydro-1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)


15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 59253-53-6 CAPLUS
CN 2 [1R]-Quinoxalinone, 6-chloro-3,4-dihydro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



XX 59253-53-7 CAPLUS
CN 2 [1R]-Quinoxalinone, 1-(2-methoxyethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



XX 59253-60-0 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

XX 59253-64-4 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



XX 59253-65-5 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-1-(2,2,2-trifluoroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)




XX 59253-66-6 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



XX 59253-67-7 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-6-methyl-1-(2,2,2-trifluoroethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 59253-61-1 CAPLUS
CN 2 [1R]-Quinoxalinone, 1-(2-chloroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



XX 59253-62-2 CAPLUS
CN 2 [1R]-Quinoxalinone, 1-(2,2-difluoroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



XX 59253-63-3 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-6-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



XX 59253-68-8 CAPLUS
CN 2 [1R]-Quinoxalinone, 3,4-dihydro-1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



XX 59253-63-5 CAPLUS
CN 2 [1R]-Quinoxalinone, 6-acetyl-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



IT 20927-51-1P 22760-18-5P 22760-35-6P
22760-27-6P 22760-60-7P 23431-64-7P
23431-76-2P 23431-51-9P 26054-70-4P
26953-46-9P 28340-57-0P 35433-20-9P
35433-25-2P 35433-15-5P 35433-18-9P
35433-20-2P 35433-22-4P 35433-27-5P
35490-29-8P 37554-35-1P 37554-37-3P
37554-39-6P 37554-40-8P 37554-98-6P
37555-03-4P 37555-17-2P 40852-34-6P
40852-35-8P 40852-40-2P 40852-44-4P
40852-52-4P 41190-30-1P 49930-42-9P
49930-89-9P 52500-75-4P 52500-32-4P
56984-09-9P 59253-44-0P 59253-45-1P
59253-46-2P 59253-47-3P 59253-48-4P
59253-49-5P 59253-69-9P 59253-70-2P
RI: 8PM (Synthetic preparation); PEPF (Preparation)
(preparation only)

13 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
 RH 20527-13-1 CAPLOS
 CH 2 (18)-Quinoxalino, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RH 22740-18-5 CAPLOS
 CH 2 (18)-Quinoxalino, 7-methyl-2-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RH 22740-25-4 CAPLOS
 CH 2 (18)-Quinoxalino, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RH 22740-37-6 CAPLOS
 CH 2 (18)-Quinoxalino, 5,7-dimethyl-2-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

13 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



RH 26113-13-9 CAPLOS
 CH 2 (18)-Quinoxalino, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RH 26824-70-4 CAPLOS
 CH 2 (18)-Quinoxalino, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RH 26957-44-8 CAPLOS
 CH 2 (18)-Quinoxalino, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



RH 22760-60-7 CAPLOS
 CH 2 (18)-Quinoxalino, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RH 23461-64-7 CAPLOS
 CH 2 (18)-Quinoxalino, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RH 23461-78-3 CAPLOS
 CH 2 (18)-Quinoxalino, 6-chloro-4-[4-methoxyphenyl]-1-methyl- (CA INDEX NAME)




15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



RH 26340-57-0 CAPLOS
 CH 2 (18)-Quinoxalino, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RH 33443-20-8 CAPLOS
 CH 2 (18)-Quinoxalino, 6-chloro-3-(cyclopropylethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RH 33443-33-3 CAPLOS
 CH 2 (18)-Quinoxalino, 1-(cyclopropylethyl)-4-phenyl-6-(trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



33 3343-35-5 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



32 3343-35-9 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



32 3343-35-2 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)


15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



32 3754-35-1 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



32 3754-37-3 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



32 3754-39-5 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



32 3754-40-8 CAPLOS

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



32 3343-32-4 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



32 3343-35-5 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)




32 33890-38-8 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CN 2 [1,8]-Quinoxalinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



32 3754-38-6 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6-nitro-4-phenyl-1-(2-propenyl)- (CA INDEX NAME)



32 3755-03-6 CAPLOS
CN 2 [1,8]-Quinoxalinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



32 3755-17-2 CAPLOS
CN 2 [1,8]-Quinoxalinone, 1-(cyclopropylmethyl)-6-methylsulfonyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 40852-74-6 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-75-5 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 40852-40-2 CAPLOS
 CN 2(1H)-Quinazolinone, 1-[2-[(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 49830-63-9 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)




RI 49830-89-9 CAPLOS
 CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 52005-75-6 CAPLOS
 CN 2(1H)-Quinazolinone, 6-methyl-3-(12,2,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 40852-44-6 CAPLOS
 CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 40852-32-6 CAPLOS
 CN 2(1H)-Quinazolinone, 4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RI 41190-30-1 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(2-methylphenylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 52568-22-6 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RI 56984-09-9 CAPLOS
 CN 2(1H)-Quinazolinone, 6-acetyl-1-methyl-4-phenyl- (CA INDEX NAME)



RI 50257-44-0 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



RI 50253-45-1 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




20 59253-46-3 CAPLOS
CN 2-[18]-Quinazolinone, 6-acetyl-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



20 59253-47-3 CAPLOS
CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)

15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




20 59253-69-9 CAPLOS
CN 2-[18]-Quinazolinone, 1-(2,2-difluoroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



20 59253-70-2 CAPLOS
CN 2-[18]-Quinazolinone, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



20 59253-48-4 CAPLOS
CN 2-[18]-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-methylphenyl)- (CA INDEX NAME)




20 59253-49-5 CAPLOS
CN 2-[18]-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methylphenyl)- (CA INDEX NAME)

15 ANSWER 238 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1576180271
DOCUMENT NUMBER: 84180271
ORIGINAL REFERENCE NO.: 84-292236, 292264
TITLE: 2,4-Dihydro-2-[18]-quinazolinones and their salts
INVENTOR(S): Doake, Shigehiko Yamamoto, Mutsuharu Ishizumi, Kazuo Mori, Kazuo Koshida, Masao Yamamoto, Rieko Fujimoto Chemical Co., Ltd., Japan
PATENT ABSTRACT(S): Ger. Offen., 35 pp. Division of Ger. Offen.
SOURCE: 2,362,327.
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2166327	A1	19731031	DE 1973-2166327	197311215
DE 2166327	B2	19760729		
DE 2166327	C3	19770331		
JP 43540478	B	19741102		
SP 43979	A3	19740935	JP 1973-1477	19710219
PL 83081	B1	19731231	SP 1973-172767	19711221
			PL 1973-352415	19711232
			JP 1973-1477	A 19710219
			JP 1971-24897	A 19710521

GZ




20 2-[18]-quinazolinone (I, R = CH₂CH₂OH) was obtained by reductive epimerization of II by NaBH₄ in DMF. Analogously obtained were I (R = CH₂CH₂OH), I (R = CH₂CH₂OH), I (R = CH₂CH₂OH). I were useful as analgesics, inflammation-inhibitors, and as central nervous system depressants.

41230-82-4P
RI: SM (Synthetic preparation); PREP (Preparation)

20 41230-82-4 CAPLOS
CN 2-[18]-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-3,4-dihydro-6-phenyl- (CA INDEX NAME)

15 ANSWER 239 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)




BN 41230-84-6 CAPLOS
 CH 21181-Quinazolinone,
 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-
 phenyl- (CA INDEX NAME)



BN 59128-74-4 CAPLOS
 CH 21181-Quinazolinone, 3-[2-(dimethylamino)ethyl]-3,4-dihydro-1-methyl-4-
 phenyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CH 1

CHN 31641-55-1
 CHN C19 H23 N3 O



CH 2

15 ANSWER 240 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1376195617 CAPLOS
 DOCUMENT NUMBER: 84155677
 ORIGINAL REFERENCE NO.: 84155534,155546
 TITLE:
 Luminescence determination of pharmaceuticals of the
 tetrahydroquinoline, carbazole, and

1,4-benzodiazepine

class:
 AUTHOR(S): De Silva, J. Arthur F.; Strojny, Herman; Stika,
 Katherine
 CORPORATE SOURCE: Dep. Biochem. Drug Metab., Hoffmann-La Roche Inc.,
 Nutley, NJ, USA
 SOURCE: Analytical Chemistry (1976), 48(1), 144-55
 CORD: ANCHAM, ISSN: 0003-2700
 Journal

DOCUMENT TYPE:

LANGUAGE: English

AB Luminescence studies were performed on thin-layer chromatog. plates at
 77°K and also with a Farrand Mark I Spectrofluorometer which was
 modified to accommodate a con. available phosphorescope. The apparatus

was
 used to obtain fluorescence and phosphorescence spectra at 77°K of
 selected tetrahydroquinolines, and carbazoles, 1,4-benzodiazepines. Some
 of the results were verified on other con. available phosphorescences, and
 the modified instrument was equal to or better in spectral quality,
 sensitivity, and precision. The simple modification employed greatly
 extends the utility of this instrument for organic luminescence
 research.

IT 20927-53-1

RI: P2P (Properties)

Luminescence of, low temperature)

BN 20187-53-1 CAPLOS

CH 21181-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 239 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

CHN 110-16-1
 CHN C4 H4 O4

Double bond geometry as shown.



15 ANSWER 241 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 137614911 CAPLOS

DOCUMENT NUMBER: 8414921

ORIGINAL REFERENCE NO.: 841834,836

TITLE:
 Benzodiazepines. X. Oxidation of
 tetrahydro-1,4-benzodiazepine derivatives
 Ishizumi, Eikuo; Mori, Kazuo; Imabe, Shigeo
 Yamanoto, Ritsuo

AUTHOR(S):

CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takazuka,
 Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1975), 23(9),
 2169-73

CORD: CPSTAL, ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 8414921

CI: For diagram(s), see printed CA Issue.

AB By uv irradiation in Me2SO or Me2CO tetrahydro-1,4-benzodiazepines I (R
 = R,

Me, X = Cy R = Me, X = R2) and 6-chloro-1-cyclopropylmethyl-4-phenyl-
 1,3,4-tetrahydroquinazolin-2-one were oxidized to the corresponding
 dihydro compounds II and III. I (R = Me, X = O) was prepared from
 4-acetyl-7-chloro-3-methyl-2,3,4,5-tetrahydro-3-phenyl-1H-1,4-
 benzodiazepine by oxidation with KMnO4 followed by acid hydrolysis.

Other

Types of 4-acylbenzodiazepine derivs. were also oxidized.

IT 36342-76-4

RI: ACT (Reactant); RACT (Reactant or reagent)

(oxidation of)

BN 36342-76-4 CAPLOS

CH 21181-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-

(CA INDEX NAME)



IT 33453-19-9P

RI: SP (Synthetic preparation); PREP (Preparation)

(Preparation of)

BN 33453-19-9 CAPLOS

CH 21181-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

13 ABSTRACT 241 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



15 ANMER 242 Q127 CARLOS COPYRIGHT 2000 ACS ON STN
 ACCESSION NUMBER: 1975:51470 CARLOS
 DOCUMENT NUMBER: 02:11470
 ORIGINAL REFERENCE NO.: 02:179874, 179904
 TITLE: Oculobacilliosis
 INVENTOR(S): Yamamoto, Michihiro; Morokoa, Hisakazu; Koshida, Masayoshi; Inaba, Shigeo; Yamamoto, Hisao
 PATENT APPLICATION(S): Sumitomo Chemical Co. Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODE: JPOCAP
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

01 For diagram(s), see printed CA issue.
 A5 Quinazolines II, R = H, alkyl, haloalkyl, cyclohexylalkyl, R1 = H, alkyl,
 R2 = Ph, were prepared by cyclization of III (R4 = trihalomethyl, CH,
 alkoxy, halogen) with NH3 or by reacting III with a reactive carbamic
 acid

17	56984-09-9F	KL: SYN (Synthetic preparation); PREP (Preparation) (preparation of)	
FN	56984-09-9 CAPLUS		
CN	2-[1H]-Quinazolinone, 6-acetyl-3-methyl-4-phenyl-	ICA INDEX NAME	



ANMERKA (44) 327 CAPS
 ACCESSION NUMBER: 01-008866 CAPSUS
 DOCUMENT NUMBER: 87-5988
 ORIGINAL REFERENCE NO.: 01-00849, 31994
 INVENTOR(S):
 Mergel, J. - substituted (210)-quinazolinone
 Pat. Manager, Inc., USA
 SOURCE: U.S. & sp. Division of U.S. 7,819,425.
 COUNTRY ORIGIN: PATENT, USCAPS
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACQ. NUM. COUNT: 5
 PARENT INFORMATION:
 PARENT NO. KIND DATE APPLICATION NO. DATE
 US 3874640 US 19750408 US 3874-45845 19740408
 US 3874640 US 1976060808 19760608
 US 3874640 US 1973-37154 19730901
 US 3874640 US 1968-48733 19680801
 PRIORITY APPL. INFO.: US 1977-37154 US 19730801

AS For diagram(s) see printed CA larve.
 AS Acetylarsenolane (no data) quinoxalinoxines I (R = H, R1 = morpholino; R = morpholino, R1 = H, R2) were prepared by either (a) treatment of benzenesulfonyl chloride with cyclo2 or (b) cycloaddition of benzenesulfonyl urethane followed successively by nitration, hydrogenation, and cycloaddition with [ArCH=CH2]2O. Treatment of 1-chloro-4-morphino-2-nitrobenzene with CuCN and then successive reduction with Fe-HCl, isopropylation, and treatment with PCl5 gave II.

WITH FULL ANALYSIS.
IT 25509-39-1P 28340-78-5P
Rt: MCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); REACT
(Reactant or reagent)
(preparation and cyclization of, with bis(bromoethyl) ether)
FIN 25509-39-1 CAPLUS
CN 2-(1H-Omparol)one, 6-amino-1-[1-methylethyl]-6-phenyl- (CA INDEX NAME)



```


NN 28340-78-5  CAPLOS
CN 2(1H)-Quinoxalinone, 6-amino-7-methyl-1-(1-methylethyl)-4-phenyl- (CA
      TRUNC NAME)

```

15 ANIMER 243 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



27 28340-53-4P
H2C [Reactant]; STM (Synthetic preparation); PREP (Preparation); RACT
[Reactant or reagent]
[Preparation and hydrogenation of]
CN 28340-53-4 CAPLOS
KH 2 (1R)-Quinoxalino[2,3-b:4',5'-d]pyridine, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA



27 2760-18-15
H₂CCT (Reactant); SPW (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
—(Preparation and nitration of)
EN 2760-18-15 CAPLOS
CN 2(1R)-Quasolazone, 7-methyl-2-[1-(methyl-ethyl)-4-phenyl]- (CA 27DEK)



```

17  22760-Q0-7P
    EL: KCT (Reactant); ESN (Synthetic preparation); PREP (Preparation); RACT
    (Reactant or reagent)
    (preparation and reduction of)
NN  22760-Q0-7  CAPLOS
CN  2-[1H]-Quinoxalino[2,3-b:4',5'-d']-6-nitro-6-phenyl-  ICA INDEX NAME

```

15 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 28340-74-1P 28340-77-6P 28340-79-6P

56158-73-7P
 Ru: SYN (Synthesis preparation) PREP (Preparation)
 (preparation of)

RN 28340-74-1 CAPLUS
 CH 2 (1R)-Quinoxalino, 3-[1-methylethyl]-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-77-4 CAPLUS
 CH 2 (1R)-Quinoxalino, 1-[1-methylethyl]-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-79-6 CAPLUS
 CH 2 (1R)-Quinoxalino, 7-methyl-3-[1-methylethyl]-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 244 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:428487 CAPLUS

DOCUMENT NUMBER: 83:28267

ORIGINAL REFERENCE NO.: 834533a, 4536a

TITLE: Quinoxalino, 7-methyl-3-[1-methylethyl]-6-(4-morpholinyl)-4-phenyl-

INVENTOR(S): Yamamoto, Masaharu; Morooka, Shigeaki; Koshida,

Masao; Inaba, Shigeo; Yamamoto, Hisao

SOURCE: Sumitomo Chemical Co., Ltd.

Jpn. Kokai Tokkyo Koho, 6 pp.

CDDEN: J0004P

PATENT: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.: KIND: DATE: APPLICATION NO.: DATE:

JP 4910681 A 19741022 JP 1973-27486 19730307

PRIORITY APPL. INFO.: JP 1973-27486 A 19730307

GI For diagram(s), see printed CA issue.

AB Quinoxalino, 7 (R) = alkoxycarbonyl, CH, COOR34, where R3 and R4 = H,

alkyl, or NR34 = 5- or 6-membered saturated heterocycle which may

contain

other hetero atoms; R2 = optionally substituted phenyl, pyridyl; R = H,

alkyl, alkenyl were prepared by (b) cyclizing trihaloacetanilides II (R =

halo) with NR3, (b) cyclizing anilines III with reactive carbonate esters,

R3CO, or the salts, or (c) alkylating 1-substituted analogs I (R = R)

with reactive esters of acid. R3B (except when R = R). 5 have

viscous,

antiinflammatory, and antiviral activities (no data). Thus, 8 g

2-trichloroacetanido-1-methoxycarbonylbenzophenone was stirred with 3.9

g NaOH in 50 ml Me2CO at room temperature for 16 hr to give 5.55 g I

(R3 = 6-CO2Me, R2 = Ph, R = R). Among 5 more I (R2 = Ph) prepared were (6-8),

R, and method given); CH, R, A: CO2Et, R, 2: CO2Me, cyclopropylmethyl, C:

CH,

cyclopropylmethyl, C. The 1-R-alkylation (method C) was accompanied by

2-C-alkylation.

IT 49830-65-1P 56017-59-1P 56017-60-8P

Ru: SYN (Synthesis preparation) PREP (Preparation)

(preparation and viscous, antiinflammatory and antiviral

activities of)

RN 49830-65-1 CAPLUS

CH 6-Quinoxalino, 7-methyl-3-[1-methylethyl]-2,2-dihydro-2-oxo-4-

phenyl-, methyl ester (CA INDEX NAME)

15 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 56158-73-7 CAPLUS

CH 2 (1R)-Quinoxalino, 1-[1-methylethyl]-7-(4-morpholinyl)-4-phenyl-,
 monohydrochloride (HCl) (CA INDEX NAME)



● HCl

15 ANSWER 244 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 56017-59-5 CAPLUS

CH 6-Quinoxalino, 7-methyl-, 1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-
 phenyl- (CA INDEX NAME)



RN 56017-60-8 CAPLUS

CH 6-Quinoxalino, 7-methyl-, 1,2-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)



13 ANSWER 248 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1975170212
 DOCUMENT NUMBER: 82171012
 ORIGINAL REFERENCE NO.: 82172374, 77340A
 TITLE: Quinolizone derivatives having central nervous system, antiinflammatory and analgesic activities, and also useful as pharmaceutical agents
 INVENTOR(S): Inaba, Shigeyo Yamamoto, Michihiro Zuhara, Katsuy Mori, Fumio Yoshida, Masao Yamamoto, Kinsao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNOR(S): Jpn. Tokyo Kasei, 4 pp. Division of Japan, 73 34,598 (See Ser. 5,314,131, CA 774 555A)
 SOURCE: Patent
 COUNTRY: JAPAN
 DOCUMENT TYPE: Japanese
 LANGUAGE: Japanese
 FAMILY ACT, NUM. CONTY: 1
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4902570	B	19740208	JP 1973-40708	19730409
PRIORITY APPL. INFO.			JP 1973-40708	19730409

G2 For diagram(s), see printed CA Insa.
 AB Quinolizones (I, R = cyclopropylmethyl, R1 = Et (II), CH2CH2CH2CH3, R = CH2CH3, R1 = CH2CH3), useful as antiinflammatory agents at 100-200 mg/kg, were prepared by reacting I (R1 = H) with the appropriate alkyl halide in the presence of NaH. Thus, I (R1 = cyclopropylmethyl, R1 = H) (3.1 g) in 50 ml DMF containing 0.42 g 63% NaH was heated 30 min at 50°, and the mixture was treated with 3.1 g EtI at 50° for 4 hr to give II.
 IT 36942-16-4 36942-01-8
 Re. ACT (Reactant) RACT (Reactant or reagent) (alkylation of)
 RE 36942-16-4 CAPLOS
 CH 2118-Quinolizone, 6-chloro-3-(4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl))- (CA INDEX NAME)



RE 36942-01-8 CAPLOS
 CH 2118-Quinolizone, 6-chloro-3-(4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl))- (CA INDEX NAME)


13 ANSWER 248 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



13 ANSWER 248 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



IT 41230-82-4P 41230-84-EP 55577-43-0P
 Re. RCT (Reactant) RACT (Reactant or reagent) (preparation of)
 RE 41230-82-4 CAPLOS
 CH 2180-Quinolizone, 6-chloro-1-(cyclopropylmethyl)-3-(2-methoxyphenyl)-4-dihydro-4-phenyl- (CA INDEX NAME)



RE 41230-84-6 CAPLOS
 CH 2180-Quinolizone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-4-dihydro-4-phenyl- (CA INDEX NAME)



RE 55577-43-0 CAPLOS
 CH 2180-Quinolizone, 6-chloro-1-(4-dihydro-3-(methoxymethyl)-4-phenyl-1-(2,2,2-trifluoroethyl))- (CA INDEX NAME)

13 ANSWER 248 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 197515246
 DOCUMENT NUMBER: 82156366
 ORIGINAL REFERENCE NO.: 82149636, 24972A
 TITLE: 6-Nitro-4-phenyl-2(18)-quinolizones
 INVENTOR(S): Yamamoto, Michihiro Morooka, Shigemasa, Koshino, Masao Inaba, Shigeyo Yamamoto, Kinsao Sumitomo Chemical Co., Ltd., Japan
 PATENT ASSIGNOR(S): Ger. Offen., 22 pp.
 SOURCE: Ger. Offen., 22 pp.
 COUNTRY: GERMANY
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACT, NUM. CONTY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2438849	A1	19760106	DE 1974-243849	19740913
JP 5004564	A	19760414	JP 1973-91590	19730914
JP 57024789	B	19820526		
US 3790854	A	19760720	US 1974-493240	19740730
AO 7476257	AC	19760205	AO 1974-71217	19740201
CA 1006089	A1	19761130	CA 1974-206126	19740201
GB 1474885	A	19770225	GB 1974-15076	19740208
NL 7410725	A	19760218	NL 1974-10725	19740209
CH 608009	AS	19761215	CH 1974-10897	19740209
BE 818784	A1	19741202	BE 1974-147551	19740213
BE 7410217	A1	19750517	BE 1974-10325	19740213
SE 408553	C	19760927		
DE 408553	B	19760628		
FR 2240716	A1	19760214	FR 1974-28057	19740213
DE 7404318	A	19750423	DE 1974-4318	19740213
DE 134550	B	19761129		
AT 7406682	A	19761215	AT 1974-6682	19740214
AT 376275	B	19770810		


PRIORITY APPL. INFO.: JP 1973-91590 A 19730914

G2 For diagram(s), see printed CA Insa.
 AB Three quinolizones I [R = 1-adamantylmethyl (II), 2-norbornylmethyl (III), or 2-(4,6-dimethylheptyl)-3-1-hept-2-en-5-ylmethyl] were prepared and useful as viricides. Thus, 1-[1-(adamantylmethyl)-3-(4-dihydro-6-nitro-4-phenyl-2(18)-quinolizone)] was treated with PhIO4 in H2O and dioxane at room temperature to give II, which was also prepared by reaction of 2-[1-(adamantylmethylamino)-5-nitrobenzophenone with H2NCOEt in the presence of Et3N at 170-180°. I [R = H] in DMF reacted with NaH and 2-(bromomethyl)norbornane at reflux to give III and 6-nitro-2-(2-norbornylmethyl)-4-phenylquinolizone. 2-[1-(4,6-dimethylheptyl)-3-(1-hept-2-en-5-ylmethylamino)-5-nitrobenzophenone] was reacted with COCl2 in CH2Cl2 containing Et3N to give IV.
 IT 55932-45-5
 Re. RCT (Reactant) RACT (Reactant or reagent) (oxidation of)
 RE 55932-45-5 CAPLOS
 CH 2180-Quinolizone, 3,4-dihydro-6-nitro-4-phenyl-3-(1-oxo-1,3,3,1,7,7-dimethyl-2-phenyl)- (CA INDEX NAME)

13 ANSWER 231 OF 327 CAPULUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1975:142164 CAPULUS
 DOCUMENT NUMBER: 82:142164
 ORIGINAL REFERENCE NO.: 82:122394, 214024
 TITLE: 1-Hydroxyalkylquinazolinone derivatives
 INVENTOR(S): Yamamoto, Michihiko; Morosaka, Shigehiko; Koshida, Masao; Inaba, Shigeo; Yamamoto, Hisao
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 DOCUMENT TYPE: CDSB, JPOCAP
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNTRY: Japanese
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4924087	A	19741014	JP 1973-19390	19730227
JP 5047423	B	19821127		
PRIOITY APPL. INFO.			JP 1973-19390	A 19730227

G1 For diagram(s), see printed CA issue.
 A5 1-Hydroxyalkylquinazolinone 1 (R = lower alkyl having 1-3 OH groups; R1 = H, halo, lower alkyl, lower alkenyl, RO2; R2 = Ph, lower alkyl, cycloalkyl, pyridyl, furyl, thienyl [12]) were prepared (1) by reacting 1 (R = H) with reactive ester of ROH, (2) by reacting 11 (R2 = trihalomethyl, cyano) with HCl, (3) by oxidizing 1V, or (4) by hydrolyzing 1 (R = lower alkyl having 1-3 lower alkenyl, lower haloalkenyl, RO2, RO2, COO2, R2CO2, CO2CH3, tetrahydropyrimidinyl, lower alkylthioalkenyl, arylalkenyl, halo or having a cyclic ether bond). 11 had ureic acid-succinate action (see detail). Thus, a mixture of 3.1 g 4-phenyl-6-nitro-2(1H)-quinazolinone and 0.6 g 5% NaH in DMF was stirred 30 min at 55°, 1-3 g HCOOCH3 added, and the whole stirred 3 hr at 100° to give 1-(2-hydroxyethyl)-4-phenyl-6-nitro-2(1H)-quinazolinone. Alcoh. 3-(2,4-dihydroxypropyl)-4-phenyl-6-nitro-2(1H)-quinazolinone was prepared
 IT 3714-19-19 53545-42-3P
 R1: SRH (Synthetic preparation); PREP (Preparation)
 (preparation of)
 R2 3714-19-19 CAPULUS
 C1: 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-4-phenyl-6-nitro-4-phenyl- (CA INDEX NAME)




13 ANSWER 232 OF 327 CAPULUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1975:17020 CAPULUS
 DOCUMENT NUMBER: 82:17020
 ORIGINAL REFERENCE NO.: 82:115754, 21678a
 TITLE: Quinazolinone compounds
 INVENTOR(S): Ishikawa, Kikuo; Mori, Kazuo; Yamamoto, Michihiko; Yamamoto, Hisao; Koshida, Masao; Inaba, Shigeo
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Can., 25 pp.
 DOCUMENT TYPE: CDSB, JPOCAP
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: Japanese
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 949573	A1	19740618	CA 1973-168918	19730417
PRIOITY APPL. INFO.			CA 1973-168918	A 19730417


OTHER SOURCE(S): MARIAT 82:17020
 G1 For diagram(s), see printed CA issue.
 A5 The quinazolinones 1 (R = Me, R1 = H, R2 = Cl; R = H, R1 = F, R2 = Cl; R = H, R1 = H, R2 = NO2) were prepared by several methods. Thus, 1-methyl-1-(2-chlorovinyl)-2-oxoquinazolin-4-one was heated and then treated with PhCO2H and the resulting oxazolinone oxidized with chromic anhydride to give 4,2-(Cl)PhCO2H(CH2)2CO2CH2CH2, which was cyclized
 with
 HCl to give 1 (R = Me, R1 = H, R2 = Cl).
 IT 2017-13-12
 R1: SRH (Synthetic preparation); PREP (Preparation)
 (preparation of)
 R2 2017-13-12 CAPULUS
 C1: 2(1H)-Quinazolinone, 6-chloro-1-(2-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 233 OF 327 CAPULUS COPYRIGHT 2008 ACS ON STN (Continued)
 R2 53546-42-3 CAPULUS
 C1: 2(1H)-Quinazolinone, 1-(2,3-dihydroxypropyl)-4-nitro-4-phenyl- (CA INDEX NAME)




13 ANSWER 233 OF 327 CAPULUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1975:38472 CAPULUS
 DOCUMENT NUMBER: 82:38472
 ORIGINAL REFERENCE NO.: 82:60824, 6066a
 TITLE: Quinazolinones and 1,4-benzodiazepines. 69.
 1-Vinyl-3,4-benzodiazepine-2-one and 1-vinylquinazolin-2(1H)-one
 AUTHOR(S): Maliszewski, J.; Feyer, R. L.
 SOURCE: J. Med. Chem. 1974, 17(11), 1228-39
 CORREL. JCNMAJ: ISSN: 0022-2625
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 G1 For diagram(s), see printed CA issue.
 A5 One-vinyl analogs of benzodiazepine tranquilizers such as 7-chloro-5-[2-(fluorophenyl)-1,3-dihydro-1-vinyl-2H-1,4-benzodiazepin-2-one (12)] [53514-78-6] had greater central nervous activity than diazepam [439-51]. The 4-oxides were less active than the corresponding 4-deoxy derivative. Several other benzodiazepine derivatives had activities close to that of diazepam, whereas analogs of quinazolinone were inactive. 1 was prepared from 7-chloro-1-[2-(diethylaminoethyl)-5-[2-(fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (17617-23-1)] by oxidation to the α-oxide [53514-87-7] and then hydrolysis.
 IT 53514-85-5P 53514-86-6P 53514-87-7P
 R1: SRH (Synthetic preparation); PREP (Preparation)
 (preparation and tranquilizer activity of)
 R2 53514-85-5 CAPULUS
 C1: 2(1H)-Quinazolinone, 6-chloro-1-[2-(dimethylaminoethyl)-4-phenyl- (CA INDEX NAME)



R2 53514-86-6 CAPULUS
 C1: 2(1H)-Quinazolinone, 6-chloro-1-[2-(dimethylaminoethyl)-4-phenyl- (CA INDEX NAME)

13 ANSWER 253 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



RR 535 79-99-9 CAPLOS
CN 2 (1R)-Quinoxalinone, 6-chloro-1-ethenyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 1974/56359 CAPLOS
DOCUMENT NUMBER: R1163549
ORIGINAL REFERENCE NO.: R125225,25226a
TITLE: Ulcerogenic agent
INVENTOR(S): Yamamoto, Michiaki; Aomori, Shunji; Nakatani, Hiroshi;
Morooka, Shigemichi; Koshida, Masayoshi; Shigeoka, Akasaka, Akira; Yamamoto, Ruzo
PATENT ASSIGNER(S): Daiichi Chemical Co., Ltd.
SOURCE: U.S., 7 pp.
CODEN: USQOAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY KEY, NUM. COMPS: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3812257	A	1974/05/31	US 1972-242215	1972/04/07
PRIORITY APPL. INFO.			US 1972-242215	A 1972/04/07

AB Uric acid [69-93-2] content of the body can be controlled by administering a quinoxaline derivative (I), where R is H, lower alkyl, lower alkenyl, aralkyl, cycloalkyl, lower cycloalkylalkyl, lower alkenylalkyl, lower alkenylalkenyl, or lower alkylthioalkyl. R1 and R2 are individually H, lower alkyl, lower alkenyl, trifluoromethyl, nitro, lower alkylthio, lower alkylsulfonyl, or halogen. X is an O or S atom, and A is <(R3)H-, where R3 is Ph, substituted Ph, cycloalkyl, pyrrolyl, pyridyl, furyl, or thienyl. An example of a quinoxaline derivative is 1-methyl-4-phenyl-6-chloro-2 (1R)-quinoxalinone [20927-53-1].
 IT 20927-53-1 20927-53-1 20927-53-1
 33443-22-0 33443-22-0 33443-22-0
 33443-22-0 33443-22-0 33443-22-0
 33443-24-4 33443-24-4 33443-24-4
 33443-27-1 33443-27-1 33443-27-1
 33443-28-4 33443-28-4 33443-28-4
 40852-50-4 52505-N-1
 R1: R10L (Biological study)
 Ulcerogenic agent
 RR 20927-53-1 CAPLOS
CN 2 (1R)-Quinoxalinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)


RR 26313-31-9 CAPLOS
CN 2 (1R)-Quinoxalinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RR 26891-11-9 CAPLOS
CN 2 (1R)-Quinoxalinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RR 33443-22-0 CAPLOS
CN 2 (1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-(4-methylphenyl)- (CA INDEX NAME)



RR 33443-33-3 CAPLOS
CN 2 (1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)

15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

RR 33443-23-5 CAPLOS
CN 2 (1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RR 33443-24-6 CAPLOS
CN 2 (1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RR 33890-29-8 CAPLOS
CN 2 (1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)


15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RR 36943-76-4 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 6-chloro-1-[(cyclopropylmethyl)-7,4-dihydro-6-phenyl-]
 (CA INDEX NAME)



RR 37554-27-1 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 6-chloro-1-[(cyclopropylmethyl)-4-(4-methoxyphenyl)-]
 (CA INDEX NAME)



15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RR 37555-17-2 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 1-[(cyclopropylmethyl)-6-(methoxycarbonyl)-4-phenyl-]
 (CA INDEX NAME)



RR 40852-50-4 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 6-nitro-1-[(cyclopropylmethyl)-4-phenyl-]
 (CA INDEX NAME)




RR 52905-76-7 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 1-[(cyclopropylmethyl)-4-(4-methoxyphenyl)-]
 (CA INDEX NAME)


15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 RR 37554-35-3 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 6-chloro-1-[(cyclopropylmethyl)-4-phenyl-]
 (CA INDEX NAME)



RR 37554-37-3 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 1-[(cyclopropylmethyl)-4-(4-methoxyphenyl)-]
 (CA INDEX NAME)



RR 37554-98-6 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 6-nitro-1-[(cyclopropylmethyl)-4-phenyl-]
 (CA INDEX NAME)



RR 37555-10-5 CAPLOS
 CN 2-[1,8]-Quinoxalinone, 8-chloro-1-[(cyclopropylmethyl)-4-phenyl-]
 (CA INDEX NAME)

15 ANSWER 254 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 235 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1974:520285 CAPLOS
 DOCUMENT NUMBER: 81122685
 ORIGINAL REFERENCE NO.: 81139294,19390A
 TITLE: 1-Substituted 4-phenyl-2 (1H)-quinazolinones
 INVENTOR(S): Yamamoto, Michihiko; Ishizumi, Kikuo; Mori, Kazuo;
 Koshida, Masayoshi; Inaba, Shigehiko; Yamamoto, Hisao
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CSDEN: JGCGXK
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4920284	A	19740118	JP 1972-72264	19720712
JP197272264			JP 1972-72264	A 19720712

GI For diagram(s), see printed CA Issue.

AB Quinazolinones 1 (R = lower alkyl, lower alkenyl, lower cycloalkylalkyl, lower polyalkenyl, lower alkoxymethyl, lower alkoxycarbonylmethyl, alkyl, R₁, R₂, and R₃ = H, lower alkyl, lower alkenyl, CF₃, Me, MeO, MeSO₂, halo).

are prepared by treating 2(1H)-quinazolinone 3-oxides (II) with reactive esters of alic. ROR'. 1 are analgesic and antiinflammatory agents. Thus, 0.75 g 4-phenyl-4-chloro-2(1H)-quinazolinone 3-oxide was treated with 0.2 g Et₃N and 10 ml DMF and heated with 0.75 g cyclopropylmethyl isocyanide at 100°C for 10 hr to give 1 (R = cyclopropylmethyl, R₁ = 6-Cl, R₂ = R₃ = H).

IT 33415-19-99
 R₁, R₂, R₃ Biological activity or effector, except adverse; RSO
 [Biological: study, unclassified]; SPN [Synthetic preparation]; TEP [Therapeutic use]; RSO [Biological study]; PREP [Preparation]; USES [Uses]
 (Preparation and analgesic and antiinflammatory activity of)

HN 33415-19-9 CAPLOS
 CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



13 ANSWER 236 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1974:520297 CAPLOS
 DOCUMENT NUMBER: 81122687
 ORIGINAL REFERENCE NO.: 81139294,19390A
 TITLE: Antiphlogistic and analgesic 1-(cyclopropylmethyl)-2(1H)-quinazolinethiones
 INVENTOR(S): Inaba, Shigehiko; Yamamoto, Michihiko; Ishizumi, Kikuo;
 Mori, Kazuo; Yamamoto, Hisao
 PATENT APPLICANT(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Ger. Offen., 19 pp. Division of Ger. Offen. 2,937,493
 (CA 78:49215) (C)
 CSDEN: OXGGRX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2045611	A	19740627	DE 1970-2045611	19700729
DE 2045611	C3	19791102	DE 1970-2045611	A 19700729

GI For diagram(s), see printed CA Issue.

AB Six quinazolinones 1 (R = cyclopropylmethyl; R = S; R₁ = 6-Cl, 6-MeO, 6-OMe,

7-Me, 6-MeS, or H), which had antiphlogistic activities on oral administration in rats and were useful as analgesics, were prepared

either by cyclization of II with H₂NHS (R = Me, R₁ or H) in AcOH at 15-45°C, or by N-alkylation of 1 (R = H), or by sulfuration of 1 (R = O) with P₂S₅ in boiling pyridine.

IT 33480-38-85
 R₁, R₂, R₃ (Reactant); SPN [Synthetic preparation]; PREP [Preparation]; RACT [Reactant or reagent]
 (Preparation and sulfuration of)

HN 33480-38-8 CAPLOS
 CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



IT 33443-28-49 53720-97-2 53720-98-2
 53720-99-3 53720-99-3 53721-01-09
 R₁, R₂ SPN [Synthetic preparation]; PREP [Preparation]
 (Preparation of)
 HN 33443-28-4 CAPLOS
 CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

13 ANSWER 235 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)

13 ANSWER 236 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



HN 53720-97-1 CAPLOS
 CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



HN 53720-98-2 CAPLOS
 CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



HN 53720-99-3 CAPLOS
 CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



328 53721-90-9 CAPLOS
 CH 2-[18]-Quinoxalinothione, 1-(cyclopropylmethyl)-6-methylthio-4-phenyl- (CA INDEX NAME)



329 53721-01-0 CAPLOS
 CH 2-[18]-Quinoxalinothione, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



33 33433-23-5
 RL ACT (Reactant); RACT (Reactant or reagent)
 (oxidation by phosphorus pentasulfide of)
 328 33433-33-5 CAPLOS
 CH 2-[18]-Quinoxalinothione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

13 ANSWER 237 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1374150180 CAPLOS
 DOCUMENT NUMBER: 81105182
 ORIGINAL REFERENCE NO.: 8115627a;16630a
 TITLE: Quinoxalinothione. II. Oxidation of 2-aminoindoles and related compounds
 AUTHOR(S): Ishihara, Kikuo; Imaba, Shigeo; Yamamoto, Hisao
 CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
 SOURCE: Journal of Organic Chemistry (1976), 39 (17), 2582-7
 DOCUMENT TYPE: JOURNAL
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 81105182
 GC For diagram(s), see printed CA Index.
 AB Oxidation of 2-aminoindole 1 (R = H₂, R₁ = Me, R₂ = H, R₃ = Cl) in HOAc gave a mixture of the 2-amino-3-indololone 2 (R = Cl) (58%) and the quinoxalinothione 3 (R = Me, R₂ = H, R₃ = Cl) (34%). 1 (R = H₂, R₁ = H, R₂ = F, R₃ = Cl) gave only 2-amino-3-indololone 2 (R = H₂, R₁ = Me, R₂ = F, R₃ = Cl) in CHCl₃ gave only 3 (R₁ = Me, R₂ = H, R₃ = Cl). Chromic acid oxidation of urethane 1 (R = MeOCH₃, R₁COCH₃, PhC(=O)CH₃) gave the corresponding allopurines, which were hydrolyzed with base or acid to give 3. Indole-3-carboxylic acid anilide 1 (R = CO₂H) gave 3 (R₁ = Me, R₂ = H, R₃ = Cl, NO₂) (44 and 43%, resp.) and small AMEs. of 3 (R = Cl, NO₂) by chromic acid oxidation, whereas 1 (R = NO₂) yielded mainly 3 (R = Cl, NO₂) (47 and 64% resp.) together with 3 (R₁ = Me, R₂ = F, R₃ = Cl, NO₂) (4 and 6%, resp.). Chromic acid oxidation of 1 (R = CO₂H, R₁ = H, R₂ = F, R₃ = Cl) gave 4,5-dichloro-PCRB(OCO) C₂H₂NO₂CO₂H. Oxidation of 1 (R = NO₂, R₁ = Me, R₂ = H, R₃ = Cl) gave the 1,1,4-dioxazol-3-one V. Hofmann reaction of 1 (R = CO₂H₂, R₁ = Me, R₂ = F, R₃ = Cl) with aqueous NaOH in THF gave 3 (R₁ = Me, R₂ = F, R₃ = Cl), but a similar reaction with aq NaOH gave the oxindoles VI (R = R₂NO₂, Cl).

329 209745-33-5
 RL SPB (Synthetic preparation); PREP (Preparation)
 (preparation of)
 328 209745-33-5 CAPLOS
 CH 2-[18]-Quinoxalinothione, 6-chloro-3-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 258 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1374149208 CAPLOS
 DOCUMENT NUMBER: 81199206
 ORIGINAL REFERENCE NO.: 8115655a;16656a
 TITLE: Stereoselectivity in enzymic biotransformation of chiral and achiral
 1,3-dihydro-2H-1,4-benzodiazepin-2-one
 AUTHOR(S): Hendle, S.; Sunic, V.; Kajfer, F.; Klasine, L.; Nidder, P.
 CORPORATE SOURCE: CAC Osepiqua Inc. Chm. S. A., Chassio, Switz.
 SOURCE: China (1974), 28 (5), 232-4
 DOCUMENT TYPE: JOURNAL
 LANGUAGE: English

AB Enzymic biotransformation in rat liver 9000 g supernatant of chiral 1,4-benzodiazepin-2-one deriv. (2) possessing a center of chirality in position 3 appears to be stereospecific for hydroxylation in aromatic rings.
 BUT not for hydroxylation in position 3 or N-demethylation.

329 2097233-1
 RL FORM (Formation, nonpreparative)
 (formation of, in benzodiazepinone derivative biotransformation)
 328 2097233-1 CAPLOS
 CH 2-[18]-Quinoxalinothione, 6-chloro-3-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 259 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1974:491467 CAPLOS
DOCUMENT NUMBER: 81:02467
ORIGINAL REFERENCE NO.: R1:146974,145004
TITLE: Quinazolines. III. Curtius and Hofmann reactions of 2-benzoylquinazolinone. Novel synthesis of quinazolines
AUTHOR(S): Ishizumi; Kikuyi Inaba, Shigeo; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Journal of Organic Chemistry (1974), 39 (17), 2587-91
CODING: JOC(Jap) 1974; 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GC: For diagram(s), see printed CA Japam.
AB: N-Substituted 2'-benzoylquinazolinone I, prepared from the reaction of the corresponding 2-aminobenzophenone II and oxalyl chloride, were converted through their azides III to quinazolines IV (R1 = Me, C6H5, C6H4Me, H, cyclopropylmethyl; R2 = Cl, NO2; R3 = H, F) in good yields by treatment with aqueous NaOH. I (R1 = H, R2 = Cl, R3 = F) gave the corresponding III, which was identical with the product of chromic acid oxidation of the corresponding indole-2-carboxylic acid azide. For the Hofmann reaction, N-(1-benzoylphenyl)oxamides V (R1 = H, Me, cyclopropylmethyl; R2 = Cl, NO2) were prepared from the corresponding I by treatment with NEt3. Similar reaction of I (R1 = Me, R2 = NO2, R3 = H) with NEt3 led to a mixture of the corresponding IV and 2-hydroxy-1-methyl-4-nitro-4-phenylquinazolinone. The desired oxamide V (R1 = Me, R2 = NO2), however, was obtained by chromic acid oxidation of indole-2-carboxamide.
VL: N-Alkyl-substituted oxamides V (R1 = Me, cyclopropylmethyl; R2 = Cl, NO2) were converted to the corresponding quinazolines IV in satisfactory yields either by treatment with aqueous NaOH in THF, or with NaOH in MeOH.
MCOL: IT 20927-53-1P 26933-46-8P 33413-13-9P 49070-84-4P 51906-15-6P
RL: SRN (Synthetic preparation); PREP (Preparation)
[Preparation of]
FR 20927-53-1 CAPLOS
CN 21181-Quinazolines, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 260 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1974:477959 CAPLOS
DOCUMENT NUMBER: 81:77559
ORIGINAL REFERENCE NO.: R1:146974,145004
TITLE: Quinazolines
AUTHOR(S): Ishizumi, Kikuyi Inaba, Shigeo; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chemical Co., Ltd., Jpn. Kokai Tokkyo Koho, 8 pp.
CODING: JOC(Jap)
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: 1

PATENT NO. KIND DATE APPLICATION NO. DATE
JP 4808053 B4 19731029 JP 1972-12977 19720205
CI For diagram(s), see printed CA Japam.
AB The title compds. (I) were prepared by hydrolyzing or by heating acyl ureas II (R1-R3 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl, polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzoyloxy, NO2, carboxyl, carbamoyl, or alkoxy-carbonyl). R, R', 1, R2, R3, R4, R5 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was I (R1, R2, R3, and R4 given): 6-Cl, H, 0-9, H. Correction CA 80:37151c.
IT 20927-53-1P
RL: SRN (Synthetic preparation); PREP (Preparation)
[Preparation of]
FR 20927-53-1 CAPLOS
CN 21181-Quinazolines, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 259 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

FR 33413-13-9 CAPLOS
CN 21181-Quinazolines, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

FR 49070-84-4 CAPLOS
CN 21181-Quinazolines, 1-[2-(acetylphenyl)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

FR 51906-15-6 CAPLOS
CN 2-Quinazolines, 1,2-dihydro-1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

FR 51906-15-6 CAPLOS
CN 2-Quinazolines, 1,2-dihydro-1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 260 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1974:477959 CAPLOS
DOCUMENT NUMBER: 81:77559
ORIGINAL REFERENCE NO.: R1:146974,145004
TITLE: Quinazolines
AUTHOR(S): Ishizumi, Kikuyi Inaba, Shigeo; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chemical Co., Ltd., Jpn. Kokai Tokkyo Koho, 8 pp.
CODING: JOC(Jap)
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: 1

PATENT NO. KIND DATE APPLICATION NO. DATE
JP 4808053 B4 19731029 JP 1972-12977 19720205
CI For diagram(s), see printed CA Japam.
AB The title compds. (I) were prepared by hydrolyzing or by heating acyl ureas II (R1-R3 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl, polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzoyloxy, NO2, carboxyl, carbamoyl, or alkoxy-carbonyl). R, R', 1, R2, R3, R4, R5 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was I (R1, R2, R3, and R4 given): 6-Cl, H, 0-9, H. Correction CA 80:37151c.
IT 20927-53-1P
RL: SRN (Synthetic preparation); PREP (Preparation)
[Preparation of]
FR 20927-53-1 CAPLOS
CN 21181-Quinazolines, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 261 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER:

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

JP 49011630

A

19740222

JP 1972-73250

19720720

JP 54620169

B

19730706

JP 1972-73250

19720720

CA 945574

A3

19740619

CA 1973-176081

19730710

DK 112430

B

19751009

DK 1973-3835

19730712

US 3949311

A

19751007

US 1973-39655

19730712

CE 585730

A5

19770315

CE 1973-10515

19730719

NL 7126615

A

19760122

NL 1973-10955

19730719

AT 7106173

A

19750815

AT 1973-4373

19730719

AT 535670

B

19760525

PL 91618

B5

19770331

PL 1973-164172

19730719

FI 56619

B

19801128

FI 1973-2282

19730719

FI 56619

C

19800310

FI 1973-2282

19730719

NO 164497

B

19750229

NO 1973-80627

19730720

JP 1972-73250

A

19720720

PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.

AB Antinflammatory quinoxalones (I, R₁, R₂, R₃ = H, halo, CF₃, NO₂, loweralkylarylthio), lower alkyl, lower alkoxy, R₄ = H, lower alkyl aralkyl,

lower alkanoyloxyalkyl, lower alkoxyalkyl, polyhaloalkyl,

cycloalkylalkyl)

were prepared by reaction of oxamide derivs. (II) with halogens in the

presence of bases or with hypohalous acid salts (e.g., NaOCl). Thus, 1 g

N-(2-hydroxy-4-chlorophenyl)-N-methylacetamide in 75% was added to a

mixture of 2.4 g NaOH and 1.92 g H₂O in 80% at -7° and stirred 2 hr to give

1.7 g of 1-methyl-4-phenyl-6-chloro-2(1H)-quinoxalinoxime.

IT 20817-53-19

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

15 ANSWER 261 OF 327 CARLUS COPYRIGHT 2008 ACS ON STM (Continued)

ACCESSION NUMBER:

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

JP 48043355

B

19731218

JP 1970-53648

19700619

PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.

AB The quinoxalinoxime 2 was prepared by cyclization of N-(1-

cyclopropylmethyl)amino-5-chlorobenzo-phenone with NaOH in DMF. I

was an inflammation inhibitor and analgesic.

IT 31443-28-69

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

JP 48043355

B

19731218

JP 1970-53648

19700619

PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.

AB The quinoxalinoxime 2 was prepared by cyclization of N-(1-

cyclopropylmethyl)amino-5-chlorobenzo-phenone with NaOH in DMF. I

was an inflammation inhibitor and analgesic.

IT 31443-28-69

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)

R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)


R1: SPH (Synthetic preparation); PREP (Preparation)

(Preparation of)


R1: SPH (Synthetic preparation); PREP (Preparation)

15 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RI 52568-16-8 CAPLUS
 CH Cyclopropanecarboxylic acid, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (CA INDEX NAME)




RI 52568-17-9 CAPLUS
 CH 2(1H)-Quinazolinone, 6-nitro-1-[2-(1-oxopropoxy)ethyl]-4-phenyl- (CA INDEX NAME)




RI 52568-18-0 CAPLUS
 CH 2-Fragranic acid, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (CA INDEX NAME)




15 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RI 52568-24-8 CAPLUS
 CH Carbamic acid, diethyl-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (PCI) (CA INDEX NAME)




RI 52561-64-5 CAPLUS
 CH Fragranic acid, 5,5-dimethyl-, (6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)methyl ester (CA INDEX NAME)




IT 52568-22-6
 RL, RCT (Reactant) / RACT (Reactant or reagent)
 (reaction of, with 8)Synolates)

RI 52568-22-6 CAPLUS
 CH 2(1H)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)


15 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RI 52568-19-1 CAPLUS
 CH Acetic acid, methoxy-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (PCI) (CA INDEX NAME)



RI 52568-20-4 CAPLUS
 CH 2(1H)-Quinazolinone, 1-[2-(acetoxy)ethyl]-6-(methanesulfonyl)-4-phenyl- (CA INDEX NAME)



RI 52568-23-7 CAPLUS
 CH Acetic acid, hydroxy-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (PCI) (CA INDEX NAME)



15 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



13 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 1976146193 CAPLOS
 DOCUMENT NUMBER: 80146193
 ORIGINAL REFERENCE NO.: 801235974, 236004
 TITLE: Quinazolinones
 INVENTOR(S): Ishizumi, Katsuyuki Mori, Kazuo Yamamoto, Michikazu
 PATENT ASSIGNEE(S): Fushiba, Masayoshi Inaba, Shigeoh Yamamoto, Hisao
 SOURCE: Shikama Chemical Co., Ltd.
 Ger. Offen., 35 pp.
 COUNTRY ORIGIN: Japan
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACT NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2341010	A1	19740211	DE 1973-2341010	19730906
JP 4942080	A	19740427	JP 1972-90215	19720907
JP 5502504	B	19800207		
DE 111779	B	19750901	DM 1975-4851	19750904
AZ 700768	A	19750911	AT 1973-7688	19750904
AT 370189	A	19760615		
GB 1398448	A	19750618	GB 1973-43215	19750905
US 392493	A	19751216	US 1973-294142	19750905
CS 546100	A5	19750315	CS 1973-12716	19750905
NL 731257	A	19740311	NL 1973-1257	19750906
CA 944575	A2	19740618	CA 1973-10467	19750906
DE 167514	B	19750719	DE 1973-80839	19750906
FR108177 APPL. INFO.	IP	1972-90215	A	19720907

GI For diagram(s), see printed CA issue.
 AB Forty-seven quinazolinones 2 (R = e.g. H, Me, AOCORCH₃, cyclopropylmethyl, MeCO, CF₃, or tetrahydrofurfuryl; R1 = e.g. Cl, Me, CF₃, or isopropyl; R2 = e.g. H or MeO; R3 = e.g. Cl or F), useful as antiproliferative, virucidal, and antitumor agents, were prepared by successive reaction of the aminoaromatics 1 with [C10C2] and NMe₃.

IT 17639-04-99 20027-03-99 22740-18-99
 22760-15-49 22760-60-79 23441-74-99
 25508-93-49 25509-17-39 26231-42-99
 26313-46-99 26447-40-99 26441-10-99
 23443-33-39 23443-33-39 23443-33-39
 23443-33-39 23443-33-39 23390-28-99
 23154-37-39 23154-40-39 23154-71-99
 23715-92-49 23715-17-39 23715-31-39
 40812-33-79 40812-34-49 40812-38-99
 40812-50-49 40812-51-39 40812-54-89
 40812-56-99 40812-57-29 40812-63-99
 40812-64-49 40812-65-29 40812-74-59
 40812-75-49 40812-76-79
 RI SPI (Synthetic preparation); PREP (Preparation)
 [Preparation: 407]
 RI 17639-04-8 CAPLOS
 CH 2118-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 RI 22760-60-7 CAPLOS
 CH 2118-Quinazolinone, 1-[1-methylethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RI 23441-74-9 CAPLOS
 CH 2118-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RI 25508-93-4 CAPLOS
 CH 2118-Quinazolinone, 3-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RI 25509-17-3 CAPLOS
 CH 2118-Quinazolinone, 6,7-dimethoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RI 26313-42-8 CAPLOS
 CH 2118-Quinazolinone, 6-chloro-3-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)

13 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 20927-53-1 CAPLOS
 CH 2118-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RI 22760-18-5 CAPLOS
 CH 2118-Quinazolinone, 7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



RI 22760-25-4 CAPLOS
 CH 2118-Quinazolinone, 7-methoxy-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



13 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26953-46-8 CAPLOS
 CH 2118-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)




RI 33443-26-8 CAPLOS
 CH 2118-Quinazolinone, 6-chloro-1-(cyclohexylethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RI 37143-30-0 CAPLOS
 CH 2118-Quinazolinone, 6-chloro-1-(2-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-33-3 CAPLOS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 33443-35-5 CAPLOS
CN 2(1R)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)




RN 33453-19-9 CAPLOS

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-37-3 CAPLOS
CN 2(1R)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLOS
CN 2(1R)-Quinazolinone, 6-chloro-1-(1,2,3-trifluoroethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-15-9 CAPLOS
CN 2(1R)-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1R)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-20-2 CAPLOS
CN 2(1R)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLOS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLOS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
RN 37555-02-6 CAPLOS
CN 2(1R)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 37555-17-2 CAPLOS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 40852-31-1 CAPLOS
CN 2(1R)-Quinazolinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-nitro- (CA INDEX NAME)



RN 40852-33-3 CAPLOS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



RII 40812-14-6 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RII 40812-18-8 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RII 40812-10-4 CAPLOS
CN 2(1R)-Quinoxalinone, 6-nitro-4-phenyl-1-[(tetrahydro-2-furylmethyl)-] (CA INDEX NAME)

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)

RII 40812-16-0 CAPLOS
CN 2(1R)-Quinoxalinone, 6-nitro-4-phenyl-1-[2-pyridylmethyl]- (CA INDEX NAME)



RII 40812-17-1 CAPLOS
CN 2(1R)-Quinoxalinone, 6-nitro-4-phenyl-1-[2-thienylmethyl]- (CA INDEX NAME)



RII 49810-61-9 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RII 49810-84-4 CAPLOS
CN 2(1R)-Quinoxalinone, 1-[2-(acetoxyethyl)]-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



RII 40812-11-5 CAPLOS
CN 2(1R)-Quinoxalinone, 6-nitro-4-phenyl-1-(tetrahydro-2H-pyran-2-yl)methyl- (CA INDEX NAME)




RII 40812-54-8 CAPLOS
CN 2(1R)-Quinoxalinone, 1-(2-furylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 265 OF 327 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)

RII 50817-24-0 CAPLOS
CN 2(1R)-Quinoxalinone, 1,6-dimethyl-4-phenyl- (CA INDEX NAME)




RII 50817-24-0 CAPLOS
CN 2(1R)-Quinoxalinone, 1,6-dimethyl-4-phenyl- (CA INDEX NAME)



RII 52505-74-5 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RII 52505-75-6 CAPLOS
CN 2(1R)-Quinoxalinone, 6-methyl-1-(2,2,3,3,3-pentafluoroethyl)-4-phenyl- (CA INDEX NAME)



RII 52505-76-7 CAPLOS
CN 2(1R)-Quinoxalinone, 1-[2-(acetoxyethyl)]-6-chloro-4-phenyl- (CA INDEX NAME)

LS ANSWER 245 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



LS ANSWER 246 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974-120987 CAPLUS
 DOCUMENT NUMBER: 80-120987
 ORIGINAL REFERENCE NO.: 80-19479a,19482a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Ishikawa, Takayoshi; Kameyama, Masamoto; Michikawa, Koshihisa; Massey, Tadashi; Shigehiro, Yamamoto; Hasegawa, Shunzo; Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.; C08B1/283A2F
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48097981	A	19731113	JP 1972-29984	197302034
JP 5402456	B	19790904		197902034
NL 7304100	A	19750926	NL 1973-4100	197502034
AT 7302564	A	19750615	AT 1973-2564	197502034
AT 358465	B	19760315		197602034
CH 567003	A5	19750930	CH 1973-4221	197502034
US 3925382	A	19751109	US 1973-34400	197502034
DE 122890	B	19760223	DE 1973-1634	197502034
PL 91828	B2	19770331	PL 1973-161447	197502034

PRIORITY APPL. INFO.: 1

GI For diagram(s), see printed CA issue.

AS The quinazolinone (I), where R₁ = H, alkyl, lower alkyl, polyalkyl, lower alkoxyalkyl, or cycloalkylalkyl; R₂ and R₃ = H, halo, CF₃, Me, lower alkyl, or lower alkoxy; were prepared by hydrolysis or reduction of 2-alkylquinazolinones (II), R₁ = H, lower alkyl; Ph, lower alkoxy, PSEUDO or by the hydrolysis of 2-alkoxyquinazolinones (III) followed by oxidation of 2-alkoxyquinazolinones (IV). I are antitumor agents. Thus, R₁ = H, R₂ =

Me, R₃ = H, R₂ = 5-Cl (VI) in PSEUDO-PHE was refluxed to give 8 g 1-methyl-3-phenyl-5-chloroquinazolinone-2-carboxylic acid benzyl ester, which (2.9g) in EtOH containing concentrated HCl was hydrolyzed in the presence of H₂O catalyst to give 1.94 g 1-methyl-2-amino-3-phenyl-5-chloroquinazolinone-2-Cl (VII, R₁ = Me, R₂ = H, R₃ = 5-Cl) (VIII). VII was kept in a desiccator at room temperature for 40 days, to give III (R₁ = Me, R₂ = H, R₃ = 5-Cl) quant., which (5 g) in CSE-aqueous NaOH was refluxed to give 3.78 g

g VII. VII and R₁=H was stirred at 65° to give VIII.

IT 20927-53-1P

RI RAC (Biological activity or effector, except address); BOP

(Biological

study, unclassified); BPH (Synthetic preparation); BIL (Biological

study); PREP (Preparation)

(Preparation and antitumor activity of)

RI 20927-53-1 CAPLUS

CN 2118: Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

LS ANSWER 246 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



LS ANSWER 246 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974-194008 CAPLUS
 DOCUMENT NUMBER: 80-194008
 ORIGINAL REFERENCE NO.: 80-15419a,15450a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Ishikawa, Takayoshi; Kameyama, Masamoto; Michikawa, Koshihisa; Massey, Tadashi; Shigehiro, Yamamoto; Hasegawa, Shunzo; Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.; C08B1/283A2F
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48099886	A	19731115	JP 1972-29986	197302031
JP 5402756	B	19790904		197902031
AT 7302479	A	19750915	AT 1973-2479	197502031
AT 324665	B	19751229		197502031
US 3923710	A	19751202	US 1973-44637	197502031
NL 7304437	A	19751002	NL 1973-4437	197502031
CA 948572	A3	19740618	CA 1973-16790	197502031
RU 164021	B	19741128	RU 1973-80910	197502031
DE 131949	B	19740301	DE 1973-16790	197502031
PL 91816	B1	19770331	PL 1973-161616	197502031
CH 56870	A5	19770630	CH 1973-4636	197502031

PRIORITY APPL. INFO.: 1

OTHER SOURCE(S): NABPAT 80-194008

GI For diagram(s), see printed CA issue.

AS Antitumor quinazolinone derivative. (I), R₁ = H, R₂ = H, halo, CF₃, Me, lower alkyl, lower alkoxy; R₃ = H, lower alkyl, alkyl, lower alkoxyalkyl, lower alkoxyalkyl, polyalkyl, cycloalkylalkyl; were prepared by reacting indole-2-acyanone derivative. (II), R₃ = OCN (III)

with oxidizing agents [e.g., R, O₂, CrO₃]. III were obtained by rearrangement of acide derivative. (IV), R₃ = HCO₂ (V). E.g., heating 2 g IV (R₁ = 5-Cl, R₂ = R₃ = H, R₄ = Me) in CSE-H₂O was at 80-85° gave III (R₁ = 5-Cl, R₂ = R₃ = H, R₄ = Me) (V). V (1.42 g) was added to an aqueous mixture

of H₂O 1.7 and R₁ 1 g 0.5, the mixture stirred 30 min 0.5, 1 hr at room temperature, and 1 hr at 70-80° to give I (R₁ = 6-Cl, R₂ = R₃ = H, R₄ = Me).

IT 20927-53-1P

RI RAC (Biological activity or effector, except address); BOP

(Biological

study, unclassified); BPH (Synthetic preparation); BIL (Biological

study); PREP (Preparation)

(Preparation of)

RI 20927-53-1 CAPLUS

CN 2118: Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 267 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 268 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:59911 CAPLUS
 DOCUMENT NUMBER: 80:59911
 ORIGINAL REFERENCE NO.: 80:9717A, 9720A
 TITLE: Syntheses of 2(1H)-quinazolinone-4-14C derivatives
 YOSHIOKA, A.; MAKARI, T.; KAWAHARA, K.; EDOY, M.
 CORPORATE SOURCE: Pharm. Div., Sumito Chem. Co., Ltd., Takarazuka, Japan
 SOURCE: Journal of Labelled Compounds (1975), 9(2), 557-44
 CDB# JGCAJ; ISSN: 0022-2135
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CI For diagram(s), see printed CA issue.
 AB 1-(Cyclopropylmethyl)-6-methoxy-4-phenyl-2(1H)-quinazolinone (I, R = MeO) (IS-173) and 1-(Cyclopropylmethyl)-6-nitro-4-phenyl-2(1H)-quinazolinone (I, R = ONO₂) (ISL-522), each labeled with carbon-14 at C-4 position were synthesized for use in metabolic studies. The syntheses were achieved by two types of reaction sequences. Overall radiochem. yields of ISL-577-4-14C and ISL-522-4-14C were 79% and 17% from carbon dioxide-14C, and their specific activities were 5.52 uCi/nmole and 3.31 uCi/nmole, resp.
 IT 51126-57-5P 51126-58-0P 51126-60-4P
 EI: STM (Synthetic preparation); PREP (Preparation)
 IT (Preparation of)
 NI 51126-57-9 CAPLUS
 CI 2(1H)-Quinazolinone-4-14C, 6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



NI 51126-58-0 CAPLUS
 CI 2(1H)-Quinazolinone-4-14C, 6-acetyl-1-(cyclopropylmethyl)-4-phenyl- (9CI)
 (CA INDEX NAME)

13 ANSWER 269 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



NI 51126-60-4 CAPLUS
 CI 2(1H)-Quinazolinone-4-14C, 1-(cyclopropylmethyl)-6-nitro-1-phenyl- (9CI)
 (CA INDEX NAME)



13 ANSWER 269 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:37151 CAPLUS
 DOCUMENT NUMBER: 80:37151
 ORIGINAL REFERENCE NO.: 80:4103A, 4106A
 TITLE: Quinazolinones
 INVENTOR(S): Lehtinen, Kari; Mori, Kazuo; Yamamoto, Masaharu;
 Koshida, Masao; Inaba, Shigeo; Yamamoto, Hisao
 SOURCE: Sumitomo Chemical Co., Ltd.
 Jpn. Kokai Tokkyo Koho, 8 pp.
 CDB# JGGAOF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47012977	B4	1973-10-29	JP 1972-12977	1970-02-05

AB For diagram(s), see printed CA issue.
 AB The title compds. (I) were prepared by hydrolyzing or by heating any

weat
 (I) where R1-2 = H, halogen, CF₃, NO₂, alkyl, or alkoxy R4 = H, alkyl, polyalkyl, or cycloalkylalkyl; R3 = H, alkyl, Ph, alkoxy, benzyl, allyl, aryl, carbonyl, carboxymethyl, or alkoxy-carbonyl. R-5, 1,3,5 or 11 (I) = 4-Cl, R2 = R3 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was (I) (R1, R2, R3, and R4 given): 6-Cl, R2 = H, R4 = H, 0-P, H.

IT 20927-52-3P
 EI: STM (Synthetic preparation); PREP (Preparation)
 IT (Preparation of)
 NI 20927-53-1 CAPLUS
 CI 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



13 ANSWER 270 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCEPTOR NUMBER: 1974:3460 CAPLOS
 DOCUMENT NUMBER: 80:2402
 ORIGINAL REFERENCE NO.: 80:6079,610a
 TITLE: Novel quinoxaline derivatives. II. A new anti-inflammatory agent, II-512
 AUTHOR(S): Yamamoto, Hasey, Kaito, Chihara, Inaba, Shigeoy
 Asahi, Shiohji, Yamamoto, Mochibayashi, Sakai, Yoshioy
 Komatsu, Toshiaki
 CORPORATE SOURCE: Takaraoka Res. Lab., Sunstone Chem. Co., Ltd.,
 Osaka,
 SOURCE: Japan
 ACTIVITY: Arzneimittel-Forschung (1973), 23(9), 1266-71
 CURRENT ADDRESS: ISSN: 0004-4172
 JOURNAL
 LANGUAGE: English
 OR For diagram(s), see printed CA Issue.
 AB II-512 (I) was prepared from the indole II by 2 methods: either by
 successive oxidation into VII, oxidation with CrO₃ to give
 4,3-di-(Fmoc)-6-ethoxycarbonyl (IV, R = Al), hydrolysis to give
 4,3-di-(Fmoc)-6-ethoxy (IV, R = Al), and ring closure with KOH to give I or
 by successive oxidation with CrO₃ to give IV (R = H), hydrolysis to give V
 (R = H), reaction with urea to give VI, which on reaction with AlR gave I.
 The anti-inflammatory effects of I on acute inflammation models were about
 twice to 4 times more potent than those of reference acid or
 benzydiazine
 and almost equal to phenylbutazone. I had also marked analgesic
 and hypotensive activities. Effects of I on adjuvant-induced arthritis were
 also exhibited, but it did not inhibit granuloma formation. Acute
 toxicity and sublethal paralytic activity of I were remarkably weaker
 than those of other anti-inflammatory agents.
 IT 33415-19-90
 RI 512 (Synthetic preparation); PKP (Preparation)
 (Preparation and inflammation inhibiting effects of)
 RI 33415-19-9 CAPLOS
 RI 2118-Quinoxalino, 6-chloro-1-(1-cyclopropylmethyl)-4-phenyl- (CA INDEX
 NAME)



13 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCEPTOR NUMBER: 1973:149325 CAPLOS
 DOCUMENT NUMBER: 79:149319
 ORIGINAL REFERENCE NO.: 79:149319,24178a
 TITLE: 2(1R)-Quinoxalino derivatives as uricosurics
 AUTHOR(S): Yamamoto, Mochibayashi, Maruoka, Shiohaji, Kashiwa,
 Masao, Kono, Shunji, Aikawa, Akira, Inaba, Shigeoy
 Nakatani, Hiroshi, Yamamoto, Kikao
 PATENT ASSIGNEE(S): Sunstone Chemical Co., Ltd.
 SOURCE: Ger. Offen. 28 pp.
 CURRENT ADDRESS: CAPLOS (OCCUR)
 DOCUMENT TITLE: Patent
 LANGUAGE: German
 FAMILY ACC. IPR. COMNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 239709	A1	19700800	JP 1970-239709	19700216
JP 4088179	A	19731133	JP 1972-17442	19720219
BE 795119	A1	19720618	BE 1973-127723	19720216
FR 2151744	A2	19731207	FR 1973-5628	19730216
FR 2151745	A2	19731207	FR 1973-5628	19730216
FR 2151746	A2	19731207	FR 1973-5629	19730216
NO 795229	A	19740822	NO 1973-52299	19730219
FR 2151746	A	19740822	JP 1972-17442	19720219

OR For diagram(s), see printed CA Issue.
 AB Fifty quinoxalino derivs. [I and II, e.g. R = Me, allyl,
 cyclopropylmethyl, CH₂CH₂, CH₂CH₂CH₂, or 1-methylcyclohexylmethyl; R₁ = Ph, 3-ClC₆H₄,
 cyclohexyl, 2-pyridyl, or 2-thienyl; R₂ = Me, Cl, Br, OCH₃, MeO, H₂N, MeS,
 MeSO₂, or MeOCH₂; R₃ = H or Me, or SO₂ = OCH₂CH₂; R₄ = H, R₅ = H or
 CH₂CH₂CH₂CH₂ or R₄R₅ = OCH₂CH₂, O(CH₂)₂, MeOCH₂CH₂, or H(CH₂)₂] or their
 hydroxolates increased urine acid excretion of mice and were useful for
 the treatment of gout. I and II were more effective than probenecid,
 e.g.,
 100 mg I (R = CH₂CH₂CH₂, R₁ = Ph, R₂ = OCH₃, R₃ = H/kg mice (orally)
 caused the excretion of 100 µg uric acid/100 g body weight
 IT 20927-33-1 22765-18-5 26921-11-8
 33413-20-2 33457-23-5 33453-24-6
 33890-08-8 33541-70-8 33544-07-1
 33514-35-1 33554-33-9 33554-39-5
 33514-15-0 33554-39-5 33554-39-5
 33555-17-2 33618-35-8 33614-47-8
 40951-19-9 40951-49-2
 40950-34-8 40950-37-1 40950-63-9
 40950-48-1 40950-72-0 40950-74-2
 40950-92-2 40950-93-9 40950-94-4
 40950-85-5 40950-86-6 40950-87-7
 40950-80-9 40950-91-3
 RI 512 (Synthetic preparation)
 RI 20927-33-1 CAPLOS
 RI 2118-Quinoxalino, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

13 ANSWER 270 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

RI 22765-18-5 CAPLOS
 RI 2118-Quinoxalino, 7-methyl-2-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



RI 26831-11-8 CAPLOS
 RI 2118-Quinoxalino, 6-chloro-1-(3-methylethyl)-4-phenyl- (CA INDEX
 NAME)



RI 33453-20-2 CAPLOS
 RI 2118-Quinoxalino, 6-bromo-1-(1-cyclopropylmethyl)-4-phenyl- (CA INDEX
 NAME)



15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 FN 37453-23-5 CAPLOS
 CN 2188-Quinalolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



FN 37453-24-6 CAPLOS
 CN 2188-Quinalolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)




FN 37490-29-8 CAPLOS
 CN 2188-Quinalolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



FN 36942-70-8 CAPLOS

15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2188-Quinalolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)




FN 37554-38-5 CAPLOS
 CN 2188-Quinalolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



FN 37554-35-8 CAPLOS
 CN 2188-Quinalolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



FN 37554-98-6 CAPLOS
 CN 2188-Quinalolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (PCI) (CA INDEX NAME)




FN 37555-03-6 CAPLOS
 CN 2188-Quinalolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2188-Quinalolinone, 1-(cyclopropylmethyl)-7,4-dihydro-6-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



FN 37554-27-1 CAPLOS
 CN 2188-Quinalolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



FN 37554-35-1 CAPLOS
 CN 2188-Quinalolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



FN 37554-37-3 CAPLOS


15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



FN 37555-17-2 CAPLOS
 CN 2188-Quinalolinone, 1-(cyclopropylmethyl)-6-(methylethyl)-4-phenyl- (CA INDEX NAME)



FN 36028-35-8 CAPLOS
 CN 2188-Quinalolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



FN 38634-47-8 CAPLOS
 CN 2188-Quinalolinone, 6-amino-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 49852-39-9 CAPLOS
CN 2 [18]-Quinazolinone, 1-(methoxymethyl)-4-nitro-4-phenyl- (CA INDEX NAME)



RN 49852-49-1 CAPLOS
CN 3 [18]-Quinazolinone, 1-(2-methyl-2-propenyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49852-56-3 CAPLOS
CN 2 [18]-Quinazolinone, 6-chloro-1-(oxiranylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-45-1 CAPLOS
CN 6-Quinazolinonecarboxylic acid, 1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)



RN 49830-72-0 CAPLOS
CN 2 [18]-Quinazolinone, 1-(cyclobutylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49830-74-2 CAPLOS
CN 2 [18]-Quinazolinone, 6-bromo-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)


15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-54-8 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-methyl-2-propenyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49830-57-1 CAPLOS
CN 2 [18]-Quinazolinone, 6-chloro-4-(3-chlorophenyl)-1-(cyclopropylmethyl)- (CA INDEX NAME)



RN 49830-63-9 CAPLOS
CN 2 [18]-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-82-2 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-hydroxybutyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 49830-83-3 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-(acetyloxy)ethyl)-6-bromo-4-phenyl- (CA INDEX NAME)




RN 49830-84-4 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-(acetyloxy)ethyl)-6-nitro-4-phenyl- (CA INDEX NAME)




RN 49830-85-5 CAPLOS


15 ABSTRACT 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CH Propanoic acid, 2-methyl-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl) ester (CA INDEX NUMBER)



26 49830-86-6 CAPLOS
 CH Acetic acid, 4-chloro-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (PCI) (CA INDEX NUMBER)



26 49830-87-7 CAPLOS
 CH 2(1H)-Quinazolinone, 1-[2-(diethylamino)ethyl]-6-nitro-4-phenyl-, monohydrochloride (PCI) (CA INDEX NUMBER)



● HCl

26 49830-89-9 CAPLOS
 CH 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NUMBER)

15 ABSTRACT 272 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:537109 CAPLOS
 DOCUMENT NUMBER: 79:137109
 ORIGINAL REFERENCE NO.: 79:122259, 2228a
 TITLE: Quinazolinone and 1,4-benzodiazepines. LIX.
 AUTHOR(S): Weiser, Armin; Silverman, Gladys; Fryer, R. Ian
 CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
 SOURCE: Journal of Organic Chemistry (1978), 58(20), 3502-7
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Index.
 AB Substituted 7-methoxy-5,10-dihydro-1-phenyl-1H-pyrrolo[2,1-c][1,4]benzodiazepine (7) were obtained from treatment of the corresponding 3-allylbenzodiazepine 4-oxides (II) with Ac2O.
 IT 2087-53-3P
 RI: 87H (Synthetic preparation); PREP (Preparation) (Preparation of)
 26 2087-53-1 CAPLOS
 CH 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NUMBER)



15 ABSTRACT 271 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 INDEX NUMBER



26 49830-91-3 CAPLOS
 CH 2(1H)-Quinazolinone, 3,4-dihydro-1-[1-(4-methylphenyl)ethyl]-6-nitro-4-phenyl- (CA INDEX NUMBER)



26 49830-93-9 CAPLOS
 CH 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NUMBER)


15 ABSTRACT 272 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:516418 CAPLOS
 DOCUMENT NUMBER: 79:115618
 ORIGINAL REFERENCE NO.: 79:187756, 18782a
 TITLE: Quinazolinone derivatives
 AUTHOR(S): Yamamoto, Mutsukuni; Ishikawa, Kazuo; Mori, Kazuo
 CORPORATE SOURCE: Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 5 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY NO.: 6
 PATENT INFORMATION:

PATENT NO.	FI	RD	DATE	APPLICATION NO.	DATE
JP 4802195A	B	19780702	JP 1970-114461	19701211	
US 572472	AS	19780213	US 1971-15572	19711026	
DE 95382	AS	19780212	DE 1971-158657	19711029	
BE 163176	B	19780628	BE 1977-50658	19711029	
SE 7602767	A	19760126	SE 1976-767	19760214	
SE 431206	B	19840213			
SE 431206	C	19840213			

PRIORITY AFFIL. INFO.:
 JP 1970-96304 A 19701030
 JP 1970-96305 A 19701030
 JP 1970-96306 A 19701030
 JP 1970-110489 A 19701211
 JP 1970-114461 A 19701211
 JP 1970-129965 A 19701228
 JP 1971-6400 A 19701223

GI For diagram(s), see printed CA Index.
 AB The quinazolinone 1 (R1, R2 = H, lower alkyl, lower alkoxy, H2O, CF3, lower alkylthio, lower alkylsulfonyl, or halogen; R3 = Ph, halophenyl, lower alkylphenyl, lower alkoxyphenyl, trifluoromethylphenyl, lower cycloalkyl, or thienyl; R4 = lower alkyl, lower alkoxy, CH3Iodine, CH3, allyl, lower cycloalkyl, lower cycloalkylalkyl, lower cycloalkyl, lower trifluoromethylalkyl, or C6H5H2H3) (n = 1-4, R4, R5 = lower alkyl); 2 = O or S) were prepared by reaction of II with halogenating agents to give
 III (X = Cl or Br), followed by the reaction with an organo-metallic compound 1
 also analgesic, anti-inflammatory agents, and agents acting on the central nervous system. Thus, a mixture of 4.2 g II (R1 = H, R2 = 4-Cl, R3 = Me, R4 = O, R5 = Cl), which was treated with 10 mg of 1 (R1 = H, R2 = 4-Cl, R3 = Me, R4 = O, R5 = Cl) in THF to give 1 (R1 = H, R2 = 4-Cl, R3 = Me, R4 = O, R5 = Cl). Among 10 similarly prepared were the following (R1, R2, R3, R4, R5 given):
 Me, Ph, Si, R, 6-Cl, cyclopropylmethyl, Ph, Si, R, 1-oxo-Ph, Si, R, 5-Cl, Me, Ph, O.

15 ANSWER 274 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



381 49796-17-2 CAPLOS
CN 2(1R)-Quinoxalinone, 1-ethylmethyl-4-phenyl- (SCI) (CA INDEX NAME)



2 (DI-Me)

15 ANSWER 275 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 1972-492248 CAPLOS
DOCUMENT NUMBER: 79:3248
ORIGINAL REFERENCE NO.: 79:14934,14934a
TITLE: Quinoxaline derivatives
Yamamoto, Michikazu; Ishizumi, Eikyo; Maki, Naoya;
Inaba, Shigehy; Yamamoto, Hisao
Suntory Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 5 pp.
C(Chem):JAGAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY NO., NUM. COMM.: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4802135	A	1970-10-02	JP 1970-110649	19701211
CR 372472	A5	1970-02-13	CR 1971-2572	19711024
CR 574418	A5	1970-04-15	CR 1975-12073	19711026
DE 95382	A5	1970-02-12	DE 1971-158437	19711029
DE 163176	B	1970-06-28	DE 1971-08088	19711029
AT 313929	B	1970-03-11	AT 1973-1779	19711029
SE 416188	B	1970-06-01	SE 1971-13749	19711029
DK 7502228	A	1970-05-04	DK 1975-228	19750214
DE 134401	B	1970-11-03		
SE 7600767	A	1970-10-16	SE 1976-767	19760216
CR 412206	B	1964-02-17		
SE 431206	C	1964-05-03		
FI 59797	B	1961-06-30		
FI 59797	C	1961-10-12		

PRIORITY APPL. INFO.

JP 1970-96704	A	19701070
JP 1970-96705	A	19701070
JP 1970-96706	A	19701070
JP 1970-110689	A	19701211
JP 1970-114461	A	19701211
JP 1970-123965	A	19701228
JP 1973-4490	A	19710223
DE 1973-5273	A	19711027
FI 1973-3074	A	19711028

CI For diagram(s), see printed CA issue.

A5 Title derive. I were prepared by treating the corresponding 4-oxo compe. with organic Mg halides or organic Li compe., followed by H2O or lower alcoh., and then heating. I had antilaminatory, analgesic, and central nervous actions. 8-9: reducing PMAGE and 5 g 1-(cyclopropylmethyl)-4-chloro-2-

15 ANSWER 276 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)
418,341-quinoxalindione 4 hr, addn. of 100 ml MeOH at 0° and 50 ml 2N MeOH-HCl, and stirring 1 hr at room temp. gave 1-(cyclopropylmethyl)-1,4-dihydro-4-methoxy-4-phenyl-6-chloro-2(1R)-quinoxalinone (II). Boiling 15 min at 220° and silica gel chromatog. gave 2 (R = cyclopropylmethyl, R1 = Ph, R2 = R3 = R4, R5 = Cl, Z = O). Also, 1 of the same type were prepd. (R to R5 and Z gives): Me, Ph, R, MeO, R, R, O, R, o-MeO, R, Cl, R, R, O, R, O, Me, Ph, R, Cl, R, MeO, R, R, O, cyclohexylmethyl, Ph, R, Cl, R, R, O, and Me, Ph, R, Cl, R, MeO, R, R, O, other 7 were also prepd.
33441-74-3P 28131-42-3P 28920-12-7P
33443-19-3P 33512-31-2P 37554-98-6P
42507-33-1P
R1: STD (Synthetic preparation); PREP (Preparation)
[preparation of]
382 23441-74-3 CAPLOS
CN 2(1R)-Quinoxalinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



382 26113-42-8 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



382 26920-12-7 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)




15 ANSWER 278 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)
CN 33453-19-9 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



381 33512-31-1 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)



381 37554-98-6 CAPLOS
CN 2(1R)-Quinoxalinone, 6-nitro-4-phenyl-1-(2-propenyl)- (SCI) (CA INDEX NAME)



381 42107-59-1 CAPLOS
CN 2(1R)-Quinoxalinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 215 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 216 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:492267 CAPLOS
 DOCUMENT NUMBER: 79:92267
 ORIGINAL REFERENCE NO.: 79:14991a,14994a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Iwabe, Shunpey Yamamoto, Michikazu Ishizumi, Eikuro Mori, Kazuo Yamamoto, Hisao Saitono Chemical Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 5 pp.
 CIBISI, JAPAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACN, NUM. COUNTRY: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48021353	B	19700102	JP 1970-96704	19701010
GB 172412	A5	19700213	GB 1971-13172	19711016
DE 170234	B	19700203	DK 1971-5233	19711017
DD 95382	A5	19700212	DD 1971-150657	19711019
BF 163176	B	19700628	BF 1971-00858	19711019
AT 312615	B	19700110	AT 1971-9571	19711019
SE 410188	B	19701001	SE 1971-13749	19711019
SE 7600767	A	19700126	SE 1976-767	19760116
SE 431206	B	19640113		
SE 431206	C	19640503		
FRIORITZ APPL. INFO. 1				
		JP 1970-96704	A	19701010
		JP 1970-96705	A	19701010
		JP 1970-96706	A	19701010
		JP 1970-110609	A	19701211
		JP 1970-114461	A	19701211
		JP 1970-129965	A	19701220
		JP 1971-6400	A	19710213

G1 For diagram(s), see printed CA issue.

A5 The quinazolinones I were prepared by treating 2-alkoxy-carbonylphenyl ketones with NE₃. I had antitumor, analgesic, and central nervous actions. E.g., 3 ml Me₂SO was dropped to a mixture of 5.5 g 2-(methoxycarbonylphenyl)-5-chlorobenzenophenone and 3 g 50% NaOH in acetone and the whole kept stirred 2 hr at room temperature to give 2-[3-methylmethoxycarbonylphenyl]-5-chlorobenzenophenone (I). A mixture of

1.5 g
 I, Me₂SO, 4 g AcOH, and 0.6 g NaOH was heated 20 hr at 130° to give 1 (R = Me, R' = Ph, R' = H, R' = Cl). Also, 1 (R to 14 given) were prepared: Me, Ph, Cl, H, H, Me, Ph, H, H, Cl; Me, Ph, H, H, H, H, H, Me, Ph, H, H, Me, Ph, H, H, Cl, H. Some 70 other I were similarly prepared
 20927-53-3F 23461-63-6P 23461-74-9P

15 ANSWER 216 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

23441-90-9P 23536-81-6P 37554-75-9P
 1L: STN (Synthetic preparation); 95EP (Preparation)
 (Prep. ref.)

20 20927-53-3 CAPLOS
 CH 2118-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



20 23441-63-6 CAPLOS
 CH 2118-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



20 23441-74-9 CAPLOS
 CH 2118-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



20 23441-90-9 CAPLOS
 CH 2118-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 216 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

20 23536-81-6 CAPLOS
 CH 2118-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



20 37554-75-9 CAPLOS
 CH 2118-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 277 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 1973/46394 CAPLOS
 DOCUMENT NUMBER: 79/66394
 ORIGINAL REFERENCE NO.: 79/10735a, 10736a
 TITLE: Quinazolinones
 INVENTOR(S): Yamamoto, Mutsukihiko; Ishazumi, Kikyo; Mori, Kazuo;
 Inaba, Shigehyo; Yamamoto, Hisao
 SOURCE: Swintow Chemical Co., Ltd.
 PATENT ASSIGNER(S): Jpn. Kokai Tokkyo Koho, 5 pp.
 CORDI: JPOKAP
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48040787	A	19790619	JP 1973-78019	19731004
JP 5022272	B	19790519		
PRIORITY AFFIL. INFO.: 1			JP 1971-79019	A 19731004

GI For diagram(s), see printed CA Issue.
 AB The title compounds. (1), antiinflammatory and analgesic drugs, were prepared by treating benzyldiaols with carbonates or cyanates followed by oxidation R, R', 3-(4,7,8-trifluoromethyl)-5-chlorobenzyldiol was heated 5 hr at 200° with Zn carbonate in the presence of ZnCl₂ and the resulting


1-(2,2,2-trifluoroethyl)-4-phenyl-6-chloro-7,8-dihydro-2(1H)-quinazolinone oxidized with PBrO₃ in dioxane to give 1 (R' = CHCF₃, R = Ph, R₂ = 6-Cl). Among 27 more 2 similarly prepared were the following (R₁, R₂, and

23 shown): cyclopropylmethyl, Ph, 6-Cl; cyclopropylmethyl, Ph, 8-Cl; cyclopropylmethyl, p-tolyl, 6-Cl; cyclopropylmethyl, 2-pyridyl, 6-Cl; cyclopropylmethyl, Ph, 6-Me.
 IT 35453-13-39 35453-24-49 37554-40-59
 37555-10-19 42026-19-19

R₁ R₂ (Synthetic preparation); PREP (Preparation)
 (preparation of)
 R₁ 35453-13-39 CAPLOS
 R₂ 35453-13-39 CAPLOS
 R₃ 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 277 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 277 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 R₁ 35453-24-4 CAPLOS
 R₂ 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



R₁ 37554-40-8 CAPLOS
 R₂ 2(1H)-Quinazolinone, 6-chloro-1-(2,2,2-trifluoroethyl)-4-phenyl- (CA INDEX NAME)



R₁ 37555-10-5 CAPLOS
 R₂ 2(1H)-Quinazolinone, 8-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



R₁ 42026-19-1 CAPLOS
 R₂ 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)

15 ANSWER 278 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 1973/46394 CAPLOS
 DOCUMENT NUMBER: 79/66394
 ORIGINAL REFERENCE NO.: 79/10735a, 10736a
 TITLE: Quinazolinones
 INVENTOR(S): Yamamoto, Mutsukihiko; Marooka, Shigeaki; Hashino, Masao; Inaba, Shigehyo; Yamamoto, Hisao
 SOURCE: Swintow Chemical Co., Ltd.
 PATENT ASSIGNER(S): Jpn. Kokai Tokkyo Koho, 7 pp.
 CORDI: JPOKAP
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 2
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48044279	A	19790626	JP 1971-81181	19731014
JP 5061272	B	19790519		
AU 7245877	AU	19740208	AU 1972-45877	19720923
GB 1394291	A	19790514	GB 1972-29236	19720923
DE 2242375	A3	19790215	DE 1972-2442375	19720819
DE 2242375	B2	19740905		
DE 2242375	C3	19750430		
AT 727429	A	19780415	AT 1972-7429	19720929
AT 727429	B	19780126		
AT 7401530	A	19780415	AT 1972-153074	19720929
CH 578642	A3	19790215	CH 1972-12121	19720821
SE 395453	SE	19770815	SE 1972-11231	19720930
JP 464043	A3	19781230	JP 1972-1621902	19720930
BE 768213	A3	19780228	BE 1972-12121	19720821
NL 7211867	A	19780305	NL 1972-11867	19720831
NO 164496	B	19780328	NO 1972-808164	19720831
CA 1006163	A3	19770301	CA 1972-10694	19720831
DE 123507	B	19760531	DE 1972-6806	19721214

PRIORITY AFFIL. INFO.: 2
 JP 1971-81181 A 19731014
 JP 1972-18220 A 19720921
 JP 1972-20356 A 19720928

GI For diagram(s), see printed CA Issue.
 AB The title compounds. (1), antiinflammatory and antiviral drugs, were prepared from the corresponding 1-unsubstituted compounds. Thus, 4-phenyl-6-chloro-2(1H)-quinazolinone in DMF was warmed with NaH and warmed further with quinacrydian to give 1 (R' = 2,2-dicyclopropyl). Similarly prepared was 1 (R' = tetrahydrofurfuryl). This was also prepared by a ring closure of 2-(tetrahydrofurfuryl)amino-5-nitrobenzenethiol or of 2-[4-(tetrahydrofurfuryl)trichloromethyl]-5-nitrobenzenethiol.
 IT 42285-36-39 42285-57-49
 42285-10-19 42285-19-19

R₁ R₂ (Synthetic preparation); PREP (Preparation)
 (preparation of)
 R₁ 42285-36-3 CAPLOS
 R₂ 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 279 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26824-70-4 CAPLOS
 CH 2 (1R)-Quinazolinone, 6-methoxy-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



RI 26871-06-1 CAPLOS
 CH 2 (1R)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



RI 26940-07-9 CAPLOS
 CH 2 (1R)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

15 ANSWER 279 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 42314-12-5 CAPLOS
 CH 2 (1R)-Quinazolinone, 7-chloro-4-phenyl-1-(2-propenyl)- (CA INDEX NAME)



15 ANSWER 279 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 27524-92-1 CAPLOS
 CH 2 (1R)-Quinazolinone, 1-(1-methylethyl)-6-(4-methylphenyl)- (CA INDEX NAME)



RI 27529-23-3 CAPLOS
 CH 2 (1R)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (CA INDEX NAME)



RI 42211-03-6 CAPLOS
 CH 2 (1R)-Quinazolinone, 6-bromo-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 280 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973/45334 CAPLOS
 DOCUMENT NUMBER: 79/53354
 ORIGINAL REFERENCE NO.: 79/65154, 6618a
 TITLE: Quinazolinone derivatives
 INVENTOR ASSIGNEE(S): Dunloco Chemical Co., Ltd.
 SOURCE: Fr. Demande, 10 pp.
 COORD. FRASE: FRASE: FRASE
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2141574	A1	19780126	FR 1973-21908	19710616
FR 2141574	B1	19740930	FR 1971-21908	19710616

PRIORITY APPL. INFO.: GI For diagram(s), see printed CA Issue.

AB The quinazolinone I was prepared by N-acylating 2,4-bis(4-chlorophenyl)-6-methyl-2,4-dihydroquinazolin-6-one and cyclizing the 2,4-bis(4-chlorophenyl)-6-methyl-2,4-dihydroquinazolin-6-one with HCl.

IT 37554-40-EP
 RI 37554-40-9 CAPLOS
 CH 2 (1R)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2-trifluoroethyl)- (CA INDEX NAME)

RI 37554-40-9 CAPLOS
 CH 2 (1R)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2-trifluoroethyl)- (CA INDEX NAME)



15 ANWER 281 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:432094 CAPLOS
 DOCUMENT NUMBER: 79:12204
 ORIGINAL REFERENCE NO.: 79:52094, 52124
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Inoue, Shigehiko Yamamoto, Michihiko Ishikawa, Kikuo Mori, Kazuo Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNOR(S): Jpn. Tokkyo Koho, 3 pp.
 SOURCE: CCHEN, JACOB
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4800513	B4	19701012	JP 1970-94304	19701010
CI	For diagram(s), see related CA issue.			
AB	Novel quinazolinone derivative, (I, A = -C(R3)H- or -C(R3)NH-, R3 = Ph, halophenyl, lower alkylphenyl, lower alkylphenyl, CF3CH2, cycloalkyl, phenyl, furyl, or thienyl, R1, R2 = H, lower alkyl, allyl, benzyl, CF3, alkylthio, alkylsulfonyl, or halo, and R is lower cycloalkyl) were prepared by hydrolysis of the corresponding 2-thio- or 2-imino- derivative in			

EtO, aic, dioxane, or Me2SO, containing acid or alkali. 3-Cyclopropylmethyl-4-phenyl-6-chloro-1H-quinazolin-2-one, n.p. 172-79, and 25 other compounds, were prepared and they showed anti-inflammatory, analgesic, and central nerve actions. They are also useful as intermediates in the preparation of pharmaceuticals.


IT 3745:19-39
 RI SR (Synthetic preparation); PREP (Preparation)
 (preparation of)

RI 3745:19-39 CAPLOS
 CH 21(8)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



15 ANWER 283 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:159459 CAPLOS
 DOCUMENT NUMBER: 79:159459
 ORIGINAL REFERENCE NO.: 79:159459, 154464
 TITLE: Dihydroquinazolinone derivatives
 INVENTOR(S): Yamamoto, Michihiko Ishikawa, Kikuo Mori, Kazuo Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNOR(S): Jpn. Tokkyo Koho, 7 pp.
 SOURCE: CCHEN, JACOB
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4800585	B4	19701016	JP 1973-24997	19701001
CI	For diagram(s), see related CA issue.			
AB	The title compounds, [2] exhibiting central nervous, anti-inflammatory, and analgesic actions, were prepared Thus, 3-[2-(diethylamino)ethyl]-4-phenyl-6-chloro-1,4-dihydro-2 (1H)-quinazolinone in DMF was warmed with NaH and stirred 4 hr at 100° with EtI to give 1-RI [RI = Me, Et, 2-(diethylamino)ethyl, X = Cl]. Similarly prepared were 1 (RI, R2, and X given), 2-(diethylamino)ethyl, 4-phenyl-6-chloro-1,4-dihydro-2 (1H)-quinazolinone, 6-chloro-3-(cyclopropylmethyl)-1-methyl-4-phenyl- (CA INDEX NAME)			



RI 3745:55-7 CAPLOS
 CH 21(8)-Quinazolinone, 3-[2-(diethylamino)ethyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

15 ANWER 282 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:432079 CAPLOS
 DOCUMENT NUMBER: 79:12079
 ORIGINAL REFERENCE NO.: 79:52094, 52124
 TITLE: Synthesis of quinazolinone derivatives
 INVENTOR(S): Inoue, Shigehiko Yamamoto, Michihiko Ishikawa, Kikuo Mori, Kazuo Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNOR(S): Jpn. Tokkyo Koho, 3 pp.
 SOURCE: CCHEN, JACOB
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4800517	B4	19701012	JP 1970-94305	19701010
CI	For diagram(s), see related CA issue.			
AB	Novel 1H-quinazolin-2-one derivative, (I, R1, R2 = H, lower alkyl, allyl, benzyl, CF3, alkylthio, alkylsulfonyl, or halo, R3 is Ph, halophenyl, alkylphenyl, CF3CH2, cycloalkyl, phenyl, furyl, or thienyl, and R is lower cycloalkyl) were prepared by oxidation of 1H-quinazolin-2-thione derivative, (II, where A = -C(R3)H- or -C(R3)NH-) with NaNO2, EtNO4, EtO2C, or MeCO2C, in the presence or absence of NaOH, EtOH, or Ca(OH)2, in EtO, MeOH, EtOH, iso-PrOH, CGM, toluene, EtO, THF, dioxane, or Me2SO.			


were prepared which are useful as intermediates for manufacture of pharmaceuticals, and they all showed anti-inflammatory, analgesic, and central nerve actions.

IT 3745:35-49
 RI SR (Synthetic preparation); PREP (Preparation)
 (preparation of)


RI 3745:35-49 CAPLOS
 CH 21(8)-Quinazolinone, 3-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)




15 ANWER 283 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STN (Continued)



RI 42130-80-2 CAPLOS
 CH 21(8)-Quinazolinone, 6-chloro-3-[2-(diethylamino)ethyl]-1-ethyl-3,4-dihydro-4-phenyl-, monohydrochloride (HCl) (CA INDEX NAME)



RI 42130-82-4 CAPLOS
 CH 21(8)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-7,4-dihydro-4-phenyl- (CA INDEX NAME)



RI 42130-84-4 CAPLOS
 CH 21(8)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)

15 ANSWER 283 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



15 ANSWER 284 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973136327 CAPLOS
 DOCUMENT NUMBER: 78116327
 ORIGINAL REFERENCE NO.: 78219054,219054
 TITLE: 1,6-Dibenzyl-2-phenyl-2(1H)-quinazolinone
 INVENTOR(S): Yamamoto, Michihiko; Ishizumi, Eikuo; Mori, Kazuo;
 Koshida, Masayoshi; Tada, Shigeo; Yamamoto, Hisao
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CDB: JPOGAP
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JF 48014605	A	19700223	JF 1971-49741	19710705
FI 57101	B	19000229	FI 1972-1902	19720704
FI 57101	C	19000610		

PRIORITY APPL. INFO.: JF 1971-49741 A 19710705

AB The title compds. (I), useful as antiinflammatory, analgesic, and central nervous system drugs, were prepared by treating the corresponding benzophenones with NEt_3 . E.g., 2-[2-methylpropanoatebenzylamino]-2-chlorobenzophenone in EtOH was let stand 3 days with saturated ethanolic NEt_3 to give I (R1 = Me, R2 = Cl). Similarly prepared were the following I (R1 and R2 given): Me, NO_2 , allyl, Cl.
 IT 20927-53-1F 23441-66-9F 20927-53-1F 23441-66-9F
 RI: SPH (Synthetic preparation); PREP (Preparation)
 Preparation of
 RI: 20927-53-1 CAPLOS
 RI: 2118-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RI 23441-66-9 CAPLOS
 RI: 2118-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (ICI) (CA INDEX NAME)

15 ANSWER 284 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RI 26953-46-8 CAPLOS
 RI: 2118-Quinazolinone, 1-methyl-4-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 285 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973136728 CAPLOS
 DOCUMENT NUMBER: 78116326
 ORIGINAL REFERENCE NO.: 78219054,219054
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Tada, Shigeo; Yamamoto, Michihiko; Ishizumi, Eikuo;
 Mori, Kazuo; Yamamoto, Hisao
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CDB: JPOGAP
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1307202	A	19700214	GB 1971-28026	19710615
PRIORITY APPL. INFO.:			GB 1971-28026	A 19710615

AB 1-(2,2,2-Trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone (I), useful as an inflammation inhibitor, was prepared by trichloroacetylation of 5',2'-Cl-CF₃-C₆H₄-NH₂.
 IT 37554-45-8
 RI: RCT (Reactant); RCT (Reactant or reagent)
 (Inflammation inhibitor)
 RI: 37554-45-8 CAPLOS
 RI: 2118-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



13 ANSWER 286 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973124224 CAPLUS
 DOCUMENT NUMBER: 78124626
 ORIGINAL REFERENCE NO.: 78120274, 20030a
 TITLE: Quinazoline derivatives
 INVENTOR(S): Morii, Kazuo; Yamamoto, Michihiko; Ishikawa, Kikuo
 PATENT ASSIGNER(S): Morii, Kazuo; Yamamoto, Hisao
 SOURCE: Sumitomo Chemical Co., Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JA 710386		19707071	JA 1971-386	19710415

CI For diagram(s), see printed CA issue.
 AB (7-*trifluoroethyl*)quinazolinone 1, possessing antiinflammatory activity,
 was prepared by condensing GILCOU with 2,5-(CF₃)₂-NHC(=O)R¹ (I); R¹ =
 - H
 - n refluxing Et₂O containing Et₃N to give II (R = CCl₃CO); the latter
 underwent ring closure with NMOH in refluxing EtOH to yield I.
 IT 37154-40-85
 RI RAC (Biological activity or effector, except adverse); RSU
 (biological)
 study, unclassified); SYN (Synthetic preparation); REOL (Biological
 study); PREP (Preparation)
 (Preparation and antiinflammatory activity of)
 RI 37154-40-8 CAPLUS
 CI 2 (18)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA
 INDEX NAME)



13 ANSWER 286 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973111147 CAPLUS
 DOCUMENT NUMBER: 78111347
 ORIGINAL REFERENCE NO.: 7811879a, 1982a
 TITLE: 1-cycloalkylmethyl-4-phenyl-2 (1H)-quinazolinones
 INVENTOR(S): Inoue, Shunsho; Yamamoto, Michihiko; Ishikawa, Kikuo
 PATENT ASSIGNER(S): Morii, Kazuo; Yoshida, Masao; Yamamoto, Hisao
 SOURCE: Sumitomo Chemical Co., Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4704836		84	19701206	19700911

CI For diagram(s), see printed CA issue.
 AB About 16 quinazolinones (1, n = 2-5; X = 6-Cl, F, Br, Me, MeO, NO₂, CF₃,
 6,7-Cl₂; Y = H, o-F, Cl, p-Me) were prepared by oxidation of II, III, or
 IV
 with KMnO₄. Thus, I (n = 2, X = 6-Cl, Y = H) was obtained by oxidizing
 II
 (same substituents) in dioxane with aqueous KMnO₄ at room temperature
 for 30 min.
 IT 36942-76-4
 RI RCT (Reactant); RAC? (Reactant or reagent)
 (oxidation of)
 RI 36942-76-4 CAPLUS
 CI 2 (18)-Quinazolinone,
 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA
 INDEX NAME)



IT 32413-19-97
 RI SYN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 32413-19-9 CAPLUS
 CI 2 (18)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA
 INDEX NAME)

15 ANSWER 287 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973111162 CAPLUS
 DOCUMENT NUMBER: 78111362
 ORIGINAL REFERENCE NO.: 7811883a, 1982a
 TITLE: 1-cycloalkylmethyl-4-phenyl-2 (1H)-quinazolinones
 INVENTOR(S): Inoue, Shunsho; Yamamoto, Michihiko; Ishikawa, Kikuo
 PATENT ASSIGNER(S): Morii, Kazuo; Yamamoto, Hisao
 SOURCE: Sumitomo Chemical Co., Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4704835		84	19701206	19700910

CI For diagram(s), see printed CA issue.
 AB About 16 quinazolinones (1, n = 2-5; X = 6-Cl, F, Br, Me, MeO, NO₂, CF₃,
 6,7-Cl₂; Y = H, o-F, Cl, p-Me), with central nervous system activation,
 were prepared by cyclization of 2-(cycloalkylmethylamino)methylphenone
 imines
 with α -Cl₂-Et₃N, N,N'-carbonyldiimidazole, and CICOEt. Thus, 104 CCl₃
 in C₆H₆ was added to 2-(cyclopropylmethylamino)-5-chlorobenzophenone
 and Et₃N in C₆H₆ and the mixture stirred 0.5 hr to give I (n = 2, X =
 6-Cl,
 Y = H).
 IT 32413-19-97
 RI SYN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RI 32413-19-9 CAPLUS
 CI 2 (18)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA
 INDEX NAME)



15 ANSWER 288 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:8440 CAPLUS
 DOCUMENT NUMBER: 78:8440
 ORIGINAL REFERENCE NO.: 78:13481A, 13484a
 TITLE: 1-(2,2,2-Trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone
 INVENTOR(S): Yamamoto, Hisao; Inaba, Shigeo; Yamamoto, Michihiko; Ishimori, Eikuo; Mori, Kazuo
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Ges. Offen., 11 pp.
 COCEN: CHAKA
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2123103	A1	19730204	DE 1973-212303	19730631
DE 2123103	B2	19740906		
DE 2123103	C3	19750619		

PRIORITY APPL. INFO.: DE 1973-212303 A 19730631

G2 For diagram(s), see printed CA issue.
 AB Referring to 5,2-Cl(CF₃CH₂CH₂COOCH₃) with Cl(COOC) in the presence of NEt₃ for 4 hr in Et₂O gave 5,2-Cl(CF₃CH₂CH₂COOCH₃) OEtCOOCH₃, which on refluxing
 IT 20 hr with Et₂O in Et₂O gave the antiproliferative title compound (I).
 IT 37554-40-SP
 RI: SP (Synthetic preparation); PREP (Preparation)
 CH 37554-40-8 CAPLUS
 CH 2118-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



13 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



13 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:84283 CAPLUS
 DOCUMENT NUMBER: 78:84283
 ORIGINAL REFERENCE NO.: 78:13481A, 13482a
 TITLE: 1-Cyclopropylmethyl-4-phenyl-6-chloro-2(1H)-quinazolinone
 INVENTOR(S): Yamamoto, Michihiko; Ishimori, Eikuo; Mori, Kazuo; Inaba, Shigeo; Yamamoto, Hisao
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 COCEN: CHAKA
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48000584	A	19730206	JP 1973-24649	19730531

PRIORITY APPL. INFO.: JP 1973-24649 19730531

AB The antitumor and analgesic title compound, was prepared in 3.15 g yield by refluxing a mixture of 3.4 g 1-cyclopropylmethyl-4-phenyl-6-chloro-2(1H)-quinazolinone and 1 g P₂S₅ in pyridine for 17 hr.
 IT 33453-39-49
 RI: SP (Synthetic preparation); PREP (Preparation)
 CH 33453-39-6 CAPLUS
 CH 2118-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



IT 33453-39-9
 RI: ACT (Reactant); RACT (Reactant or reagent)
 CH 33453-39-9 CAPLUS
 CH 2118-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

13 ANSWER 291 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973:72196 CAPLUS
 DOCUMENT NUMBER: 78:72196
 ORIGINAL REFERENCE NO.: 78:13481A, 13484a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Yamamoto, Michihiko; Ishimori, Eikuo; Mori, Kazuo; Inaba, Shigeo; Yamamoto, Hisao
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 COCEN: CHAKA
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47042780	A	19731236	JP 1973-23224	19740531
DE 405728	B	19740405	DE 1972-6352	19750509
DE 405728	B	19741227		
CH 217952	B2	19800225	CH 1972-2173	19750531
NL 171254	B	19800216	NL 1972-4409	19750531
NL 171254	B	19800718		

PRIORITY APPL. INFO.: JP 1973-23224 A 19730531
 JP 1973-24694 A 19750531

G2 For diagram(s), see printed CA issue.
 AB 4-Phenyl-6-chloro-2(1H)-quinazolinone (5.13 g) in DMF was heated 30 min at 100° with 62N NaH and further heated 8 hr at 140° with 10 g 2,2,2-trifluoroethyl iodide to give 3.5 g 1-(2,2,2-trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone (I) and 2 g 2-(2,2,2-trifluoroethyl)-4-phenyl-6-chloroquinazolinone.
 IT 37554-40-SP
 RI: SP (Synthetic preparation); PREP (Preparation)
 CH 37554-40-8 CAPLUS
 CH 2118-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



13 ANSWER 232 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973;72190 CAPLOS

DOCUMENT NUMBER: 78;72190

ORIGINAL REFERENCE NO.: 78;114814,11484a

TITLE: Inaba, Shigeharu Yamamoto, Mutsuhiko Takiuchi, Kikuo Takahashi, Keiichi Mori, Kazuo Yamamoto, Ritsuo Funatsu Chemical Co., Ltd.

INVENTOR(S):

PATENT ASSIGNMENT(S): Jpn. Tokkyo Koho, 3 pp.

SOURCE: COMB. INCOG

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4704515	B4	19721117	JP 1969-64334	19690801

GI For diagram(s), see printed CA issue.

AB The title compds. [I] with a central nervous system activity were prepared by R-alkylation of the quinazoline ring. Thus, 4-(o-fluorophenyl)-6-chloro-2(1H)-quinazolinone was added to NaH in DMF and the mixture heated with CICH₂COCl at 50° to give crystalline 1-BCI (R = Cl, Y = F, R = Et).Rei. Also prepared were 1 [Y = H, X = NEt₂, R = Et; X = Me, NEt₂ = piperidinyl X = Me, NEt₂ = morpholinyl].

26111-52-OP 37554-43-EP 40069-71-4P

40069-72-1P 40069-73-4P

R1a SPN [Synthetic preparation]; FREEP [Preparation]

[Preparation of]

RE 26111-52-OP CAPLOS

CH 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-[2-(1-fluorophenyl)-

6-chloro-1-[2-(diethylamino)ethyl]-4-(2-fluorophenyl)-

monohydrochloride (BCI) (CA INDEX NAME)

LS ANSWER 293 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



LS ANSWER 294 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973-72041 CAPLUS
 DOCUMENT NUMBER: 78-72041
 ORIGINAL REFERENCE NO.: 78-11453a, 11454a
 TITLE: Novel quinazolinone derivatives. 1. Synthesis and preliminary pharmacological evaluation of an antiinflammatory agents SL-573
 AUTHOR(S): Kawanishi, Yoshiaki; Arita, Hiroshi; Sakai, Yuriko; Imaka, Toshiji; Yamamoto, Michiharu; Inaba, Shigeoh; Yamamoto, Masao
 CORPORATE SOURCE: Takaratsuka Res. Lab., Sumitomo Chem. Co., Ltd., Osaka, Japan
 SOURCE: Arzneimittelforschung (1972), 22(11), 1950-62
 COUNTRY: GERMANY; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 DT: For diagram(s), see printed CA issue.
 AB: The title compound (I) was prepared in 84.9% yield by reaction of p-MeOCCl₂ with cyclopropenecarbonyl chloride, LiAlH₄ reduction, treatment of the resulting 3-(cyclopropylmethyl)-p-anilide with sodium cyanide in Ac₂O, ring closure of the resulting urea with H₂ in F₂SO₄ in the presence of p-MeOC₆H₄CO₂H, and dehydrogenation. I had antiinflammatory and analgesic properties in rats and low toxicity, and was effective against adjuvant-induced arthritis.
 IT: 33453-23-5P 36342-71-9P
 RU: SPN (Synthetic preparation); PREP (Preparation) [preparation of]
 RH: 33453-23-5 CAPLUS
 CN: 2(18)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RH 36342-71-9 CAPLUS
 CN: 2(18)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)

LS ANSWER 294 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



LS ANSWER 295 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1973-62136 CAPLUS
 DOCUMENT NUMBER: 78-62136
 ORIGINAL REFERENCE NO.: 78-9823a, 9828a
 TITLE: New tablet disintegrating agent. Crosslinked poly(vinylpyrrolidone)
 AUTHOR(S): Kornblum, Saul S.; Stoopak, Samuel B.
 CORPORATE SOURCE: Pharm. Res. Dev. Dep., Sandoz-Heider, Inc., East Hanover, NJ, USA
 SOURCE: Journal of Pharmaceutical Sciences (1973), 62(1), 43-9
 COUNTRY: JPN; ISSN: 0022-3549
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: Cross-linked poly(vinylpyrrolidone) (I) was studied for its disintegration property in comparison to starch USP and alginic acid. Certain phys. parameters of the disintegrants (maximum moisture sorption, hydration capacity, bulk d., and sp. surface area) were determined for the purpose of differentiating their relative efficiency. A linear relation existed when the maximum moisture sorption was plotted vs. the sp. surface area for each disintegrant. Capillary activity of cross-linked I for H₂O appears responsible for its tablet disintegration property. Cross-linked I demonstrated superiority over starch USP and alginic acid in most of the exptl. tablet correlations made by either dry or wet granulation. A quinazolinone derivative was formulated into tablets employing each disintegrant to provide identical disintegration times, and these tablets were submitted to disint. rate anal. The disint. results showed some differences for those made by direct compression but no variation for wet granulated tablets.
 IT: 27760-18-5
 RU: BTDL (Biological study) (tablets, solubility of, disintegrants effect on)
 RH: 27760-18-5 CAPLUS
 CN: 2(18)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 296 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1973:4278 CAPLOS
 DOCUMENT NUMBER: 77:4278
 ORIGINAL REFERENCE NO.: 78:7139, 723a
 TITLE: 1-Methyl-4-phenyl-6-nitro-2(1H)-quinazolinone
 INVENTOR(S): Inaba, Shigeharu Yamamoto, Michihiko Ishiguro, Kikuo Takahashi, Kei Muri, Kazuo Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNEE(S): Jpn. Tokkyo Koho, 2 pp.
 SOURCE: CSDM: JGAGD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4704057	B4	19721009	JP 1969-88516	19691104

AB The title analgesic and antinflammatory compound, was prepared in 1.4 g yield by heating 2.6 g 2-(methylamino)-5-nitrobenzophenone (I) with Et carbamide, and EtCl, using 2-(methylamino)-5-nitrobenzophenimine instead of I also gave the same compound

IT 24951-46-39
 RI: S20 (Synthetic preparation); PREP (Preparation)
 (preparation of)

EN 24951-46-39 CAPLOS
 CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



13 ANMER 298 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1972:140130 CAPLOS
 DOCUMENT NUMBER: 77:140130
 ORIGINAL REFERENCE NO.: 77:23949a, 13952a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Inaba, Shigeharu Yamamoto, Michihiko Ishiguro, Kikuo Takahashi, Kei Muri, Kazuo Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNEE(S): Jpn. Tokkyo Koho, 3 pp.
 SOURCE: CSDM: JGAGD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4702105	B4	19720720	JP 1969-89448	19691107

AB The title compounds, i.e., central nervous system depressant, antinflammatory agents, and analgesics, were prepared by treating trichloroacetoxybenzophenones (I) with HCl. Ex., II (R1 = Me, R2 = SO2) on test-3008 was kept 2 days with ethanolic HCl to give I (R1 = Me, R2 = SO2). Among 8 more 2 similarly prepared were the following (I) and (J)

KJ given: Me, MeO, Me, CF3, Et, NO2, PhCH2, NO2, 2-phenethyl, NO2.
 2341-83-29 23336-81-49 21509-93-49
 24951-46-89 37155-03-49 37671-75-10
 RI: S20 (Synthetic preparation); PREP (Preparation)
 (preparation of)

EN 2341-83-29 CAPLOS
 CN 2(1H)-Quinazolinone, 1-methyl-4-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



EN 23336-81-4 CAPLOS
 CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



13 ANMER 297 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1972:52212 CAPLOS
 DOCUMENT NUMBER: 77:152212
 ORIGINAL REFERENCE NO.: 77:25031a, 25034a
 TITLE: Quinazolinone derivatives
 INVENTOR(S): Yamamoto, Michihiko Ishiguro, Kikuo Muri, Kei Muri, Shigeharu Yamamoto, Hisao Sumitomo Chemical Co., Ltd.
 PATENT ASSIGNEE(S): Jpn. Tokkyo Koho, 4 pp.
 SOURCE: CSDM: JGAGD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4701885	B4	19720918	JP 1971-4400	19710213

AB 1-(Cyclopropylmethyl)-4-phenyl-6-amino-2(1H)-quinazolinone, a central depressant, antinflammatory, and analgesic, was prepared by reducing 1-(cyclopropylmethyl)-4-phenyl-6-nitro-2(1H)-quinazolinone in AcOH-H2O with Fe powder at 100° for 3 hr.

IT 39434-47-49
 RI: S20 (Synthetic preparation); PREP (Preparation)
 (preparation of)

EN 39434-47-49 CAPLOS
 CN 2(1H)-Quinazolinone, 6-amino-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



13 ANMER 298 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)
 EN 25509-93-4 CAPLOS
 CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



EN 24951-46-8 CAPLOS
 CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



EN 37155-03-4 CAPLOS
 CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylethyl)- (CA INDEX NAME)



EN 37671-75-1 CAPLOS
 CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-phenylethyl)- (CA INDEX NAME)



13	ANMERKUNG 299 OF	CARLOS COPYRIGHT 2009 ACS on STN
	ACCESSION NUMBER:	1972:5402:29
	DOCUMENT NUMBER:	77:1401:29
	ORIGINAL REFERENCE NO.:	77:2504:0, 230524
	TITLE:	212H-Quinacridonolones
	INVENTOR(S):	Yamanoto, Mochihiko; Koashika, Masao; Inaba, Shigehiro
	PATENT ASSIGNEE(S):	Yamanoto, Hisao Sunikono Chemical Co., Ltd.
	SOURCE:	Ger. Offen., 22 pp. C2020; F00000
	DOCUMENT TYPE:	Patent
	LANGUAGE:	German
	FAMILY AC NUM COUNT:	1
	ADDITIONAL INFORMATION:	

PATIENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 219682	C1	19700223	DE 1971-219685	19711206
DE 219655	C2	19703221		
DE 219653	R3	19705226		
DE 219651		19706228	JP 1970-109975	19701108
JP 516074	A1	19706228		
CS 558860	A1	19705214	CS 1971-17423	19711210
CS 190074	A1	19706123	CS 1971-16340	19711211
NO 713634	A1	19706007	NO 1971-36340	19711213
DE 2157301	A2	19702212	FA 1971-44282	19711202
DE 2157300	A1	19702212	FA 1971-44287	19711202
DE 2157309	A1	19705225	DE 1971-26623	19711204
DE 776132	A1	19704044	DE 1971-11515	19711207
DE 776131	A2	19706212	DE 1971-11519	19711207
NO 91684	A1	19703220	NO 1971-91683	19711207
NO 512424	A1	19706005	NO 1971-512376	19711207
SE 397038	R2	19711207	SE 1971-58485	19711207
DE 163952	R2	19711218	DE 1971-10578	19711208
FR 510272	2F	19711218	FR 1971-510272	19711208

[illegible]

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



```

FN  22760-25-4  CAPLOS
CN  2[1E]-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl-  (CA INDEX
NAME)

```



HN	22760-60-7	CAPLUS	
CN	21181-00-0	Oxazepam, 1-[2-methylethyl]-6-nitro-4-phenyl-	(CA INDEX NAME)



218]-Quarazolinone, 6-phloro-[ethyl-4-phenyl- (CA INDEX NAME)



CN 21181-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

33443-20-8P	33443-22-0P	33443-23-1P
33443-24-8P	33443-25-3P	33443-26-6P
33443-33-3P	33443-35-5P	33453-19-9P
33453-20-2P	33453-21-3P	33453-22-4P
33453-23-5P	33453-24-6P	33512-31-1P
33890-29-8P	37554-27-1P	37554-35-1P
37554-37-3P	37554-38-4P	37554-39-5P
37554-40-8P	37554-41-9P	37554-43-1P
37554-75-9P	37554-98-6P	37555-00-2P
37555-03-6P	37555-05-9P	37555-09-2P
37555-10-5P	37555-17-2P	37837-21-1P
90039-35-9P		

KL: ESW (Synthetic preparation); PREP (Preparation)

IN	20927-53-1	CAPLUS	
CR	2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl-	(CA INDEX NAME)	



HN 22760-16-3 CAP1/78
 CN (13B)-Quinazolinone, 6,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



89 22760-10-5 CAPLOS

CN 2(18)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA 18
NAME)

L5 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



```

NN 23443-71-6 CAPLOS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-chloropropyl)-4-phenyl- (CA INDEX
NAME)

```



HN	23441-78-3	CAPLUS	
CH	2(1H)-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-3-methyl-	(CA INDEX	



```

R01 23441-81-8 CAPLOS
CN 2(1H)-Quinoxalinone, 1-methyl-6-(methylthio)-4-phenyl- (CA INDEX NAME)

```



HN 23441-83-0 CAPLITE

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CH 2 [18]-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RI 23441-95-5 CAPLUS
 CH 2 [18]-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RI 23465-52-3 CAPLUS
 CH 2 [18]-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RI 23465-55-6 CAPLUS
 CH 2 [18]-Quinazolinone, 6-(3-chlorophenyl)-4-methoxy-1-methyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 25508-93-4 CAPLUS
 CH 2 [18]-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RI 25509-43-7 CAPLUS
 CH 2 [18]-Quinazolinone, 1-ethyl-6-methyl-4-phenyl- (CA INDEX NAME)



RI 25509-45-9 CAPLUS
 CH 2 [18]-Quinazolinone, 1-ethyl-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RI 25509-93-1 CAPLUS
 CH 2 [18]-Quinazolinone, 3-ethyl-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 25558-81-4 CAPLUS
 CH 2 [18]-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoroethyl)- (CA INDEX NAME)



RI 25508-87-6 CAPLUS
 CH 2 [18]-Quinazolinone, 1-ethyl-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RI 25508-91-2 CAPLUS
 CH 2 [18]-Quinazolinone, 1-ethyl-4-phenyl-6-(trifluoroethyl)- (CA INDEX NAME)



15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 26313-42-8 CAPLUS
 CH 2 [18]-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



RI 26313-31-9 CAPLUS
 CH 2 [18]-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RI 26772-86-1 CAPLUS
 CH 2 [18]-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)




15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 FH 26311-13-8 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-[(1-methylethyl)-4-phenyl]- (CA INDEX NAME)



FH 26913-46-8 CAPLOS
 CH 2181-Quinoxalino, 1-methyl-6-ethoxy-4-phenyl- (CA INDEX NAME)



FH 27247-21-8 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-[(2-fluorophenyl)-4-(2-fluorophenyl)-ethyl]- (CA INDEX NAME)



●, HCl

FH 33443-20-8 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



FH 33443-24-2 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-(cyclopentylmethyl)-4-phenyl- (CA INDEX NAME)



FH 33443-25-3 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-(cyclopentylmethyl)-4-phenyl- (CA INDEX NAME)




FH 33443-26-4 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-cyclohexyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



FH 33443-22-0 CAPLOS
 CH 2181-Quinoxalino, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



FH 33443-23-1 CAPLOS
 CH 2181-Quinoxalino, 6,7-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



FH 33443-32-3 CAPLOS
 CH 2181-Quinoxalino, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



FH 33443-35-5 CAPLOS
 CH 2181-Quinoxalino, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



FH 33453-19-9 CAPLOS
 CH 2181-Quinoxalino, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



33 33453-20-2 CAPLUS
CN 2(1R)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



32 33453-21-3 CAPLUS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-fluoro-4-phenyl- (CA INDEX NAME)



32 33453-22-4 CAPLUS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-phenyl- (CA INDEX NAME)


15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



33 33490-39-8 CAPLUS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



33 37514-07-1 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



33 37514-35-3 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



33 33453-23-5 CAPLUS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-4-methoxy-6-phenyl- (CA INDEX NAME)



33 33453-24-6 CAPLUS
CN 2(1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)




33 33512-31-1 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



33 37554-37-3 CAPLUS
CN 2(1R)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



33 37554-38-4 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-1-(2-hydroxyethyl)- (CA INDEX NAME)



33 37554-39-5 CAPLUS
CN 2(1R)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)




33 37554-40-8 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CN INDEX NAME




RN 37554-43-9 CAPLOS
CN 21181-Quinazolinone, 1-[2-(diethylamino)ethyl]-6-nitro-4-phenyl-,
hydrochloride (9C7) (CA INDEX NAME)



● = HCl

RN 37554-45-1 CAPLOS
CN 21181-Quinazolinone, 1-[2-[4-morpholinylethyl]-6-nitro-4-phenyl]-
(CA INDEX NAME)




RN 37554-75-9 CAPLOS


15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CN 21181-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



RN 37554-98-6 CAPLOS
CN 21181-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9C1) (CA INDEX NAME)



RN 37555-00-3 CAPLOS
CN 21181-Quinazolinone, 6-chloro-1-[3-methyl-2-butenyl]-4-phenyl- (9C1) (CA INDEX NAME)



RN 37555-03-6 CAPLOS
CN 21181-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-05-8 CAPLOS
CN 21181-Quinazolinone, 6-chloro-1-[2-(4-fluorophenyl)methyl]-4-phenyl- (CA INDEX NAME)



RN 37555-09-2 CAPLOS
CN 21181-Quinazolinone, 7-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)



RN 37555-10-5 CAPLOS
CN 21181-Quinazolinone, 8-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 299 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLOS
CN 21181-Quinazolinone, 1-(cyclohexylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 37837-21-1 CAPLOS
CN 21181-Quinazolinone, 6-chloro-1-(cyclohexylethyl)-4-phenyl- (9C1) (CA INDEX NAME)



RN 39018-35-8 CAPLOS
CN 21181-Quinazolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

```

IN  23463-54-5  CAPLUS
CN  I(2H)-Quinazolinacetic acid, 6-chloro-2-oxo-4-phenyl-, methyl ester  (CA
INDEX NAME)

```

15 ANSWER 301 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-35-5 CAPLOS
 CN 21(R)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-24-6 CAPLOS
 CN 21(R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 39018-33-6 CAPLOS
 CN 21(R)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 301 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19701514422 CAPLOS
 DOCUMENT NUMBER: 77114442
 ORIGINAL REFERENCE NO.: 7719887a, 1986a
 TITLE: Synthesis of 21(R)-quinazolinones
 INVENTOR(S): Inaba, Shigehiko; Yamamoto, Michikazu; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 11 pp.
 DOCUMENT TYPE: JAPANESE PATENT
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 4701429 34 19700616 JP 1970-6608 19700124
 01 For diagram(s), see printed CA issue.
 AB The title compounds, [I] with antiinflammatory and analgesic activities were prepared from the indole deriva. [II] by oxidation to give benzophenone deriva. [III], which were hydrolyzed to give 2-aminobenzophenone deriva., followed by condensation with K₂CO₃ or K₂CO₃ (X = halo) and cyclization using NEt₃. Thus a suspension of 22 (R₁ = H, R₂ = 5-Cl, R₃ = COEt, R₄ = COEt) in AcOH was treated with aqueous CrO₃ solution at room temperature to give 22 (R₁ = 4-Cl, R₂ = H, R₃ = COEt). Refluxing 22 in H₂O containing NaOH gave 2-amine-5-chloro-benzophenone (IV). IV in benzene was treated with Cl₃CCOCl to give 2-trichloroacetamide-5-chlorobenzophenone (V). A solution of V in MeOH in a sealed vessel was heated with 104 NEt₃ to give I (R₁ = H, R₂ = H, R₃ = 5-Cl, R₄ = H). Eight I (R₁ = H, R₂ = 5-Cl, R₃ = o-F, R₄ = Me, R₅ = 5-Cl, R₆ = H, R₇ = CH₂CH₂CO₂Et, R₈ = 5-Cl, R₉ = o-F, R₁₀ = cyclopropylmethyl, R₁₁ = 5-Cl, R₁₂ = H, R₁₃ = cyclopropylmethyl, R₁₄ = 5-Cl, R₁₅ = H) were similarly prepared.
 IT 2341-90-9F 26977-54-5F 26977-55-6F
 R₁, R₂, R₃ (Synthesis preparation); PREP (Preparation)
 [Preparation of]
 RN 2341-90-9 CAPLOS
 CN 21(R)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)




RN 26977-54-5 CAPLOS
 CN 21(R)-Quinazolinone, 5-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

15 ANSWER 301 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 39018-35-8 CAPLOS
 CN 21(R)-Quinazolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 302 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 26977-55-6 CAPLOS
 CN 21(R)-Quinazolinone, 5-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 28349-74-1 CAPLUS
CI 21181-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RI 28349-77-4 CAPLUS
CI 21181-Quinazolinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RI 28349-79-6 CAPLUS
CI 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 333 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 19721448498 CAPLUS
DOCUMENT NUMBER: 77168498
ORIGINAL REFERENCE NO.: 77168498, 8051a
TITLE: 21181-Quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNER(S): Sandoz Ltd.
SOURCE: Patentblatt (Switz.), 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 520498	A	1972/0331	CH 1969-520689	1969/031
PRIORITY APPL. INFO.:			CH 1972-1976	A 1969/031

GI For diagram(s), see printed CA Issue.
AB 4,2-Me(MeCH₂CH₂)C₆H₄CO₂H, prepared from 4,2-Me(RN)C₆H₃CO₂H and ICMe₂,
was
treated with urethan at 130° for 5.5 hr to give quinazolinone (I, R
= Me, R₁ = Me), which was nitrated with HNO₃-H₂SO₄ at 5-5° for 20
min to give I (R = O₂N, R₁ = Me) (II). Stirring II in MeOH containing

base:
RI and R₂CO gave I (R = Me₂N, R₁ = Me). Nine addl. I (R = Me₂N,
R₂CO₂H, R₁ = Me₂CH₂, R₁ = morpholinol; R₁ = Me, R₂ = Me₂, Cl, morpholinol)
were prepared analogously.
IT 12760-18-19 28349-53-6P 28349-54-7P
28349-57-2P 28349-61-6P 28349-64-8P
28349-65-2P 28349-69-6P 28349-74-1P
28349-77-4P 28349-78-6P 28349-80-8P
RI, SFO (Synthetic preparation); PREP (Preparation)
(preparation of)

RI 28349-18-5 CAPLUS
CI 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 28349-53-6 CAPLUS
CI 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 334 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 37133-54-3 CAPLUS
CI 21181-Quinazolinone, 6-[bis(1-methylethyl)amino]-3-(1-methylethyl)-4-phenyl-1, naphthylchloride (ICI) (CA INDEX NAME)



● ICI

RI 37133-60-1 CAPLUS
CI 21181-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 335 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RI 28349-54-7 CAPLUS
CI 21181-Quinazolinone, 6-(dimethylamino)-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 28349-57-0 CAPLUS
CI 21181-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 28349-61-6 CAPLUS
CI 21181-Quinazolinone, 6-[bis(1-methylethyl)amino]-1-(1-methylethyl)-4-phenyl-1, hydrochloride (ICI) (CA INDEX NAME)

15 ANSWER 305 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



●, HCl

28740-64-9 CAPLOS
 2(1R)-Quinoxalinone, 7-(4-phenyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



28740-65-0 CAPLOS
 2(1R)-Quinoxalinone, 7-(4-phenyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



28740-69-4 CAPLOS
 2(1R)-Quinoxalinone, 7-chloro-4-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 305 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



27556-28-8 CAPLOS
 2(1R)-Quinoxalinone, 6-(dimethylamino)-2,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 305 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



28740-74-1 CAPLOS
 2(1R)-Quinoxalinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



28740-77-4 CAPLOS
 2(1R)-Quinoxalinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



28740-79-4 CAPLOS
 2(1R)-Quinoxalinone, 7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 305 OF 327 CAPLOS COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 1572437252 CAPLOS
 DOCUMENT NUMBER: 77,9252
 ORIGINAL REFERENCE NO.: 7744952,6498a
 TITLE: Improving drug absorption in body fluids
 INVENTOR(S): Mullinger, Guido W.
 PATENT ASSIGNEE(S): Sandoz Ltd.
 SOURCE: Ger. Offen., 17 pp.
 COUNTRY: GERMANY
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2145335	A	19730329	DE 1971-2145335	19710910
NL 7112289	A	19720320	NL 1971-12289	19710907
BE 72594	A1	19720314	BE 1971-100156	19710914
FR 2145453	A5	19720505	FR 1971-23150	19710915
AD 7133517	A	19720322	AD 1971-23517	19710915
PRIORITY APPLICATION INFO.			CS 1970-72529	A 19720214

AB The absorption of drugs which are insol. or practically insol. in body fluids, such as griseofulvin, ergot alkaloids, or phenylquinazoline drugs, is improved by dissolving the drugs in urethane (I), adding poly(vinylpyrrolidone) (II), preferably in the ratio 2:3-7:2 I:II, and heating the solution to 30-120° until all I is evaporated if required

the solution is absorbed on a suitable carrier, such as lactose before I is evaporated

IT 22760-15-5
 N/A: BOLD (Biological study)
 (absorption of, by digestive tract, poly(vinylpyrrolidone) and urethane for promotion of)

22760-15-5 CAPLOS
 2(1R)-Quinoxalinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



15 ANSWER 307 OF 327 CAPLOS COPYRIGHT 2006 ACS ON STN (Continued)



BN 36943-74-2 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(4-chlorophenyl)-3,4-dihydro-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 36942-76-4 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(4-fluorophenyl)-3,4-dihydro-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 36943-01-8 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(4-trifluoromethylphenyl)-3,4-dihydro-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)

15 ANSWER 308 OF 327 CAPLOS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1972:127009
DOCUMENT NUMBER: 76:127009
ORIGINAL REFERENCE NO.: 76:127009, 1957a
TITLE: Antiinflammatory morpholino-substituted 2-substituted-2-[1,8]-quinoxalino-6-yl-1H-imidazo[1,2-b]quinoxalines
INVENTOR(S): Ott, Hans
PATENT APPLICANT(S): Sandoz-Hebden, Inc.
SOURCE: U.S., 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3642791	A	19720215	US 1969-849863	19690813
US 3939215	A	19740625	US 1971-177154	19730901
US 3874640	A	19750409	US 1974-458545	19740409
PRIORITY APPL. INFO.			US 1969-849863	A3 19690513
			US 1971-177154	A3 19730901

GI For diagram(s), see printed CA issue.
AB The title compounds, II, R = morpholino, R1 = H (II); R = H, R1 = morpholino; and R = Me, R1 = morpholino were antiinflammatories and analgesics.
Thus, II; (R = PhCH2, R1 = H) (IV) and R1H was added to COCl2 in CH2Cl2 at room temperature to give VI, which was converted to the HCl salt. IV was prepared from R1H2SO4 (Cl)-H2O-1,3 by heating with [R(CH2)2]O at 160° to give III (R = Cl, R1 = NO2); subsequent cyanation, reduction, and N-depropylation to III (R = CH3, R1 = NHPr-iso) (VI); and treatment of V with PhLi.
IT 22740-15-4p 22740-10-7p 25509-23-1p
28340-13-4p 28340-74-2p 28340-73-2p
28340-77-4p 28340-75-5p 28340-74-6p
R1, R2 SYN (Synthesis preparation) PREP (Preparation)
(preparation of)
BN 22740-15-5 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 22740-40-7 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-nitro-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)

15 ANSWER 307 OF 327 CAPLOS COPYRIGHT 2006 ACS ON STN (Continued)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)



BN 25509-39-1 CAPLOS
CN 2 [1,8]-Quinoxalino-6-yl-1-(1-methylethyl)-4-phenyl-1H-imidazo[1,2-b]quinoxaline (CA INDEX NAME)

13 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



● a RCL

RI 28340-77-4 CAPLUS
 CH 2[18]-Quinoxalinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RI 28340-78-5 CAPLUS
 CH 2[18]-Quinoxalinone, 6-amino-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RI 28340-79-6 CAPLUS
 CH 2[18]-Quinoxalinone, 7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)

13 ANSWER 309 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 137034287 CAPLUS
 DOCUMENT NUMBER: 7634287
 ORIGINAL REFERENCE NO.: 7635584, 5558a
 TITLE: New quinoxaline derivatives
 INVENTOR(S): Maruyama, Tameji; Yamamoto, Hisao
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Tokyo Koho, 3 pp.
 COUNTRY: JAPAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4603970	B4	19711122	JP	19690214
GI	For diagram(s), see printed CA issue.			
AB	1, useful as an antiinflammatory drug, was manufactured by reducing II.			
EW	II (3,4-Me, 3,4-Cl) in AcOH was hydrogenated over PtO to give I (3,4-Me, 3,4-Cl). Similarly prepared was 2 (3,4-Me, 3,4-Cl).			
IT	26772-95-7P 26772-95-2P			
RI	RI: SYN (Synthesis preparation); PREP (Preparation)			
RI	(Preparation of)			
RI	26772-95-7 CAPLUS			
CH	2[18]-Quinoxalinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)			



RI 26772-95-2 CAPLUS
 CH 2[18]-Quinoxalinone, 6-chloro-3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)




15 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



15 ANSWER 310 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 137034288 CAPLUS
 DOCUMENT NUMBER: 7634288
 ORIGINAL REFERENCE NO.: 7635584, 5558a
 TITLE: 1-Methyl-4-phenyl-6-chloro-3,4-dihydroquinoxalin-2-one-3-acetic acid
 INVENTOR(S): Maruyama, Tameji; Yamamoto, Hisao
 PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd.
 SOURCE: Jpn. Tokyo Koho, 3 pp.
 COUNTRY: JAPAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4603970	B4	19711122	JP	19690214
GI	For diagram(s), see printed CA issue.			
AB	The title product (I), useful as an antiinflammatory drug, was manufactured by heating 1-methyl-4-phenyl-6-chloro-3,4-dihydroquinoxalin-2(1H)-one in PhMe-DMF with NaH and EtOAcOEt followed by hydrolyzing with HCl.			
IT	26754-53-5P			
RI	RI: SYN (Synthesis preparation); PREP (Preparation)			
RI	(Preparation of)			
RI	26754-53-5 CAPLUS			
CH	3[28]-Quinoxalinoneacetic acid, 6-chloro-1,4-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)			



15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 197115403977 CAPLUS
 DOCUMENT NUMBER: 751240977
 ORIGINAL REFERENCE NO.: 75122323,2238A
 TITLE: 1-Alkylquinazolinone derivatives
 INVENTOR(S): Inaba, Shigehiro Yamamoto, Michihito Ishimori, Kikuo Takahashi, Kenji Mori, Kazuo Yamamoto, Hisao Saitono, Imperial Co., Ltd.
 PATENT ASSIGNER(S): Cpn. Tokyo Kasei, Ltd.
 SOURCE: Jpn. Kokai Patent Publication, 1998-000000
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACT. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 46203658	B4	19750831	JP	19681210
A2 1-methyl-4-phenyl-6-oxo-2(1H)-quinazolinone, useful as an antiinflammatory drug, was manufactured by methylating 4-phenyl-6-oxo-2(1H)-quinazolinone in DMF with MeI.				
IT 26513-46-39				
ZT 3443-24-39 (Synthetic preparation); PREP (Preparation) [preparation of]				
ZB 3443-46-8 CAPLUS				
CN 2(1H)-Quinazolinone, 1-methyl-4-oxo-4-phenyl- (CA INDEX NAME)				



15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 and 1-(cyclopropylmethyl)-4-phenyl-6-chloroquinazolinone. Also prep. are the 2(1H)-quinazolinones II with 3 = cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, or 3-cyclohexylethyl, R1 = Ph, o-FC6H4, o-ClC6H4, p-tolyl, or 2-pyridyl, R2 = H, Cl, Br, F, Me, CF3, MeO, or NO2, and R3 = H or Cl and the quinazolinone III with n = 1,2,3, or 4 and with R1, R2, and R3 as described for II.

IT 3343-20-39 3343-21-39 3343-22-39
 3343-23-39 3343-24-39 3343-25-39
 3343-26-39 3343-28-39 3343-29-39
 3343-33-39 3343-39-39 3343-20-39
 3343-21-39 3343-22-39 3343-23-39
 3343-24-39 3343-25-39 3343-26-39
 R1: SPH (Synthetic preparation); PREP (Preparation) [preparation of]

ZB 3343-25-8 CAPLUS
 CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



ZB 3343-21-9 CAPLUS
 CN 2(1H)-Quinazolinone, 6-chloro-4-(o-chlorophenyl)-1-(cyclopropylmethyl)- (CA INDEX NAME)



ZB 3343-22-0 CAPLUS
 CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)


15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971523928 CAPLUS
 DOCUMENT NUMBER: 751240928
 ORIGINAL REFERENCE NO.: 75120503,2050A
 TITLE: Antiinflammatory and analgesic quinazolinone derivatives
 INVENTOR(S): Inaba, Shigehiro Yamamoto, Michihito Ishimori, Kikuo Mori, Kazuo Yamamoto, Hisao Saitono, Imperial Co., Ltd.
 PATENT ASSIGNER(S): Cpn. Tokyo Kasei, Ltd.
 SOURCE: Jpn. Kokai Patent Publication, 1998-000000
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACT. NUM. COUNTRY: 2
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JA 7000127	A1	19700428	JA	1970-5070
FR 1040075	A1	19700611	FR	1970-2817
DE 301555	B	19700911	AT	1971-0857
BE 419634	A3	19740705	SV	1970-167064
CH 170971	RE	19700729	CH	1970-4718
US 3757797	US	19710823	US	1970-29724

PRIORITY APPL. INFO.: JP 1969-61222 A 19690804
 JP 1969-70453 A 19690904
 JP 1969-102810 A 19691208
 JP 1969-30536 A 19691208
 JP 1969-39196 A 19691208
 JP 1970-6571 A 19700127
 JP 1970-6628 A 19700124
 JP 1970-14069 A 19700217
 US 1970-59337 A3 19700729

01 For diagram(s), see related CA issue.
 AB 2-(Cyclopropylmethylimino)-5-chlorobenzophenone in AcOH is treated with EtOH to prepare 1-(cyclopropylmethylimino)-5-chloro-2(1H)-quinazolinone [I] which has 6 times the antiinflammatory activity of phenylbutazone and is much less toxic. 1-(Cyclopropylmethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone is prepared similarly but with NaOEt instead of EtOH.
 A DMF solution of 4-phenyl-6-chloro-2(1H)-quinazolinone is added to NaH in DMF and then treated with cyclopropylmethyl bromide to give a 2:1 mixture of I

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



FR 3343-23-1 CAPLUS
 CN 2(1H)-Quinazolinone, 6,7-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



FR 3343-24-2 CAPLUS
 CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclobutylmethyl)-4-phenyl- (CA INDEX NAME)



FR 3343-25-3 CAPLUS
 CN 2(1H)-Quinazolinone, 6-chloro-3-(cyclopentylmethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



BN 33443-26-6 CAPLUS
CN 2 (1R)-Quinazolinone, 6-chloro-1-(cyclohexyl)-4-phenyl- (CA INDEX NAME)



BN 33443-28-6 CAPLUS
CN 2 (1R)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



BN 33443-30-0 CAPLUS
CN 2 (1R)-Quinazolinone, 6-chloro-1-(2-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
CN 2 (1R)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



BN 33453-21-3 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-fluoro-4-phenyl- (CA INDEX NAME)




BN 33453-22-4 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



BN 33453-23-5 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



BN 33443-33-3 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



BN 33453-19-9 CAPLUS
CN 2 (1R)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



BN 33453-20-2 CAPLUS

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



BN 33453-24-6 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



BN 33512-31-1 CAPLUS
CN 2 (1R)-Quinazolinone, 6-chloro-1-(cyclohexylethyl)-4-phenyl- (CA INDEX NAME)



BN 33590-29-8 CAPLUS
CN 2 (1R)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

15 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



15 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1971:43104 CAPLUS
DOCUMENT NUMBER: 75:36104
ORIGINAL REFERENCE NO.: 75:57134, 57164
TITLE: Heterocyclic compounds
INVENTOR(S): Masuda, Toru; Fujii, Shoichiro; Maeto, Kenzo
PATENT ASSIGNOR(S): Takeda Chemical Industries, Ltd.
SOURCE: Jpn. Tokyo Kogyo, 4 pp.
CDBRI: JACQAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACT: SEIN. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4601500	B4	19710416	JP	19671115

GI For diagram(s), see printed CA issue.
AB 7, useful as sedatives, are manufactured 7-chloro-1,2-dihydro-1-methylamino-2-benzyl-5-phenyl-3H-1,4-benzodiazepine (7.5) in 10 ml AcOH is kept 20 hr with 1 ml H₂O to give 1-AOH (8). R₁ = Me, R₂ = Me, R₃ = Ph, R₄ = Cl; X = O, n = 170-2⁺ (decomposition); the free base n. 179-81⁺ (decomposition) (Mol). Similarly prepared are 1 (6), 21, R₂, R₃, R₄, and R₅.
[decomposition] given: C₂, R, Ph, Ph, Cl, 118-15⁺; C₂, R, Me, Ph, Me, 200-14⁺; C₂, R, Me, 2H(CR2)3, Ph, Cl, 115-22⁺; C₂, R, Me, Ph, Cl, 170-11⁺; C₂, R, R, Ph, Cl, 100-90⁺; C₂, R, R, Ph, Cl, - (monoacetate n. 101-5⁺); C₂, R, iso-Pr, Ph, Cl, - (triacetate n. 138-7⁺); C₂, R, iso-But, CR, Cl, - (monoacetate n. 153-5⁺); C₂, R, pentyl, Ph, Me, - (monoacetate n. 163-3⁺); C₂, R, pentyl, p-tolyl, Me, - (monoacetate n. 158-60⁺); C₂, Me, Me, Ph, Me, - (monoacetate n. 158-8⁺); C₂, R, cyanoethyl, Ph, Cl, - (triacetate n. 158-00⁺); C₂, R, nonyl, Ph, Cl, - (monoacetate n. 153-4⁺); C₂, R, p-tolyl, Ph, Cl, 190-3⁺; C₂, CR(CR2)3, Ph, Cl, - (monoacetate n. 148-3⁺).
IT 32558-23-39 32558-24-39 32558-25-39
32558-26-39 32558-27-39 32558-28-40
32558-29-39 32558-29-39 32558-31-39
32558-32-39 32558-33-39 32558-34-39
32558-35-39 32558-36-40 32558-37-39
32558-38-40 32559-12-40
EI: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
NN 32558-23-9 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-6-phenyl-, monoacetate (salt) (8C) (CA INDEX NAME)
CN 1
CIN 32558-24-0
CIN C17 H10 Cl N3 O2

15 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



CN 2
CIN 64-19-7
CIN C2 H4 O2



NN 32558-24-0 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-6-phenyl-, (CA INDEX NAME)




NN 32558-25-1 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3,4-diphenyl-, (CA INDEX NAME)




NN 32558-26-2 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-3-methyl-6-nitro-6-phenyl-, (CA INDEX NAME)


15 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




NN 32558-27-3 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-[3-(dimethylamino)propyl]-3,4-dihydro-4-hydroxy-4-phenyl-, (CA INDEX NAME)



NN 32558-28-4 CAPLUS
CN 2118) Quinazolinethione, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-6-phenyl-, (CA INDEX NAME)



NN 32558-29-5 CAPLUS
CN 2118) Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-ethyl-3,4-dihydro-4-hydroxy-4-phenyl-, (CA INDEX NAME)



NN 32558-30-8 CAPLUS

10/ 540,359

13 ANSWER 313 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-4-phenyl-3-propyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

CN 3

CHN 47416-36-4
CNF C19 H22 Cl N3 O2



CN 2

CHN 64-19-7
CNF C2 H4 O2



RU 32558-33-9 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-2-isopropyl-4-phenyl-, triacetate (salt) (RC2) (CA INDEX NAME)

CN 3


CHN 47416-34-0
CNF C19 H22 Cl N3 O2



CN 2

CHN 64-19-7

13 ANSWER 313 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



CN 2

CHN 64-19-7
CNF C2 H4 O2



RU 32558-34-2 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-3-pentyl-4-p-tolyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

CN 3

CHN 47522-66-7
CNF C22 H29 N3 O2



CN 2

CHN 64-19-7
CNF C2 H4 O2



13 ANSWER 313 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

CN 2 H4 O2



RU 32558-35-0 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-2-isobutyl-4-phenyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

CN 3

CHN 47427-96-9
CNF C19 H24 Cl N3 O2



CN 2

CHN 64-19-7
CNF C2 H4 O2



RU 32558-33-1 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-6-nitro-3-pentyl-4-phenyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

CN 3

CHN 47627-09-9
CNF C21 H26 N4 O4



13 ANSWER 313 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)


RU 32558-35-3 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-3-methyl-6-nitro-4-phenyl-, monoacetate (salt) (RC1) (CA INDEX NAME)



RU 32558-36-4 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-benzyl-3,4-dihydro-4-hydroxy-4-phenyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

CN 3

CHN 47563-23-5
CNF C22 H29 Cl N3 O2




CN 2

CHN 64-19-7
CNF C2 H4 O2




RU 32558-37-5 CAPLOS
CN 2 [18]-Quinazolinone, 1-(2-aminoethyl)-3-benzyl-4-chloro-3,4-dihydro-4-hydroxy-4-phenyl-, monoacetate (salt) (RC1) (CA INDEX NAME)

15 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



3H 31559-38-6 CAPLUS
 CH 313H-Quinoxalinesuccinic acid, 1-(2-aminoethyl)-6-chloro-1,4-dihydro-4-hydroxy-2-oxo-1-phenyl-, ethyl ester, monomethyl salt (ICI) (CA INDEX NAME)
 CM 1
 CR2 47563-12-4
 CMF C16 K2 C1 N1 O4



CM 2
 CHN 64-19-7
 CMF C2 R4 O2




3H 31689-12-6 CAPLUS
 CH 313H-Quinoxalinesuccinic acid, 1-(2-aminoethyl)-6-chloro-1,4-dihydro-4-hydroxy-2-oxo-1-phenyl-, triacetate salt (ICI) (CA INDEX NAME)
 CM 1
 CR2 47447-97-0
 CMF C19 K3 C1 N4 O2

15 ANSWER 314 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 19711405945 CAPLUS
 DOCUMENT NUMBER: 74141687
 ORIGINAL REFERENCE NO.: 74141687
 TITLE: Thiocarbamide derivatives with tuberculostatic action.
 1. Heterocyclic compounds with the thiocarbamide skeleton
 Solymar, Sandor; Kozsika, Istvan; Toth, Gabor; Toldy, Lajos
 Inst. Med. Res., Budapest, Hung.
 Acta Chimica Academiae Scientiarum Hungaricae (1971), 69(1), 93-122
 CODEN: ACAHAJ; ISSN: 0001-5407
 Journal
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 AB For diagram(s), see printed CA Index.
 AB Heterocyclic thiocarbonyl compds. including 1-331 (R = alkyl; R = substituted aryl; n = 1 or 2) as well as open-chain compds.
 KLMKSCSCNCH and KLMKSCN(CH2)3CNCN (107 compds.) were prepared from amino acids and the corresponding isothiocyanates. The thiohydantoins 1 had antitubercular activity in vitro, but were highly toxic to mice. The diaminopyrimidines 2 showed tranquillizing activity. The other compds. showed little or no antitubercular activity

IT 32162-36-59
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 3H 31262-36-5 CAPLUS
 CH 312H-Quinoxalinesuccinic acid, 4-phenyl-2-thioxo-, ethyl ester (CA INDEX NAME)



15 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



CM 2
 CHN 64-19-7
 CMF C2 R4 O2




15 ANSWER 315 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 1971141687 CAPLUS
 DOCUMENT NUMBER: 74141687
 ORIGINAL REFERENCE NO.: 74141687
 TITLE: Reactions of 2,4-(1H,3H)-quinoxalinediones
 El-Kharaf, Mohamed A. F.; Abdel-Meguid, Farouk M. E.; Mokhtar, Kamel E.; Saki, Kamel E. M.
 Nat. Res. Cent., Cairo, Egypt
 JOURNAL OF THE CHEMICAL SOCIETY [SECTION C]: ORGANIC (1971), (6), 1055-8
 CODEN: JOCOR; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Index.
 AB 6-Chloro-3-phenyl-2,4-(1H,3H)-quinoxalinedione (I) reacted with PC15 or POCl3 to give 2,6-dichloro-3-phenyl-4(3H)-quinoxalinedione (II). II reacted with NEt3, K2CO3, NaHCO3, POCNMe3, and POCNMe2 to give the corresponding 2-amino analogs. 3-Phenyl-2,4-(1H,3H)-quinoxalinediones (I, II, and IV) reacted with PPhMe2 to give 1,1,7,7-tetrahydro-2,4-dihydro-2,4-(1H,3H)-quinoxalinediones (VI). The products of treating I with MeHgCl and p-MeOC6H4NH2 underwent dehydration to 6-chloro-3,4-dihydro-2-ethyl-4-methylene-3-phenylquinoxaline and 6-chloro-3,4-dihydro-2,4-bis(p-methoxyphenyl)-3-phenyl-4-quinoxalinedione, resp.
 2,4-(1H,3H)-Quinoxalinedione
 reacted with EtNHMe and PPhMe2 to give 2,4-diethyl- and 2,4-diphenylquinoxaline, resp.
 IT 31730-59-2F 31730-59-7F
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 3H 31730-59-2 CAPLUS
 CH 2,4-Quinoxalinedione,
 6-chloro-1,2,3,4-tetrahydro-1-methyl-2,3,4-triphenyl-
 (CA INDEX NAME)



3H 31730-59-3 CAPLUS
 CH 2,4-Quinoxalinedione,
 6-chloro-1,2,3,4-tetrahydro-1-methyl-2,3,4-triphenyl-
 1-methyl-1,3-phenyl- (ICI) (CA INDEX NAME)

15 ANSWER 315 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

321 31822-52-3 CAPLUS
CN 2182-Quinazolinone, 1-(1,1-dimethylethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 316 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 1971-125720 CAPLUS
DOCUMENT NUMBER: 74-125720
ORIGINAL REFERENCE NO.: 74-20715a, 20715a
TITLE: Tertiary-butylamino-benzonemes, useful as intermediates in preparing pharmacologically active 1-substituted-4-aryl-2,18-quinazolinones
INVENTOR(S): Coombs, Robert V; Barthman, Gert E.
PATENT ASSIGNMENT(S): Sandoz-Wander, Inc.
SOURCE: U.S., 4 pp
CDBN: 0550AM
DOCUMENT TYPE: Patent
LANGUAGES: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7443151	A	19701117	US 1968-70725a	19681224
PRIORITY APPL. INFO.:			US 1968-70725a	A 19681224

01 For diagram(s), see printed CA issue.

AS The title compds. (I) are prepared by thermal rearrangement of the corresponding 1-tert-butyl-3-aryl-2,1-benzoxazole (III). Thus, 5-chloro-6-methyl-3-phenyl-2,1-benzoxazole in NaOH kept 60 hr at 20° with Me₂CO and 60% aqueous H₂SO₄ and diluted with anhydrous Et₂O yielded 1-tert-butyl-5-chloro-6-methyl-3-phenyl-2,1-benzoxazolinium perchlorate (VII), m. 185-5°. VII in absolute alc. treated portionwise in 15 min with NaH₂ and the cooled mixture diluted with Et₂O gave 1-tert-butyl-5-chloro-6-methyl-3-phenyl-2,1-benzoxazolinone (IV), m. 114-15°. IV kept 4 hr at 160° and the brown oil product taken up in CH₂Cl₂, chromatographed on Al₂O₃ and eluted with CH₂Cl₂ gave 2-(tert-butylamino)-5-chloro-6-methylbenzoxazine (VI), m. 70-5°. V heated 2 days at 120° in a stainless steel cylinder with NH₃ and Et₂O gave only 2-(tert-butylamino)-5-chloro-6-methylbenzoxazolinone which with Et₂N in Et₂O treated at 5-20° with 1% CsCl in Et₂O and the reaction on evaporation taken up in 0-5% Na₂CO₃ yielded the quinazolinone (VI), s. 6-Cl, 7-Me, 7'-H, m. 145-50°. V hydrogenated catalytically over Pt-C in 3:1 MeOH-EtOAc containing KOH gave 2-(tert-butylamino)-6-methylbenzoxazolinone, m. 57-63°, oxidized in Et₂O with Na₂Cr₂O₇ in AcOH-EtOAc at 0-5° to give only 1 (I, s. 4-Me, 7'-H, R, converted with NH₃ in the presence of Et₂O to the corresponding imine, and transformed as above to the corresponding VI (s. 7-Me, 7'-H, R).

R, m. 143-3°. VI have antiinflammatory activity.

17 31822-48-7P 31822-52-3P

RU 87H (synthetic preparation); PREP (Preparation)

[Preparation of]

RU 31822-48-7 CAPLUS

CN 2182-Quinazolinone, 1-tert-butyl-6-chloro-7-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 316 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

321 31822-52-3 CAPLUS
CN 2182-Quinazolinone, 1-(1,1-dimethylethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 1970-44504
DOCUMENT NUMBER: 75-4541
ORIGINAL REFERENCE NO.: 75-1534, 752a
TITLE: Antiinflammatory 1-alkyl-4-phenyl-2-quinazolinones
INVENTOR(S): Sandoz Ltd.
PATENT ASSIGNMENT(S): Sandoz Ltd.
SOURCE: S. Africa, 25 pp.
CDBN: 0550AM
DOCUMENT TYPE: Patent
LANGUAGES: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SA 6803796		19691127		

01 For diagram(s), see printed CA issue.

AS The title compds. (I), useful as antipyretic and analgesic agents, are prepared. 4-phenylquinazolinone (II) (I) in 10 ml MeI kept overnight at 20° and refluxed 5 hr gave 11 MeI (VII), m. 200-1°. To a solution of 4 g RMO4 in 150 ml H₂O at 25° was slowly added a suspension of 5.7 g VII in 300 ml dioxane, and the mixture kept 15 min to give I (R₁ = H, R₂ = R₃ = H) (IV), m. 142-3° (AcOEt-Et₂O). VII (18 g) in 500 ml EtOH and 250 ml CH₂Cl₂ was treated portionwise at room temperature with 6 g NaH₂ and the mixture kept 45 min to give 1-methyl-4-phenyl-1,2,3,4-tetrahydroquinazolinone (V), oil. Oxidation of V in 500 ml dioxane with 13.2 g RMO4 in 250 ml H₂O at 20° gave IV, also prepared by heating a mixture of 1 g 2-MeMe₂CH₂CH₂, 2 g R₂HCO₂Et, and 20 mg Et₂Cl₂ 1.25 hr at 180-20°. To 2.2 g 4-phenyl-2,18-quinazolinone in 50 ml EtOH at 20° was added 0.75 g NaH (50% in oil) and the mixture stirred 15 min, treated with 4 ml Et₂, stirred 0.5 hr, and heated 0.5 hr at 60° to give I (R₁ = H, R₂ = R₃ = H) (IV), m. 223-4° (AcOEt). I (R₁ = H, R₂ = 6-Cl, R₃ = H, m. 223-4° (AcOEt), was similarly prepared. To ethereal 4-ClCH₂CH₂ prepared from 4-BrCH₂CH₂ and 3.1 ml 1.6N NaOH in hexane was added 0.65 g quinazolinone in 10 ml Et₂O and the mixture stirred 10 min to give 4-(4-chlorophenyl)-3,4-dihydroquinazolinone (VII), m. 166-7° (AcOEt). Oxidation of 5 g VI with 5.27 g RMO4 gave 4-(4-chlorophenyl)quinazolinone, m. 122-3° (Et₂O) methiodide (VII) m. 222-5°. Reduction of VII with NaH₂ and oxidation of the only 1-methyl-4-(4-chlorophenyl)-1,2,3,4-tetrahydroquinazolinone formed with RMO4 gave I (R₁ = H, R₂ = H, R₃ = 4-Cl), m. 185°. The following quinazolinone isomers were prepared (substituents and m.p. given):

1-methyl-4-(4-methoxyphenyl)-, 228-25° (EtOH); 1-methyl-4-(4,4-dimethoxyphenyl)-, 198-204° (decomposition); 1-methyl-3-(4-chlorophenyl)-, m. 200-10°; 1-methyl-4-(3-trifluoromethylphenyl)-, 7 and 1-methyl-4-(2,3-dimethylphenyl)-, 200-10°. Reduction of 1-methyl-4-phenyl-1,2,3,4-tetrahydroquinazolinone (V) with RMO4 gave the following I (R₁ = Me, R₂ = H (R₃ and n.p. given) 4-MeO (VII), 184° (AcOEt); 2,6-(MeO)₂, 166-17° (AcOEt); 3-Cl, 95-4° (Et₂O-petroleum ether); 3-FCO₂, 165-7° (AcOEt-Et₂O); and 2,7-Me₂, 186-9° (AcOEt). The following I (R₁ = R₂ = H, R₃ and n.p. given) were prepared: R₁, 171°; R₂, 180-4° (AcOEt-Et₂O); CO₂H, 123-24°; CH₂CH₂CH₂, 159-60°; CH₂CH₂CH₂CH₂CH₂, 180-10° (AcOEt); and 181° (EtOH). I (R₁ = Me, R₂ = 6-Cl, R₃ = 2-Cl), m. 191-4°, was prepared by methylation of 4-chloro-4-(2-chlorophenyl)-2,18-

15 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 quinazolinone. Refining a mixt. of 3 g VIII and 20 ml 40% aq. HBr 20 hr gave 1 [R1 = Me, R2 = H, R3 = 4-OMe, n = 2(1-3* (AcOEt)). By analogous method were prepd. the following 1 [R1, R2, R3, and n.p. [AcOEt] given]: iso-Pr, n. 120-17°; CH₃(CMe₂Me, R, H, 141-17°; R, 6-Cl, n. 153°; iso-Pr, R, H, 140°; iso-Pr, 6-Cl, R, 149-50° (Me₂CO); iso-Pr, 6-Cl, 2-Cl, 147-9° (Me₂CO); iso-Pr, R, 4-Me, 139-42° (Me₂CO); and iso-Pr, 7-Cl, R, 165-9°. Daily oral doses of 1 are in the range 37.5-500 mg. Typical tablets contain 50% by wt. Va.
 IT 170-24-2P 209217-53-3P 23441-64-7P
 23441-88-5P 26721-86-1P 26824-71-5P
 26724-77-3P 26824-90-6P 26824-94-1P
 26824-92-8P 26824-94-0P 26824-94-2P
 26824-96-4P 26824-97-5P 26831-05-1P
 26831-07-2P 26831-08-3P 26831-09-4P
 26831-11-6P 26840-07-0P 27524-93-1P
 27524-93-2P 27529-13-3P 27559-10-5P
 R1, R2 (Synthetic preparation); PREP (Preparation)
 (preparation of)
 R3 170-24-2 CAPLUS
 CN 21(8)-Quinazolinone, 3-methyl-4-phenyl- (CA INDEX NAME)



R3 209217-53-1 CAPLUS
 CN 21(8)-Quinazolinone, 6-chloro-1-methyl-6-phenyl- (CA INDEX NAME)



R3 23441-64-7 CAPLUS
 CN 21(8)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 R3 26824-77-1 CAPLUS
 CN 21(8)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



R3 26824-90-6 CAPLUS
 CN 21(8)-Quinazolinone, 4-phenyl-1-propyl- (CA INDEX NAME)



R3 26824-93-7 CAPLUS
 CN 21(8)-Quinazolinone, 1-allyl-4-phenyl- (CA INDEX NAME)



R3 26824-92-8 CAPLUS
 CN 21(8)-Quinazolinone, 1-pentyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



R3 23441-88-5 CAPLUS
 CN 21(8)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



R3 26721-86-1 CAPLUS
 CN 21(8)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



R3 26824-71-5 CAPLUS
 CN 21(8)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (R1) (CA INDEX NAME)



15 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 R3 26824-84-0 CAPLUS
 CN 21(8)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (R1, R2) (CA INDEX NAME)



R3 26824-94-2 CAPLUS
 CN 21(8)-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



R3 26824-96-4 CAPLUS
 CN 21(8)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



R3 26824-97-5 CAPLUS
 CN 21(8)-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)



15 ANSWER 317 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RE 26831-06-1 CAPLOS
CN 2(18)-Quinazolinone, 6-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



RE 26831-07-2 CAPLOS
CN 2(18)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RE 26831-08-3 CAPLOS
CN 2(18)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

15 ANSWER 317 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RE 27524-92-1 CAPLOS
CN 2(18)-Quinazolinone, 1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RE 27524-93-2 CAPLOS
CN 2(18)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RE 27529-23-3 CAPLOS
CN 2(18)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (9CI) (CA INDEX NAME)

15 ANSWER 317 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RE 26831-09-4 CAPLOS
CN 2(18)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-(1-methylethyl)- (CA INDEX NAME)



RE 26831-11-8 CAPLOS
CN 2(18)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RE 26940-07-8 CAPLOS
CN 2(18)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

15 ANSWER 317 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RE 27528-10-0 CAPLOS
CN 2(18)-Quinazolinone, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



LS ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



32 26824-94-2 CAPLUS
CN 2 [18]-Quinoxalinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



33 26824-96-6 CAPLUS
CN 2 [18]-Quinoxalinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



34 26824-97-8 CAPLUS
CN 2 [18]-Quinoxalinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)

LS ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



35 26823-06-1 CAPLUS
CN 2 [18]-Quinoxalinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



36 26831-07-2 CAPLUS
CN 2 [18]-Quinoxalinone, 1-methyl-4-phenyl- (CA INDEX NAME)



37 26831-08-3 CAPLUS
CN 2 [18]-Quinoxalinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

LS ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



38 26840-07-9 CAPLUS
CN 2 [18]-Quinoxalinone, 1-methyl-4-([3-(trifluoromethyl)phenyl])-1-methyl- (CA INDEX NAME)



LS ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STN

1570100737 CAPLUS
DOCUMENT NUMBER: 72100737
ORIGINAL REFERENCE NO.: 72100737, 182546
TITLE: Antiinflammatory
1-alkyl-4-phenyl-2 [18]-quinoxalinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNOR(S): Baxxys Ltd.
SOURCE: Ger. Offen., 64 pp.
DOCUMENT TYPE: OTHER OTHERS
LANGUAGE: German
FAMILY ACC. NUM. COUNTRY: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1932402	A	19700305	DE 1969-1932402	19690626
DE 1932402	B2	19800905		
DE 1932402	C3	19910903		
GB 3549235	A	19701222	GB 1969-741506	19690701
CH 514552	A	19711021	CH 1969-514552	19690622
CH 514553	A	19711021	CH 1969-514553	19690622
CH 514554	A	19711021	CH 1969-514554	19690622
CH 514603	A	19711021	CH 1969-514603	19690622
GB 1280553	A	19700705	GB 1969-1280553	19690623
GB 1280553	A	19700705	GB 1969-1280553	19690623
DE 129047	B	19700912	DE 1969-3229	19690626
NO 54693	A1	19700217	NO 1969-60372	19690628
NO 57329	A1	19700215	NO 1969-62546	19690628
NO 57381	A1	19700415	NO 1969-62145	19690628
IL 32305	A	19700330	IL 1969-32305	19690629
FR 2012061	A5	19700313	FR 1969-21894	19690630
SE 369946	A1	19710716	SE 1969-369946	19690630
BR 6910202	B0	19700209	BR 1969-210002	19690630
AT 306723	B	19700425	AT 1969-6237	19690630
AT 306731	B	19700425	AT 1971-5061	19690630
NO 396022	A3	19700808	NO 1969-1343969	19690630
NO 44367	A3	19700925	NO 1969-1407624	19690630
CA 956954	A1	19711029	CA 1969-58727	19690630
SA 6904678	A1	19710214	SA 1969-4678	19690701
BR 373154	A1	19700201	BR 1970-373154	19700429
KE 379155	A1	19700201	KE 1970-379155	19700429
KE 379156	A1	19700201	KE 1970-379156	19700429
KE 379157	A1	19700201	KE 1970-379157	19700429
KE 379158	A1	19700201	KE 1970-379158	19700429
KE 379159	A1	19700201	KE 1970-379159	19700429
KE 379160	A1	19700201	KE 1970-379160	19700429
KE 381047	A1	19700316	KE 1970-381047	19700429
KE 381048	A1	19700403	KE 1970-381048	19700429
BR 7505420	A	19750512	BR 1975-5420	19750512
FR103177 AUPH, INFO.			FR 1969-814306	19690701
			US 1969-741507	A 19690701
			US 1969-707252	A 19691226
			US 1969-707254	A 19691226
			US 1969-816383	A 19690415

LS ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 US 1969-B19435 A 19690425
 US 1969-B19435 A 19690425
 US 1969-B19451 A 19690425

GI For diagram(s), see printed CA issue.

AB The title compds. (I) were prepared Thus, 100 g, 4,3-Cl-(O2N)C6H3Me, 40 g CuCl₂, and 150 ml AcOH, was refluxed 4.5 hr to give 4,3-Cl-(O2N)C6H3Me, 40 g

n. 96-7%, which was redissolved with Fe-HCl in EtOH to give 18, m. 68-90° in 150 g, 120 ml iso-Pr, 36 g K2CO₃, and 0.5 g powdered Cu was refluxed 9 days to give 18, 10 (5.22 g) in 40 ml EtOH and 90 milliliter PhH in 1:1 EtOH:CH₂Cl₂ gave 19; isolate 19, 11-24%, 10 (5 g), 3 ml ClO₂CH₃, and 30 ml CH₂ was refluxed 2.5 hr (method A) to give 11

1 (R₂ = iso-Pr, R₃ = R₄ = Me) (II), m. 137-8°. Ring closure of 10 to 11 was also performed by ClO₂CH₃ in the presence of Et₃N,

by oxidation in the absence of Et₃N (method B), by ClO₂CH₃ (method C), and by 1,1'-oxybis(4-fluorobenzene) (method D). 11 was also prepared from 1d, 10, 1048-75, 9.5, and R₂Cl 4.2 g in 100 ml MeCO by refluxing 3 hr and hydrolyzing the 2-thione, m. 185-90°, with NaOH (method E). 3-MeC₆H₄-CH₂-iso (III), b.p. 109°, was prepared from m-toluidine, iso-Pr, and Et₃N in PhH (11), 4.3 g nitroarene, and 20 ml EtOH was heated on a steam bath 2 hr to give 3-MeC₆H₄(Pr)-iso(CO₂Et) (IV), m. 59-94°, 20 (12 g), 0.4 g R₂N, and 50 ml CH₂ in the presence of approx. 10 mg p-MeC₆H₄SO₃Na was refluxed 22 hr to give the corresponding dihydroquinazolinone, m. 169°, which was dehydrogenated to 11 by refluxing with MeCO (method F). 11 by method G gave the N-benzyloxy derivative, m. 115-13°, and 3-MeC₆H₄(Pr)-iso(CO₂Et) (IV), m. 136-17°, V (12 g), 0.5 g R₂N, and 25 ml Et₃N-saturated CH₂Cl₂ was refluxed 15 hr to give the corresponding dihydroquinazolinone-2-thione, m. 125-17°, which was oxidized with KMnO₄ to 12 (method G). Similarly prepared were the following 1 (R₂, R₃, R₄, R₅, n.p., and method given):

Et, R₂, Me, Me, 176-80°, A and D; Et, R₂, R, CF₃, R, 180°, A; Et, R, Me, R, 150-15°, A; Me, R, Me, Me, 187-8°, A; Et, R, Me, R, 135-42°, R; Et, R, R, R, 204-15°, R; Me, R, R, R (V), 141-34°, R; C, and R, Me, R, Cl, R (VI), 223-4°, R; C, R, and R, Me, CCl₃, R, R, 122-2°, C; Et, R, R, R (VII), 125-3°, C and R; Me, CMe₃, R, R, 184°, C; iso-Pr, 2-Cl, Cl, R, 147-30°, C; iso-Pr, R, R, R (IX), 145°, C and R; iso-Pr, R, Cl, R, 169-10°, C; iso-Pr, R, Me, R, 190-2°, C; iso-Pr, R, Me, R, 170-17°, C; iso-Pr, R, Me, R, 157-3°, C; Et, R, R, Cl, 181-5°, C; iso-Pr, R, CN, R, 155-8°, D; iso-Pr, R, Me, R (X), 125-17°, F; iso-Pr, R, Me, R (XI), 140-37°, R; allyl, R, R, R (XII), 129-68°, R. 4-Cl-C₆H₄CO₂Et 63.8, R(CO₂Me) 28.7, and concentrated H₂SO₄ 2 g was heated to give the N-formyl-N-methyl derivative, b.p. 130-40°, 50 g of which was refluxed 19 hr with 200 ml 10N HCl to give 4-Cl-C₆H₄SO₃Na, b.p. 143-4°. The latter and nitroarene formed the corresponding urea derivative, 0.5 g of which was refluxed 20 hr with

0.25 g R₂ in the presence of p-MeC₆H₄SO₃Na and dehydrogenation of the resulting

LS ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 US 22760-16-3 CAPLOS
 CN 2128-Quinazolinone, 6,7-dimethyl-1-(1-methylthyl)-4-phenyl- (CA INDEX NAME)



RU 22760-17-4 CAPLOS
 CN 2128-Quinazolinone, 6-methyl-1-(1-methylthyl)-4-phenyl- (CA INDEX NAME)



RU 22760-18-5 CAPLOS
 CN 2128-Quinazolinone, 7-methyl-1-(1-methylthyl)-4-phenyl- (CA INDEX NAME)



RU 22760-23-4 CAPLOS
 CN 2128-Quinazolinone, 7-methoxy-1-(1-methylthyl)-4-phenyl- (CA INDEX NAME)



LS ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 dihydro-quinazolinone, m. 184-7°, with MeCO gave VII. Similarly prepd. was 1-dihydro deriv., m. 154-40°, 2-MeC₆H₄CH₂CO (15 g) and 15 g urea was heated 15 hr at 150° under H to give 1-methyl-2(18)-quinazolinonyl hydrochloride (XIII) m. 232-5°, XIII (1 g), 200 ml tetrahydrofuran, and 5 ml 2N PhH, in 7:3 CH₂Cl₂:Et₂O at 25-30° gave the dihydroquinazolinone, m. 183-4°, which was oxidized with KMnO₄ to give VI, 2-MeC₆H₄CH₂CO (10 g), 10 g Na₂CO₃, and 50 ml iso-Pr was refluxed 5 days to give 2-iso-Pr-HEC₆H₄Me, 30 g of which was added to 11.3 g NH₄SCN and 10.4 g R₂Cl in 100 ml MeCO and refluxed 7 hr to give the 2-thione, m. 212-14°. A₁ hydrolysis of the latter gave III. Similarly prepd. were the 2-thione of VII, m. 232-7°, of VII, m. 228-30°, of III, m. 140-45°, and of XII, m. 190-4°. 10 and 11 have analgesic and anti-inflammatory activities, resp.

IT 20929-04-SP 20927-53-IP 22760-16-IP
 22760-17-4P 22760-18-5P 22760-15-4P
 22760-40-7P 25509-87-6P 25509-91-2P
 25509-95-4P 25509-41-5P 25509-43-7P
 25509-17-3P 25509-41-9P 26772-84-1P
 26772-86-7P 26772-95-2P 26772-96-7P
 26824-16-4P 26824-66-8P 26824-68-0P
 26824-69-1P 26824-70-4P 26824-71-5P
 26824-74-9P 26823-06-1P 26823-07-2P
 26823-08-7P 26823-09-4P 26823-11-8P
 R₂1 SP (Synthetic preparation); FREE (Preparation)

RU 17629-04-8 CAPLOS
 CN 2128-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RU 20927-53-1 CAPLOS
 CN 2128-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



LS ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 US 22760-40-7 CAPLOS
 CN 2128-Quinazolinone, 1-(1-methylthyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RU 25508-87-6 CAPLOS
 CN 2128-Quinazolinone, 1-ethyl-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RU 25508-91-2 CAPLOS
 CN 2128-Quinazolinone, 1-ethyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RU 25508-93-4 CAPLOS
 CN 2128-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RU 25509-41-5 CAPLOS

13 ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CN 6-Quinazolinemethanitrile, 1,2-dihydro-1-isopropyl-2-oxo-6-phenyl- (BCI)
 (CA INDEX NAME)



RN 25509-43-7 CAPLOS
 CN 2 (18)-Quinazolinone, 1-ethyl-6-methyl-4-phenyl- (CA INDEX NAME)



RN 25509-57-3 CAPLOS
 CN 2 (18)-Quinazolinone, 6,7-dimethoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 25509-61-9 CAPLOS
 CN 2 (18)-Quinazolinone, 1-ethyl-6-methoxy-6-phenyl- (CA INDEX NAME)



15 ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-56-6 CAPLOS
 CN 2 (18)-Quinazolinone, 7-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26824-66-9 CAPLOS
 CN 2 (18)-Quinazolinone, 3,4-dihydro-2-methyl-4-phenyl- (CA INDEX NAME)



RN 26824-68-0 CAPLOS
 CN 2 (18)-Quinazolinethione, 1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



RN 26824-69-1 CAPLOS
 CN 2 (18)-Quinazolinethione, 7-methyl-2-[1-methylethyl]-4-phenyl- (CA INDEX NAME)

15 ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

RN 26772-86-1 CAPLOS
 CN 2 (18)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-90-7 CAPLOS
 CN 2 (18)-Quinazolinone, 7,4-dihydro-7-methyl-3-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



RN 26772-95-2 CAPLOS
 CN 2 (18)-Quinazolinone, 6-chloro-3,4-dihydro-7-methyl-4-phenyl- (CA INDEX NAME)



RN 26772-96-3 CAPLOS
 CN 2 (18)-Quinazolinone, 3,4-dihydro-6,7-dimethyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



15 ANSWER 319 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-70-4 CAPLOS
 CN 2 (18)-Quinazolinone, 6-methoxy-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



RN 26824-71-5 CAPLOS
 CN 2 (18)-Quinazolinone, 4-phenyl-1-[2-propenyl]- (PCI) (CA INDEX NAME)



RN 26824-74-8 CAPLOS
 CN 2 (18)-Quinazolinethione, 3,4-dihydro-7-methyl-1-[1-methylethyl]-4-phenyl- (CA INDEX NAME)



RN 26831-04-1 CAPLOS
 CN 2 (18)-Quinazolinone, 4-(4-chlorophenyl)-3-methyl- (CA INDEX NAME)

LS ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RI 2141-92-1 CAPLUS
 CI 2181-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (8C1) (CA INDEX NAME)




RI 21465-52-3 CAPLUS
 CI 2181-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)




RI 21465-55-6 CAPLUS
 CI 2181-Quinazolinone, 4-(3-chlorophenyl)-6-methoxy-1-methyl- (CA INDEX NAME)

LS ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RI 2147-21-8 CAPLUS
 CI 2181-Quinazolinone, 4-chloro-1-(2-(dimethylamino)ethyl)-4-(2-fluorophenyl)-, hydrochloride (9C1) (CA INDEX NAME)



●, 8C1

LS ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



RI 21558-81-4 CAPLUS
 CI 2181-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoroacetyl)- (CA INDEX NAME)



RI 2633-42-8 CAPLUS
 CI 2181-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



RI 2633-51-9 CAPLUS
 CI 2181-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

LS ANSWER 321 OF 327 CAPLUS COPYRIGHT 2008 ACS ON STM

ACCESSION NUMBER: 157066976 CAPLUS
 DOCUMENT NUMBER: 7266976
 ORIGINAL REFERENCE NO.: 72122354,12338a
 TITLE: Antinflammatory quinazolinones
 PATENT ASSIGNMENT(S): Boussel-LOEAP
 SOURCE: Fr. M., 7 pp.
 CODES: FMC6A7
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6159		19600808	FR	19670518

OTHER SOURCE(S): MARRAT 7266976
 GI For diagram(s), see printed CA issue.
 AB 2-Quinazolinones I show useful antinflammatory activity at a daily adult oral dose of 0.1-2 g daily. Heating a mixture of 9.4 g II, 3.84 g NaOH, and 96 ml MeOH at 60° 16 h gave I (X = R2 = H, Y = 2-MeC6H4, R1 = Cl), (II), m. 267-8°. A mixture of 4.5 g III and 840 mg NaH (50% in oil) in 100 ml MeOH was stirred until H evolution ceased, treated with 3.4 g MeI in 30 ml MeOH and stirred 15 h to give 3.125 g I (R1 = Cl, R2 = H, X = Me, Y = 2-MeC6H4), m. 210-13°. By similar methods were prepared 93.5% I (X = R2 = H, Y = Ph, R1 = OMe), m. 287° (MeOH). 75% I (R1 = OMe, R2 = H, X = Me, Y = Ph), m. 168°, I (X = R2 = H, Y = Ph, R1 = Cl), m. 286-7° (EtOH); I (R1 = H, R2 = Cl, X = Me, Y = Ph), m. 190° (EtOH); 46% I (R1 = Cl, R2 = H, X = Et, Y = Ph), m. 168° (FMeO); I (R1 = Cl, R2 = H, X = H, Y = 4-ClC6H4), m. 276°. In the last two tests, I showed good antinflammatory activity in the oral dose range 10-50 mg/kg.

IT 2144-63-4P 2144-64-7P 2144-74-5P
 2144-92-1P 2144-93-2P
 RI: STM (Synthetic preparation); PREP (Preparation)
 Preparation of
 RI 2144-63-6 CAPLUS
 CI 2181-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RI 2144-64-7 CAPLUS
 CI 2181-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 321 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-92-1 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (ICI INDEX NAME)



RN 23441-93-2 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-1-methyl-6-o-tolyl- (ICI INDEX NAME)

15 ANSWER 322 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
ACCESSION NUMBER: 1370335763 CAPLUS

DOCUMENT NUMBER: 72135763

ORIGINAL REFERENCE NO.: 72165894, 6592a

TITLE: Problems in application of the Hammett equation to a heterocyclic series

AUTHOR(S): Wolfert, Ernst; Solis, Paul; Mathieu, Jean

CORPORATE SOURCE: Centre Rech., Roussel-Uclaf, Neuillyville, Fr.

SOURCE: Chimica Therapeutica (1969), 4(4), 257-9

CODEN: CHTPMA; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: French

QC For Diagram(s), see printed CA Issue.

AB Application of the Hammett equation (CA 67:11372a) to 6-substituted quinazolinones, 7H = CH, OMe, O(COEt), O(COEt)COEt & F, Cl, CF₃, SO₂Me, and SO₂

with regard to antiinflammatory activity was attempted. The Hammett para ρ values showed linear relations with carbonyl stretching frequencies and with half-neutralization potentials. When Hammett's

solubility parameter, para ρ , was replaced by a modified function, ρ^* [$\rho^* = 1.2841\rho - 1.0202\rho^2 + 0.2974$], taking into account the influence of electronic effects on solubility, improved correlation with the biol.

activity was observed.

IT 17629-04-8 26937-53-3 23441-63-6

23441-74-9 23441-83-0 23536-81-4

26953-39-9 26953-41-3 26953-42-4

26953-46-8

XL PPP (Properties)

(substituent constant of)

RN 17629-04-8 CAPLUS

CN 2(1R)-Quinazolinone, 1-methyl-4-phenyl- (ICI INDEX NAME)



RN 20971-53-1 CAPLUS
CN 2(1R)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-63-6 CAPLUS

15 ANSWER 323 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (ICI INDEX NAME)




RN 26953-39-9 CAPLUS
CN 2(1R)-Quinazolinone, 6-hydroxy-1-methyl-4-phenyl- (ICI INDEX NAME)

15 ANSWER 322 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



320 26933-41-3 CAPLOS
 CH 2-[1R]-Quinoxalino[6,5-b]pyridine, 6-ethyl-1-methyl-4-phenyl- (CA INDEX NAME)



320 26933-42-4 CAPLOS
 CH 2-[1R]-Quinoxalino[6,5-b]pyridine, 6-fluoro-1-methyl-4-phenyl- (CA INDEX NAME)



320 26933-46-8 CAPLOS
 CH 2-[1R]-Quinoxalino[6,5-b]pyridine, 1-methyl-4-nitro-4-phenyl- (CA INDEX NAME)



15 ANSWER 323 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1969:479754 CAPLOS
 DOCUMENT NUMBER: 71:79754
 ORIGINAL REFERENCE NO.: 71:14753a,14754a
 TITLE: Microbiological modification of benzodiazepines
 Greenknap, George; Kuehli, Hans M.; Alberty, Harvey
 INVENTOR(S):
 PATENT ASSIGNOR(S): American Home Products Corp.
 SOURCE: U.S., 6 pp.
 COUNTRY: US:0000
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3433179	A	19690701	US 1967-614409	19670207
PRIORITY APPL. INFO:			US 1967-614409	A 19670207

A process for the microbial modification of benzodiazepine derivative, including diazepam, by fermentation of such derivative in the presence of certain strains of the fungus, *Pellissaria filamentosa*, is described. The products obtained are benzodiazepine derivative and quinoxalino[6,5-b]pyridine, which are useful as intermediates for preparing other benzodiazepine and quinoxalino[6,5-b]pyridine derivative, and (or) also for their pharmaceutical activity per se as tranquilizing agents. Thus, an agar slant of *P. filamentosa* f. microdiferentia CBS was washed with 5 ml. of distilled water, and one-half of the resulting suspension was transferred to a 250-ml. flask containing 50 ml. of the following medium (g./l.): corn-steep liquor 5, dextrose 20, peptone 20, distilled water 1000 ml. The flask was incubated on a rotary shaker, 250 rpm., at 28°. After 66 hrs. of agitation, a 10% mycelial transfer was made to a new flask of medium. Following 24 hrs. of incubation at above 11.5 mg. of diazepam in 0.5 ml. of EtOH was added, returning the flask to the shaker. Five-ml. samples were taken after 1, 2, 3, and 6 days. The pH of the samples was adjusted to 10-11 with 2N NaOH, and 1 ml. of methylisobutyl ketone was added to each sample prior to equilibration. An aliquot of the extract was spotted on Whatman Number 4 paper, and the paper was run in toluene-propylene glycol. The products were detected by uv absorption and a fluorescent screen.

27 20927-33-1P
 NL: BW (Biochemical manufacture); BIO: (Biological study); PREP (Preparation)
 (Manufacture of, by *Ellisostoma solana*)

320 20927-53-1 CAPLOS
 CH 2-[1R]-Quinoxalino[6,5-b]pyridine, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 322 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

15 ANSWER 323 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



13 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



INN	23441-72-7	CAPLUS	
CN	11281	Quinoxalineacetic acid, 6-chloro-2-oxo-4-phenyl-	(CA INDEX NAME)



```

C02 2[1X]-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)

```



```

IN  25441-78-3  CAPLUS
CN  2[1E]-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX
    NAME)

```

15 ANSWER 324 OF 327 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



FN 23441-88-5 CASUS
 CN 2-[2E]-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX
 NAME)



FIN	23441-90-9	CASLUS	
CN	2-[1 <i>H</i>]-Quinazolinone, 5-chloro-1-methyl-4-phenyl-		(CA INDEX NAME)



RN 23441-92-1 CASLUS
 CN 2-[18]-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (8CI) (CA
 INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



```

RN  23441-81-8  CAPLOS
CN  2-(1H)-Quinazolinone, 1-methyl-6-(methylthio)-4-phenyl-  (CA INDEX NAME)

```



```

NN 23441-83-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX
    SUME)

```



FN	23441-95-2	CAPLUS	
CN	2(1H)-Quinazolinone, 6, 8-dichloro-1-methyl-4-phenyl-	(CA INDEX NAME)	

L5 ANSWER 324 OF 327 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



23441-93-2 CAPLUS
2(1H)-Quinazolinone, 6-chloro-1-methyl-4-o-tolyl- (9CI) (CA INDEX NAME)




EN	23465-52-3	CAPLUS	
CN	2(1H)-Quinoxalino[2,3-b]pyridine, 6-chloro-4-phenyl-1-(phenylmethyl)-	(CA INDEX NAME)	



```

IN  23465-53-4  CAPLUS
CN  2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-phenyl-  (CA
INDEX NAME)

```



15 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)

350 23465-54-5 CAPLUS
 351 2 (1R)-Quinazolinone, 6-chloro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)



352 23465-55-6 CAPLUS
 353 2 (1R)-Quinazolinone, 4-[(3-chlorophenyl)-6-methoxy-1-methyl- (CA INDEX NAME)]



354 23536-81-4 CAPLUS
 355 2 (1R)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



356 23536-82-5 CAPLUS
 357 2 (1R)-Quinazolinone, 6-chloro-1,8-dimethyl-4-phenyl- (CA INDEX NAME)

15 ANSWER 325 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 136911668 CAPLUS
 DOCUMENT NUMBER: 7011668
 ORIGINAL REFERENCE NO.: 7012187a, 2190a
 TITLE: 1-Methyl-4-phenyl-2 (1R)-quinazolinone
 AUTHOR(S): Ovi, Ranj; Denner, Max
 CORPORATE SOURCE: Sandoz Pharm., Hanover, NH, USA
 SOURCE: Journal of Organic Chemistry (1969), 33(11), 4263-4
 CODEN: JOCKAS 358N: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 G1 For diagram(s), see printed CA Issue.
 A8 1-Methyl-4-phenyl-1,1,2,4-tetra-hydroquinazolinone (II) is prepared by the
 Hantz reduction of 4-phenylquinazolinone methiodide. I is treated with
 HNO₃ to give 1-methyl-4-phenyl-2 (1R)-quinazolinone (II). II is also prepared
 from o-MeNHCO₂CH₃ and H₂NCO₂Et and from 4-phenyl-2 (1R)-quinazolinone and
 Me₂C.
 I1 17629-04-8P
 R1 SPH (Synthetic preparation); PREP (Preparation)
 I1 Preparation of
 358 17629-04-8 CAPLUS
 359 2 (1R)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



15 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



15 ANSWER 326 OF 327 CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 136914090 CAPLUS
 DOCUMENT NUMBER: 7014090
 ORIGINAL REFERENCE NO.: 70145a, 768a
 TITLE: Quinazolinones and 1,4-benzodiazepines. XLIII.
 Oxidations with ruthenium tetroxide
 AUTHOR(S): Felix, Arthur M.; Marley, J. V.; Fryer, R. Ian
 Sternbach, L. R.
 CORPORATE SOURCE: Chen. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
 SOURCE: Journal of Heterocyclic Chemistry (1968), 5(5), 731-4
 CODEN: JHETCA 358N: 0022-152X
 LANGUAGE: English
 OTHER SOURCE(S): CHEMABSTRACT 70:4090
 G1 For diagram(s), see printed CA Issue.
 A8 7-Chloro-1-methyl-5-phenyl-1,2,4,5-tetrahydro-3H-1,4-benzodiazepine (I) was oxidized with RuO₄ to 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine, which on further treatment with RuO₄ at 0° gave 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (II), further oxidized to 6-chloro-1,2-dihydro-1-methyl-4-phenylquinazolin-2-one, also prepared by HCl treatment of 7-chloro-1-methyl-1-phenyl-1H-1,4-benzodiazepine-2,3-dione and RuO₄ oxidation of 7-chloro-4,5-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2,3-dione. RuO₄ oxidation of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-1H-1,4-benzodiazepin-2-one led to 7-chloro-5-phenyl-1H-1,4-benzodiazepine-2,3-dione.
 I1 20921-53-1P
 R1 SPH (Synthetic preparation); PREP (Preparation)
 I1 Preparation of
 359 20921-53-1 CAPLUS
 360 2 (1R)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



LS	ANMERK 327 OF 327	CAPLUS COPYRIGHT 2009 ACE on STN
	ACCESSION NUMBER:	1915:9607 CAPLUS
	DOCUMENT NUMBER:	9:9607
	ORIGINAL REFERENCE NO.:	9:1485a-1,1486a-e
	TITLE:	Dianylidenes
	AUTHOR(S):	Mann, Otto; Besse, Hugo; Volquart, Hans
	CORPORATE SOURCE:	Univ Kiel
	SOURCE:	Berichte der Deutschen Chemischen Gesellschaft (1915),

ANAL. $\text{C}_{27}\text{H}_{32}\text{O}_4$ (424.50) Calcd: C, 73.97%; H, 7.35%. Found: C, 73.9%; H, 7.4%. IR (KBr): 1735 (C=O), 1615 (C=C), 1510 (C=C), 1450 (C=C), 1380 (C=C), 1320 (C=C), 1280 (C=C), 1240 (C=C), 1200 (C=C), 1160 (C=C), 1120 (C=C), 1080 (C=C), 1040 (C=C), 1000 (C=C), 960 (C=C), 920 (C=C), 880 (C=C), 840 (C=C), 800 (C=C), 760 (C=C), 720 (C=C), 680 (C=C), 640 (C=C), 600 (C=C), 560 (C=C), 520 (C=C), 480 (C=C), 440 (C=C), 400 (C=C), 360 (C=C), 320 (C=C), 280 (C=C), 240 (C=C), 200 (C=C), 160 (C=C), 120 (C=C). ^1H NMR (CDCl₃): δ 7.2 (d, 1H, J = 10 Hz, H-1), 6.8 (d, 1H, J = 10 Hz, H-2), 6.4 (d, 1H, J = 10 Hz, H-3), 6.0 (d, 1H, J = 10 Hz, H-4), 5.6 (d, 1H, J = 10 Hz, H-5), 5.2 (d, 1H, J = 10 Hz, H-6), 4.8 (d, 1H, J = 10 Hz, H-7), 4.4 (d, 1H, J = 10 Hz, H-8), 4.0 (d, 1H, J = 10 Hz, H-9), 3.6 (d, 1H, J = 10 Hz, H-10), 3.2 (d, 1H, J = 10 Hz, H-11), 2.8 (d, 1H, J = 10 Hz, H-12), 2.4 (d, 1H, J = 10 Hz, H-13), 2.0 (d, 1H, J = 10 Hz, H-14), 1.6 (d, 1H, J = 10 Hz, H-15), 1.2 (d, 1H, J = 10 Hz, H-16), 0.8 (d, 1H, J = 10 Hz, H-17), 0.4 (d, 1H, J = 10 Hz, H-18), 0.0 (d, 1H, J = 10 Hz, H-19). Mass (ESI): m/z 425.0 (M⁺), 424.0 (M⁺), 423.0 (M⁺), 422.0 (M⁺), 421.0 (M⁺), 420.0 (M⁺), 419.0 (M⁺), 418.0 (M⁺), 417.0 (M⁺), 416.0 (M⁺), 415.0 (M⁺), 414.0 (M⁺), 413.0 (M⁺), 412.0 (M⁺), 411.0 (M⁺), 410.0 (M⁺), 409.0 (M⁺), 408.0 (M⁺), 407.0 (M⁺), 406.0 (M⁺), 405.0 (M⁺), 404.0 (M⁺), 403.0 (M⁺), 402.0 (M⁺), 401.0 (M⁺), 400.0 (M⁺), 399.0 (M⁺), 398.0 (M⁺), 397.0 (M⁺), 396.0 (M⁺), 395.0 (M⁺), 394.0 (M⁺), 393.0 (M⁺), 392.0 (M⁺), 391.0 (M⁺), 390.0 (M⁺), 389.0 (M⁺), 388.0 (M⁺), 387.0 (M⁺), 386.0 (M⁺), 385.0 (M⁺), 384.0 (M⁺), 383.0 (M⁺), 382.0 (M⁺), 381.0 (M⁺), 380.0 (M⁺), 379.0 (M⁺), 378.0 (M⁺), 377.0 (M⁺), 376.0 (M⁺), 375.0 (M⁺), 374.0 (M⁺), 373.0 (M⁺), 372.0 (M⁺), 371.0 (M⁺), 370.0 (M⁺), 369.0 (M⁺), 368.0 (M⁺), 367.0 (M⁺), 366.0 (M⁺), 365.0 (M⁺), 364.0 (M⁺), 363.0 (M⁺), 362.0 (M⁺), 361.0 (M⁺), 360.0 (M⁺), 359.0 (M⁺), 358.0 (M⁺), 357.0 (M⁺), 356.0 (M⁺), 355.0 (M⁺), 354.0 (M⁺), 353.0 (M⁺), 352.0 (M⁺), 351.0 (M⁺), 350.0 (M⁺), 349.0 (M⁺), 348.0 (M⁺), 347.0 (M⁺), 346.0 (M⁺), 345.0 (M⁺), 344.0 (M⁺), 343.0 (M⁺), 342.0 (M⁺), 341.0 (M⁺), 340.0 (M⁺), 339.0 (M⁺), 338.0 (M⁺), 337.0 (M⁺), 336.0 (M⁺), 335.0 (M⁺), 334.0 (M⁺), 333.0 (M⁺), 332.0 (M⁺), 331.0 (M⁺), 330.0 (M⁺), 329.0 (M⁺), 328.0 (M⁺), 327.0 (M⁺), 326.0 (M⁺), 325.0 (M⁺), 324.0 (M⁺), 323.0 (M⁺), 322.0 (M⁺), 321.0 (M⁺), 320.0 (M⁺), 319.0 (M⁺), 318.0 (M⁺), 317.0 (M⁺), 316.0 (M⁺), 315.0 (M⁺), 314.0 (M⁺), 313.0 (M⁺), 312.0 (M⁺), 311.0 (M⁺), 310.0 (M⁺), 309.0 (M⁺), 308.0 (M⁺), 307.0 (M⁺), 306.0 (M⁺), 305.0 (M⁺), 304.0 (M⁺), 303.0 (M⁺), 302.0 (M⁺), 301.0 (M⁺), 300.0 (M⁺), 299.0 (M⁺), 298.0 (M⁺), 297.0 (M⁺), 296.0 (M⁺), 295.0 (M⁺), 294.0 (M⁺), 293.0 (M⁺), 292.0 (M⁺), 291.0 (M⁺), 290.0 (M⁺), 289.0 (M⁺), 288.0 (M⁺), 287.0 (M⁺), 286.0 (M⁺), 285.0 (M⁺), 284.0 (M⁺), 283.0 (M⁺), 282.0 (M⁺), 281.0 (M⁺), 280.0 (M⁺), 279.0 (M⁺), 278.0 (M⁺), 277.0 (M⁺), 276.0 (M⁺), 275.0 (M⁺), 274.0 (M⁺), 273.0 (M⁺), 272.0 (M⁺), 271.0 (M⁺), 270.0 (M⁺), 269.0 (M⁺), 268.0 (M⁺), 267.0 (M⁺), 266.0 (M⁺), 265.0 (M⁺), 264.0 (M⁺), 263.0 (M⁺), 262.0 (M⁺), 261.0 (M⁺), 260.0 (M⁺), 259.0 (M⁺), 258.0 (M⁺), 257.0 (M⁺), 256.0 (M⁺), 255.0 (M⁺), 254.0 (M⁺), 253.0 (M⁺), 252.0 (M⁺), 251.0 (M⁺), 250.0 (M⁺), 249.0 (M⁺), 248.0 (M⁺), 247.0 (M⁺), 246.0 (M⁺), 245.0 (M⁺), 244.0 (M⁺), 243.0 (M⁺), 242.0 (M⁺), 241.0 (M⁺), 240.0 (M⁺), 239.0 (M⁺), 238.0 (M⁺), 237.0 (M⁺), 236.0 (M⁺), 235.0 (M⁺), 234.0 (M⁺), 233.0 (M⁺), 232.0 (M⁺), 231.0 (M⁺), 230.0 (M⁺), 229.0 (M⁺), 228.0 (M⁺), 227.0 (M⁺), 226.0 (M⁺), 225.0 (M⁺), 224.0 (M⁺), 223.0 (M⁺), 222.0 (M⁺), 221.0 (M⁺), 220.0 (M⁺), 219.0 (M⁺), 218.0 (M⁺), 217.0 (M⁺), 216.0 (M⁺

15 ANSWER 327 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
C21 21(L)-Quinazolinone, 3,4-dihydro-4-hydroxy-1-methyl-3,4-diphenyl- (CA
INDEX NAME)



10/ 540,359

=> d his

(FILE 'HOME' ENTERED AT 16:56:23 ON 29 MAY 2008)

FILE 'REGISTRY' ENTERED AT 16:56:51 ON 29 MAY 2008

L1 STRUCTURE UPLOADED
L2 36 S L1
L3 1304 S L1 FUL

FILE 'CAPLUS' ENTERED AT 16:57:23 ON 29 MAY 2008

L4 370 S L3
L5 327 S L4 NOT (ISOPROPYL OR CYCLOPENTYL)

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1788.79	1967.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-261.60	-261.60

STN INTERNATIONAL LOGOFF AT 17:00:39 ON 29 MAY 2008